
<html lang="en"     class="pb-page"  data-request-id="6dd8e520-30cc-495b-b1ff-5fa16acadfc2"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.0c00343;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-11"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Anticancer Melatplatin Prodrugs: High Effect and Low Toxicity, MT1-ER-Target and Immune Response In Vivo" /></meta><meta name="dc.Creator" content="Xue-Qing  Song" /></meta><meta name="dc.Creator" content="Rui-Ping  Liu" /></meta><meta name="dc.Creator" content="Shu-Qing  Wang" /></meta><meta name="dc.Creator" content="Zhe  Li" /></meta><meta name="dc.Creator" content="Zhong-Ying  Ma" /></meta><meta name="dc.Creator" content="Ran  Zhang" /></meta><meta name="dc.Creator" content="Cheng-Zhi  Xie" /></meta><meta name="dc.Creator" content="Xin  Qiao" /></meta><meta name="dc.Creator" content="Jing-Yuan  Xu" /></meta><meta name="dc.Description" content="Multitargeted therapy could rectify various oncogenic pathways to block tumorigenesis and progression. The combination of endocrine-, immune-, and chemotherapy might exert a highly synergistic effe..." /></meta><meta name="Description" content="Multitargeted therapy could rectify various oncogenic pathways to block tumorigenesis and progression. The combination of endocrine-, immune-, and chemotherapy might exert a highly synergistic effe..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 13, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00343" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00343" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00343" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00343" /></link>
        
    
    

<title>Anticancer Melatplatin Prodrugs: High Effect and Low Toxicity, MT1-ER-Target and Immune Response In Vivo | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00343" /></meta><meta property="og:title" content="Anticancer Melatplatin Prodrugs: High Effect and Low Toxicity, MT1-ER-Target and Immune Response In Vivo" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0007.jpeg" /></meta><meta property="og:description" content="Multitargeted therapy could rectify various oncogenic pathways to block tumorigenesis and progression. The combination of endocrine-, immune-, and chemotherapy might exert a highly synergistic effect against certain tumors. Herein, a series of smart Pt(IV) prodrugs 3–6, named Melatplatin, were rationally designed not only to multitarget DNA, MT1, and estrogen receptor (ER) but also to activate immune response. Melatplatin, conjugating first-line chemotherapeutic Pt drugs with human endogenous melatonin (MT), significantly enhanced drug efficacy especially in ER high-expression (ER+) cells, among which 3 presented the most potent cytotoxicity toward ER+ MCF-7 with nanomolar IC50 values 100-fold lower than cisplatin. Melatplatin could bind well to melatonin receptor (MT1) according to molecular docking. Besides, 3 evidently increased intracellular accumulation and DNA damage, upregulated γH2AX and P53, and silenced NF-κB to induce massive apoptosis. Most strikingly, 3 effectively inhibited tumor growth and attenuated systemic toxicity compared to cisplatin in vivo, promoting lymphocyte proliferation in spleen to achieve immune modulation." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00343"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00343">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00343&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00343&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00343&amp;href=/doi/10.1021/acs.jmedchem.0c00343" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 6096-6106</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00295" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00361" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Anticancer Melatplatin Prodrugs: High Effect and Low Toxicity, MT1-ER-Target and Immune Response <i>In Vivo</i></span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xue-Qing Song</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xue-Qing Song</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xue-Qing++Song">Xue-Qing Song</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rui-Ping Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rui-Ping Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rui-Ping++Liu">Rui-Ping Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shu-Qing Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shu-Qing Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shu-Qing++Wang">Shu-Qing Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhe Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhe Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhe++Li">Zhe Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhong-Ying Ma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhong-Ying Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhong-Ying++Ma">Zhong-Ying Ma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ran Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ran Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ran++Zhang">Ran Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cheng-Zhi Xie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cheng-Zhi Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cheng-Zhi++Xie">Cheng-Zhi Xie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xin Qiao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xin Qiao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Qiao">Xin Qiao</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jing-Yuan Xu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jing-Yuan Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#077f726d6e69607e72666947736a7229626372296469"><span class="__cf_email__" data-cfemail="1068657a797e776965717e50647d653e7574653e737e">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jing-Yuan++Xu">Jing-Yuan Xu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1660-412X" title="Orcid link">http://orcid.org/0000-0002-1660-412X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00343&amp;href=/doi/10.1021%2Facs.jmedchem.0c00343" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 6096–6106</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 13, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 February 2020</li><li><span class="item_label"><b>Published</b> online</span>13 May 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 June 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00343" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00343</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6096%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXue-Qing%2BSong%252C%2BRui-Ping%2BLiu%252C%2BShu-Qing%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D11%26contentID%3Dacs.jmedchem.0c00343%26title%3DAnticancer%2BMelatplatin%2BProdrugs%253A%2BHigh%2BEffect%2Band%2BLow%2BToxicity%252C%2BMT1-ER-Target%2Band%2BImmune%2BResponse%2BIn%2BVivo%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6106%26publicationDate%3DJune%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00343"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1061</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">6</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00343" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Anticancer Melatplatin Prodrugs: High Effect and Low Toxicity, MT1-ER-Target and Immune Response In Vivo&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xue-Qing&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Rui-Ping&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Shu-Qing&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Zhe&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Zhong-Ying&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Ran&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Cheng-Zhi&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Qiao&quot;},{&quot;first_name&quot;:&quot;Jing-Yuan&quot;,&quot;last_name&quot;:&quot;Xu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;6096-6106&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00343&quot;},&quot;abstract&quot;:&quot;Multitargeted therapy could rectify various oncogenic pathways to block tumorigenesis and progression. The combination of endocrine-, immune-, and chemotherapy might exert a highly synergistic effect against certain tumors. Herein, a series of smart Pt(IV) prodrugs 3–6, named Melatplatin, were rationally designed not only to multitarget DNA, MT1, and estrogen receptor (ER) but also to activate immune response. Melatplatin, conjugating first-line chemotherapeutic Pt drugs with human endogenous melatonin (MT), significantly enhanced drug efficacy especially in ER high-expression (ER+) cells, among which 3 presented the most potent cytotoxicity toward ER+ MCF-7 with nanomolar IC50 values 100-fold lower than cisplatin. Melatplatin could bind well to melatonin receptor (MT1) according to molecular docking. Besides, 3 evidently increased intracellular accumulation and DNA damage, upregulated γH2AX and P53, and silenced NF-κB to induce massive apoptosis. Most strikingly, 3 effectively inhibited tumor growth and atte&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00343&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00343" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00343&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00343" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00343&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00343" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00343&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00343&amp;href=/doi/10.1021/acs.jmedchem.0c00343" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00343" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00343" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00343%26sid%3Dliteratum%253Aachs%26pmid%3D32401032%26genre%3Darticle%26aulast%3DSong%26date%3D2020%26atitle%3DAnticancer%2BMelatplatin%2BProdrugs%253A%2BHigh%2BEffect%2Band%2BLow%2BToxicity%252C%2BMT1-ER-Target%2Band%2BImmune%2BResponse%2BIn%2BVivo%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D11%26spage%3D6096%26epage%3D6106%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (8)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292098" title="Platinum">Platinum</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/jmcmar.2020.63.issue-11/20200611/jmcmar.2020.63.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/medium/jm0c00343_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00343&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Multitargeted therapy could rectify various oncogenic pathways to block tumorigenesis and progression. The combination of endocrine-, immune-, and chemotherapy might exert a highly synergistic effect against certain tumors. Herein, a series of smart Pt(IV) prodrugs <b>3</b>–<b>6</b>, named Melatplatin, were rationally designed not only to multitarget DNA, MT1, and estrogen receptor (ER) but also to activate immune response. Melatplatin, conjugating first-line chemotherapeutic Pt drugs with human endogenous melatonin (MT), significantly enhanced drug efficacy especially in ER high-expression (ER<sup>+</sup>) cells, among which <b>3</b> presented the most potent cytotoxicity toward ER<sup>+</sup> MCF-7 with nanomolar IC<sub>50</sub> values 100-fold lower than cisplatin. Melatplatin could bind well to melatonin receptor (MT1) according to molecular docking. Besides, <b>3</b> evidently increased intracellular accumulation and DNA damage, upregulated γH2AX and P53, and silenced NF-κB to induce massive apoptosis. Most strikingly, <b>3</b> effectively inhibited tumor growth and attenuated systemic toxicity compared to cisplatin <i>in vivo</i>, promoting lymphocyte proliferation in spleen to achieve immune modulation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28818" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28818" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Breast cancer (BC), a highly complex and multistate disease, has become one of the most primary health threats to women worldwide, and even increasingly more incidences occur among younger women.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Epidemiological surveys showed that BC is always related to the risk factors affecting hormone levels, such as premature menarche or menopausal delay, repeated abortion, lack of breast feeding, etc.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In addition, family medical history, gene mutations, and unhealthy lifestyles are commonly considered.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> As a ligand-activated transcription factor, estrogen receptor (ER) including α and β subtypes, which could be activated <i>via</i> binding to estrogen, plays a pivotal role in promoting tumorigenesis and progression.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> According to the reports, there were approximately 75% of BC patients with ER highly expressed.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Besides, ER was also found overexpressed in many different kinds of tumors, such as estrogen-dependent ovarian cancer,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> endometrial cancer,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> cervical cancer,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> estrogen-independent liver cancer,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> gastric cancer,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> lung cancer,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> colorectal cancer,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> etc. ER is therefore considered to be a key indicator in clinical treatment and prognosis. Furthermore, ER could regulate a lot of cancerous genes such as c-Myc, cathepsin D, EGFR, Cyclin-D1, E-cadherin, TGF-β, c-fos, etc.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">Owing to the benefit of ER on mammary tumors progression, scientists have correspondingly designed various target agents including selective estrogen receptor/enzyme modulators (SERM/SEEM) recommended as endocrine therapy for patients.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Tamoxifen, a well-known SERM, is a conventional prescription in clinic toward most ER-responsive tumors. However, it still causes severe adverse effects such as slow onset, night sweats, hot flashes, depression, forgetfulness, and gynecologic symptoms, as well as prone to drug resistance and tumor recurrence/metastasis. Most worryingly, it will occasionally induce endometrial cancer, venous thromboembolic disease, etc.,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> which further negatively influence the quality of life of patients.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">Melatonin (MT, <i>N</i>-acetyl-5-methoxytryptamine) is reported as a hormone secreted by pineal gland in response to circadian rhythms,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and it has repeatedly been confirmed to possess a wide spectrum of regulatory role in physiological functions.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Already in the 1980s, a potential relationship was found between breast cancer and hormonal activity of pineal gland.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> And the data statistics revealed that most women patients had predominantly experienced shift work or exposure to light at night, which induce the disorder of melatonin level, before BC diagnosis.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Strikingly, MT was proved to (i) downregulate ERα expression <i>via</i> binding to its melatonin membrane receptor (MT1), a high-affinity G coupled receptor; (ii) counteract calmodulin function on ER activation and translocation into nucleus <i>via</i> suppressing ERα phosphorylation;<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> (iii) and destroy the stability of the estradiol–ERα complex, thereby failing to bind with estrogen response element (ERE) situated at DNA promoters, eventually interfering the expression of various estradiol-responsive genes. Except the SERM function, MT also performs SEEM actions through inhibiting the activity of some enzymes including 17β-hydroxysteroid dehydrogenase (type I), P450 aromatase, and steroid sulfatase, which are responsible for the conversion of estrogen to its active formation.<a onclick="showRef(event, 'cit21b'); return false;" href="javascript:void(0);" class="ref cit21b">(21b)</a></div><div class="NLM_p">Besides, since immunosuppression caused by pinealectomy was discovered by Maestroni et al., increasing research supported that MT possesses immunomodulatory properties.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p">There has been a positive relation between MT and immune cells proliferation, and it was also demonstrated that the change of MT levels would affect spleen and thymus weight in a period of time.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In the immunosuppressive process, the increase of T-reg lymphocytes plays a fundamental role in the failure of immune system against tumor. Fortunately, MT could trigger anticancer immunity through altering populations of CD4<sup>+</sup> and CD25<sup>+</sup> T-reg in the tumor microenvironment to promote tumor cells death and silence NF-κB and its downstream cytokines.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> In fact, melatonin not only acts as an immunological buffer but also exerts potent antioxidant, anti-inflammatory, and other effects.<a onclick="showRef(event, 'cit24c'); return false;" href="javascript:void(0);" class="ref cit24c">(24c)</a> However, MT can only be used as an adjuvant in conjunction with existing chemotherapy or radiotherapy because it does not meet the requirements of clinical cancer treatment alone.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Therefore, the conventional cytotoxic chemotherapy remains one of the key elements of a therapeutic arsenal.</div><div class="NLM_p">Cisplatin (CDDP), carboplatin, and oxaliplatin are classical chemotherapy agents in clinic for the majority of solid tumors.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> They are usually believed to rapidly trigger cancer cell death through losing nonamine ligands and then covalently binding with adjacent purines of nucleobases to form Pt-DNA adducts.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Despite their success in some cases, the severe side effects and recurring drug resistance largely limit their clinical application and pose a big problem regarding its efficacy.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> These include off-target effects prior to DNA binding and low selectivity for cancer cells, leading to nephrotoxicity, myelo-suppression, nerve damage, ototoxicity, immunosuppression, etc.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Currently, octahedral Pt(IV) complexes are considered as ideal candidates of a new generation platinum drugs because their axial positions permit modification of diverse functional groups to reinforce kinetic inertness in the circulation system and promote cellular uptake and synergistic anticancer action.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> And satraplatin (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), as a successful Pt(IV) prodrug, has already entered phase III clinical trials, even with the hope of achieving oral medication, but it failed to improve the overall survival of cancer patients.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Metal complexes or organometallic compounds, such as ruthenium, iridium, rhodium, etc., are developed as treatment and diagnosis agents for cancer patients; however, platinum-based drugs are still most widely used in clinic at present.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/medium/jm0c00343_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of cisplatin, oxoplatin, staraplatin, MT, and compounds <b>1</b>–<b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00343&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Based on these facts and observations, we intended to set MT molecules into platinum(IV) scaffold to obtain a series of unprecedented multifunction Pt(IV) prodrugs, Melatplatins. Unlike the previous design of Pt(IV) drugs, such as Asplatin based on aspirin,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Fuplatin based on fluorouracil,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Platin-Cbl based on chlorambucil, etc.,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> the introduced axial ligands still brought about additional toxic side effects.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In this work, the MT counterpart not only owns its clearly metabolic pathways without any toxicity<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> but also improves the selectivity of platinum prodrug toward hormone refractory cancers and simultaneously activates the body’s immune response during <i>in vivo</i> therapy.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55104" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55104" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis and Characterization of Compounds</h3><div class="NLM_p">Herein, we first designed and synthesized four new Melatplatin compounds <b>3</b>–<b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) by introducing melatonin into the axial positions of Pt(IV) center with the help of succinic or glutaric anhydride, and the synthetic routes are shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The <i>c</i>,<i>c</i>,<i>t</i>-Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>(OH)<sub>2</sub> (oxoplatin) was synthesized by the oxidation of cisplatin with hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The final products <b>3</b>–<b>6</b> were obtained by oxoplatin reacting with melatonin derivatives <b>1</b> and <b>2</b> at room temperature. The structures of all compounds were characterized by <sup>1</sup>H/<sup>13</sup>C NMR and high-resolution mass spectrometry (HR-MS). The purity over 95% and stability of compounds in phosphate-buffered saline (PBS) were monitored by high-performance liquid chromatography (HPLC) (all data are presented in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_001.pdf" class="ext-link">Figures S1–S26</a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/medium/jm0c00343_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route of Compounds <b>1</b>–<b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00343&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Condition and reagents: (a) succinic anhydride or glutaric anhydride, acetonitrile, triethylamine (TEA), 4-dimethylaminopyridine (DMAP), 50 °C, overnight; (b) H<sub>2</sub>O<sub>2</sub> (30%), 70 °C, 5 h; (c) 2-(1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethyl-uronium tetrafluoroborate (TBTU), TEA, dimethyl sulfoxide (DMSO), room temperature, overnight; (d) TBTU, TEA, dimethylformamide (DMF), room temperature, 48 h.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Anticancer Activity and Selectivity of the Compounds</h3><div class="NLM_p">First, all of the synthesized compounds were screened for cytotoxicity on the cancer cells MCF-7, MDA-MB-231, A549, and HeLa, and normal model cells, human umbilical vein endothelial cell (HUVEC). Data showed that all Pt(IV) compounds had a potent cytotoxicity to the cells used, among which two monosubstituted Pt(IV) <b>3</b> and <b>4</b> have superior antiproliferation effects compared to CDDP, oxoplatin, satraplatin, and their diverse combination therapies in all of the tested cell lines (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Especially, the cytotoxicity of <b>3</b> with IC<sub>50</sub> values of 0.06 ± 0.01 μM was up to 100-fold higher than that of CDDP with IC<sub>50</sub> of 5.93 ± 0.40 μM in MCF-7 cells. Such a trend was also observed in the other tested ER<sup>+</sup> cancer cells. In stark contrast, in MDA-MB-231 cells, there was only an approximately 32-fold increase for <b>3</b> compared to CDDP. We presumed that the difference of ER expression might well explain these data.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> To further ensure the accuracy of our experiments, we detected ER protein in different kinds of cells by western blot assay. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a,c, all of the tested cells, especially MCF-7, displayed high ER expression except MDA-MB-231, which are consistent with the reported literature.<a onclick="showRef(event, 'cit39b'); return false;" href="javascript:void(0);" class="ref cit39b">(39b)</a> Just as we expected, the ERα expression in MCF-7 was dramatically inhibited by <b>3</b> and followed the order of <b>3</b> > mixture> MT > CDDP > control after the cells were treated with 10 μM compounds for 4 h (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b,d). It is worth noting that compounds <b>3</b> and <b>4</b> exhibited a much higher selectivity index (SI) between MCF-7 and HUVEC with SI values of 22.5 and 7.00 than CDDP with 0.46, suggesting their low toxicity.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/medium/jm0c00343_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. ERα expression was measured by western blot assay. (a) ERα expressions of MCF-7, MDA-MB-231, A549, HeLa, and HUVEC cells. (b) Inhibition of ERα in compounds treatment groups (10 μM). (c) Statistics analysis of protein gray values relative to GAPDH. <sup>***</sup><i>P</i> < 0.001 compared to MDA-MB-231 cells. (d) Statistics analysis of protein gray values relative to β-tubulin. <sup>***</sup><i>P</i> < 0.001 compared to the control group. (e) Crystal structure of beta1-adrenergic receptor (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VT4">2VT4</a>) was downloaded as template from RCSB Protein Data Bank. The lowest-energy structure of compounds MT (blue), <b>3</b> (green), and <b>4</b> (yellow) to dock with MT1 receptor. (f) Accumulation of Pt in MCF-7 that was exposed to CDDP, mixture, and compounds <b>3</b>–<b>6</b> at 10 μM for 5 h, respectively. <sup>***</sup><i>P</i> < 0.001, <sup>**</sup><i>P</i> < 0.01, compared with the CDDP group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00343&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory Effect of Compounds on Five Cell Lines for 72 h</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center">MCF-7 (ER<sup>+</sup>)</th><th class="colsep0 rowsep0" align="center">MDA-MB-231 (ER<sup>–</sup>)</th><th class="colsep0 rowsep0" align="center">A549 (ER<sup>+</sup>)</th><th class="colsep0 rowsep0" align="center">HeLa (ER<sup>+</sup>)</th><th class="colsep0 rowsep0" align="center">HUVEC (ER<sup>+</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">SI<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char=".">SI<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MT</td><td class="colsep0 rowsep0" align="left">16.49 ± 0.91</td><td class="colsep0 rowsep0" align="left">59.32 ± 2.12</td><td class="colsep0 rowsep0" align="left">60.04 ± 24.19</td><td class="colsep0 rowsep0" align="left">60.27 ± 1.71</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="char" char=".">3.60</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">12.57 ± 5.03</td><td class="colsep0 rowsep0" align="left">88.55 ± 11.94</td><td class="colsep0 rowsep0" align="left">63.58 ± 4.53</td><td class="colsep0 rowsep0" align="left">49.28 ± 2.19</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="char" char=".">7.04</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">12.30 ± 0.29</td><td class="colsep0 rowsep0" align="left">107.34 ± 16.84</td><td class="colsep0 rowsep0" align="left">70.69 ± 10.71</td><td class="colsep0 rowsep0" align="left">44.72 ± 0.95</td><td class="colsep0 rowsep0" align="left">>100</td><td class="colsep0 rowsep0" align="char" char=".">8.73</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">0.06 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.36 ± 0.11</td><td class="colsep0 rowsep0" align="left">0.06 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.06 ± 0.03</td><td class="colsep0 rowsep0" align="left">1.35 ± 0.82</td><td class="colsep0 rowsep0" align="char" char=".">6.00</td><td class="colsep0 rowsep0" align="char" char=".">22.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">0.16 ± 0.07</td><td class="colsep0 rowsep0" align="left">0.50 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.09 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.15 ± 0.06</td><td class="colsep0 rowsep0" align="left">1.12 ± 0.31</td><td class="colsep0 rowsep0" align="char" char=".">3.13</td><td class="colsep0 rowsep0" align="char" char=".">7.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">5.80 ± 0.39</td><td class="colsep0 rowsep0" align="left">65.62 ± 1.19</td><td class="colsep0 rowsep0" align="left">13.63 ± 4.45</td><td class="colsep0 rowsep0" align="left">6.46 ± 0.45</td><td class="colsep0 rowsep0" align="left">12.05 ± 1.32</td><td class="colsep0 rowsep0" align="char" char=".">11.31</td><td class="colsep0 rowsep0" align="char" char=".">2.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">2.23 ± 0.78</td><td class="colsep0 rowsep0" align="left">12.26 ± 0.13</td><td class="colsep0 rowsep0" align="left">18.56 ± 3.81</td><td class="colsep0 rowsep0" align="left">6.52 ± 3.64</td><td class="colsep0 rowsep0" align="left">9.38 ± 0.41</td><td class="colsep0 rowsep0" align="char" char=".">5.50</td><td class="colsep0 rowsep0" align="char" char=".">4.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDDP</td><td class="colsep0 rowsep0" align="left">5.93 ± 0.40</td><td class="colsep0 rowsep0" align="left">11.68 ± 0.06</td><td class="colsep0 rowsep0" align="left">3.81 ± 0.19</td><td class="colsep0 rowsep0" align="left">4.94 ± 0.31</td><td class="colsep0 rowsep0" align="left">2.73 ± 0.77</td><td class="colsep0 rowsep0" align="char" char=".">1.97</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDDP + MT</td><td class="colsep0 rowsep0" align="left">3.03 ± 0.12</td><td class="colsep0 rowsep0" align="left">5.54 ± 1.70</td><td class="colsep0 rowsep0" align="left">4.21 ± 0.75</td><td class="colsep0 rowsep0" align="left">3.69 ± 0.96</td><td class="colsep0 rowsep0" align="left">2.77 ± 0.34</td><td class="colsep0 rowsep0" align="char" char=".">1.83</td><td class="colsep0 rowsep0" align="char" char=".">0.91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oxoplatin</td><td class="colsep0 rowsep0" align="left">10.86 ± 2.17</td><td class="colsep0 rowsep0" align="left">33.83 ± 7.91</td><td class="colsep0 rowsep0" align="left">43.28 ± 1.48</td><td class="colsep0 rowsep0" align="left">21.32 ± 7.14</td><td class="colsep0 rowsep0" align="left">43.62 ± 5.19</td><td class="colsep0 rowsep0" align="char" char=".">3.11</td><td class="colsep0 rowsep0" align="char" char=".">4.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oxoplatin + MT</td><td class="colsep0 rowsep0" align="left">9.90 ± 0.72</td><td class="colsep0 rowsep0" align="left">24.20 ± 2.56</td><td class="colsep0 rowsep0" align="left">27.13 ± 2.53</td><td class="colsep0 rowsep0" align="left">16.67 ± 0.83</td><td class="colsep0 rowsep0" align="left">21.07 ± 0.52</td><td class="colsep0 rowsep0" align="char" char=".">2.44</td><td class="colsep0 rowsep0" align="char" char=".">2.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">satraplatin</td><td class="colsep0 rowsep0" align="left">1.75 ± 0.34</td><td class="colsep0 rowsep0" align="left">1.64 ± 0.07</td><td class="colsep0 rowsep0" align="left">1.50 ± 0.19</td><td class="colsep0 rowsep0" align="left">0.47 ± 0.20</td><td class="colsep0 rowsep0" align="left">2.41 ± 0.13</td><td class="colsep0 rowsep0" align="char" char=".">0.94</td><td class="colsep0 rowsep0" align="char" char=".">1.38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FI<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">98.83</td><td class="colsep0 rowsep0" align="left">32.44</td><td class="colsep0 rowsep0" align="left">63.50</td><td class="colsep0 rowsep0" align="left">82.33</td><td class="colsep0 rowsep0" align="left">2.02</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FI<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">37.06</td><td class="colsep0 rowsep0" align="left">23.36</td><td class="colsep0 rowsep0" align="left">42.33</td><td class="colsep0 rowsep0" align="left">32.93</td><td class="colsep0 rowsep0" align="left">2.43</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FI<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">29.17</td><td class="colsep0 rowsep0" align="left">4.56</td><td class="colsep0 rowsep0" align="left">11.53</td><td class="colsep0 rowsep0" align="left">7.83</td><td class="colsep0 rowsep0" align="left">1.79</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FI<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">10.94</td><td class="colsep0 rowsep0" align="left">3.28</td><td class="colsep0 rowsep0" align="left">7.14</td><td class="colsep0 rowsep0" align="left">3.13</td><td class="colsep0 rowsep0" align="left">2.15</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">FI, fold increase, IC<sub>50</sub>(CDDP)/IC<sub>50</sub>(compound <b>3</b>).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub>(CDDP)/IC<sub>50</sub>(compound <b>4</b>).</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">IC<sub>50</sub>(satraplatin)/IC<sub>50</sub>(compound <b>3</b>).</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">IC<sub>50</sub> (satraplatin)/IC<sub>50</sub>(compound <b>4</b>).</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">SI, selectivity index, IC<sub>50</sub>(in MDA-MB-231)/IC<sub>50</sub>(in MCF-7).</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">IC<sub>50</sub>(in HUVEC)/IC<sub>50</sub>(in MCF-7).</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Molecular Modeling</h3><div class="NLM_p">As known, MT itself needs to bind to its receptor MT1,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> then to inhibit ERα transcriptional activity and downregulate ERα expression,<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and to exert SERM and SEEM effects as well as the immunomodulatory effect, which were discussed above. Apparently, whether MT groups of Melatplatins still keep their action would be the next concerned issue. The affinity between MT1 and compounds might offer more explanation for the results of biological activity and ERα suppression.</div><div class="NLM_p">Molecular modeling was performed to simulate and evaluate the binding ability of the compounds to MT1, respectively. Based on the crystal structure of beta1-adrenergic receptor (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VT4">2VT4</a>), we constructed the 3D model of MT1 receptor by the homology modeling package Modeler.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> MT interacted with amino acid residues on receptors in two main ways: hydrogen bonds and π–π interactions.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Taking <b>3</b> and <b>4</b> as examples, docking results showed that the MT motif of Melatplatin compounds could bind well to the receptor in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>e. The binding free energy of compounds MT (−4.20 kcal/mol), <b>3</b> (−4.98 kcal/mol), and <b>4</b> (−4.78 kcal/mol) showed that the ligands <b>1</b> and <b>2</b> introduced into platinum(IV) compounds could enhance the binding ability of MT itself to the receptor to some extent. The docked conformations of compounds <b>3</b> and <b>4</b> were shown by two-dimensional (2D) interaction graph (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The amide bond and the indole nitrogen of MT could establish hydrogen bonds with the close neighborhood residues for Ser 156 and ASN 229; the indole ring could establish a stable structure by π–π interactions with VAL 165; and the benzene ring formed Pi-alkyl with VAL 85. Compounds <b>3</b> and <b>4</b> bind to the MT1 receptor in a similar way to MT, but the presence of amino and oxygen on the platinum atoms make the compounds bind to the receptor more firmly through hydrogen bonds. For compound <b>3</b>, the amino and oxygen groups on platinum can form hydrogen bonds with some amino acids like ASN 136, THR 141, PHE 153, GLN 155, and TYR 161, and for compound <b>4</b>, they can form hydrogen bonds with ASN 136, THR 141, PHE 153, GLN 155, TYR 161, and ASN 229. The binding free energies of compounds <b>5</b> (−2.15 kcal/mol) and <b>6</b> (−3.17 kcal/mol) were slightly higher than that of MT, which might be due to the increase of steric hindrance from the double substituents introduced. Molecular dockings showed that Melatplatin prodrugs possess an affinity to MT1, which is consistent with the above cytotoxicity results and meets our primary design idea of multitargeted synergistic therapy.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/medium/jm0c00343_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Molecular docking data of MT, <b>3</b>, and <b>4</b> with MT receptor MT1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00343&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Intracellular Accumulation of Compounds</h3><div class="NLM_p last">According to the above data, the cytotoxicity of <b>3</b> was much higher than those of <b>4</b>–<b>6</b> in the tested cancer cells. There is a common recognition that the modification by lipophilic ligands at the axial positions of Pt(IV) drugs could affect the membrane penetration, so the intracellular uptake of compounds was determined.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>f, after treatment with 10 μM compounds in MCF-7 cells for 5 h, the Pt content of <b>3</b> (724.2 ± 33.8 ng Pt/10<sup>6</sup> cells) was much higher than those of <b>4</b> (262.6 ± 61.1 ng Pt/10<sup>6</sup> cells), CDDP (9.5 ± 0.8 ng Pt/10<sup>6</sup> cells), and mixture (9.76 ± 1.1 ng Pt/10<sup>6</sup> cells) groups. In addition, monosubstituted <b>3</b> and <b>4</b> had much higher Pt content than disubstituted <b>5</b> (58.4 ± 10.9 ng Pt/10<sup>6</sup> cells) and <b>6</b> (61.9 ± 20.6 ng Pt/10<sup>6</sup> cells) in cells. These figures were essentially in agreement with the previously published report of Zhu et al., where they supposed that the intake of monosubstituted Pt(IV) compounds might prefer to depend on active transport.<a onclick="showRef(event, 'ref38 ref45'); return false;" href="javascript:void(0);" class="ref ref38 ref45">(38,45)</a></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Reduction of Compounds <b>3</b>–<b>6</b></h3><div class="NLM_p last">To reveal the intracellular action manner of the Pt(IV) prodrugs, we tried to analyze the reduction process that might have an influence on cytotoxicity.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Previous studies elaborated that Pt(IV) compounds are commonly activated by intra- or extracellular reductants such as glutathione (GSH), thiol groups of proteins, ascorbic acid (AsA), etc.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Thus, cyclic voltammetry (CV) and HPLC methods<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> were employed to monitor the reduction of compounds. CV experiments displayed that the reduction potential of compounds <b>3</b>–<b>6</b> were −0.489, −0.469, −0.494, and −0.464 V, respectively, relative to Ag/AgCl, suggesting that all of them could be reduced in theory (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_001.pdf" class="ext-link">Figure S27</a>). HPLC monitoring further confirmed that all Pt(IV) compounds were reduced in the solution of 1 mM AsA (a cytoplasmic concentration), up to 100% in 1.5 h for <b>3</b> and <b>4</b>, while only about 50% in 48 h for <b>5</b> and <b>6</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_001.pdf" class="ext-link">Figure S28</a>). Our results coincided with the study of Zhu et al.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and Choi et al.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> that faster reduction rates were correlated with higher cytotoxic activity for Pt(IV) compounds.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Cells Response Caused by Compound <b>3</b></h3><div class="NLM_p">Due to the release of mother nucleus during the reduction, the possible effects of platinum(II) drugs were investigated. It is well known that the antitumor effect of platinum(II) drugs is mainly based on DNA target, including DNA damage, blocking genomic replication and transcription, and inducing apoptosis.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a, γH2AX is recognized as one of the biomarkers of DNA lesions, and it will exhibit obvious intranuclear accumulation under the stimulation of cisplatin.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> As expected, the upregulation of γH2AX occurred in <b>3</b>, CDDP, and mixture groups, while not in control and MT ones. And the p53 expressions of the above groups were also detected (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b), inasmuch as it is extremely sensitive to a very small number of DNA strand breaks or single-stranded gaps in early detection. Meanwhile, as a tumor suppressor gene, p53 is also involved in cell cycle arrest or apoptosis to prevent the malignant progression of cancer cells.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The p53 expression of drug-treated groups significantly increased, showing a high staining compared to control. Besides, in the cell cycle analysis (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>c), compound <b>3</b> exerted the most serious S-phase arrest on MCF-7 cells compared to CDDP and the mixture group. Cyclin D1 is an indispensable factor in the G1/S checkpoint of cell cycle, which promotes the transition of tumor cells from G1 to S phase.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Then, in the western blot assay, Cyclin-D1 treated with <b>3</b> was elevated apparently (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_001.pdf" class="ext-link">Figure S30</a>). In addition, it can be seen from <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>e and <a href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_001.pdf" class="ext-link">Table S1</a> that the combination of MT and cisplatin has a certain synergistic action on apoptosis,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> and compound <b>3</b> significantly induced apoptosis up to 90% and cell death nearly 100%, which are much higher than the other groups under the same concentration and time conditions. Bax is one of the most essential proapoptotic members of Bcl-2 family and it is ubiquitously expressed in human tissues.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>f, it was markedly upregulated after treated with 5 μM compound <b>3</b> for 24 h.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/medium/jm0c00343_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Imaging of compound <b>3</b> (10 μM), MT (10 μM), CDDP (10 μM), and an equimolar mixture of CDDP and MT treatment in fixed MCF-7 cells using Alexa Fluor 594-conjugated Goat Anti-Rabbit IgG (H + L). Single image planes of Alexa Fluor 594 (red), 4′,6-diamidino-2-phenylindole (DAPI) (blue), merged red and blue channels are displayed. (a) The γH2AX expression (9 h treatment) and (b) the p53 expression (12 h treatment). (c) Cell cycle distribution after treatment with 0.1 μM compounds for 24 h in MCF-7 cells. (d) The expression of Cyclin D1 in compound <b>3</b> treatment group (5 μM) tested by western blot assay. (e) MCF-7 cell apoptosis induced by compounds at 10 μM for 24 h tested by Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) double staining. (f) The expression of proapoptotic protein Bax in compound <b>3</b> treatment group (5 μM) tested by western blot assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00343&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> <i>In Vivo</i> Antitumor Activity and Immune Response</h3><div class="NLM_p">To evaluate the <i>in vivo</i> antitumor activity of drugs, MCF-7 tumor xenograft BALB/c nude mice models were established. All of the tested compounds were administered, respectively, <i>via</i> tail intravenous injection in 4 day intervals at a dose of 2 mg-Pt/kg for 6 times. As displayed in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a,b, compound <b>3</b>, CDDP, and the mixture group presented effective tumor inhibitory activity with inhibition rates of ∼47.4, ∼42.6, and ∼39.3%, respectively, compared to PBS- and MT-treated groups. It is well known that the severe side effects of cisplatin have been an important cause to restrain its clinical application, so the physiological status of the mice was carefully observed in this work. During administration, the body weights between PBS- and MT-treated mice were basically not different, and those in compound <b>3</b> group slightly decreased in the early stage but increased later, which was consistent with the trend of the mixture group. However, in the CDDP group, the mice weights decreased throughout and hence the survival rate dropped to 33.33% at the end of the experiment (the number of mice death includes dead mice and those lost weight over 20%; <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>c,d). To further evaluate the efficacy and toxicity of the drugs, the Pt content in tissues was measured.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>e and <a href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_001.pdf" class="ext-link">S31</a>, the Pt accumulation in tumors in the compound <b>3</b>-treated group is more than those in CDDP and the mixture, but there was no significant difference (<i>P</i> > 0.05) between them in the heart, liver, lungs, and kidneys, which suggested that compound <b>3</b> is the most effective among three groups. Amazingly, in the CDDP-treated group, Pt most reached the spleen rather than other organs in a substantial proportion compared to other groups, which is consistent with the spleen index in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>f. Thus, we speculated that the spleen may be a major tissue to respond to the <i>in vivo</i> toxicity of cisplatin.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/medium/jm0c00343_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antitumor effect in BALB/c nude mice model bearing MCF-7 tumors with different treatments (compound <b>3</b> at 2 mg-Pt/kg, MT equal to the mole number of Pt per mouse, CDDP at 2 mg-Pt/kg, and an equimolar mixture of CDDP and MT) in a period of 22 days. (a) Tumor volume in each group. <sup>***</sup><i>P</i> < 0.001, *<i>P</i> < 0.05, compared to the PBS group. (b) Tumor weight after final treatments. <sup>***</sup><i>P</i> < 0.001, compared to the PBS group. (c) Changes of mice bodyweight during treatments. <sup>###</sup><i>P</i> < 0.001, compared to the CDDP group. (d) Survival rate of mice. (The number of death includes dead mice and those lost weight over 20%). (e) Pt content in spleens and tumors. *<i>P</i> < 0.05. (f) Spleen index of mice. *<i>P</i> < 0.05, compared to the CDDP group. (g) Imaging of NF-κB expression in MCF-7 cells after exposed to compound <b>3</b> (1 μM), MT (1 μM), CDDP (1 μM), and an equimolar mixture of CDDP and MT for 12 h. Single image planes of Alexa Fluor 594-conjugated Goat Anti-Rabbit IgG (H + L) (red), DAPI (blue), and merged red and blue channels are displayed. (h) Hematoxylin and eosin (H&E) staining pictures of mice organs (spleen, kidney, and tumor).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00343&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further confirm the above deduction, we conducted a histopathological evaluation. Studies revealed that the occurrence of tumors is closely related to immune system dysregulation.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Spleen is the largest organ in the immune system of vertebrates and plays a significant role in monitoring body state. And it was found that spleen itself rarely breeds primary tumors or metastasized ones.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> During the H&E section observation, compared to the PBS group, the density of the red and white pulps of spleen slices in the CDDP-treated group was markedly reduced and even accompanied by amyloid deposition and lymphocytoponia. However, in MT-, mixture-, or compound <b>3</b>-treated groups, there was a massive proliferation of lymphocytes in the spleen. These results completely matched with the literature reporting that MT administration could inhibit tumor progression and promote lymphocyte and macrophage proliferation to exert anticancer immunity function.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> And studies proposed that the spleen toxicity introduced by cisplatin was mainly <i>via</i> the activation of nuclear factor κB (NF-κB), c-jun N-terminal kinase (JNK), and extrinsic apoptotic pathway.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> NF-κB is a pivotal regulator in the innate and adaptive immune responses of the host, and its disorder or imbalance would lead to a pathological state. Once it continues to be overactivated, cells will produce a lot of proinflammatory cytokines (including TNF-α, IL6, etc.) and enter into an excited or inflammatory state, thereby suppressing the anticancer immunity, promoting immune escape and tumor deterioration, as well as causing poor prognosis.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Besides, Karin et al. also reviewed that the inhibition of NF-κB could convert inflammation-induced tumor growth to regression.<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a> As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>g, the strong fluorescence staining indicated that NF-κB was greatly triggered by CDDP, whereas the introduction of MT controlled the activation of NF-κB, especially in the compound <b>3</b> group.</div><div class="NLM_p last">Most inspiringly, the H&E staining of tumor slices showed severe necrosis with the complete dispersion of the majority of nucleus in the compound <b>3</b> group. Besides, CDDP was a typical nephrotoxic agent,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> and we indeed found a lower renal index, and obvious renal cortical congestion and glomerular hyperplasia in CDDP-treated slices. However, encouragingly, these phenomena were not observed in the other groups. Thus, all <i>in vivo</i> results indicated that compound <b>3</b> makes a major breakthrough in achieving antitumor activity of high effect and low toxicity, simultaneously accompanied by apparent immune response.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25706" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25706" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The combination of immunization and chemotherapy is currently an indubitable hotspot for cancer treatment. The clinical key indicator ER has been a rational target for endocrine therapy. The tumorigenesis and progression of ER<sup>+</sup> breast cancer is closely related with insufficient MT. With these ideas in mind, we designed and prepared a series of smart platinum(IV) prodrugs with selectivity for ER<sup>+</sup> tumor and immune response to conquer the chemotherapy barriers in clinic. To investigate the structure–activity relationship of free ligands MT, CDDP, and compounds <b>3</b>–<b>6</b>, we first performed the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay to screen out the cytotoxicity in the order of <b>3</b> > <b>4</b> > <b>6</b> > <b>5</b> > CDDP > MT, suggesting that the introduction of MT ligands at the axial position of Pt(IV) complexes did improve the antiproliferation effect compared to MT and CDDP. The above result was confirmed by the inductively coupled plasma mass spectrometry (ICP-MS) measurement and reduction experiments. The increased cellular uptake and duly (relatively fast) reduction rate will help to improve the cytotoxicity of Pt(IV) prodrugs. As for the possibility of synergistic anticancer action, molecular docking was employed to simulate and evaluate the binding ability of the compounds to MT1, indicating that MT can keep its function even after conjugating with the Pt(IV) center. Thus, the most promising candidate <b>3</b> was selected for further study on the possible mechanism, and it markedly increased the expression of γH2AX and p53 and induced S-phase arrest and apoptosis. Furthermore, compound <b>3</b> displayed excellent <i>in vivo</i> antitumor activity that could not only inhibit tumor growth with high effect and low toxicity but also activate spleen immune modulation, improving the overall survival in ER<sup>+</sup> MCF-7 tumor xenografts BALB/c nude mice. This design concept, combining endocrine-, chemo-, and immunotherapy, might provide a novel strategy for the development of preferably subsequent chemotherapy agents.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85665" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85665" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Synthesis of Compounds <b>1</b> and <b>2</b></h3><div class="NLM_p">Melatonin (1 g, 4.31 mmol), succinic anhydride (0.86 g, 8.62 mmol) or glutaric anhydride (0.98 g, 8.60 mmol), triethylamine (TEA) (1.80 mL, 12.93 mmol), and 4-dimethylaminopyridine (DMAP) (52.5 mg, 0.43 mmol) were mixed in anhydrous acetonitrile (10 mL) and stirred at 50 °C for 24 h under nitrogen. The solvent was evaporated in vacuum, and the residue was neutralized by 1 M hydrochloric acid. Then, the solution was extracted with ethyl acetate. After separation, the aqueous layer was extracted by ethyl acetate three times (60 mL). All of the organic phase was washed with saturated NH<sub>4</sub>Cl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated by rotary evaporation. The resulting samples were purified by silica gel column chromatography (dichloromethane/methanol, 20:1), yielding a white solid of <b>1</b> (yield: 0.80 g, 56%) or a light yellow solid of <b>2</b> (yield: 1.039 g, 70%).</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 4-(3-(2-Acetamidoethyl)-5-methoxy-1<i>H</i>-indol-1-yl)-4-oxo-butanoic Acid (<b>1</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) = 12.27 (s, 1H), 8.20 (d, <i>J</i> = 8.9 Hz, 1H), 8.04 (t, <i>J</i> = 5.4 Hz, 1H), 7.72 (s, 1H), 7.15 (d, <i>J</i> = 2.2 Hz, 1H), 6.92 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 3.81 (s, 3H), 3.40–3.35 (m, 2H), 3.20 (t, <i>J</i> = 6.1 Hz, 2H), 2.79 (t, <i>J</i> = 7.0 Hz, 2H), 2.65 (t, <i>J</i> = 6.1 Hz, 2H), 1.82 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) = 173.63, 170.16, 169.20, 155.86, 131.40, 129.79, 123.52, 119.21, 116.64, 112.89, 101.90, 55.39, 38.14, 29.92, 28.18, 24.77, 22.64. HR-MS (<i>m</i>/<i>z</i>): calcd for C<sub>17</sub>H<sub>20</sub>N<sub>2</sub>O<sub>5</sub> (M + H)<sup>+</sup>, 333.1406; found: 333.1443. Purity (HPLC): 98.574%. Elemental analysis (%): calcd for C<sub>17</sub>H<sub>20</sub>N<sub>2</sub>O<sub>5</sub>: C, 61.44; H, 6.07; N, 8.43. Found: C, 61.57; H, 6.18; N, 8.51.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 5-(3-(2-Acetamidoethyl)-5-methoxy-1<i>H</i>-indol-1-yl)-5-oxo-pentanoic Acid (<b>2</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) = 8.22 (d, <i>J</i> = 8.9 Hz, 1H), 8.08 (t, <i>J</i> = 5.4 Hz, 1H), 7.69 (s, 1H), 7.14 (d, <i>J</i> = 2.2 Hz, 1H), 6.93 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 3.81 (s, 3H), 3.39–3.34 (m, 2H), 3.00 (t, <i>J</i> = 6.9 Hz, 2H), 2.78 (t, <i>J</i> = 6.8 Hz, 2H), 2.37 (t, <i>J</i> = 6.3 Hz, 2H), 1.92 (m, 2H), 1.82 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) = 174.21, 170.81, 169.20, 155.84, 131.40, 129.79, 123.67, 119.08, 116.72, 112.86, 101.88, 55.33, 38.14, 33.92, 32.78, 24.76, 22.63, 19.80. HR-MS (<i>m</i>/<i>z</i>): calcd for C<sub>18</sub>H<sub>22</sub>N<sub>2</sub>O<sub>5</sub> (M + H)<sup>+</sup>, 347.1562; found: 347.1598. Purity (HPLC): 98.475%. Elemental analysis (%): calcd for C<sub>18</sub>H<sub>22</sub>N<sub>2</sub>O<sub>5</sub>: C, 62.42; H, 6.40; N, 8.09. Found: C, 62.29; H, 6.49; N, 8.16.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Synthesis of Compounds <b>3</b> and <b>4</b></h3><div class="NLM_p">Oxoplatin was synthesized as described previously.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Cisplatin (1 g, 3.33 mmol) reacted with 30% H<sub>2</sub>O<sub>2</sub> (6 mL) at 70 °C for 5 h. The resulting yellow solution was kept at 4 °C overnight in the dark. Bright yellow solids were separated by centrifugation and then washed several times with ethanol and ethyl ether to get a yellow product. Yield: 80%. HR-MS (<i>m</i>/<i>z</i>): calcd for Cl<sub>2</sub>H<sub>8</sub>N<sub>2</sub>O<sub>2</sub>Pt (M + H)<sup>+</sup>, 333.9689; found, 334.2917. Compound <b>1</b> (100 mg, 0.30 mmol) or <b>2</b> (104 mg, 0.30 mmol), TBTU (116 mg, 0.36 mmol), and TEA (50 μL, 0.36 mmol) were added into dried DMSO (2 mL) in a 10 mL round-bottom flask and stirred for 15 min. Then, oxoplatin (100.2 mg, 0.30 mmol) was added and reacted for 24 h at room temperature under nitrogen protection to get orange clear solutions. Next, chloroform (4 × 12 mL) was added to the reaction solution to obtain white solids, which were washed twice by chloroform and diethyl ether, respectively, and dried to give crude products. The products were purified by silica gel (dichloromethane/methanol, 5:1) to give a light yellow solid <b>3</b> (yield: 52.4 mg, 26.9%) or <b>4</b> (yield: 84 mg, 42.3%).</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> <i>cis</i>,<i>cis</i>-Diamminedichloro-{4-(3-(2-acetamidoethyl)-5-meth-oxy-1<i>H</i>-indol-1-yl)-4-oxobutanoato}-hydroxoplatinum(IV) (<b>3</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) = 8.21 (d, <i>J</i> = 8.9 Hz, 1H), 8.16 (t, <i>J</i> = 5.0 Hz, 1H), 7.71 (s, 1H), 7.14 (d, <i>J</i> = 1.9 Hz, 1H), 6.91 (dd, <i>J</i> = 8.9, 1.9 Hz, 1H), 6.10 (t, 6H), 3.81 (s, 3H), 3.40–3.32 (m, 2H), 3.13 (t, <i>J</i> = 6.6 Hz, 2H), 2.79 (t, <i>J</i> = 7.0 Hz, 2H), 2.65 (t, <i>J</i> = 6.6 Hz, 2H), 1.82 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) = 179.69, 170.68, 169.25, 155.83, 131.44, 129.89, 123.63, 119.06, 116.74, 112.82, 101.96, 55.41, 38.22, 31.58, 30.98, 24.75, 22.67. HR-MS (<i>m</i>/<i>z</i>): calcd for C<sub>17</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>6</sub>Pt (M + H)<sup>+</sup>, 649.4010; found: 649.0915. Purity (HPLC): 97.638%. Elemental analysis (%): calcd for C<sub>17</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>6</sub>Pt: C, 31.49; H, 4.04; N, 8.64. Found: C, 31.26; H, 4.15; N, 8.52.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>cis</i>,<i>cis</i>-Diamminedichloro-{5-(3-(2-acetamidoethyl)-5-meth-oxy-1<i>H</i>-indol-1-yl)-5-oxopentanoato}-hydroxoplatinum(IV) (<b>4</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) = 8.29–8.88 (m, 2H), 7.73 (s, 1H), 7.14 (d, <i>J</i> = 1.4 Hz, 1H), 6.91 (dd, <i>J</i> = 8.9, 1.4 Hz, 1H), 6.42–5.95 (m, 6H), 3.81 (s, 3H), 3.39–3.35 (m, 2H), 3.02 (t, <i>J</i> = 6.9 Hz, 2H), 2.78 (t, <i>J</i> = 6.8 Hz, 2H), 2.31 (t, <i>J</i> = 6.8 Hz, 2H), 1.91–1.83 (m, 2H), 1.82 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) = 180.36, 171.34, 169.29, 155.79, 131.44, 129.76, 123.98, 118.91, 116.71, 112.83, 101.87, 55.36, 38.27, 35.47, 34.21, 24.76, 22.70, 21.00. HR-MS (<i>m</i>/<i>z</i>): calcd for C<sub>18</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>6</sub>Pt (M + H)<sup>+</sup>, 663.4280; found: 663.1076. Purity (HPLC): 98.186%. Elemental analysis (%): calcd for C<sub>18</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>6</sub>Pt: C, 32.64; H, 4.26; N, 8.46. Found: C, 32.71; H, 4.35; N, 8.58.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Synthesis of Compounds <b>5</b> and <b>6</b></h3><div class="NLM_p">Compound <b>1</b> (299 mg, 0.90 mmol) or <b>2</b> (311 mg, 0.90 mmol), TBTU (289 mg, 0.90 mmol), and TEA (125 μL, 0.90 mmol) were added into 2 mL of dried DMF and stirred for 15 min at room temperature. Then, oxoplatin (100.2 mg, 0.30 mmol) was added and reacted for 48 h under nitrogen protection. Solvent was concentrated in a rotary evaporator at 65 °C. The product was purified by silica gel (dichloromethane/methanol, 10:1) to give a white solid <b>5</b> (yield: 122.9 mg, 42.6%) or a light yellow solid <b>6</b> (yield: 60 mg, 20.2%).</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>cis</i>,<i>cis</i>-Diamminedichloro-bis{4-(3-(2-acetamidoethyl)-5-methoxy-1<i>H</i>-indol-1-yl)-4-oxobutanoato}-platinum(IV) (<b>5</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) = 8.18 (d, <i>J</i> = 8.9 Hz, 2H), 8.04 (t, <i>J</i> = 4.8 Hz, 2H), 7.67 (s, 2H), 7.12 (d, <i>J</i> = 1.9 Hz, 2H), 6.89 (dd, <i>J</i> = 8.9, 1.9 Hz, 2H), 6.51 (s, 6H), 3.79 (s, 6H), 3.37–3.33 (m, 4H), 3.10 (t, <i>J</i> = 5.8 Hz, 4H), 2.82–2.67 (m, 8H), 1.81 (s, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) = 179.53, 170.39, 169.20, 155.81, 131.40, 129.83, 123.56, 119.08, 116.76, 112.86, 101.86, 55.33, 38.17, 30.70, 29.74, 24.78, 22.67. HR-MS (<i>m</i>/<i>z</i>): calcd for C<sub>34</sub>H<sub>44</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>10</sub>Pt (M + H)<sup>+</sup>, 963.7420; found: 963.2196. Purity (HPLC): 97.256%. Elemental analysis (%): calcd for C<sub>34</sub>H<sub>44</sub>Cl<sub>2</sub>N<sub>6</sub>O<sub>10</sub>Pt: C, 42.42; H, 4.61; N, 8.73. Found: C, 42.31; H, 4.52; N, 8.62.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>cis</i>,<i>cis</i>-Diamminedichloro-bis{5-(3-(2-acetamidoethyl)-5-methoxy-1<i>H</i>-indol-1-yl)-5-oxopentanoato}-platinum(IV) (<b>6</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) = 8.23 (d, <i>J</i> = 8.9 Hz, 2H), 8.05 (s, 2H), 7.69 (s, 2H), 7.14 (d, <i>J</i> = 2.2 Hz, 2H), 6.92 (dd, <i>J</i> = 8.9, 2.2 Hz, 2H), 6.62 (s, 6H), 3.81 (s, 6H), 3.39–3.30 (m, 4H), 3.06–3.00 (m, 4H), 2.79 (t, <i>J</i> = 6.8 Hz, 4H), 2.39 (t, <i>J</i> = 6.8 Hz, 4H), 1.94–1.82 (m, 4H), 1.82 (s, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ (ppm) = 180.18, 171.17, 169.25, 155.81, 131.41, 129.77, 123.81, 118.94, 116.72, 112.86, 101.87, 55.34, 38.25, 34.68, 34.00, 24.81, 22.68, 20.74. HR-MS (<i>m</i>/<i>z</i>): calcd for C<sub>36</sub>H<sub>48</sub>C<sub>12</sub>N<sub>6</sub>O<sub>10</sub>Pt (M + H)<sup>+</sup>, 991.7960; found: 991.2514. Purity (HPLC): 96.301%. Elemental analysis (%): calcd for C<sub>36</sub>H<sub>48</sub>C<sub>12</sub>N<sub>6</sub>O<sub>10</sub>Pt: C, 43.64; H, 4.88; N, 8.48. Found: C, 43.27; H, 4.96; N, 8.67.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00343" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00343?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00343</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">HR-MS spectra of oxoplatin; <sup>1</sup>H/<sup>13</sup>C NMR, HR-MS spectra, and HPLC of all of the target compounds; HPLC for the stability and reduction of compounds <b>3</b>–<b>6</b>; cyclic voltammetry for compounds <b>3</b>–<b>6</b>; isobolograms and combination index for the combination of CDDP/MT; Pt biodistribution in mice, organ indexes, H&E staining, and tumor image; materials and instrumentations; and all of the bioassay details (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Docking of MT (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Docking of compound <b>3</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Docking of compound <b>4</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Docking of compound <b>5</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_006.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Docking of compound <b>6</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_007.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Modeled from <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2vt4">2vt4</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_008.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_001.pdf">jm0c00343_si_001.pdf (2.9 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_002.csv">jm0c00343_si_002.csv (1.44 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_003.pdb">jm0c00343_si_003.pdb (2.17 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_004.pdb">jm0c00343_si_004.pdb (3.08 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_005.pdb">jm0c00343_si_005.pdb (3.16 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_006.pdb">jm0c00343_si_006.pdb (6.59 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_007.pdb">jm0c00343_si_007.pdb (6.79 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_008.pdb">jm0c00343_si_008.pdb (377.2 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00343" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06318" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06318" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing-Yuan Xu</span> - <span class="hlFld-Affiliation affiliation">Tianjin Key Laboratory on
Technologies Enabling Development of Clinical Therapeutics and Diagnostics
(Theranostics), School of Pharmacy, Tianjin
Medical University, Tianjin 300070, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1660-412X" title="Orcid link">http://orcid.org/0000-0002-1660-412X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b9c1ccd3d0d7dec0ccd8d7f9cdd4cc97dcddcc97dad7"><span class="__cf_email__" data-cfemail="0f777a65666168767a6e614f7b627a216a6b7a216c61">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xue-Qing Song</span> - <span class="hlFld-Affiliation affiliation">Tianjin Key Laboratory on
Technologies Enabling Development of Clinical Therapeutics and Diagnostics
(Theranostics), School of Pharmacy, Tianjin
Medical University, Tianjin 300070, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rui-Ping Liu</span> - <span class="hlFld-Affiliation affiliation">Tianjin Key Laboratory on
Technologies Enabling Development of Clinical Therapeutics and Diagnostics
(Theranostics), School of Pharmacy, Tianjin
Medical University, Tianjin 300070, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shu-Qing Wang</span> - <span class="hlFld-Affiliation affiliation">Tianjin Key Laboratory on
Technologies Enabling Development of Clinical Therapeutics and Diagnostics
(Theranostics), School of Pharmacy, Tianjin
Medical University, Tianjin 300070, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhe Li</span> - <span class="hlFld-Affiliation affiliation">Tianjin Key Laboratory on
Technologies Enabling Development of Clinical Therapeutics and Diagnostics
(Theranostics), School of Pharmacy, Tianjin
Medical University, Tianjin 300070, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhong-Ying Ma</span> - <span class="hlFld-Affiliation affiliation">Tianjin Key Laboratory on
Technologies Enabling Development of Clinical Therapeutics and Diagnostics
(Theranostics), School of Pharmacy, Tianjin
Medical University, Tianjin 300070, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ran Zhang</span> - <span class="hlFld-Affiliation affiliation">Tianjin Key Laboratory on
Technologies Enabling Development of Clinical Therapeutics and Diagnostics
(Theranostics), School of Pharmacy, Tianjin
Medical University, Tianjin 300070, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng-Zhi Xie</span> - <span class="hlFld-Affiliation affiliation">Tianjin Key Laboratory on
Technologies Enabling Development of Clinical Therapeutics and Diagnostics
(Theranostics), School of Pharmacy, Tianjin
Medical University, Tianjin 300070, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Qiao</span> - <span class="hlFld-Affiliation affiliation">Tianjin Key Laboratory on
Technologies Enabling Development of Clinical Therapeutics and Diagnostics
(Theranostics), School of Pharmacy, Tianjin
Medical University, Tianjin 300070, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>X.-Q.S., R.-P.L., and S.-Q.W. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e2324-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33256" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33256" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by National Natural Science Foundation of China (21977080, 21371135, and 21772146) and Tianjin Municipal Natural Science Foundation (17JCZDJC33100).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">MT</td><td class="NLM_def"><p class="first last">melatonin</p></td></tr><tr><td class="NLM_term">MT1</td><td class="NLM_def"><p class="first last">melatonin receptor 1</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">BC</td><td class="NLM_def"><p class="first last">breast cancer</p></td></tr><tr><td class="NLM_term">SERM/SEEM</td><td class="NLM_def"><p class="first last">selective estrogen receptor/enzyme modulators</p></td></tr><tr><td class="NLM_term">ERE</td><td class="NLM_def"><p class="first last">estrogen response element</p></td></tr><tr><td class="NLM_term">CDDP</td><td class="NLM_def"><p class="first last">cisplatin</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">trimethylamine</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last">2-(1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethyl-uronium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">AsA</td><td class="NLM_def"><p class="first last">ascorbic acid</p></td></tr><tr><td class="NLM_term">CV</td><td class="NLM_def"><p class="first last">cyclic voltammetry</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor κB</p></td></tr><tr><td class="NLM_term">JNK</td><td class="NLM_def"><p class="first last">c-jun N-terminal kinase</p></td></tr><tr><td class="NLM_term">HR-MS</td><td class="NLM_def"><p class="first last">high-resolution mass spectra</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide</p></td></tr><tr><td class="NLM_term">SDS-PAGE</td><td class="NLM_def"><p class="first last">sodium dodecyl sulfate-polyacrylamide gel electrophoresis</p></td></tr><tr><td class="NLM_term">PVDF</td><td class="NLM_def"><p class="first last">polyvinylidene difluoride</p></td></tr><tr><td class="NLM_term">TBST</td><td class="NLM_def"><p class="first last">tris buffered saline with 0.1% Tween-20</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57765" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57765" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 63 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wassermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelber, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddy, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamimi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Come, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partridge, A. H.</span></span> <span> </span><span class="NLM_article-title">Nonadherent Behaviors among Young Women on Adjuvant Endocrine Therapy for Breast Cancer</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">3266</span>– <span class="NLM_lpage">3274</span>, <span class="refDoi"> DOI: 10.1002/cncr.32192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fcncr.32192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=31120571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12hur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2019&pages=3266-3274&author=J.+Wassermannauthor=S.+I.+Gelberauthor=S.+M.+Rosenbergauthor=K.+J.+Ruddyauthor=R.+M.+Tamimiauthor=L.+Schapiraauthor=V.+F.+Borgesauthor=S.+E.+Comeauthor=M.+E.+Meyerauthor=A.+H.+Partridge&title=Nonadherent+Behaviors+among+Young+Women+on+Adjuvant+Endocrine+Therapy+for+Breast+Cancer&doi=10.1002%2Fcncr.32192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer</span></div><div class="casAuthors">Wassermann, Johanna; Gelber, Shari I.; Rosenberg, Shoshana M.; Ruddy, Kathryn J.; Tamimi, Rulla M.; Schapira, Lidia; Borges, Virginia F.; Come, Steven E.; Meyer, Meghan E.; Partridge, Ann H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3266-3274</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Young age is a known factor assocd. with suboptimal adherence to endocrine therapy (ET) for adjuvant breast cancer (BC) treatment.  This study was aimed at assessing nonadherent behaviors and assocd. factors among young women with early-stage hormone receptor-pos. BC.  As part of a multicenter, prospective cohort of women with a diagnosis of BC at or under the age of 40 years, participants were surveyed 30 mo after their diagnosis about adherent behaviors.  Among those who reported taking ET, adherence was measured with a 3-item Likert-type scale: Do you ever forget to take your ET If you feel worse when you take your ET, do you stop taking it Did you take your ET exactly as directed by your doctor over the last 3 mo Women reporting at least 1 nonadherent behavior were classified as nonadherers.  Variables with a P value <.20 were included in a multivariable logistic model.  Among 384 women, 194 (51%) were classified as nonadherers.  Univariate factors that retained significance in the multivariable model included educational level (odds ratio [OR], 0.50 for high vs low; P = .04), level of social support according to the Medical Outcome Study Social Support Survey (OR, 0.98 per 1 point; P = .01), and confidence with the decision regarding ET measured on a 0 to 10 numerical scale (OR, 0.63 for high vs low; P = .04).  Findings from this study could help to identify young patients at higher risk for nonadherence.  Interventions adapted to the level of education and aimed at reinforcing support and patients' confidence in their decision to take ET could improve adherence and assocd. outcomes in this population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLP3Fz60_42LVg90H21EOLACvtfcHk0lj2WF2378LFWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12hur3I&md5=c7e2f829fb89107a079931f9db4f4391</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1002%2Fcncr.32192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.32192%26sid%3Dliteratum%253Aachs%26aulast%3DWassermann%26aufirst%3DJ.%26aulast%3DGelber%26aufirst%3DS.%2BI.%26aulast%3DRosenberg%26aufirst%3DS.%2BM.%26aulast%3DRuddy%26aufirst%3DK.%2BJ.%26aulast%3DTamimi%26aufirst%3DR.%2BM.%26aulast%3DSchapira%26aufirst%3DL.%26aulast%3DBorges%26aufirst%3DV.%2BF.%26aulast%3DCome%26aufirst%3DS.%2BE.%26aulast%3DMeyer%26aufirst%3DM.%2BE.%26aulast%3DPartridge%26aufirst%3DA.%2BH.%26atitle%3DNonadherent%2520Behaviors%2520among%2520Young%2520Women%2520on%2520Adjuvant%2520Endocrine%2520Therapy%2520for%2520Breast%2520Cancer%26jtitle%3DCancer%26date%3D2019%26volume%3D125%26spage%3D3266%26epage%3D3274%26doi%3D10.1002%2Fcncr.32192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bahmanpour, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheervalilou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choupani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaniani, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montazeri, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derakhshan, S. M.</span></span> <span> </span><span class="NLM_article-title">A New Insight on Serum MicroRNA Expression as Novel Biomarkers in Breast Cancer Patients</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">19199</span>– <span class="NLM_lpage">19211</span>, <span class="refDoi"> DOI: 10.1002/jcp.28656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fjcp.28656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=31026062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1MXot1Cis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2019&pages=19199-19211&author=Z.+Bahmanpourauthor=R.+Sheervalilouauthor=J.+Choupaniauthor=M.+S.+Khanianiauthor=V.+Montazeriauthor=S.+M.+Derakhshan&title=A+New+Insight+on+Serum+MicroRNA+Expression+as+Novel+Biomarkers+in+Breast+Cancer+Patients&doi=10.1002%2Fjcp.28656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">A new insight on serum microRNA expression as novel biomarkers in breast cancer patients</span></div><div class="casAuthors">Bahmanpour, Zahra; Sheervalilou, Roghayeh; Choupani, Jalal; Shekari Khaniani, Mahmoud; Montazeri, Vahid; Mansoori Derakhshan, Sima</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">19199-19211</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Breast cancer (BC) is one of the widespread lethal diseases affecting a large no. of women worldwide.  As such, employing and identifying significant markers for detecting BC in different stages can assist in better diagnosis and management of the disease.  Several diverse markers have been introduced for diagnosis, but their limitations, including low specificity and sensitivity, reduce their application. microRNAs (miRNAs), as short noncoding RNAs, have been shown to significantly influence gene expression in different disease pathologies, esp. BC.  Clearly, among different samples used for detecting miRNA expressions, circulating miRNAs present as promising and useful biomarkers.  Among different body fluid samples, serum serves as one of the most reliable samples, thanks to its high stability under various severe conditions and some unique features.  Extensive research has suggested that BC-related miRNAs can remain stable in the serum.  The objective of this review is to describe different samples used for detecting miRNAs in BC subjects with emphasis on serum miRNAs.  So, this study highlights serum miRNAs with the potential of acting as biomarkers for different stages of BC.  We reviewed the possible correlation between potential miRNAs and the risk of early breast cancer, metastatic breast cancer, response to chemotherapy, and relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobGWCxO5A0yLVg90H21EOLACvtfcHk0ljSQa_nQ4iQiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXot1Cis70%253D&md5=723c540bd4b9b6ec2183b7d33e1ce03a</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1002%2Fjcp.28656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.28656%26sid%3Dliteratum%253Aachs%26aulast%3DBahmanpour%26aufirst%3DZ.%26aulast%3DSheervalilou%26aufirst%3DR.%26aulast%3DChoupani%26aufirst%3DJ.%26aulast%3DKhaniani%26aufirst%3DM.%2BS.%26aulast%3DMontazeri%26aufirst%3DV.%26aulast%3DDerakhshan%26aufirst%3DS.%2BM.%26atitle%3DA%2520New%2520Insight%2520on%2520Serum%2520MicroRNA%2520Expression%2520as%2520Novel%2520Biomarkers%2520in%2520Breast%2520Cancer%2520Patients%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D234%26spage%3D19199%26epage%3D19211%26doi%3D10.1002%2Fjcp.28656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penault-Llorca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houssami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poortmans, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, F.</span></span> <span> </span><span class="NLM_article-title">Breast Cancer</span>. <i>Nat. Rev. Dis. Primers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1038/s41572-019-0111-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1038%2Fs41572-019-0111-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=31548545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhsFSguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=66-96&author=N.+Harbeckauthor=F.+Penault-Llorcaauthor=J.+Cortesauthor=M.+Gnantauthor=N.+Houssamiauthor=P.+Poortmansauthor=K.+Ruddyauthor=J.+Tsangauthor=F.+Cardoso&title=Breast+Cancer&doi=10.1038%2Fs41572-019-0111-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer</span></div><div class="casAuthors">Harbeck Nadia; Penault-Llorca Frederique; Cortes Javier; Cortes Javier; Gnant Michael; Houssami Nehmat; Poortmans Philip; Poortmans Philip; Ruddy Kathryn; Tsang Janice; Cardoso Fatima</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Breast cancer is the most frequent malignancy in women worldwide and is curable in ~70-80% of patients with early-stage, non-metastatic disease.  Advanced breast cancer with distant organ metastases is considered incurable with currently available therapies.  On the molecular level, breast cancer is a heterogeneous disease; molecular features include activation of human epidermal growth factor receptor 2 (HER2, encoded by ERBB2), activation of hormone receptors (oestrogen receptor and progesterone receptor) and/or BRCA mutations.  Treatment strategies differ according to molecular subtype.  Management of breast cancer is multidisciplinary; it includes locoregional (surgery and radiation therapy) and systemic therapy approaches.  Systemic therapies include endocrine therapy for hormone receptor-positive disease, chemotherapy, anti-HER2 therapy for HER2-positive disease, bone stabilizing agents, poly(ADP-ribose) polymerase inhibitors for BRCA mutation carriers and, quite recently, immunotherapy.  Future therapeutic concepts in breast cancer aim at individualization of therapy as well as at treatment de-escalation and escalation based on tumour biology and early therapy response.  Next to further treatment innovations, equal worldwide access to therapeutic advances remains the global challenge in breast cancer care for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEOiYgsNcoF0loaUqgkFHkfW6udTcc2eYP_nWdp7Fbfbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhsFSguw%253D%253D&md5=e1d6ae6f77bff6a8fe96a0aa3364dd7c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fs41572-019-0111-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41572-019-0111-2%26sid%3Dliteratum%253Aachs%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DHoussami%26aufirst%3DN.%26aulast%3DPoortmans%26aufirst%3DP.%26aulast%3DRuddy%26aufirst%3DK.%26aulast%3DTsang%26aufirst%3DJ.%26aulast%3DCardoso%26aufirst%3DF.%26atitle%3DBreast%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Dis.%2520Primers%26date%3D2019%26volume%3D5%26spage%3D66%26epage%3D96%26doi%3D10.1038%2Fs41572-019-0111-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narod, S. A.</span></span> <span> </span><span class="NLM_article-title">Modifiers of Risk of Hereditary Breast Cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5832</span>– <span class="NLM_lpage">5836</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1209870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1038%2Fsj.onc.1209870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=16998497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVSgurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=5832-5836&author=S.+A.+Narod&title=Modifiers+of+Risk+of+Hereditary+Breast+Cancer&doi=10.1038%2Fsj.onc.1209870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Modifiers of risk of hereditary breast cancer</span></div><div class="casAuthors">Narod, S. A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">5832-5836</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mutations in the BRCA1 and BRCA2 genes confer a high lifetime risk of breast and ovarian cancer.  The risk varies from individual to individual, and it appears that the risk has increased in recent generations.  These observations imply that non-genetic factors may modify the inherited risk.  To date, the factors that appear most strongly to modify the risk include reproductive histories and exogenous hormones.  Oral contraceptives are assocd. with a profound redn. in the risk of ovarian cancer, and with little or no increase in the risk of breast cancer.  Other modifying factors include age of menarche, parity, breastfeeding and oophorectomy.  The effect of parity is different in BRCA1 and BRCA2 carriers.  Multiparity appears to be protective in BRCA1 carriers, but is assocd. with an increase in risk in BRCA2 carriers.  Oophorectomy has been assocd. with redns. in both the risk of breast and ovarian cancer.  Knowledge of these risk factors will be useful for managing risk and for developing prevention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-lcpbhzNenrVg90H21EOLACvtfcHk0liKstQ8Biugpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVSgurvK&md5=b85f97831ecd3530658f1b6213e6eb52</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209870%26sid%3Dliteratum%253Aachs%26aulast%3DNarod%26aufirst%3DS.%2BA.%26atitle%3DModifiers%2520of%2520Risk%2520of%2520Hereditary%2520Breast%2520Cancer%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D5832%26epage%3D5836%26doi%3D10.1038%2Fsj.onc.1209870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carascossa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briand, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, D.</span></span> <span> </span><span class="NLM_article-title">CARM1 Mediates the Ligand-Independent and Tamoxifen-Resistant Activation of the Estrogen Receptor alpha by cAMP</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">719</span>, <span class="refDoi"> DOI: 10.1101/gad.568410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1101%2Fgad.568410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=20360387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltFWls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=708-719&author=S.+Carascossaauthor=P.+Dudekauthor=B.+Cenniauthor=P.+A.+Briandauthor=D.+Picard&title=CARM1+Mediates+the+Ligand-Independent+and+Tamoxifen-Resistant+Activation+of+the+Estrogen+Receptor+alpha+by+cAMP&doi=10.1101%2Fgad.568410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor α by cAMP</span></div><div class="casAuthors">Carascossa, Sophie; Dudek, Peter; Cenni, Bruno; Briand, Pierre-Andre; Picard, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">708-719</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The estrogen receptor α (ERα) is activated as a transcription factor by both estrogen and a large variety of other extracellular signals.  The mechanisms of this ligand-independent activation, notably by cAMP signaling, are still largely unknown.  We now close the gap in the signaling pathway between cAMP and ERα.  Whereas the direct phosphorylation of ERα by the cAMP-activated protein kinase A (PKA) is dispensable, the phosphorylation of the coactivator-assocd. arginine methyltransferase 1 (CARM1) by PKA at a single serine is necessary and sufficient for direct binding to the unliganded hormone-binding domain (HBD) of ERα, and the interaction is necessary for cAMP activation of ERα.  Sustained PKA activity promoting a constitutive interaction may contribute to tamoxifen resistance of breast tumors.  Binding and activation involve a novel regulatory groove of the ERα HBD.  As a result, depending on the activating signal, ERα recruits different coactivator complexes to regulate alternate sets of target genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0maunIKcwK7Vg90H21EOLACvtfcHk0liKstQ8Biugpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltFWls78%253D&md5=17eb8d03810f76ba763d622729952c25</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1101%2Fgad.568410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.568410%26sid%3Dliteratum%253Aachs%26aulast%3DCarascossa%26aufirst%3DS.%26aulast%3DDudek%26aufirst%3DP.%26aulast%3DCenni%26aufirst%3DB.%26aulast%3DBriand%26aufirst%3DP.%2BA.%26aulast%3DPicard%26aufirst%3DD.%26atitle%3DCARM1%2520Mediates%2520the%2520Ligand-Independent%2520and%2520Tamoxifen-Resistant%2520Activation%2520of%2520the%2520Estrogen%2520Receptor%2520alpha%2520by%2520cAMP%26jtitle%3DGenes%2520Dev.%26date%3D2010%26volume%3D24%26spage%3D708%26epage%3D719%26doi%3D10.1101%2Fgad.568410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gornowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymanowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymanowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czarnomysy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaluza, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, K.</span></span> <span> </span><span class="NLM_article-title">Monoclonal Anti-MUC1 Antibody with Novel Octahydropyrazino[2,1-a:5,4-a′]diisoquinoline Derivative as a Potential Multi-Targeted Strategy in MCF-7 Breast Cancer Cells</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1391</span>– <span class="NLM_lpage">1403</span>, <span class="refDoi"> DOI: 10.3892/or.2019.7256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3892%2For.2019.7256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVOrur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=1391-1403&author=A.+Gornowiczauthor=W.+Szymanowskiauthor=A.+Bielawskaauthor=A.+Szymanowskaauthor=R.+Czarnomysyauthor=Z.+Kaluzaauthor=K.+Bielawski&title=Monoclonal+Anti-MUC1+Antibody+with+Novel+Octahydropyrazino%5B2%2C1-a%3A5%2C4-a%E2%80%B2%5Ddiisoquinoline+Derivative+as+a+Potential+Multi-Targeted+Strategy+in+MCF-7+Breast+Cancer+Cells&doi=10.3892%2For.2019.7256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Monoclonal anti-MUC1 antibody with novel octahydropyrazino[2,1-a:5,4-a']diisoquinoline derivative as a potential multi-targeted strategy in MCF-7 breast cancer cells</span></div><div class="casAuthors">Gornowicz, Agnieszka; Szymanowski, Wojciech; Bielawska, Anna; Szymanowska, Anna; Czarnomysy, Robert; Kaluza, Zbigniew; Bielawski, Krzysztof</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1391-1403</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The aim of the present study was to examine the multi-targeted potential of a monoclonal antibody against mucin-1 (MUC1) and novel octahydropyrazin[2,1-a:5,4-a'] diisoquinoline deriv. (OM-86II) in estrogen receptor-pos. MCF-7 human breast cancer cells.  The cell viability was measured by an MTT assay.  The analyses of cell cycle and disruption of mitochondrial membrane potential were performed by flow cytometry.  Fluorescent microscopy and flow cytometry were used to demonstrate the effect of the compds. on apoptosis.  ELISA was conducted to check the concns. of proteins involved in multiple intracellular signaling pathways, responsible for the promotion of tumor growth and breast cancer progression, namely matrix metalloproteinase (MMP)-2, matrix MMP-9, tumor necrosis factor-α (TNF-α), cyclooxygenase-2 (COX-2), sol. intercellular adhesion mol. 1 (sICAM1) and mTOR.  The combination therapy based on anti-MUC1 antibody and novel OM-86II inhibited the proliferation of MCF-7 breast cancer cells.  Its inhibitory effects were assocd. with the induction of cell cycle arrest and apoptosis.  It was demonstrated that anti-MUC1 antibody with OM-86II decreased the concns. of MMP-2, MMP-9, sICAM1 and mTOR.  In addn., the combined therapy exhibited anti inflammatory activity, which was demonstrated by a decrease in TNF-α and COX-2 concns.  The present data provided evidence that the combination of anti-MUC1 antibody with novel OM-86II represents a multi-targeted strategy in MCF-7 breast cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnmyS4F66MoLVg90H21EOLACvtfcHk0ljwmw9fzJUqQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVOrur7N&md5=4ad21b4bd41e99fccb502a5a78e5f9e0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3892%2For.2019.7256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2019.7256%26sid%3Dliteratum%253Aachs%26aulast%3DGornowicz%26aufirst%3DA.%26aulast%3DSzymanowski%26aufirst%3DW.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DSzymanowska%26aufirst%3DA.%26aulast%3DCzarnomysy%26aufirst%3DR.%26aulast%3DKaluza%26aufirst%3DZ.%26aulast%3DBielawski%26aufirst%3DK.%26atitle%3DMonoclonal%2520Anti-MUC1%2520Antibody%2520with%2520Novel%2520Octahydropyrazino%255B2%252C1-a%253A5%252C4-a%25E2%2580%25B2%255Ddiisoquinoline%2520Derivative%2520as%2520a%2520Potential%2520Multi-Targeted%2520Strategy%2520in%2520MCF-7%2520Breast%2520Cancer%2520Cells%26jtitle%3DOncol.%2520Rep.%26date%3D2019%26volume%3D42%26spage%3D1391%26epage%3D1403%26doi%3D10.3892%2For.2019.7256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghasemi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeidi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohtashami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashemy, S. I.</span></span> <span> </span><span class="NLM_article-title">Estrogen-Independent Role of ERα in Ovarian Cancer Progression Induced by Leptin/Ob-Rb Axis</span>. <i>Mol. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>458</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1007/s11010-019-03544-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1007%2Fs11010-019-03544-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=31077012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSqsrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=458&publication_year=2019&pages=207-217&author=A.+Ghasemiauthor=J.+Saeidiauthor=M.+Mohtashamiauthor=S.+I.+Hashemy&title=Estrogen-Independent+Role+of+ER%CE%B1+in+Ovarian+Cancer+Progression+Induced+by+Leptin%2FOb-Rb+Axis&doi=10.1007%2Fs11010-019-03544-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen-independent role of ERα in ovarian cancer progression induced by leptin/Ob-Rb axis</span></div><div class="casAuthors">Ghasemi, Ahmad; Saeidi, Jafar; Mohtashami, Mahnaz; Hashemy, Seyed Isaac</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">458</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">207-217</span>CODEN:
                <span class="NLM_cas:coden">MCBIB8</span>;
        ISSN:<span class="NLM_cas:issn">0300-8177</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The present study was designed to evaluate the E2-independent effect of ERα/β on leptin-mediated cell invasion and cell proliferation in ovarian cancer.  We utilized SKOV3 cancer (expressing OB-Rb and ERα/β, insensitive to estrogen) and OVCAR3 (expressing OB-Rb) cell lines to show the involvement of ER in leptin-mediated effects in an E2-independent manner.  MTT, BrdU, and BD matrigel invasion assays were applied to analyze cell growth, proliferation, and invasion.  The siRNA approach was used to confirm the role of ERα/β in leptin effects.  Moreover, western blotting and Real-time PCR were employed to detect the OB-Rb, ER, MMP9/7, and upA proteins and mRNAs.  Leptin, in the absence of E2, increased ERα expression in SKOV3 cells, which was attenuated using knockdown of OB-Rb gene by siRNA.  The effect of leptin on the cell growth was promoted in the presence of PPT, but not in the presence of DNP and E2, which was lost when OB-Rb siRNA was transfected.  Furthermore, ERα gene silencing and/or pre-incubation with ER antagonist (ICI 182,780, 10 nM) significantly reduced cell invasion and MMP9 expression stimulated by leptin.  In conclusion, our findings demonstrated that ERα, but not ERβ, is involved in leptin-induced ovarian cancer in an E2-independent manner, providing new evidence for cancer progression in obesity-assocd. ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodd53zranoz7Vg90H21EOLACvtfcHk0ljwmw9fzJUqQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSqsrvN&md5=567fe5723be71002d3ff25335addab22</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs11010-019-03544-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11010-019-03544-5%26sid%3Dliteratum%253Aachs%26aulast%3DGhasemi%26aufirst%3DA.%26aulast%3DSaeidi%26aufirst%3DJ.%26aulast%3DMohtashami%26aufirst%3DM.%26aulast%3DHashemy%26aufirst%3DS.%2BI.%26atitle%3DEstrogen-Independent%2520Role%2520of%2520ER%25CE%25B1%2520in%2520Ovarian%2520Cancer%2520Progression%2520Induced%2520by%2520Leptin%252FOb-Rb%2520Axis%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2019%26volume%3D458%26spage%3D207%26epage%3D217%26doi%3D10.1007%2Fs11010-019-03544-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilder, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shajahan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khattar, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilder, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rushing, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaven, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaetzel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueland, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Nagell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryscio, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lele, S. M.</span></span> <span> </span><span class="NLM_article-title">Tamoxifen-Associated Malignant Endometrial Tumors: Pathologic Features and Expression of Hormone Receptors Estrogen-α, Estrogen-β and Progesterone; A Case Controlled Study</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1016/j.ygyno.2003.10.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.ygyno.2003.10.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=14766247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptV2rug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2004&pages=553-558&author=J.+L.+Wilderauthor=S.+Shajahanauthor=N.+H.+Khattarauthor=D.+M.+Wilderauthor=J.+Yinauthor=R.+S.+Rushingauthor=R.+Beavenauthor=C.+Kaetzelauthor=F.+R.+Uelandauthor=J.+R.+van+Nagellauthor=R.+J.+Kryscioauthor=S.+M.+Lele&title=Tamoxifen-Associated+Malignant+Endometrial+Tumors%3A+Pathologic+Features+and+Expression+of+Hormone+Receptors+Estrogen-%CE%B1%2C+Estrogen-%CE%B2+and+Progesterone%3B+A+Case+Controlled+Study&doi=10.1016%2Fj.ygyno.2003.10.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-α, estrogen-β and progesterone; a case controlled study</span></div><div class="casAuthors">Wilder, James L.; Shajahan, Shahin; Khattar, Nada H.; Wilder, Dawn M.; Yin, Jianming; Rushing, Rodney S.; Beaven, Rick; Kaetzel, Charlotte; Ueland, Frederick R.; van Nagell, John R.; Kryscio, Richard J.; Lele, Subodh M.</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">553-558</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">Objective: Expression anal. of estrogen receptor-beta (ER-β) and estrogen receptor-alpha (ER-α) in tamoxifen-assocd. malignant endometrial tumors (TAMET) has not previously been published.  Antiestrogens complexed with ER-β have been reported to result in activation of the activator protein-1 (AP-1) pathway that may result in cell proliferation and tumor growth.  In this study, the pathol. features and expression of ER-α, ER-β and progesterone receptor (PR) in TAMET were detd. and compared to matched cases of non-tamoxifen-assocd. endometrial cancers.  Methods: TAMET (n = 33) were evaluated for pathol. features (tumor type, grade, depth of myometrial invasion, lymph-vascular space invasion and lymph node status), expression of ER-α, ER-β and PR, and survival data (mean follow-up: 28.7 mo).  Each case was matched to two control patients with spontaneous endometrial cancers according to tumor type, grade and stage as well as patient age and wt. (mean follow-up: 51.5 mo).  Formalin-fixed paraffin-embedded tissue sections were immunostained with anti-ER-α (1D5, Dako, Carpinteria, CA) and anti-PR (PgR636, Dako).  Expression scores were detd. as a sum of the product of staining intensity and proportion of cells staining (H-score).  Deparaffinized sections of tumor were microdissected followed by RNA isolation.  Quantification of ER-β mRNA was performed by real-time quant. RT-PCR with results expressed as a percentage of β-actin mRNA.  Results: Of the 33 cases 20 were endometrioid (8 grade 1, 10 grade 2, 2 grade 3), 9 papillary serous and 4 malignant mullerian mixed tumors.  Using a multivariate conditional regression model, TAMET had lower ER-α expression (P = 0.018), higher PR expression (P = 0.029), and more frequent expression of ER-β (P = 0.032) as compared to control cases.  Cases with TAMET had more deaths from cancer and significantly worse survival from disease than controls (P = 0.01 by a log rank test).  Conclusion: TAMET are characterized by a lower expression of ER-α, higher expression of PR and more frequent expression of ER-β as compared to spontaneous tumors.  Differential expression of ER-α and ER-β may alter the expression of key target genes (such as those induced by AP-1-dependent gene transcription), and contribute to the pathogenesis and clin. behavior of these tumors.  Survival from disease was significantly worse for cases with TAMET as compared to controls.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfx490_iAxSLVg90H21EOLACvtfcHk0ljwmw9fzJUqQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptV2rug%253D%253D&md5=41223c87f69fad44a572052b4a119fc9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2003.10.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2003.10.040%26sid%3Dliteratum%253Aachs%26aulast%3DWilder%26aufirst%3DJ.%2BL.%26aulast%3DShajahan%26aufirst%3DS.%26aulast%3DKhattar%26aufirst%3DN.%2BH.%26aulast%3DWilder%26aufirst%3DD.%2BM.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DRushing%26aufirst%3DR.%2BS.%26aulast%3DBeaven%26aufirst%3DR.%26aulast%3DKaetzel%26aufirst%3DC.%26aulast%3DUeland%26aufirst%3DF.%2BR.%26aulast%3Dvan%2BNagell%26aufirst%3DJ.%2BR.%26aulast%3DKryscio%26aufirst%3DR.%2BJ.%26aulast%3DLele%26aufirst%3DS.%2BM.%26atitle%3DTamoxifen-Associated%2520Malignant%2520Endometrial%2520Tumors%253A%2520Pathologic%2520Features%2520and%2520Expression%2520of%2520Hormone%2520Receptors%2520Estrogen-%25CE%25B1%252C%2520Estrogen-%25CE%25B2%2520and%2520Progesterone%253B%2520A%2520Case%2520Controlled%2520Study%26jtitle%3DGynecol.%2520Oncol.%26date%3D2004%26volume%3D92%26spage%3D553%26epage%3D558%26doi%3D10.1016%2Fj.ygyno.2003.10.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, O. P.</span></span> <span> </span><span class="NLM_article-title">Estrogen Receptor 1 Mutations in 260 Cervical Cancer Samples from Chinese Patients</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2771</span>– <span class="NLM_lpage">2776</span>, <span class="refDoi"> DOI: 10.3892/ol.2019.10612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3892%2Fol.2019.10612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=31452755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjvFaiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=2771-2776&author=X.+M.+Yangauthor=Z.+M.+Wuauthor=H.+Huangauthor=X.+Y.+Chuauthor=J.+Louauthor=L.+X.+Xuauthor=Y.+T.+Chenauthor=L.+Q.+Wangauthor=O.+P.+Huang&title=Estrogen+Receptor+1+Mutations+in+260+Cervical+Cancer+Samples+from+Chinese+Patients&doi=10.3892%2Fol.2019.10612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor 1 mutations in 260 cervical cancer samples from Chinese patients</span></div><div class="casAuthors">Yang, Xin-Min; Wu, Zhi-Min; Huang, Huang; Chu, Xiao-Yan; Lou, Jun; Xu, Li-Xian; Chen, Yuan-Ting; Wang, Li-Qun; Huang, Ou-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2771-2776</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1082</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Cervical cancer is one of the leading causes of cancer-assocd. mortality among females; however, the underlying mol. mechanisms of its carcinogenesis remain largely unclear.  Previous comprehensive genomic studies have revealed prevalent estrogen receptor 1 (ESR1) mutations in breast cancer, which are rare in certain other types of cancer.  To the best of our knowledge, it is unknown whether ESR1 mutations also exist in cervical cancer.  Considering the evidence that cervical cancer shares certain genetic aberrations with breast cancer, and that the progression of both breast and cervical cancers can be affected by estrogen, it is possible that cervical cancer may also harbor ESR1 mutations.  In the present study, a total of 260 Chinese cervical cancer samples with distinct subtypes were tested for the presence of ESR1 mutations.  A total of three heterozygous missense ESR1 mutations, p.K303R (c.908A>G), p.T311M (c.932C>T) and p.Y537C (c.1610A>G), were identified in 3/207 (1.4%) cervical squamous cell carcinoma samples, which were absent in 27 adenosquamous carcinomas and 26 adenocarcinomas samples.  Of the three individuals with an ESR1mutation, 1 patient was also diagnosed with ovarian endometriosis and the other 2 patients were diagnosed with a uterine fibroid.  A bioinformatics anal. suggested that these ESR1 mutations may be pathogenic by promoting the development of cervical cancer.  Furthermore, a previous comprehensive study confirmed that individuals with cervical squamous cell carcinoma possessed ESR1 mutations.  These combined studies indicate that ESR1 mutations may participate in the carcinogenesis of cervical squamous cell carcinoma, albeit at a low frequency.  In conclusion, the present study identified three potentially pathogenic ESR1 mutations in Chinese cervical squamous cell carcinoma samples, but not in other subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr80XndRdfJ-bVg90H21EOLACvtfcHk0lhHinytwvxbnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjvFaiurg%253D&md5=bce4a98bc70904e4150b149bb087139b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3892%2Fol.2019.10612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2019.10612%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%2BM.%26aulast%3DWu%26aufirst%3DZ.%2BM.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DChu%26aufirst%3DX.%2BY.%26aulast%3DLou%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DL.%2BX.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DWang%26aufirst%3DL.%2BQ.%26aulast%3DHuang%26aufirst%3DO.%2BP.%26atitle%3DEstrogen%2520Receptor%25201%2520Mutations%2520in%2520260%2520Cervical%2520Cancer%2520Samples%2520from%2520Chinese%2520Patients%26jtitle%3DOncol.%2520Lett.%26date%3D2019%26volume%3D18%26spage%3D2771%26epage%3D2776%26doi%3D10.3892%2Fol.2019.10612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaturantabut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shwartz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evason, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labella, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepers, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acuna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houvras, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancio-Silva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelick, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zon, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goessling, W.</span></span> <span> </span><span class="NLM_article-title">Estrogen Activation of G-Protein-Coupled Estrogen Receptor 1 Regulates Phosphoinositide 3-Kinase and mTOR Signaling to Promote Liver Growth in Zebrafish and Proliferation of Human Hepatocytes</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2019.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1053%2Fj.gastro.2019.01.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2019&pages=1-17&author=S.+Chaturantabutauthor=A.+Shwartzauthor=K.+J.+Evasonauthor=A.+G.+Coxauthor=K.+Labellaauthor=A.+G.+Schepersauthor=S.+Yangauthor=M.+Acunaauthor=Y.+Houvrasauthor=L.+Mancio-Silvaauthor=S.+Romanoauthor=D.+A.+Gorelickauthor=D.+E.+Cohenauthor=L.+I.+Zonauthor=S.+N.+Bhatiaauthor=T.+E.+Northauthor=W.+Goessling&title=Estrogen+Activation+of+G-Protein-Coupled+Estrogen+Receptor+1+Regulates+Phosphoinositide+3-Kinase+and+mTOR+Signaling+to+Promote+Liver+Growth+in+Zebrafish+and+Proliferation+of+Human+Hepatocytes&doi=10.1053%2Fj.gastro.2019.01.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2019.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2019.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DChaturantabut%26aufirst%3DS.%26aulast%3DShwartz%26aufirst%3DA.%26aulast%3DEvason%26aufirst%3DK.%2BJ.%26aulast%3DCox%26aufirst%3DA.%2BG.%26aulast%3DLabella%26aufirst%3DK.%26aulast%3DSchepers%26aufirst%3DA.%2BG.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DAcuna%26aufirst%3DM.%26aulast%3DHouvras%26aufirst%3DY.%26aulast%3DMancio-Silva%26aufirst%3DL.%26aulast%3DRomano%26aufirst%3DS.%26aulast%3DGorelick%26aufirst%3DD.%2BA.%26aulast%3DCohen%26aufirst%3DD.%2BE.%26aulast%3DZon%26aufirst%3DL.%2BI.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26aulast%3DNorth%26aufirst%3DT.%2BE.%26aulast%3DGoessling%26aufirst%3DW.%26atitle%3DEstrogen%2520Activation%2520of%2520G-Protein-Coupled%2520Estrogen%2520Receptor%25201%2520Regulates%2520Phosphoinositide%25203-Kinase%2520and%2520mTOR%2520Signaling%2520to%2520Promote%2520Liver%2520Growth%2520in%2520Zebrafish%2520and%2520Proliferation%2520of%2520Human%2520Hepatocytes%26jtitle%3DGastroenterology%26date%3D2019%26volume%3D156%26spage%3D1%26epage%3D17%26doi%3D10.1053%2Fj.gastro.2019.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. B.</span></span> <span> </span><span class="NLM_article-title">Prognostic Role of Estrogen Receptor α and Estrogen Receptor beta in Gastric Cancer</span>. <i>Ann. Surg. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2503</span>– <span class="NLM_lpage">2509</span>, <span class="refDoi"> DOI: 10.1245/s10434-010-1031-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1245%2Fs10434-010-1031-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=20339947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BC3cjmtVCksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=2503-2509&author=C.+Y.+Xuauthor=J.+L.+Guoauthor=Z.+N.+Jiangauthor=S.+D.+Xieauthor=J.+G.+Shenauthor=J.+Y.+Shenauthor=L.+B.+Wang&title=Prognostic+Role+of+Estrogen+Receptor+%CE%B1+and+Estrogen+Receptor+beta+in+Gastric+Cancer&doi=10.1245%2Fs10434-010-1031-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic role of estrogen receptor alpha and estrogen receptor beta in gastric cancer</span></div><div class="casAuthors">Xu C Y; Guo J L; Jiang Z N; Xie S D; Shen J G; Shen J Y; Wang L B</div><div class="citationInfo"><span class="NLM_cas:title">Annals of surgical oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2503-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The presence of estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta) have been reported in cell and tissue level in gastric cancer, but its impact on patients' survival remains unclear.  This study was designed to investigate the expression level of ERalpha and ERbeta and to assess clinical significance of ERalpha and ERbeta expression in gastric cancer.  METHODS:  The expression level of ERalpha and ERbeta were assessed by reverse-transcriptase polymerase chain reaction (RT-PCR) in 35 surgically resected gastric cancer and corresponding normal tissues and by immunohistochemical staining in 211 surgically resected gastric cancer and match normal tissues.  RESULTS:  The expression level between ERalpha mRNA expression in gastric cancer tissues and match normal tissues had no statistically significant difference.  The ERbeta mRNA level in normal tissues was significantly higher than that observed in gastric cancer tissues (P = 0.001).  Neither ERalpha nor ERbeta mRNA expression levels had significant correlation with clinicopathologic parameters.  Forty-eight of 211 (22.7%) gastric cancer tissues showed positive expression of ERalpha and ERbeta detected in gastric cancer.  ERalpha-positive expression correlated with poorer overall survival (P = 0.014), as did the absence of ERbeta expression in patients with gastric cancer (P = 0.001).  In multivariate analysis, the positive expression of ERalpha and the absence of ERbeta were significant independent prognostic factors for overall survival (hazard ratio 2.159, P = 0.013, and hazard ratio 2.016, P = 0.025 respectively).  CONCLUSIONS:  Our results indicated that ERalpha and ERbeta were expressed in both gastric cancer and corresponding normal tissues.  ERalpha expression and the absence of ERbeta expression are associated with poor survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIclrO6TQgB5PlX7E30qdzfW6udTcc2ebvh_r2W3CmRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjmtVCksw%253D%253D&md5=92664c4e682b25d838bdfa9a6cf9fbd3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1245%2Fs10434-010-1031-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1245%252Fs10434-010-1031-2%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DC.%2BY.%26aulast%3DGuo%26aufirst%3DJ.%2BL.%26aulast%3DJiang%26aufirst%3DZ.%2BN.%26aulast%3DXie%26aufirst%3DS.%2BD.%26aulast%3DShen%26aufirst%3DJ.%2BG.%26aulast%3DShen%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DL.%2BB.%26atitle%3DPrognostic%2520Role%2520of%2520Estrogen%2520Receptor%2520%25CE%25B1%2520and%2520Estrogen%2520Receptor%2520beta%2520in%2520Gastric%2520Cancer%26jtitle%3DAnn.%2520Surg.%2520Oncol.%26date%3D2010%26volume%3D17%26spage%3D2503%26epage%3D2509%26doi%3D10.1245%2Fs10434-010-1031-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, S. H.</span></span> <span> </span><span class="NLM_article-title">Estrogen, Estrogen Receptor and Lung Cancer</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>, <span class="NLM_elocation-id">1713</span> <span class="refDoi"> DOI: 10.3390/ijms18081713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3390%2Fijms18081713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWgu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&author=L.+H.+Hsuauthor=N.+M.+Chuauthor=S.+H.+Kao&title=Estrogen%2C+Estrogen+Receptor+and+Lung+Cancer&doi=10.3390%2Fijms18081713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen, estrogen receptor and lung cancer</span></div><div class="casAuthors">Hsu, Li-Han; Chu, Nei-Min; Kao, Shu-Huei</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1713/1-1713/17</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Estrogen has been postulated as a contributor for lung cancer development and progression.  We reviewed the current knowledge about the expression and prognostic implications of the estrogen receptors (ER) in lung cancer, the effect and signaling pathway of estrogen on lung cancer, the hormone replacement therapy and lung cancer risk and survival, the mechanistic relationship between the ER and the epidermal growth factor receptor (EGFR), and the relevant clin. trials combining the ER antagonist and the EGFR antagonist, to investigate the role of estrogen in lung cancer.  Estrogen and its receptor have the potential to become a prognosticator and a therapeutic target in lung cancer.  On the other hand, tobacco smoking aggravates the effect of estrogen and endocrine disruptive chems. from the environment targeting ER may well contribute to the lung carcinogenesis.  They have gradually become important issues in the course of preventive medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhkIb2iEDMi7Vg90H21EOLACvtfcHk0liaXgbSTEuRNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWgu7fN&md5=6a4b45e178f28aebe507db8a8af401fa</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3390%2Fijms18081713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18081713%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DL.%2BH.%26aulast%3DChu%26aufirst%3DN.%2BM.%26aulast%3DKao%26aufirst%3DS.%2BH.%26atitle%3DEstrogen%252C%2520Estrogen%2520Receptor%2520and%2520Lung%2520Cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26doi%3D10.3390%2Fijms18081713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foley, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jazaeri, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shupnik, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jazaeri, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, L. W.</span></span> <span> </span><span class="NLM_article-title">Selective Loss of Estrogen Receptor β in Malignant Human Colon</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">248</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10667568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtVahsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=245-248&author=E.+F.+Foleyauthor=A.+A.+Jazaeriauthor=M.+A.+Shupnikauthor=O.+Jazaeriauthor=L.+W.+Rice&title=Selective+Loss+of+Estrogen+Receptor+%CE%B2+in+Malignant+Human+Colon"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Selective loss of estrogen receptor β in malignant human colon</span></div><div class="casAuthors">Foley, Eugene F.; Jazaeri, Amir A.; Shupnik, Margaret A.; Jazaeri, Omid; Rice, Laurel W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-248</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Epidemiol. data suggest a protective effect for estrogen replacement therapy on colon cancer.  The ER-β isoform is functionally similar to ER-α but has a distinct pattern of expression and transcriptional response to selective estrogen response modulators.  The authors' goal was to investigate the presence of ER-α and ER-β in normal and malignant colon tissue.  Human colon cancer tissue and adjacent normal colon tissue were harvested from five male and six female patients undergoing segmental colon resection for colon cancer.  Western blot anal. revealed very low levels of ER-α protein in tumor and normal colon tissue.  In both male and female patients, malignant colon tissue showed a selective loss of ER-β protein expression when compared to normal colon tissue in the same patient.  Semiquant. reverse transcription-PCR revealed no difference in ER-β mRNA levels between normal and malignant colon tissue.  Malignant transformation of the colon is assocd. with a marked diminution of ER-β protein expression, possibly through a posttranscriptional mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYQq9J7Jcn-LVg90H21EOLACvtfcHk0liaXgbSTEuRNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtVahsro%253D&md5=0cc9bc561c56ffa131999db98dfb1513</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFoley%26aufirst%3DE.%2BF.%26aulast%3DJazaeri%26aufirst%3DA.%2BA.%26aulast%3DShupnik%26aufirst%3DM.%2BA.%26aulast%3DJazaeri%26aufirst%3DO.%26aulast%3DRice%26aufirst%3DL.%2BW.%26atitle%3DSelective%2520Loss%2520of%2520Estrogen%2520Receptor%2520%25CE%25B2%2520in%2520Malignant%2520Human%2520Colon%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D245%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pasqualini, J. R.</span></span> <span> </span><span class="NLM_article-title">The Selective Estrogen Enzyme Modulators in Breast Cancer: A Review</span>. <i>Biochim. Biophys. Acta, Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1654</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1016/j.bbcan.2004.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.bbcan.2004.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=15172700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVCitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1654&publication_year=2004&pages=123-143&author=J.+R.+Pasqualini&title=The+Selective+Estrogen+Enzyme+Modulators+in+Breast+Cancer%3A+A+Review&doi=10.1016%2Fj.bbcan.2004.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">The selective estrogen enzyme modulators in breast cancer: a review</span></div><div class="casAuthors">Pasqualini, Jorge R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1654</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-143</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  It is well established that increased exposure to estradiol (E2) is an important risk factor for the genesis and evolution of breast tumors, most of which (approx. 95-97%) in their early stage are estrogen-sensitive.  However, two thirds of breast cancers occur during the postmenopausal period when the ovaries have ceased to be functional.  Despite the low levels of circulating estrogens, the tissular concns. of these hormones are significantly higher than those found in the plasma or in the area of the breast considered as normal tissue, suggesting a specific tumoral biosynthesis and accumulation of these hormones.  Several factors could be implicated in this process, including higher uptake of steroids from plasma and local formation of the potent E2 by the breast cancer tissue itself.  This information extends the concept of intracrinol. where a hormone can have its biol. response in the same organ where it is produced.  There is substantial information that mammary cancer tissue contains all the enzymes responsible for the local biosynthesis of E2 from circulating precursors.  Two principal pathways are implicated in the last steps of E2 formation in breast cancer tissues: the aromatase pathway which transforms androgens into estrogens, and the sulfatase pathway which converts estrone sulfate (E1S) into E1 by the estrone-sulfatase.  The final step of steroidogenesis is the conversion of the weak E1 to the potent biol. active E2 by the action of a reductive 17β-hydroxysteroid dehydrogenase type 1 activity (17β-HSD-1).  Quant. evaluation indicates that in human breast tumor E1S via sulfatase is a much more likely precursor for E2 than is androgens via aromatase.  Human breast cancer tissue contains all the enzymes (estrone sulfatase, 17β-hydroxysteroid dehydrogenase, aromatase) involved in the last steps of E2 biosynthesis.  This tissue also contains sulfotransferase for the formation of the biol. inactive estrogen sulfates.  In recent years, it was demonstrated that various progestins (promegestone, nomegestrol acetate, medrogestone, dydrogesterone, norelgestromin), tibolone and its metabolites, as well as other steroidal (e.g., sulfamates) and non-steroidal compds., are potent sulfatase inhibitors.  Various progestins can also block 17β-hydroxysteroid dehydrogenase activities.  In other studies, it was shown that medrogestone, nomegestrol acetate, promegestone or tibolone can stimulate the sulfotransferase activity for the local prodn. of estrogen sulfates.  All these data, in addn. to numerous agents which can block the aromatase action, lead to the new concept of 'Selective Estrogen Enzyme Modulators' (SEEM) which can largely apply to breast cancer tissue.  The exploration of various progestins and other active agents in trials with breast cancer patients, showing an inhibitory effect on sulfatase and 17β-hydroxysteroid dehydrogenase, or a stimulatory effect on sulfotransferase and consequently on the levels of tissular levels of E2, will provide a new possibility in the treatment of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcF-MirOzz5LVg90H21EOLACvtfcHk0lg9FwfvwFlsVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVCitr8%253D&md5=667fc99e8162752fc15702951c26e15b</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2004.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2004.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DPasqualini%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520Selective%2520Estrogen%2520Enzyme%2520Modulators%2520in%2520Breast%2520Cancer%253A%2520A%2520Review%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2004%26volume%3D1654%26spage%3D123%26epage%3D143%26doi%3D10.1016%2Fj.bbcan.2004.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Roger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daures, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maudelonde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pignodel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleizes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapelle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marty-Double, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mares, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffargue, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochefort, H.</span></span> <span> </span><span class="NLM_article-title">Dissociated Overexpression of Cathepsin D and Estrogen Receptor alpha in Preinvasive Mammary Tumors</span>. <i>Hum. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1053/hp.2000.6687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1053%2Fhp.2000.6687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10836299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvFShtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2000&pages=593-600&author=P.+Rogerauthor=J.+P.+Dauresauthor=T.+Maudelondeauthor=C.+Pignodelauthor=M.+Gleizesauthor=J.+Chapelleauthor=C.+Marty-Doubleauthor=P.+Baldetauthor=P.+Maresauthor=F.+Laffargueauthor=H.+Rochefort&title=Dissociated+Overexpression+of+Cathepsin+D+and+Estrogen+Receptor+alpha+in+Preinvasive+Mammary+Tumors&doi=10.1053%2Fhp.2000.6687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors</span></div><div class="casAuthors">Roger, Pascal; Daures, Jean-Pierre; Maudelonde, Thierry; Pignodel, Christine; Gleizes, Michel; Chapelle, Jean; Marty-Double, Christiane; Baldet, Pierre; Mares, Pierre; Laffargue, Francois; Rochefort, Henri</div><div class="citationInfo"><span class="NLM_cas:title">Human Pathology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">593-600</span>CODEN:
                <span class="NLM_cas:coden">HPCQA4</span>;
        ISSN:<span class="NLM_cas:issn">0046-8177</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">The role of estrogen as a promoter agent of sporadic breast cancer has been considered by assaying, in benign breast disease (BBD) and in situ carcinomas (CIS), 2 markers, the estrogen receptor α (ERα) and cathepsin D (cath-D) involved in estrogen action on mammary tissue.  ERα and cath-D were assayed by quant. immunohistochem. using an image analyzer in 170 lesions of varying histol. risk (94 BBD and 76 CIS), and in "normal" glands close to these lesions.  The ERα level increased significantly in proliferative BBD with atypia (P < .001), in non-high-grade CIS (P < .001), and in adjacent "normal" glands.  ERα level was decreased in high-grade ductal CIS (DCIS) and also in adjacent "normal" glands.  Cath-D level increased in ductal proliferative BBD (P ≤ .01) and in high-grade DCIS (P ≤ .003), but not in the other lesions.  After menopause, ERα level was increased (P = .012) but not cath-D level.  According to Mac Neman test, the high-grade DCIS were predominantly ERα neg. and cath-D pos. (P = .0017), and the other CIS were predominantly ERα pos. and cath-D neg. (P = .0002).  The 2 markers are overexpressed early in premalignant lesions, but independently.  This dissocn. suggests a branched model of mammary carcinogenesis involving 1 estrogen-independent pathway with high cath-D and low ERα levels (including high-grade DCIS) and 1 estrogen-dependent pathway, with high ERα level (including proliferative BBD with atypia and low-grade DCIS).  We propose that ERα-neg. breast cancers may develop directly from high-grade DCIS and that ERα assay in preinvasive lesions should be considered in prevention trials with antiestrogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKc7B_4chCabVg90H21EOLACvtfcHk0lg9FwfvwFlsVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvFShtLg%253D&md5=3b09b5c0343d1c0c3e1b86df4bd3b79a</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1053%2Fhp.2000.6687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fhp.2000.6687%26sid%3Dliteratum%253Aachs%26aulast%3DRoger%26aufirst%3DP.%26aulast%3DDaures%26aufirst%3DJ.%2BP.%26aulast%3DMaudelonde%26aufirst%3DT.%26aulast%3DPignodel%26aufirst%3DC.%26aulast%3DGleizes%26aufirst%3DM.%26aulast%3DChapelle%26aufirst%3DJ.%26aulast%3DMarty-Double%26aufirst%3DC.%26aulast%3DBaldet%26aufirst%3DP.%26aulast%3DMares%26aufirst%3DP.%26aulast%3DLaffargue%26aufirst%3DF.%26aulast%3DRochefort%26aufirst%3DH.%26atitle%3DDissociated%2520Overexpression%2520of%2520Cathepsin%2520D%2520and%2520Estrogen%2520Receptor%2520alpha%2520in%2520Preinvasive%2520Mammary%2520Tumors%26jtitle%3DHum.%2520Pathol.%26date%3D2000%26volume%3D31%26spage%3D593%26epage%3D600%26doi%3D10.1053%2Fhp.2000.6687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, J.</span></span> <span> </span><span class="NLM_article-title">ER-alpha 36, A Novel Variant of Estrogen Receptor alpha, is Involved in EGFR-Related Carcinogenesis in Endometrial Cancer</span>. <i>Am. J. Obstet. Gynecol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1016/j.ajog.2011.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.ajog.2011.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=22088891" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2011&pages=1-6&author=B.+B.+Tuauthor=S.+L.+Linauthor=L.+Y.+Yanauthor=Z.+Y.+Wangauthor=Q.+Y.+Sunauthor=J.+Qiao&title=ER-alpha+36%2C+A+Novel+Variant+of+Estrogen+Receptor+alpha%2C+is+Involved+in+EGFR-Related+Carcinogenesis+in+Endometrial+Cancer&doi=10.1016%2Fj.ajog.2011.04.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1016%2Fj.ajog.2011.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajog.2011.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DB.%2BB.%26aulast%3DLin%26aufirst%3DS.%2BL.%26aulast%3DYan%26aufirst%3DL.%2BY.%26aulast%3DWang%26aufirst%3DZ.%2BY.%26aulast%3DSun%26aufirst%3DQ.%2BY.%26aulast%3DQiao%26aufirst%3DJ.%26atitle%3DER-alpha%252036%252C%2520A%2520Novel%2520Variant%2520of%2520Estrogen%2520Receptor%2520alpha%252C%2520is%2520Involved%2520in%2520EGFR-Related%2520Carcinogenesis%2520in%2520Endometrial%2520Cancer%26jtitle%3DAm.%2520J.%2520Obstet.%2520Gynecol.%26date%3D2011%26volume%3D205%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.ajog.2011.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latimer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt-Enderby, P. A.</span></span> <span> </span><span class="NLM_article-title">Melatonin and Breast Cancer: Cellular Mechanisms, Clinical Studies and Future Perspectives</span>. <i>Expert Rev. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e5</span> <span class="refDoi"> DOI: 10.1017/S1462399409000982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1017%2FS1462399409000982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=19193248" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&author=S.+G.+Grantauthor=M.+A.+Melanauthor=J.+J.+Latimerauthor=P.+A.+Witt-Enderby&title=Melatonin+and+Breast+Cancer%3A+Cellular+Mechanisms%2C+Clinical+Studies+and+Future+Perspectives&doi=10.1017%2FS1462399409000982"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1017%2FS1462399409000982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1462399409000982%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DS.%2BG.%26aulast%3DMelan%26aufirst%3DM.%2BA.%26aulast%3DLatimer%26aufirst%3DJ.%2BJ.%26aulast%3DWitt-Enderby%26aufirst%3DP.%2BA.%26atitle%3DMelatonin%2520and%2520Breast%2520Cancer%253A%2520Cellular%2520Mechanisms%252C%2520Clinical%2520Studies%2520and%2520Future%2520Perspectives%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Med.%26date%3D2009%26volume%3D11%26doi%3D10.1017%2FS1462399409000982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajapaksa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolos, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, J. A.</span></span> <span> </span><span class="NLM_article-title">Estrogen Receptor beta Inhibits Migration and Invasion of Breast Cancer Cells by Regulating E-cadherin Levels</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">2</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2&author=C.+Thomasauthor=G.+Rajapaksaauthor=F.+Nikolosauthor=J.+A.+Gustafsson&title=Estrogen+Receptor+beta+Inhibits+Migration+and+Invasion+of+Breast+Cancer+Cells+by+Regulating+E-cadherin+Levels"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DC.%26aulast%3DRajapaksa%26aufirst%3DG.%26aulast%3DNikolos%26aufirst%3DF.%26aulast%3DGustafsson%26aufirst%3DJ.%2BA.%26atitle%3DEstrogen%2520Receptor%2520beta%2520Inhibits%2520Migration%2520and%2520Invasion%2520of%2520Breast%2520Cancer%2520Cells%2520by%2520Regulating%2520E-cadherin%2520Levels%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landberg, G.</span></span> <span> </span><span class="NLM_article-title">Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1457</span>– <span class="NLM_lpage">1469</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-1583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1158%2F0008-5472.CAN-14-1583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=25833830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsleisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1457-1469&author=S.+Buschauthor=A.+H.+Simsauthor=O.+Stalauthor=M.+Fernoauthor=G.+Landberg&title=Loss+of+TGF%CE%B2+Receptor+Type+2+Expression+Impairs+Estrogen+Response+and+Confers+Tamoxifen+Resistance&doi=10.1158%2F0008-5472.CAN-14-1583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13fR"><div class="casContent"><span class="casTitleNuber">13f</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance</span></div><div class="casAuthors">Busch, Susann; Sims, Andrew H.; Stal, Olle; Fernoe, Marten; Landberg, Goeran</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1457-1469</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This important study not only advances understanding of tamoxifen resistance in breast cancer, but it also raises concerns about the use of TGFβ-targeting therapies to attack ER+ tumors, given evidence of how disruption of TGFβ signaling appears to generate endocrine resistance.  One third of the patients with estrogen receptor α (ERα)-pos. breast cancer who are treated with the antiestrogen tamoxifen will either not respond to initial therapy or will develop drug resistance.  Endocrine response involves crosstalk between ERα and TGFβ signaling, such that tamoxifen nonresponsiveness or resistance in breast cancer might involve aberrant TGFβ signaling.  In this study, we analyzed TGFβ receptor type 2 (TGFBR2) expression and correlated it with ERα status and phosphorylation in a cohort of 564 patients who had been randomized to tamoxifen or no-adjuvant treatment for invasive breast carcinoma.  We also evaluated an addnl. four independent genetic datasets in invasive breast cancer.  In all the cohorts we analyzed, we documented an assocn. of low TGFBR2 protein and mRNA expression with tamoxifen resistance.  Functional investigations confirmed that cell cycle or apoptosis responses to estrogen or tamoxifen in ERα-pos. breast cancer cells were impaired by TGFBR2 silencing, as was ERα phosphorylation, tamoxifen-induced transcriptional activation of TGFβ, and upregulation of the multidrug resistance protein ABCG2.  Acquisition of low TGFBR2 expression as a contributing factor to endocrine resistance was validated prospectively in a tamoxifen-resistant cell line generated by long-term drug treatment.  Collectively, our results established a central contribution of TGFβ signaling in endocrine resistance in breast cancer and offered evidence that TGFBR2 can serve as an independent biomarker to predict treatment outcomes in ERα-pos. forms of this disease.  Cancer Res; 75(7); 1457-69. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm2HO3eedBYbVg90H21EOLACvtfcHk0lhKaFG8WU2jZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsleisLc%253D&md5=dd086c6cd8aaaf83618b046e533f00f3</span></div><a href="/servlet/linkout?suffix=cit13f&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1583%26sid%3Dliteratum%253Aachs%26aulast%3DBusch%26aufirst%3DS.%26aulast%3DSims%26aufirst%3DA.%2BH.%26aulast%3DStal%26aufirst%3DO.%26aulast%3DFerno%26aufirst%3DM.%26aulast%3DLandberg%26aufirst%3DG.%26atitle%3DLoss%2520of%2520TGF%25CE%25B2%2520Receptor%2520Type%25202%2520Expression%2520Impairs%2520Estrogen%2520Response%2520and%2520Confers%2520Tamoxifen%2520Resistance%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D1457%26epage%3D1469%26doi%3D10.1158%2F0008-5472.CAN-14-1583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, S. R.</span></span> <span> </span><span class="NLM_article-title">Drugs for the Gynecologist to Prescribe in the Prevention of Breast Cancer: Current Status and Future Trends</span>. <i>Am. J. Obstet. Gynecol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1126</span>, <span class="refDoi"> DOI: 10.1067/mob.2000.105941</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1067%2Fmob.2000.105941" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10819845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BD3c3nvFOhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2000&pages=1121-1126&author=S.+R.+Goldstein&title=Drugs+for+the+Gynecologist+to+Prescribe+in+the+Prevention+of+Breast+Cancer%3A+Current+Status+and+Future+Trends&doi=10.1067%2Fmob.2000.105941"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs for the gynecologist to prescribe in the prevention of breast cancer: current status and future trends</span></div><div class="casAuthors">Goldstein S R</div><div class="citationInfo"><span class="NLM_cas:title">American journal of obstetrics and gynecology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1121-6</span>
        ISSN:<span class="NLM_cas:issn">0002-9378</span>.
    </div><div class="casAbstract">Tamoxifen was approved for breast cancer prevention in October 1998.  Thus, for the first time, we as gynecologists are being asked to prescribe this drug to healthy women.  In the past each one of us has cared for women with breast cancer who have been treated with tamoxifen by oncologists or breast surgeons for the malignancy.  Effects of tamoxifen on the uterus resulting in carcinomas, hyperplasia, and polyps are well known.  Furthermore, tamoxifen has estrogenic properties in the venous system, increasing the incidence of deep vein thrombosis and pulmonary emboli.  A new SERM (selective estrogen receptor modulator), raloxifene, has been approved for prevention and treatment of osteoporosis in postmenopausal women.  It does not have stimulatory effects on the endometrium; however, it is estrogenic in the venous system.  Preclinical data, as well as the breast cancer incidence reported in studies of the skeleton, seem to indicate that its effects in the breast are similar to those of tamoxifen.  This article reviews tamoxifen and the new SERM, raloxifene, in an attempt to help gynecologists better understand each compound and what data are currently known, what we hope to learn from future studies, and what currently makes sense for clinical practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTln8cwbv12mf9pSBfyDvp7fW6udTcc2ebkuQzsR_xntbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3nvFOhtA%253D%253D&md5=4fd9b209e80195111d7d6389ee931d18</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1067%2Fmob.2000.105941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmob.2000.105941%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DS.%2BR.%26atitle%3DDrugs%2520for%2520the%2520Gynecologist%2520to%2520Prescribe%2520in%2520the%2520Prevention%2520of%2520Breast%2520Cancer%253A%2520Current%2520Status%2520and%2520Future%2520Trends%26jtitle%3DAm.%2520J.%2520Obstet.%2520Gynecol.%26date%3D2000%26volume%3D182%26spage%3D1121%26epage%3D1126%26doi%3D10.1067%2Fmob.2000.105941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lorizio, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerlikowske, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv, E.</span></span> <span> </span><span class="NLM_article-title">Clinical and Biomarker Predictors of Side Effects from Tamoxifen</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1118</span>, <span class="refDoi"> DOI: 10.1007/s10549-011-1893-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1007%2Fs10549-011-1893-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=22207277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFWgsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2012&pages=1107-1118&author=W.+Lorizioauthor=A.+H.+Wuauthor=M.+S.+Beattieauthor=H.+Rugoauthor=S.+Tchuauthor=K.+Kerlikowskeauthor=E.+Ziv&title=Clinical+and+Biomarker+Predictors+of+Side+Effects+from+Tamoxifen&doi=10.1007%2Fs10549-011-1893-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and biomarker predictors of side effects from tamoxifen</span></div><div class="casAuthors">Lorizio, Wendy; Wu, Alan H. B.; Beattie, Mary S.; Rugo, Hope; Tchu, Simone; Kerlikowske, Karla; Ziv, Elad</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1107-1118</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Tamoxifen decreases breast cancer recurrence, mortality, and breast cancer risk in high-risk women.  Despite these proven benefits, tamoxifen use is often limited due to side effects.  We identified predictors of tamoxifen-induced side effects based on clin. variables and serum tamoxifen metabolite biomarkers in a cross-sectional study of patients taking tamoxifen.  We enrolled 241 women and collected data on demographics, tamoxifen use and side effects, as well as potential clin. and serum predictors.  We used logistic regression models and adjusted for age, body mass index, ethnicity, education, prior post-menopausal hormone therapy (HT), tamoxifen duration, and endoxifen levels to identify factors assocd. with side effects.  Common tamoxifen attributed side effects were hot flashes (64%), vaginal dryness (35%), sleep problems (36%), wt. gain (6%), and depression, irritability or mood swings (6%).  In multi-variate models, tamoxifen duration, age, prior post-menopausal HT, and endoxifen levels all predicted side effects.  Women who had been on tamoxifen for >12 mo were less likely to report side effects (OR 0.15, 95% CI 0.04-0.58) or severe side effects (OR 0.05, 95% CI 0.005-0.58) compared to women on tamoxifen for <12 mo.  Compared to women younger than 50, women who were age 60-70 and older than 70 were less likely to report side effects (OR 0.22, 95% CI 0.03-1.35; OR 0.13, 95% CI 0.01-0.99; resp.).  Women who previously took post-menopausal HT were more likely to report severe side effects.  Women with higher endoxifen levels were more likely to report side effects (OR 1.67, 95% CI 1.01-2.77 per std. deviation increase in endoxifen).  Clinicians should consider closely monitoring adherence in women taking tamoxifen, esp. in younger women, and women who previously took HT.  The assocn. between endoxifen levels and side effects is consistent with the data that suggest that endoxifen is the most highly active metabolite of tamoxifen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ8fSi9MklsLVg90H21EOLACvtfcHk0lhKaFG8WU2jZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFWgsro%253D&md5=e5792fcc5ec6e4f6cc1de3703295473e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1893-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1893-4%26sid%3Dliteratum%253Aachs%26aulast%3DLorizio%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DA.%2BH.%26aulast%3DBeattie%26aufirst%3DM.%2BS.%26aulast%3DRugo%26aufirst%3DH.%26aulast%3DTchu%26aufirst%3DS.%26aulast%3DKerlikowske%26aufirst%3DK.%26aulast%3DZiv%26aufirst%3DE.%26atitle%3DClinical%2520and%2520Biomarker%2520Predictors%2520of%2520Side%2520Effects%2520from%2520Tamoxifen%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D132%26spage%3D1107%26epage%3D1118%26doi%3D10.1007%2Fs10549-011-1893-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. D.</span></span> <span> </span><span class="NLM_article-title">MiR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1159/000493964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1159%2F000493964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=30278449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2is7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=136-149&author=J.+Liauthor=M.+J.+Luauthor=J.+Jinauthor=X.+Y.+Luauthor=T.+P.+Xuauthor=S.+D.+Jin&title=MiR-449a+Suppresses+Tamoxifen+Resistance+in+Human+Breast+Cancer+Cells+by+Targeting+ADAM22&doi=10.1159%2F000493964"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22</span></div><div class="casAuthors">Li, Jun; Lu, Mingjie; Jin, Jiao; Lu, Xiyi; Xu, Tongpeng; Jin, Shidai</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">136-149</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background/Aims: Most of estrogen receptor pos. breast cancer patients respond well initially to endocrine therapies, but often develop resistance during treatment with selective estrogen receptor modulators (SERMs) such as tamoxifen.  Altered expression and functions of microRNAs (miRNAs) have been reportedly assocd. with tamoxifen resistance.  Thus, it is necessary to further elucidate the function and mechanism of miRNAs in tamoxifen resistance.  Methods: Tamoxifen sensitivity was validated by using Cell Counting Kit-8 in tamoxifen-sensitive breast cancer cells (MCF-7, T47D) and tamoxifen-resistant cells (MCF-7/TAM, T47D/ TAM).  Quant. real-time polymerase chain reaction (qRT-PCR) was performed to detect the expression level of miR-449a in tamoxifen-sensitive/-resistant cells and patient serums.  Dual-luciferase assay was used to identify the binding of miR-449a and predicted gene ADAM22.  The expression level of ADAM22 was detd. by qRT-PCR and western blotting in miR-449a /- breast cancer cells.  Subsequently, rescue expts. were carried out to identify the function of ADAM22 in miR-449a-reduced tamoxifen resistance.  Finally, Gene ontol. (GO) and Protein-protein interaction analyses were performed to evaluate the potential mechanisms of ADAM22 in regulating tamoxifen resistance.  Results: MiR-449a levels were downregulated significantly in tamoxifen-resistant breast cancer cells when compared with their parental cells, as well as in clin. breast cancer serum samples.  Overexpression of miR-449a re-sensitized the tamoxifen-resistant breast cancer cells, while inhibition of miR-449a conferred tamoxifen resistance in parental cells.  Luciferase assay identified ADAM22 as a direct target gene of miR-449a.  Addnl., silencing of ADAM22 could reverse tamoxifen resistance induced by miR-449a inhibition in ER-pos. breast cancer cells.  GO anal. results showed ADAM22 was mainly enriched in the biol. processes of cell adhesion, cell differentiation, gliogenesis and so on.  Protein-protein interaction analyses appeared that ADAM22 might regulate tamoxifen resistance through PPARG, LGI1, KRAS and LYN.  Conclusion: Decreased miR-449a causes the upregulation of ADAM22, which induces tamoxifen resistance of breast cancer cells.  These results suggest that miR-449a, functioning by targeting ADAM22, contributes to the mechanisms underlying breast cancer endocrine resistance, which may provide a potential therapeutic strategy in ER-pos. breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvLKyxaG9dULVg90H21EOLACvtfcHk0lgkGJ1QwFhFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2is7%252FP&md5=111b8ef79a762491c2e1949f6af920e6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1159%2F000493964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000493964%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DM.%2BJ.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%2BY.%26aulast%3DXu%26aufirst%3DT.%2BP.%26aulast%3DJin%26aufirst%3DS.%2BD.%26atitle%3DMiR-449a%2520Suppresses%2520Tamoxifen%2520Resistance%2520in%2520Human%2520Breast%2520Cancer%2520Cells%2520by%2520Targeting%2520ADAM22%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2018%26volume%3D50%26spage%3D136%26epage%3D149%26doi%3D10.1159%2F000493964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubocovich, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delagrange, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardinali, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olcese, J.</span></span> <span> </span><span class="NLM_article-title">International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1124/pr.110.002832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1124%2Fpr.110.002832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=20605968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=343-380&author=M.+L.+Dubocovichauthor=P.+Delagrangeauthor=D.+N.+Krauseauthor=D.+Sugdenauthor=D.+P.+Cardinaliauthor=J.+Olcese&title=International+Union+of+Basic+and+Clinical+Pharmacology.+LXXV.+Nomenclature%2C+Classification%2C+and+Pharmacology+of+G+Protein-Coupled+Melatonin+Receptors&doi=10.1124%2Fpr.110.002832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors</span></div><div class="casAuthors">Dubocovich, Margarita L.; Delagrange, Philippe; Krause, Diana N.; Sugden, David; Cardinali, Daniel P.; Olcese, James</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">343-380</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The hormone melatonin (5-methoxy-N-acetyltryptamine) is synthesized primarily in the pineal gland and retina, and in several peripheral tissues and organs.  In the circulation, the concn. of melatonin follows a circadian rhythm, with high levels at night providing timing cues to target tissues endowed with melatonin receptors.  Melatonin receptors receive and translate melatonin's message to influence daily and seasonal rhythms of physiol. and behavior.  The melatonin message is translated through activation of two G protein-coupled receptors, MT1 and MT2, that are potential therapeutic targets in disorders ranging from insomnia and circadian sleep disorders to depression, cardiovascular diseases, and cancer.  This review summarizes the steps taken since melatonin's discovery by Aaron Lerner in 1958 to functionally characterize, clone, and localize receptors in mammalian tissues.  The pharmacol. and mol. properties of the receptors are described as well as current efforts to discover and develop ligands for treatment of a no. of illnesses, including sleep disorders, depression, and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwVZWJdmiBObVg90H21EOLACvtfcHk0lgkGJ1QwFhFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbP&md5=85e94b5269c550f2509992830f6012c1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.002832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.002832%26sid%3Dliteratum%253Aachs%26aulast%3DDubocovich%26aufirst%3DM.%2BL.%26aulast%3DDelagrange%26aufirst%3DP.%26aulast%3DKrause%26aufirst%3DD.%2BN.%26aulast%3DSugden%26aufirst%3DD.%26aulast%3DCardinali%26aufirst%3DD.%2BP.%26aulast%3DOlcese%26aufirst%3DJ.%26atitle%3DInternational%2520Union%2520of%2520Basic%2520and%2520Clinical%2520Pharmacology.%2520LXXV.%2520Nomenclature%252C%2520Classification%252C%2520and%2520Pharmacology%2520of%2520G%2520Protein-Coupled%2520Melatonin%2520Receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2010%26volume%3D62%26spage%3D343%26epage%3D380%26doi%3D10.1124%2Fpr.110.002832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales-Corral, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acuna-Castroviejo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span> <span> </span><span class="NLM_article-title">Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">843</span>, <span class="refDoi"> DOI: 10.3390/ijms18040843</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3390%2Fijms18040843" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGjs7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=843&author=R.+J.+Reiterauthor=S.+A.+Rosales-Corralauthor=D.+X.+Tanauthor=D.+Acuna-Castroviejoauthor=L.+Qinauthor=S.+F.+Yangauthor=K.+Xu&title=Melatonin%2C+a+Full+Service+Anti-Cancer+Agent%3A+Inhibition+of+Initiation%2C+Progression+and+Metastasis&doi=10.3390%2Fijms18040843"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis</span></div><div class="casAuthors">Reiter, Russel J.; Rosales-Corral, Sergio A.; Tan, Dun-Xian; Acuna-Castroviejo, Dario; Qin, Lilan; Yang, Shun-Fa; Xu, Kexin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">843/1-843/47</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">There is highly credible evidence that melatonin mitigates cancer at the initiation, progression and metastasis phases.  In many cases, the mol. mechanisms underpinning these inhibitory actions have been proposed.  What is rather perplexing, however, is the large no. of processes by which melatonin reportedly restrains cancer development and growth.  These diverse actions suggest that what is being obsd. are merely epiphenomena of an underlying more fundamental action of melatonin that remains to be disclosed.  Some of the arresting actions of melatonin on cancer are clearly membrane receptor-mediated while others are membrane receptor-independent and involve direct intracellular actions of this ubiquitously-distributed mol.  While the emphasis of melatonin/cancer research has been on the role of the indoleamine in restraining breast cancer, this is changing quickly with many cancer types having been shown to be susceptible to inhibition by melatonin.  There are several facets of this research which could have immediate applications at the clin. level.  Many studies have shown that melatonin's co-administration improves the sensitivity of cancers to inhibition by conventional drugs.  Even more important are the findings that melatonin renders cancers previously totally resistant to treatment sensitive to these same therapies.  Melatonin also inhibits mol. processes assocd. with metastasis by limiting the entrance of cancer cells into the vascular system and preventing them from establishing secondary growths at distant sites.  This is of particular importance since cancer metastasis often significantly contributes to death of the patient.  Another area that deserves addnl. consideration is related to the capacity of melatonin in reducing the toxic consequences of anti-cancer drugs while increasing their efficacy.  Although this information has been available for more than a decade, it has not been adequately exploited at the clin. level.  Even if the only beneficial actions of melatonin in cancer patients are its ability to attenuate acute and long-term drug toxicity, melatonin should be used to improve the phys. wellbeing of the patients.  The exptl. findings, however, suggest that the advantages of using melatonin as a co-treatment with conventional cancer therapies would far exceed improvements in the wellbeing of the patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozdzwNs8nI5bVg90H21EOLACvtfcHk0lgkGJ1QwFhFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGjs7bP&md5=1bb28bdff4aa4e971c76c069cc72f341</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.3390%2Fijms18040843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18040843%26sid%3Dliteratum%253Aachs%26aulast%3DReiter%26aufirst%3DR.%2BJ.%26aulast%3DRosales-Corral%26aufirst%3DS.%2BA.%26aulast%3DTan%26aufirst%3DD.%2BX.%26aulast%3DAcuna-Castroviejo%26aufirst%3DD.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%2BF.%26aulast%3DXu%26aufirst%3DK.%26atitle%3DMelatonin%252C%2520a%2520Full%2520Service%2520Anti-Cancer%2520Agent%253A%2520Inhibition%2520of%2520Initiation%252C%2520Progression%2520and%2520Metastasis%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D843%26doi%3D10.3390%2Fijms18040843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Santos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Blanco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casado-Zapico, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Sanchez, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puente-Moncada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anitua, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antolin, I.</span></span> <span> </span><span class="NLM_article-title">Mechanisms Involved in the Pro-Apoptotic Effect of Melatonin in Cancer Cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">6597</span>– <span class="NLM_lpage">6613</span>, <span class="refDoi"> DOI: 10.3390/ijms14046597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3390%2Fijms14046597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=23528889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslCntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=6597-6613&author=C.+Rodriguezauthor=V.+Martinauthor=F.+Herreraauthor=G.+Garcia-Santosauthor=J.+Rodriguez-Blancoauthor=S.+Casado-Zapicoauthor=A.+M.+Sanchez-Sanchezauthor=S.+Suarezauthor=N.+Puente-Moncadaauthor=M.+J.+Anituaauthor=I.+Antolin&title=Mechanisms+Involved+in+the+Pro-Apoptotic+Effect+of+Melatonin+in+Cancer+Cells&doi=10.3390%2Fijms14046597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms involved in the pro-apoptotic effect of melatonin in cancer cells</span></div><div class="casAuthors">Rodriguez, Carmen; Martin, Vanesa; Herrera, Federico; Garcia-Santos, Guillermo; Rodriguez-Blanco, Jezabel; Casado-Zapico, Sara; Sanchez-Sanchez, Ana Maria; Suarez, Santos; Puente-Moncada, Noelia; Anitua, Maria Jose; Antolin, Isaac</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6597-6613</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  It is well established that melatonin exerts antitumoral effects in many cancer types, mostly decreasing cell proliferation at low concns.  On the other hand, induction of apoptosis by melatonin has been described in the last few years in some particular cancer types.  The cytotoxic effect occurs after its administration at high concns., and the mol. pathways involved have been only partially detd.  Moreover, a synergistic effect has been found in several cancer types when it is administered in combination with chemotherapeutic agents.  In the present review, we will summarize published work on the pro-apoptotic effect of melatonin in cancer cells and the reported mechanisms involved in such action.  We will also construct a hypothesis on how different cell signaling pathways may relate each other on account for such effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAoiJPXexfObVg90H21EOLACvtfcHk0lhr7mJ50rmzFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslCntbk%253D&md5=475b8d1d97165d1b0e41b037d9eaffa3</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.3390%2Fijms14046597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms14046597%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DV.%26aulast%3DHerrera%26aufirst%3DF.%26aulast%3DGarcia-Santos%26aufirst%3DG.%26aulast%3DRodriguez-Blanco%26aufirst%3DJ.%26aulast%3DCasado-Zapico%26aufirst%3DS.%26aulast%3DSanchez-Sanchez%26aufirst%3DA.%2BM.%26aulast%3DSuarez%26aufirst%3DS.%26aulast%3DPuente-Moncada%26aufirst%3DN.%26aulast%3DAnitua%26aufirst%3DM.%2BJ.%26aulast%3DAntolin%26aufirst%3DI.%26atitle%3DMechanisms%2520Involved%2520in%2520the%2520Pro-Apoptotic%2520Effect%2520of%2520Melatonin%2520in%2520Cancer%2520Cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2013%26volume%3D14%26spage%3D6597%26epage%3D6613%26doi%3D10.3390%2Fijms14046597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabner, B.</span></span> <span> </span><span class="NLM_article-title">Role of Pineal Gland in Aetiology and Treatment of Breast Cancer</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">814</span>– <span class="NLM_lpage">816</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(78)92591-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2FS0140-6736%2878%2992591-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=81365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADyaE1MXhvVCmsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1978&pages=814-816&author=M.+Cohenauthor=M.+Lippmanauthor=B.+Chabner&title=Role+of+Pineal+Gland+in+Aetiology+and+Treatment+of+Breast+Cancer&doi=10.1016%2FS0140-6736%2878%2992591-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Role of pineal gland in etiology and treatment of breast cancer</span></div><div class="casAuthors">Cohen, Michael; Lippman, Marc; Chabner, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8094</span>),
    <span class="NLM_cas:pages">814-16</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0023-7507</span>.
    </div><div class="casAbstract">The hypothesis discussed is that diminished pineal gland function may promote the development of breast cancer in humans, as suggested by the relation between breast cancer and prolonged estrogen excess, and by the inhibition by melatonin of ovarian estrogen prodn., pituitary gonadotropin prodn., and sexual development and maturation.  The hypothesis is supported by the relations between pineal calcification, breast cancer incidence, and chlorpromazine's effect on serum melatonin, and by pineal gland and melatonin influences on tumor induction and growth in exptl. animals, the presence of a melatonin receptor in the human ovary, and the pineal's role in the stimulation of puberty.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfJzghfAG6z7Vg90H21EOLACvtfcHk0lhr7mJ50rmzFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXhvVCmsro%253D&md5=08c22e5f4df934d47bcc7dbca57c81e8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2878%2992591-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252878%252992591-6%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%26aulast%3DLippman%26aufirst%3DM.%26aulast%3DChabner%26aufirst%3DB.%26atitle%3DRole%2520of%2520Pineal%2520Gland%2520in%2520Aetiology%2520and%2520Treatment%2520of%2520Breast%2520Cancer%26jtitle%3DLancet%26date%3D1978%26volume%3D2%26spage%3D814%26epage%3D816%26doi%3D10.1016%2FS0140-6736%2878%2992591-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rondanelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milena Anna, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neldo, A.</span></span> <span> </span><span class="NLM_article-title">Update on the Role of Melatonin in the Prevention of Cancer Tumorigenesis and in the Management of Cancer Correlates, Such as Sleep-Wake and Mood Disturbances: Review and Remarks</span>. <i>Aging: Clin. Exp. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.1007/s40520-013-0118-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1007%2Fs40520-013-0118-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=24046037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BC3sbpsVOmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2013&pages=499-510&author=M.+Rondanelliauthor=F.+Milena+Annaauthor=P.+Simoneauthor=A.+Neldo&title=Update+on+the+Role+of+Melatonin+in+the+Prevention+of+Cancer+Tumorigenesis+and+in+the+Management+of+Cancer+Correlates%2C+Such+as+Sleep-Wake+and+Mood+Disturbances%3A+Review+and+Remarks&doi=10.1007%2Fs40520-013-0118-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks</span></div><div class="casAuthors">Rondanelli Mariangela; Faliva Milena Anna; Perna Simone; Antoniello Neldo</div><div class="citationInfo"><span class="NLM_cas:title">Aging clinical and experimental research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">499-510</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The aim of this article was to perform a systematic review on the role of melatonin in the prevention of cancer tumorigenesis--in vivo and in vitro--as well as in the management of cancer correlates, such as sleep-wake and mood disturbances.  The International Agency for Research on Cancer recently classified "shift-work that involves circadian disruption" as "probably carcinogenic to humans" (Group 2A) based on "limited evidence in humans for the carcinogenicity of shift-work that involves night-work", and "sufficient evidence in experimental animals for the carcinogenicity of light during the daily dark period (biological night)".  The clinical implications and the potential uses of melatonin in terms of biologic clock influence (e.g. sleep and mood), immune function, cancer initiation and growth, as well as the correlation between melatonin levels and cancer risk, are hereinafter recorded and summarized.  Additionally, this paper includes a description of the newly discovered effects that melatonin has on the management of sleep-wake and mood disturbances as well as with regard to cancer patients' life quality.  In cancer patients depression and insomnia are frequent and serious comorbid conditions which definitely require a special attention.  The data presented in this review encourage the performance of new clinical trials to investigate the possible use of melatonin in cancer patients suffering from sleep-wake and mood disturbances, also considering that melatonin registered a low toxicity in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9jVqKKGuAQ3l8icjszYl0fW6udTcc2eZwVdjaoZDt_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbpsVOmtg%253D%253D&md5=cc6df920d1d49851ea650b902c47847c</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1007%2Fs40520-013-0118-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40520-013-0118-6%26sid%3Dliteratum%253Aachs%26aulast%3DRondanelli%26aufirst%3DM.%26aulast%3DMilena%2BAnna%26aufirst%3DF.%26aulast%3DSimone%26aufirst%3DP.%26aulast%3DNeldo%26aufirst%3DA.%26atitle%3DUpdate%2520on%2520the%2520Role%2520of%2520Melatonin%2520in%2520the%2520Prevention%2520of%2520Cancer%2520Tumorigenesis%2520and%2520in%2520the%2520Management%2520of%2520Cancer%2520Correlates%252C%2520Such%2520as%2520Sleep-Wake%2520and%2520Mood%2520Disturbances%253A%2520Review%2520and%2520Remarks%26jtitle%3DAging%253A%2520Clin.%2520Exp.%2520Res.%26date%3D2013%26volume%3D25%26spage%3D499%26epage%3D510%26doi%3D10.1007%2Fs40520-013-0118-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, J.</span></span> <span> </span><span class="NLM_article-title">Increased Breast Cancer Risk among Women Who Work Predominantly at Night</span>. <i>Epidemiology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1097/00001648-200101000-00013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1097%2F00001648-200101000-00013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=11138824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BD3M7hsFKjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=74-77&author=J.+Hansen&title=Increased+Breast+Cancer+Risk+among+Women+Who+Work+Predominantly+at+Night&doi=10.1097%2F00001648-200101000-00013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Increased breast cancer risk among women who work predominantly at night</span></div><div class="casAuthors">Hansen J</div><div class="citationInfo"><span class="NLM_cas:title">Epidemiology (Cambridge, Mass.)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-7</span>
        ISSN:<span class="NLM_cas:issn">1044-3983</span>.
    </div><div class="casAbstract">Irregular working hours, including working at night, have serious psychological and physiological effects.  In a nationwide population-based case-control study, we investigated the breast cancer risk among 30- to 54-year-old Danish women who worked predominantly at night.  Individual employment histories were reconstructed back to 1964 for each of 7035 women with breast cancer and their individually matched controls from the records of a nationwide pension scheme with compulsory membership.  Odds ratios, including 5 years of induction time and adjusted for socio-economic status, age at the birth of first and last child and number of children, were estimated by conditional logistic regression analysis.  The odds ratio for breast cancer among women who worked at night at least half of a year was 1.5 (95% confidence interval, 1.2 to 1.7), and there was a tendency to increasing odds ratio by increasing duration of nighttime employment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkuxKQQB4KCjAyhZbj3lKdfW6udTcc2eb3IVFNuHYVErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7hsFKjtg%253D%253D&md5=7e0563f19a8c5f5c80e47790c37939bb</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1097%2F00001648-200101000-00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001648-200101000-00013%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DJ.%26atitle%3DIncreased%2520Breast%2520Cancer%2520Risk%2520among%2520Women%2520Who%2520Work%2520Predominantly%2520at%2520Night%26jtitle%3DEpidemiology%26date%3D2001%26volume%3D12%26spage%3D74%26epage%3D77%26doi%3D10.1097%2F00001648-200101000-00013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nooshinfar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safaroghli-Azar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashash, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbari, M. E.</span></span> <span> </span><span class="NLM_article-title">Melatonin, an Inhibitory Agent in Breast Cancer</span>. <i>Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1007/s12282-016-0690-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1007%2Fs12282-016-0690-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=27017208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BC28fktFeiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=42-51&author=E.+Nooshinfarauthor=A.+Safaroghli-Azarauthor=D.+Bashashauthor=M.+E.+Akbari&title=Melatonin%2C+an+Inhibitory+Agent+in+Breast+Cancer&doi=10.1007%2Fs12282-016-0690-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin, an inhibitory agent in breast cancer</span></div><div class="casAuthors">Nooshinfar Elaheh; Akbari Mohammad Esmaeil; Nooshinfar Elaheh; Safaroghli-Azar Ava; Bashash Davood</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The heterogeneous nature of breast cancer makes it one of the most challenging cancers to treat.  Due to the stimulatory effect of estrogen in mammary cancer progression, anti-estrogenic agents like melatonin have found their way into breast cancer treatment.  Further studies confirmed a reverse correlation between nocturnal melatonin levels and the development of mammary cancer.  In this study we reviewed the molecular inhibitory effects of melatonin in breast cancer therapy.  METHODS:  To open access the articles, Google scholar and science direct were used as a motor search.  We used from valid external and internal databases.  To reach the search formula, we determined mean key words like breast cancer, melatonin, cell proliferation and death.  To retrieval the related articles, we continuously search the articles from 1984 to 2015.  The relevance and the quality of the 480 articles were screened; at least we selected 80 eligible articles about melatonin molecular mechanism in breast cancer.  RESULT:  The results showed that melatonin not only inhibits breast cancer cell growth, but also is capable of inhibiting angiogenesis, cancer cell invasion, and telomerase activity.  Interestingly this hormone is able to induce apoptosis through the suppression or induction of a wide range of signaling pathways.  Moreover, it seems that the concomitant administration of melatonin with other conventional chemotherapy agents had beneficial effects for patients with breast cancer, by alleviating unfavorable effects of those agents and enhancing their efficacy.  CONCLUSION:  The broad inhibitory effects of melatonin in breast cancer make it a promising agent and may add it to the list of potential drugs in treatment of this cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2IPvZKjsw6r9KldV63DuefW6udTcc2eb3IVFNuHYVErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fktFeiug%253D%253D&md5=7291353056e47afe950610f4ee4c9eff</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1007%2Fs12282-016-0690-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12282-016-0690-7%26sid%3Dliteratum%253Aachs%26aulast%3DNooshinfar%26aufirst%3DE.%26aulast%3DSafaroghli-Azar%26aufirst%3DA.%26aulast%3DBashash%26aufirst%3DD.%26aulast%3DAkbari%26aufirst%3DM.%2BE.%26atitle%3DMelatonin%252C%2520an%2520Inhibitory%2520Agent%2520in%2520Breast%2520Cancer%26jtitle%3DBreast%2520Cancer%26date%3D2017%26volume%3D24%26spage%3D42%26epage%3D51%26doi%3D10.1007%2Fs12282-016-0690-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">González-González, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mediavilla, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Barcelo, E. J.</span></span> <span> </span><span class="NLM_article-title">Melatonin: A Molecule for Reducing Breast Cancer Risk</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.3390/molecules23020336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3390%2Fmolecules23020336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Gqsr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=336-356&author=A.+Gonz%C3%A1lez-Gonz%C3%A1lezauthor=M.+D.+Mediavillaauthor=E.+J.+Sanchez-Barcelo&title=Melatonin%3A+A+Molecule+for+Reducing+Breast+Cancer+Risk&doi=10.3390%2Fmolecules23020336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin: a molecule for reducing breast cancer risk</span></div><div class="casAuthors">Gonzalez-Gonzalez, Alicia; Mediavilla, Maria Dolores; Sanchez-Barcelo, Emilio J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">336/1-336/21</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The objective of this article is to review the basis supporting the usefulness of melatonin as an adjuvant therapy for breast cancer (BC) prevention in several groups of individuals at high risk for this disease.  Melatonin, as a result of its antiestrogenic and antioxidant properties, as well as its ability to improve the efficacy and reduce the side effects of conventional antiestrogens, could safely be assocd. with the antiestrogenic drugs presently in use.  In individuals at risk of BC due to night shift work, the light-induced inhibition of melatonin secretion, with the consequent loss of its antiestrogenic effects, would be countered by administering this neurohormone.  BC risk from exposure to metalloestrogens, such as cadmium, could be treated with melatonin supplements to individuals at risk of BC due to exposure to this xenoestrogen.  The BC risk related to obesity may be reduced by melatonin which decrease body fat mass, inhibits the enhanced aromatase expression in obese women, increases adiponectin secretion, counteracts the oncogenic effects of elevated concns. of leptin; and decreases blood glucose levels and insulin resistance.  Despite compelling exptl. evidence of melatonin's oncostatic actions being susceptible to lowering BC risk, there is still a paucity of clin. trials focused on this subject.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8UGQHhSdACrVg90H21EOLACvtfcHk0lipcTrc_X2j9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Gqsr3P&md5=305a6032e9bf987174057ff63203fd75</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23020336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23020336%26sid%3Dliteratum%253Aachs%26aulast%3DGonz%25C3%25A1lez-Gonz%25C3%25A1lez%26aufirst%3DA.%26aulast%3DMediavilla%26aufirst%3DM.%2BD.%26aulast%3DSanchez-Barcelo%26aufirst%3DE.%2BJ.%26atitle%3DMelatonin%253A%2520A%2520Molecule%2520for%2520Reducing%2520Breast%2520Cancer%2520Risk%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26spage%3D336%26epage%3D356%26doi%3D10.3390%2Fmolecules23020336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Maestroni, G. J.</span></span> <span> </span><span class="NLM_article-title">The Immunoneuroendocrine Role of Melatonin</span>. <i>J. Pineal Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1111/j.1600-079X.1993.tb00478.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1111%2Fj.1600-079X.1993.tb00478.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=8483103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADyaK3sXksVWjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1993&pages=1-10&author=G.+J.+Maestroni&title=The+Immunoneuroendocrine+Role+of+Melatonin&doi=10.1111%2Fj.1600-079X.1993.tb00478.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">The immunoneuroendocrine role of melatonin</span></div><div class="casAuthors">Maestroni, Georges J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pineal Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">JPRSE9</span>;
        ISSN:<span class="NLM_cas:issn">0742-3098</span>.
    </div><div class="casAbstract">A review, with 55 refs., of the physiol. link between the pineal gland and the immune system.  This link might reflect the evolutionary connection between self-recognition and reprodn.  Pinealectomy or other exptl. methods which inhibit melatonin synthesis and secretion induce a state of immunodepression which is counteracted by melatonin.  In general, melatonin seems to have an immunoenhancing effect that is particularly apparent in immunodepressive states.  The neg. effect of acute stress or immunosuppressive pharmacol. treatments on various immune parameters are counteracted by melatonin.  It seems important to note that one of the main targets of melatonin is the thymus, i.e., the central organ of the immune system.  The immunoenhancing action of melatonin seems to be mediated by T-helper cell-derived opioid peptides, as well as by lymphokines and, perhaps, by pituitary hormones.  Melatonin-induced-immuno-opioids (MIIO) and lymphokines imply the presence of specific binding sites or melatonin receptors on cells of the immune system.  On the other hand, lymphokines such as γ-interferon and interleukin-2, as well as thymic hormones, can modulate the synthesis of melatonin in the pineal gland.  The pineal gland might thus be viewed as the crux of a sophisticated immunoneuroendocrine network which functions as an unconscious, diffuse sensory organ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs8O6nPK4EI7Vg90H21EOLACvtfcHk0liIXIi15Rg7aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXksVWjtLw%253D&md5=ce5cc71ae8a75eff491d9316269c52f8</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-079X.1993.tb00478.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-079X.1993.tb00478.x%26sid%3Dliteratum%253Aachs%26aulast%3DMaestroni%26aufirst%3DG.%2BJ.%26atitle%3DThe%2520Immunoneuroendocrine%2520Role%2520of%2520Melatonin%26jtitle%3DJ.%2520Pineal%2520Res.%26date%3D1993%26volume%3D14%26spage%3D1%26epage%3D10%26doi%3D10.1111%2Fj.1600-079X.1993.tb00478.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paola, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caputi, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuzzocrea, S.</span></span> <span> </span><span class="NLM_article-title">Melatonin Limits Lung Injury in Bleomycin Treated Mice</span>. <i>J. Pineal Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1111/j.1600-079X.2005.00229.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1111%2Fj.1600-079X.2005.00229.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=16098086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD2MXovFSjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2005&pages=105-112&author=T.+Genoveseauthor=R.+Di+Paolaauthor=E.+Mazzonauthor=C.+Muiaauthor=A.+P.+Caputiauthor=S.+Cuzzocrea&title=Melatonin+Limits+Lung+Injury+in+Bleomycin+Treated+Mice&doi=10.1111%2Fj.1600-079X.2005.00229.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin limits lung injury in bleomycin treated mice</span></div><div class="casAuthors">Genovese, Tiziana; Di Paola, Rosanna; Mazzon, Emanuela; Muia, Carmelo; Caputi, Achille P.; Cuzzocrea, Salvatore</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pineal Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-112</span>CODEN:
                <span class="NLM_cas:coden">JPRSE9</span>;
        ISSN:<span class="NLM_cas:issn">0742-3098</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Melatonin is the principal secretory product of the pineal gland and its role as an immuno-modulator is well established.  Recent evidence shows that melatonin is a scavenger of oxyradicals and peroxynitrite and exerts protective effects in septic shock, hemorrhagic shock and inflammation.  The aim of this study was to investigate the effect of melatonin on the lung injury caused by bleomycin (BLM) administration.  Mice subjected to intratracheal administration of BLM developed significant lung injury characterized by a marked neutrophil infiltration [assessed by myeloperoxidase (MPO) activity] and by tissue edema.  In addn., an increase of immunoreactivity to nitrotyrosine, poly-ADP-ribose (PAR) was also obsd. in the lung of BLM-treated mice.  Also, lung injury induced by BLM administration was correlated with a significant loss of body wt. and with a significant mortality.  Administration of melatonin (10 mg/kg i.p.) daily significantly reduced the (i) loss of body wt., (ii) mortality rate, (iii) infiltration of the lung with polymorphonuclear neutrophils (MPO activity), (iv) edema formation and (v) histol. evidence of lung injury.  Administration of melatonin also markedly reduced the nitrotyrosine and PAR formation.  Taken together, the authors' results demonstrate that treatment with melatonin significantly reduces lung injury induced by BLM in the mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq30-KSeLz7hLVg90H21EOLACvtfcHk0liIXIi15Rg7aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXovFSjsbw%253D&md5=d25274492616031bba2f8768b8b3fb7e</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-079X.2005.00229.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-079X.2005.00229.x%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DT.%26aulast%3DDi%2BPaola%26aufirst%3DR.%26aulast%3DMazzon%26aufirst%3DE.%26aulast%3DMuia%26aufirst%3DC.%26aulast%3DCaputi%26aufirst%3DA.%2BP.%26aulast%3DCuzzocrea%26aufirst%3DS.%26atitle%3DMelatonin%2520Limits%2520Lung%2520Injury%2520in%2520Bleomycin%2520Treated%2520Mice%26jtitle%3DJ.%2520Pineal%2520Res.%26date%3D2005%26volume%3D39%26spage%3D105%26epage%3D112%26doi%3D10.1111%2Fj.1600-079X.2005.00229.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drazen, D. L.</span></span> <span> </span><span class="NLM_article-title">Melatonin Mediates Seasonal Adjustments in Immune Function</span>. <i>Reprod., Nutr., Dev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1051/rnd:19990310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1051%2Frnd%3A19990310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10420440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADyaK1MXksVaqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1999&pages=383-398&author=R.+J.+Nelsonauthor=D.+L.+Drazen&title=Melatonin+Mediates+Seasonal+Adjustments+in+Immune+Function&doi=10.1051%2Frnd%3A19990310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin mediates seasonal adjustments in immune function</span></div><div class="casAuthors">Nelson, Randy J.; Drazen, Deborah L.</div><div class="citationInfo"><span class="NLM_cas:title">Reproduction, Nutrition, Development</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-398</span>CODEN:
                <span class="NLM_cas:coden">RNDEE5</span>;
        ISSN:<span class="NLM_cas:issn">0926-5287</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review, with 148 refs.  The authors discuss photoperiod control of reprodn. and immune function; energetics of immune function; and melatonin effects on immune function and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6soG1vAT8-bVg90H21EOLACvtfcHk0lh21TXwmxxEfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksVaqtLc%253D&md5=99ac0a68bce9f7270bcc3276b56304c2</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1051%2Frnd%3A19990310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1051%252Frnd%253A19990310%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DR.%2BJ.%26aulast%3DDrazen%26aufirst%3DD.%2BL.%26atitle%3DMelatonin%2520Mediates%2520Seasonal%2520Adjustments%2520in%2520Immune%2520Function%26jtitle%3DReprod.%252C%2520Nutr.%252C%2520Dev.%26date%3D1999%26volume%3D39%26spage%3D383%26epage%3D398%26doi%3D10.1051%2Frnd%3A19990310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Moradkhani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moloudizargari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asghari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoei, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asghari, M. H.</span></span> <span> </span><span class="NLM_article-title">Immunoregulatory Role of Melatonin in Cancer</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>235</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">757</span>, <span class="refDoi"> DOI: 10.1002/jcp.29036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fjcp.29036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=31270813" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2019&pages=745-757&author=F.+Moradkhaniauthor=M.+Moloudizargariauthor=M.+Fallahauthor=N.+Asghariauthor=H.+H.+Khoeiauthor=M.+H.+Asghari&title=Immunoregulatory+Role+of+Melatonin+in+Cancer&doi=10.1002%2Fjcp.29036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1002%2Fjcp.29036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.29036%26sid%3Dliteratum%253Aachs%26aulast%3DMoradkhani%26aufirst%3DF.%26aulast%3DMoloudizargari%26aufirst%3DM.%26aulast%3DFallah%26aufirst%3DM.%26aulast%3DAsghari%26aufirst%3DN.%26aulast%3DKhoei%26aufirst%3DH.%2BH.%26aulast%3DAsghari%26aufirst%3DM.%2BH.%26atitle%3DImmunoregulatory%2520Role%2520of%2520Melatonin%2520in%2520Cancer%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D235%26spage%3D745%26epage%3D757%26doi%3D10.1002%2Fjcp.29036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, V. W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yau, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiu, S. Y. W.</span></span> <span> </span><span class="NLM_article-title">Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.3390/ijms18010001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3390%2Fijms18010001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ahtrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1-13&author=V.+W.+S.+Liuauthor=W.+L.+Yauauthor=C.+W.+Tamauthor=K.+M.+Yaoauthor=S.+Y.+W.+Shiu&title=Melatonin+Inhibits+Androgen+Receptor+Splice+Variant-7+%28AR-V7%29-Induced+Nuclear+Factor-Kappa+B+%28NF-%CE%BAB%29+Activation+and+NF-%CE%BAB+Activator-Induced+AR-V7+Expression+in+Prostate+Cancer+Cells%3A+Potential+Implications+for+the+Use+of+Melatonin+in+Castration-Resistant+Prostate+Cancer+%28CRPC%29+Therapy&doi=10.3390%2Fijms18010001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of biosynthesis, accumulation and antioxidant activityof vitamin E in sweet corn (Zea mays L.) during kernel development</span></div><div class="casAuthors">Xie, Lihua; Yu, Yongtao; Mao, Jihua; Liu, Haiying; Hu, Jian Guang; Li, Tong; Guo, Xinbo; Liu, Rui Hai</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Sweet corn kernels were used in this research to study the dynamics of vitamin E, by evaluatingthe expression levels of genes involved in vitamin E synthesis, the accumulation of vitamin E, and the antioxidant activity during the different stage of kernel development.  Results showed that expression levels of ZmHPT and ZmTC genes increased, whereas Zm TMT gene dramatically decreased during kernel development.  The contents of all the types of vitamin E in sweet corn had a significant upward increase during kernel development, and reached the highest level at 30 days after pollination (DAP).  Amongst the eight isomers of vitamin E, the content of γ-tocotrienol was the highest, and increased by 14.9 folds, followed by α-tocopherolwith an increase of 22 folds, and thecontents of isomers γ-tocopherol, α-tocotrienol, and -tocopherol were also followed during kernel development.  The antioxidant activity of sweet corn during kernel development was increased, and was up to 101.8 ± 22.3 mol of -tocopherol equivlent/100 g in fresh wt. (FW) at 30 DAP.  There was a pos. correlation between vitamin E contents and antioxidant activity in sweet corn during the kernel development, and a neg. correlation between the expressions of ZmTMT gene and vitamin E contents.  These results revealed the relations amongst the content of vitamin E isomers and the gene expression, vitamin E accumulation, and antioxidant activity.  The study can provide a harvesting strategy for vitamin E bio-fortification in sweet corn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZFo7iD4oyhrVg90H21EOLACvtfcHk0lh21TXwmxxEfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ahtrvM&md5=cbefcf9854cfa99501420817639dff62</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.3390%2Fijms18010001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18010001%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DV.%2BW.%2BS.%26aulast%3DYau%26aufirst%3DW.%2BL.%26aulast%3DTam%26aufirst%3DC.%2BW.%26aulast%3DYao%26aufirst%3DK.%2BM.%26aulast%3DShiu%26aufirst%3DS.%2BY.%2BW.%26atitle%3DMelatonin%2520Inhibits%2520Androgen%2520Receptor%2520Splice%2520Variant-7%2520%2528AR-V7%2529-Induced%2520Nuclear%2520Factor-Kappa%2520B%2520%2528NF-%25CE%25BAB%2529%2520Activation%2520and%2520NF-%25CE%25BAB%2520Activator-Induced%2520AR-V7%2520Expression%2520in%2520Prostate%2520Cancer%2520Cells%253A%2520Potential%2520Implications%2520for%2520the%2520Use%2520of%2520Melatonin%2520in%2520Castration-Resistant%2520Prostate%2520Cancer%2520%2528CRPC%2529%2520Therapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1%26epage%3D13%26doi%3D10.3390%2Fijms18010001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit24c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mirza-Aghazadeh-Attari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mostavafi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihanfar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghazizadeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadighparvar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gholamzadeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majidinia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yousefi, B.</span></span> <span> </span><span class="NLM_article-title">Melatonin: An Important Anticancer Agent in Colorectal Cancer</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>235</i></span>,  <span class="NLM_fpage">804</span>– <span class="NLM_lpage">817</span>, <span class="refDoi"> DOI: 10.1002/jcp.29049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fjcp.29049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=31276205" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2019&pages=804-817&author=M.+Mirza-Aghazadeh-Attariauthor=A.+Mohammadzadehauthor=S.+Mostavafiauthor=A.+Mihanfarauthor=S.+Ghazizadehauthor=S.+Sadighparvarauthor=S.+Gholamzadehauthor=M.+Majidiniaauthor=B.+Yousefi&title=Melatonin%3A+An+Important+Anticancer+Agent+in+Colorectal+Cancer&doi=10.1002%2Fjcp.29049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=10.1002%2Fjcp.29049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.29049%26sid%3Dliteratum%253Aachs%26aulast%3DMirza-Aghazadeh-Attari%26aufirst%3DM.%26aulast%3DMohammadzadeh%26aufirst%3DA.%26aulast%3DMostavafi%26aufirst%3DS.%26aulast%3DMihanfar%26aufirst%3DA.%26aulast%3DGhazizadeh%26aufirst%3DS.%26aulast%3DSadighparvar%26aufirst%3DS.%26aulast%3DGholamzadeh%26aufirst%3DS.%26aulast%3DMajidinia%26aufirst%3DM.%26aulast%3DYousefi%26aufirst%3DB.%26atitle%3DMelatonin%253A%2520An%2520Important%2520Anticancer%2520Agent%2520in%2520Colorectal%2520Cancer%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D235%26spage%3D804%26epage%3D817%26doi%3D10.1002%2Fjcp.29049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menéndez-Menéndez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Campa, C.</span></span> <span> </span><span class="NLM_article-title">Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers</span>. <i>Int. J. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2018</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1155/2018/3271948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1155%2F2018%2F3271948" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2018&publication_year=2018&pages=1-20&author=J.+Men%C3%A9ndez-Men%C3%A9ndezauthor=C.+Martinez-Campa&title=Melatonin%3A+An+Anti-Tumor+Agent+in+Hormone-Dependent+Cancers&doi=10.1155%2F2018%2F3271948"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1155%2F2018%2F3271948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2018%252F3271948%26sid%3Dliteratum%253Aachs%26aulast%3DMen%25C3%25A9ndez-Men%25C3%25A9ndez%26aufirst%3DJ.%26aulast%3DMartinez-Campa%26aufirst%3DC.%26atitle%3DMelatonin%253A%2520An%2520Anti-Tumor%2520Agent%2520in%2520Hormone-Dependent%2520Cancers%26jtitle%3DInt.%2520J.%2520Endocrinol.%26date%3D2018%26volume%3D2018%26spage%3D1%26epage%3D20%26doi%3D10.1155%2F2018%2F3271948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangoda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. R.</span></span> <span> </span><span class="NLM_article-title">Coordination-Driven Self-Assembly of a Pt(IV) Prodrug-Conjugated Supramolecular Hexagon</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">734</span>, <span class="refDoi"> DOI: 10.1039/C7CC07622C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1039%2FC7CC07622C" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=731-734&author=Z.+Z.+Yueauthor=H.+Wangauthor=Y.+M.+Liauthor=Y.+Qinauthor=L.+Xuauthor=D.+J.+Bowersauthor=M.+Gangodaauthor=X.+P.+Liauthor=H.+B.+Yangauthor=Y.+R.+Zheng&title=Coordination-Driven+Self-Assembly+of+a+Pt%28IV%29+Prodrug-Conjugated+Supramolecular+Hexagon&doi=10.1039%2FC7CC07622C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2FC7CC07622C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CC07622C%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DZ.%2BZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%2BM.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DBowers%26aufirst%3DD.%2BJ.%26aulast%3DGangoda%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%2BP.%26aulast%3DYang%26aufirst%3DH.%2BB.%26aulast%3DZheng%26aufirst%3DY.%2BR.%26atitle%3DCoordination-Driven%2520Self-Assembly%2520of%2520a%2520Pt%2528IV%2529%2520Prodrug-Conjugated%2520Supramolecular%2520Hexagon%26jtitle%3DChem.%2520Commun.%26date%3D2018%26volume%3D57%26spage%3D731%26epage%3D734%26doi%3D10.1039%2FC7CC07622C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Cellular Processing of Platinum Anti-cancer Drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1038/nrd1691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1038%2Fnrd1691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=15789122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVart7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=307-320&author=D.+Wangauthor=S.+J.+Lippard&title=Cellular+Processing+of+Platinum+Anti-cancer+Drugs&doi=10.1038%2Fnrd1691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular processing of platinum anticancer drugs</span></div><div class="casAuthors">Wang, Dong; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-320</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cisplatin, carboplatin and oxaliplatin are platinum-based drugs that are widely used in cancer chemotherapy.  Platinum-DNA adducts, which are formed following uptake of the drug into the nucleus of cells, activate several cellular processes that mediate the cytotoxicity of these platinum drugs.  This review focuses on recently discovered cellular pathways that are activated in response to cisplatin, including those involved in regulating drug uptake, the signaling of DNA damage, cell-cycle checkpoints and arrest, DNA repair and cell death.  Such knowledge of the cellular processing of cisplatin adducts with DNA provides valuable clues for the rational design of more efficient platinum-based drugs as well as the development of new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHJfZNaqwy67Vg90H21EOLACvtfcHk0lhMnFDs_5BtYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVart7c%253D&md5=e44a8e87683ba5cfe3e165f9f4229fee</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrd1691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1691%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DCellular%2520Processing%2520of%2520Platinum%2520Anti-cancer%2520Drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D307%26epage%3D320%26doi%3D10.1038%2Fnrd1691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Florea, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busselberg, D.</span></span> <span> </span><span class="NLM_article-title">Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1351</span>– <span class="NLM_lpage">1371</span>, <span class="refDoi"> DOI: 10.3390/cancers3011351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3390%2Fcancers3011351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=24212665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVWiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1351-1371&author=A.+M.+Floreaauthor=D.+Busselberg&title=Cisplatin+as+an+Anti-Tumor+Drug%3A+Cellular+Mechanisms+of+Activity%2C+Drug+Resistance+and+Induced+Side+Effects&doi=10.3390%2Fcancers3011351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects</span></div><div class="casAuthors">Florea, Ana-Maria; Buesselberg, Dietrich</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1351-1371</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Platinum complexes are clin. used as adjuvant therapy of cancers aiming to induce tumor cell death.  Depending on cell type and concn., cisplatin induces cytotoxicity, e.g., by interference with transcription and/or DNA replication mechanisms.  Addnl., cisplatin damages tumors via induction of apoptosis, mediated by the activation of various signal transduction pathways, including calcium signaling, death receptor signaling, and the activation of mitochondrial pathways.  Unfortunately, neither cytotoxicity nor apoptosis are exclusively induced in cancer cells, thus, cisplatin might also lead to diverse side-effects such as neuro- and/or renal-toxicity or bone marrow-suppression.  Moreover, the binding of cisplatin to proteins and enzymes may modulate its biochem. mechanism of action.  While a combination-chemotherapy with cisplatin is a cornerstone for the treatment of multiple cancers, the challenge is that cancer cells could become cisplatin-resistant.  Numerous mechanisms of cisplatin resistance were described including changes in cellular uptake, drug efflux, increased detoxification, inhibition of apoptosis and increased DNA repair.  To minimize cisplatin resistance, combinatorial therapies were developed and have proven more effective to defeat cancers.  Thus, understanding of the biochem. mechanisms triggered by cisplatin in tumor cells may lead to the design of more efficient platinum derivates (or other drugs) and might provide new therapeutic strategies and reduce side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-7eCBHQ5T5rVg90H21EOLACvtfcHk0lhMnFDs_5BtYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVWiuro%253D&md5=368b8ef25e06a41747ec0940872966b3</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.3390%2Fcancers3011351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers3011351%26sid%3Dliteratum%253Aachs%26aulast%3DFlorea%26aufirst%3DA.%2BM.%26aulast%3DBusselberg%26aufirst%3DD.%26atitle%3DCisplatin%2520as%2520an%2520Anti-Tumor%2520Drug%253A%2520Cellular%2520Mechanisms%2520of%2520Activity%252C%2520Drug%2520Resistance%2520and%2520Induced%2520Side%2520Effects%26jtitle%3DCancers%26date%3D2011%26volume%3D3%26spage%3D1351%26epage%3D1371%26doi%3D10.3390%2Fcancers3011351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">A Novel Ion-Imprinted Membrane Induced by Amphiphilic Block Copolymer for Selective Separation of Pt(IV) from Aqueous Solutions</span>. <i>J. Membr. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>572</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1016/j.memsci.2018.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.memsci.2018.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSqsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=572&publication_year=2019&pages=428-441&author=J.+X.+Zengauthor=C.+Q.+Lvauthor=G.+Q.+Liuauthor=Z.+Zhangauthor=Z.+H.+Dongauthor=J.+Y.+Liuauthor=Y.+Wang&title=A+Novel+Ion-Imprinted+Membrane+Induced+by+Amphiphilic+Block+Copolymer+for+Selective+Separation+of+Pt%28IV%29+from+Aqueous+Solutions&doi=10.1016%2Fj.memsci.2018.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A novel ion-i61printed membrane induced by amphiphilic block copolymer for selective separation of Pt(IV) from aqueous solutions</span></div><div class="casAuthors">Zeng, Jianxian; Lv, Chaoqiang; Liu, Guoqing; Zhang, Zhe; Dong, Zhihui; Liu, JinYan; Wang, Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Membrane Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">572</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">428-441</span>CODEN:
                <span class="NLM_cas:coden">JMESDO</span>;
        ISSN:<span class="NLM_cas:issn">0376-7388</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel ion-imprinted blend membrane was fabricated to sep. selectively platinum(IV) from aq. media.  An amphiphilic copolymer poly(Me methacrylate)-b-poly(4-vinylpyridine) (PMMA-b-P4VP) was firstly synthesized via the reversible addn. fragmentation chain transfer polymn., and characterized by 1H NMR, FT-IR and GPC.  Subsequently, poly(vinylidene fluoride) (PVDF) blend membranes were prepd. using PMMA-b-P4VP as a blending additive.  Effects of the following factors on performance of blend membranes were systematically examd.: P4VP content of PMMA-b-P4VP, solvent type, and PMMA-b-P4VP/PVDF ratio.  Further, platinum(IV) ion-imprinted membrane (Pt(IV)-IIM) was fabricated by blending polymer-Pt(IV) complexes with PVDF.  SEM, FTIR-ATR, contact angle, water flux and adsorption capacity were employed to characterize all membranes.  Results indicated that the membrane, which was prepd. using the copolymer with high P4VP content (polymn. time 10 h) as a functional polymer, N,N-dimethylacetamide as a solvent and PMMA-b-P4VP/PVDF ratio of 30 wt%, exhibited an intriguing morphol. and much higher performance.  Pt(IV)-IIM showed higher adsorption and selectivity for Pt(IV) (selectivity coeffs. of 27.66 ± 1.38 and 77.16 ± 3.86 for Pt(IV)/Cu(II) and Pt(IV)/Ni(II), resp.) compared with a non-imprinted membrane.  During membrane filtration, Pt(IV)-IIM was effective and selective for sepn. of Pt(IV) in the presence of Cu(II) and Ni(II) ions.  Also, Pt(IV)-IIM was chem. stable, and had a good regeneration performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosJwNL--aBL7Vg90H21EOLACvtfcHk0lhMnFDs_5BtYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSqsb7E&md5=689eff676e437578afaa537a46284ae6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.memsci.2018.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.memsci.2018.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DJ.%2BX.%26aulast%3DLv%26aufirst%3DC.%2BQ.%26aulast%3DLiu%26aufirst%3DG.%2BQ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DZ.%2BH.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DA%2520Novel%2520Ion-Imprinted%2520Membrane%2520Induced%2520by%2520Amphiphilic%2520Block%2520Copolymer%2520for%2520Selective%2520Separation%2520of%2520Pt%2528IV%2529%2520from%2520Aqueous%2520Solutions%26jtitle%3DJ.%2520Membr.%2520Sci.%26date%3D2019%26volume%3D572%26spage%3D428%26epage%3D441%26doi%3D10.1016%2Fj.memsci.2018.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">3436</span>– <span class="NLM_lpage">3486</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=3436-3486&author=T.+C.+Johnstoneauthor=K.+Suntharalingamauthor=S.+J.+Lippard&title=The+Next+Generation+of+Platinum+Drugs%3A+Targeted+Pt%28II%29+Agents%2C+Nanoparticle+Delivery%2C+and+Pt%28IV%29+Prodrugs&doi=10.1021%2Facs.chemrev.5b00597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</span></div><div class="casAuthors">Johnstone, Timothy C.; Suntharalingam, Kogularamanan; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3436-3486</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic.  Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs.  The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs.  In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs.  The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished.  We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compds., platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes.  Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles.  Addnl. nanoformulations, including supramol. self-assembled structures, proteins, peptides, metal-org. frameworks, and coordination polymers, will then be described.  Finally, the significant clin. progress made by nanoparticle formulations of platinum(II) agents will be reviewed.  We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKCOwDrVtJrVg90H21EOLACvtfcHk0liuFB4FRdbT4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D&md5=d7adf3279441d8e56bddf501f06cda6e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00597%26sid%3Dliteratum%253Aachs%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520Next%2520Generation%2520of%2520Platinum%2520Drugs%253A%2520Targeted%2520Pt%2528II%2529%2520Agents%252C%2520Nanoparticle%2520Delivery%252C%2520and%2520Pt%2528IV%2529%2520Prodrugs%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26spage%3D3436%26epage%3D3486%26doi%3D10.1021%2Facs.chemrev.5b00597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choy, H.</span></span> <span> </span><span class="NLM_article-title">An Orally Available Platinum Analog for the Treatment of Cancer</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">982</span>, <span class="refDoi"> DOI: 10.1586/14737140.6.7.973</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1586%2F14737140.6.7.973" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=16831070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvVeqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=973-982&author=H.+Choy&title=An+Orally+Available+Platinum+Analog+for+the+Treatment+of+Cancer&doi=10.1586%2F14737140.6.7.973"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Satraplatin: an orally available platinum analog for the treatment of cancer</span></div><div class="casAuthors">Choy, Hak</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">973-982</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Satraplatin is a novel, orally bioavailable, platinum anticancer drug.  Platinum analogs form the mainstay of treatment for a no. of cancers, including lung, ovarian, colorectal and head and neck cancer.  A disadvantage of the currently marketed platinum analogs is that they must all be administered via i.v. infusion.  In addn., their utility is often limited by toxicity, particularly neurotoxicity, ototoxicity and renal toxicity.  Satraplatin has preclin. antitumor activity comparable with that of cisplatin and, clin., has a more manageable side-effect profile.  Satraplatin is active in lung, ovarian and prostate cancer, and appears to have good efficacy in combination with radiation for lung and head and neck cancer.  Preclin. data suggest it may also be effective for the treatment of certain cisplatin-refractory tumors.  A large, randomized Phase III trial is currently evaluating Satraplatin in combination with prednisone for the treatment of patients with hormone-refractory prostate cancer whose disease has progressed following prior systemic therapy.  Pos. results from this trial would support regulatory approval for satraplatin for this indication.  The availability of an active oral platinum agent, such as satraplatin, with few of the serious toxicities assocd. with traditional i.v. platinum compds. makes satraplatin an alternative to other platinum agents and a new treatment option in the oncologist's armamentarium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozCHqYYpVjzLVg90H21EOLACvtfcHk0liuFB4FRdbT4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvVeqtL0%253D&md5=00660d58a909b1f2a7b1f73ddafa68cf</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1586%2F14737140.6.7.973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.6.7.973%26sid%3Dliteratum%253Aachs%26aulast%3DChoy%26aufirst%3DH.%26atitle%3DAn%2520Orally%2520Available%2520Platinum%2520Analog%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2006%26volume%3D6%26spage%3D973%26epage%3D982%26doi%3D10.1586%2F14737140.6.7.973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S. W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, B. Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. H.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">13091</span>– <span class="NLM_lpage">13095</span>, <span class="refDoi"> DOI: 10.1002/anie.201807305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fanie.201807305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlCls7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=13091-13095&author=G.+Y.+Yangauthor=W.+Wangauthor=S.+W.+F.+Mokauthor=C.+Wuauthor=B.+Y.+K.+Lawauthor=X.+M.+Miaoauthor=K.+J.+Wuauthor=H.+J.+Zhongauthor=C.+Y.+Wongauthor=V.+K.+W.+Wongauthor=D.+L.+Maauthor=C.+H.+Leung&title=Selective+Inhibition+of+Lysine-Specific+Demethylase+5A+%28KDM5A%29+Using+a+Rhodium%28III%29+Complex+for+Triple-Negative+Breast+Cancer+Therapy&doi=10.1002%2Fanie.201807305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy</span></div><div class="casAuthors">Yang, Guan-Jun; Wang, Wanhe; Mok, Simon Wing Fai; Wu, Chun; Law, Betty Yuen Kwan; Miao, Xiang-Min; Wu, Ke-Jia; Zhong, Hai-Jing; Wong, Chun-Yuen; Wong, Vincent Kam Wai; Ma, Dik-Lung; Leung, Chung-Hang</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">13091-13095</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Lysine-specific demethylase 5A (KDM5A) has recently become a promising target for epigenetic therapy.  In this study, the authors designed and synthesized metal complexes bearing ligands with reported demethylase and p27 modulating activities.  The Rh(III) complex 1 (I) was identified as a direct, selective and potent inhibitor of KDM5A that directly abrogate KDM5A demethylase activity via antagonizing the KDM5A-tri-/di-methylated histone 3 protein-protein interaction (PPI) in vitro and in cellulo.  Complex 1 induced accumulation of H3K4me3 and H3K4me2 levels in cells, causing growth arrest at G1 phase in the triple-neg. breast cancer (TNBC) cell lines, MDA-MB-231 and 4T1.  Finally, 1 exhibited potent anti-tumor activity against TNBC xenografts in an in vivo mouse model, presumably via targeting of KDM5A and hence upregulating p27.  Moreover, complex 1 was less toxic compared with two clin. drugs, cisplatin and doxorubicin.  To the authors' knowledge, complex 1 is the first metal-based KDM5A inhibitor reported in the literature.  The authors anticipate that complex 1 may be used as a novel scaffold for the further development of more potent epigenetic agents against cancers, including TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriUnhpINRuOrVg90H21EOLACvtfcHk0liuFB4FRdbT4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlCls7vM&md5=9a8f6097e7401592667690c255f1c9e6</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201807305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201807305%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DG.%2BY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMok%26aufirst%3DS.%2BW.%2BF.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DLaw%26aufirst%3DB.%2BY.%2BK.%26aulast%3DMiao%26aufirst%3DX.%2BM.%26aulast%3DWu%26aufirst%3DK.%2BJ.%26aulast%3DZhong%26aufirst%3DH.%2BJ.%26aulast%3DWong%26aufirst%3DC.%2BY.%26aulast%3DWong%26aufirst%3DV.%2BK.%2BW.%26aulast%3DMa%26aufirst%3DD.%2BL.%26aulast%3DLeung%26aufirst%3DC.%2BH.%26atitle%3DSelective%2520Inhibition%2520of%2520Lysine-Specific%2520Demethylase%25205A%2520%2528KDM5A%2529%2520Using%2520a%2520Rhodium%2528III%2529%2520Complex%2520for%2520Triple-Negative%2520Breast%2520Cancer%2520Therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D13091%26epage%3D13095%26doi%3D10.1002%2Fanie.201807305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. L.</span></span> <span> </span><span class="NLM_article-title">Identification of an Iridium(III)-Based Inhibitor of Tumor Necrosis Factor-α</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4026</span>– <span class="NLM_lpage">4031</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00112</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00112" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOjur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4026-4031&author=T.+S.+Kangauthor=Z.+Maoauthor=C.+T.+Ngauthor=M.+Wangauthor=W.+Wangauthor=C.+Wangauthor=S.+M.+Y.+Leeauthor=Y.+Wangauthor=C.+H.+Leungauthor=D.+L.+Ma&title=Identification+of+an+Iridium%28III%29-Based+Inhibitor+of+Tumor+Necrosis+Factor-%CE%B1&doi=10.1021%2Facs.jmedchem.6b00112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an Iridium(III)-Based Inhibitor of Tumor Necrosis Factor-α</span></div><div class="casAuthors">Kang, Tian-Shu; Mao, Zhifeng; Ng, Chan-Tat; Wang, Modi; Wang, Wanhe; Wang, Chunming; Lee, Simon Ming-Yuen; Wang, Yitao; Leung, Chung-Hang; Ma, Dik-Lung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4026-4031</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The novel iridium(III) complex 1 was verified as a potent inhibitor of the TNF-α-TNFR protein-protein interaction in vitro and in cellulo.  The iridium(III) center plays a crit. role in organizing the structure of the bioactive metal complex, as the isolated ligands were found to be completely inactive.  Both iridium enantiomers inhibited TNF-α-induced NF-κB activity and TNF-α-TNFR binding. 1 represents a promising scaffold for the further development of more potent organometallic TNF-α inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGSZhWsnl-lLVg90H21EOLACvtfcHk0lhWeLNGVSMutg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOjur8%253D&md5=646d93f9b37bed3dd865bd59499ad54f</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00112%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DT.%2BS.%26aulast%3DMao%26aufirst%3DZ.%26aulast%3DNg%26aufirst%3DC.%2BT.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DS.%2BM.%2BY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLeung%26aufirst%3DC.%2BH.%26aulast%3DMa%26aufirst%3DD.%2BL.%26atitle%3DIdentification%2520of%2520an%2520Iridium%2528III%2529-Based%2520Inhibitor%2520of%2520Tumor%2520Necrosis%2520Factor-%25CE%25B1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4026%26epage%3D4031%26doi%3D10.1021%2Facs.jmedchem.6b00112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, D.</span></span> <span> </span><span class="NLM_article-title">Platinum Drugs: from Pt(II) Compounds, Pt(IV) Prodrugs, to Pt Nanocrystals/Nanoclusters</span>. <i>Sci. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">596</span>, <span class="refDoi"> DOI: 10.1016/j.scib.2017.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.scib.2017.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGjsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2017&pages=589-596&author=X.+Huauthor=F.+Liauthor=N.+Noorauthor=D.+Ling&title=Platinum+Drugs%3A+from+Pt%28II%29+Compounds%2C+Pt%28IV%29+Prodrugs%2C+to+Pt+Nanocrystals%2FNanoclusters&doi=10.1016%2Fj.scib.2017.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32cR"><div class="casContent"><span class="casTitleNuber">32c</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum drugs: from Pt(II) compounds, Pt(IV) prodrugs, to Pt nanocrystals/nanoclusters</span></div><div class="casAuthors">Hu, Xi; Li, Fangyuan; Noor, Nabila; Ling, Daishun</div><div class="citationInfo"><span class="NLM_cas:title">Science Bulletin</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">589-596</span>CODEN:
                <span class="NLM_cas:coden">SBCUA5</span>;
        ISSN:<span class="NLM_cas:issn">2095-9281</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Platinum (Pt) based drugs, such as cisplatin, are widely used as anti-cancer agents, but their severe adverse reactions and resistance of cancer patients have limited their board clin. use.  For the last few decades, Pt(II) compds., Pt(IV) prodrugs as well as smart drug delivery systems have been developed to overcome these problems.  However, most conventional strategies rely on the similar anti-cancer mechanism with cisplatin and consequently only achieve limited success.  Recently, Pt nanocrystals/nanoclusters (Pt NCs), with a brand new anti-cancer mechanism, have shown a promising potential in targeted cancer therapy, esp. in Pt resistance circumvention.  This review is helpful to understand the research strategies of Pt drugs, particularly, the recent developments and medical applications of Pt NCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-Chotf7yUtrVg90H21EOLACvtfcHk0lhWeLNGVSMutg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGjsLrM&md5=deca656db6fa01b915776a4c5c17ca52</span></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=10.1016%2Fj.scib.2017.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.scib.2017.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DNoor%26aufirst%3DN.%26aulast%3DLing%26aufirst%3DD.%26atitle%3DPlatinum%2520Drugs%253A%2520from%2520Pt%2528II%2529%2520Compounds%252C%2520Pt%2528IV%2529%2520Prodrugs%252C%2520to%2520Pt%2520Nanocrystals%252FNanoclusters%26jtitle%3DSci.%2520Bull.%26date%3D2017%26volume%3D62%26spage%3D589%26epage%3D596%26doi%3D10.1016%2Fj.scib.2017.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span> <span> </span><span class="NLM_article-title">Platinum(IV) Prodrugs with Long Lipid Chains for Drug Delivery and Overcoming Cisplatin Resistance</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5369</span>– <span class="NLM_lpage">5372</span>, <span class="refDoi"> DOI: 10.1039/C8CC02791A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1039%2FC8CC02791A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=29744485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVOntrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2018&pages=5369-5372&author=Q.+Chenauthor=Y.+Yangauthor=X.+Linauthor=W.+Maauthor=G.+Chenauthor=W.+Liauthor=X.+Wangauthor=Z.+Yu&title=Platinum%28IV%29+Prodrugs+with+Long+Lipid+Chains+for+Drug+Delivery+and+Overcoming+Cisplatin+Resistance&doi=10.1039%2FC8CC02791A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32dR"><div class="casContent"><span class="casTitleNuber">32d</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum(IV) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance</span></div><div class="casAuthors">Chen, Qiling; Yang, Yuanyuan; Lin, Xun; Ma, Wen; Chen, Gui; Li, Wenliang; Wang, Xuefeng; Yu, Zhiqiang</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">5369-5372</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Platinum(IV) prodrugs of clin. used cisplatin and oxaliplatin with two axial long lipid chains were developed for nanoparticle delivery to combat cisplatin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_iuw0-GjjL7Vg90H21EOLACvtfcHk0lhWeLNGVSMutg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVOntrk%253D&md5=64089c68c1063bb1f5e4c43b83aee428</span></div><a href="/servlet/linkout?suffix=cit32d&amp;dbid=16384&amp;doi=10.1039%2FC8CC02791A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CC02791A%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DZ.%26atitle%3DPlatinum%2528IV%2529%2520Prodrugs%2520with%2520Long%2520Lipid%2520Chains%2520for%2520Drug%2520Delivery%2520and%2520Overcoming%2520Cisplatin%2520Resistance%26jtitle%3DChem.%2520Commun.%26date%3D2018%26volume%3D54%26spage%3D5369%26epage%3D5372%26doi%3D10.1039%2FC8CC02791A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrache, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berding, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, S.</span></span> <span> </span><span class="NLM_article-title">The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1963</span>– <span class="NLM_lpage">1967</span>, <span class="refDoi"> DOI: 10.1002/anie.201308899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fanie.201308899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1963-1967&author=R.+K.+Pathakauthor=S.+Marracheauthor=J.+H.+Choiauthor=T.+B.+Berdingauthor=S.+Dhar&title=The+Prodrug+Platin-A%3A+Simultaneous+Release+of+Cisplatin+and+Aspirin&doi=10.1002%2Fanie.201308899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin</span></div><div class="casAuthors">Pathak, Rakesh K.; Marrache, Sean; Choi, Joshua H.; Berding, Trenton B.; Dhar, Shanta</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1963-1967</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cancer-assocd. inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers.  The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin.  Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin.  These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHIPcwRalkB7Vg90H21EOLACvtfcHk0liCuPJWvVBF1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyktrw%253D&md5=d40b197ee5448e5a64a60c656eb0fde9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fanie.201308899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201308899%26sid%3Dliteratum%253Aachs%26aulast%3DPathak%26aufirst%3DR.%2BK.%26aulast%3DMarrache%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DJ.%2BH.%26aulast%3DBerding%26aufirst%3DT.%2BB.%26aulast%3DDhar%26aufirst%3DS.%26atitle%3DThe%2520Prodrug%2520Platin-A%253A%2520Simultaneous%2520Release%2520of%2520Cisplatin%2520and%2520Aspirin%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D1963%26epage%3D1967%26doi%3D10.1002%2Fanie.201308899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. Y.</span></span> <span> </span><span class="NLM_article-title">Fuplatin: An Efficient and Low-Toxic Dual-Prodrug</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4543</span>– <span class="NLM_lpage">4554</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00128</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00128" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFCgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4543-4554&author=R.+Zhangauthor=X.+Q.+Songauthor=R.+P.+Liuauthor=Z.+Y.+Maauthor=J.+Y.+Xu&title=Fuplatin%3A+An+Efficient+and+Low-Toxic+Dual-Prodrug&doi=10.1021%2Facs.jmedchem.9b00128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Fuplatin: An Efficient and Low-Toxic Dual-Prodrug</span></div><div class="casAuthors">Zhang, Ran; Song, Xue-Qing; Liu, Rui-Ping; Ma, Zhong-Ying; Xu, Jing-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4543-4554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As FDA-approved chemotherapeutic agents, cisplatin, oxaliplatin, and 5-fluorouracil are widely used in clinic but limited by severe side-effects.  To ameliorate their resp. defects, a series of "dual-prodrug" by linking oxoplatin and 5-FU were designed and synthesized.  The assembled compds. 10-17, named Fuplatin, exhibited much higher cytotoxicity against the tested cancer cells while lower cytotoxicity toward the human normal lung cells than free drugs or their combinations.  Among them, 14 enhanced cellular accumulation with 62- and 825-fold amt. of oxaliplatin and 8 at 9 h, resp., significantly induced DNA damage and cell apoptosis, and inhibited migration and invasion in HCT-116 cells.  Compd. 14 arrested the cell cycle at S and G2 phases and up-regulated thymidylate synthase and p53, consistent with the results of the combination, suggesting 14 adopted a collaborative mode of 5-FU and oxaliplatin to kill cancer cells.  In vivo, compd. 14 showed high antitumor effect and no observable toxicity in NOD/SCID mice bearing HCT-116 tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhZrU6zmfHWbVg90H21EOLACvtfcHk0liCuPJWvVBF1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFCgs7Y%253D&md5=4dc3d04c95e2f9fb1266e25511e6e491</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00128%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DSong%26aufirst%3DX.%2BQ.%26aulast%3DLiu%26aufirst%3DR.%2BP.%26aulast%3DMa%26aufirst%3DZ.%2BY.%26aulast%3DXu%26aufirst%3DJ.%2BY.%26atitle%3DFuplatin%253A%2520An%2520Efficient%2520and%2520Low-Toxic%2520Dual-Prodrug%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4543%26epage%3D4554%26doi%3D10.1021%2Facs.jmedchem.9b00128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolishetti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, S.</span></span> <span> </span><span class="NLM_article-title">A Prodrug of Two Approved Drugs, Cisplatin and Chlorambucil, for Chemo War against Cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1158%2F1535-7163.MCT-16-0445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=28148716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlOqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=625-636&author=R.+K.+Pathakauthor=R.+Wenauthor=N.+Kolishettiauthor=S.+Dhar&title=A+Prodrug+of+Two+Approved+Drugs%2C+Cisplatin+and+Chlorambucil%2C+for+Chemo+War+against+Cancer&doi=10.1158%2F1535-7163.MCT-16-0445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A Prodrug of Two Approved Drugs, Cisplatin and Chlorambucil, for Chemo War Against Cancer</span></div><div class="casAuthors">Pathak, Rakesh K.; Wen, Ru; Kolishetti, Nagesh; Dhar, Shanta</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">625-636</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cancer cells maintain normal mitochondrial glutathione as one of the defense mechanisms to inhibit mitochondrial membrane polarization and hence apoptosis.  A combinational therapeutic modality Platin-Cbl, a prodrug of FDA-approved chemotherapeutic agents, cisplatin and chlorambucil (Cbl), was synthesized and characterized to explore the potential of this compd. to initiate chemo war on cancer cells using the active drugs, cisplatin and Cbl, when delivered to the cellular power house mitochondrion using a targeted nanoparticle designed to get assocd. with this organelle.  Platin-Cbl demonstrated significantly high cytotoxic activity across a no. of tumor cell lines as well as in a cisplatin-resistant cancer cell line compared with cisplatin or its mixt. with Cbl suggesting its unique potency in cisplatin-resistant tumors.  A mitochondria-targeted nanoparticle formulation of Platin-Cbl allowed for its efficacious mitochondrial delivery.  In vitro studies documented high potency of Platin-Cbl nanoparticle formulations.  Cisplatin-resistant cells upon treatment with Platin-Cbl were still able to manage energy prodn. to a certain extent via fatty acid pathway; the advantage of using T-Platin-Cbl-NP is that this nanoparticle treatment causes impairment of all metabolic pathways in cisplatin-resistant cells forcing the cells to undergo efficient apoptosis.  This study highlights a combination of several beneficial effects for a cascade of events to overcome resistance assocd. with single drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfFjdSpGRDPrVg90H21EOLACvtfcHk0liCuPJWvVBF1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlOqurg%253D&md5=09c2ece4b1c1dde0da12ac78ee282b26</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0445%26sid%3Dliteratum%253Aachs%26aulast%3DPathak%26aufirst%3DR.%2BK.%26aulast%3DWen%26aufirst%3DR.%26aulast%3DKolishetti%26aufirst%3DN.%26aulast%3DDhar%26aufirst%3DS.%26atitle%3DA%2520Prodrug%2520of%2520Two%2520Approved%2520Drugs%252C%2520Cisplatin%2520and%2520Chlorambucil%252C%2520for%2520Chemo%2520War%2520against%2520Cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D625%26epage%3D636%26doi%3D10.1158%2F1535-7163.MCT-16-0445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Forsgård, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korpela, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frias, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spillmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterlund, P.</span></span> <span> </span><span class="NLM_article-title">Intestinal Permeability to Iohexol as An in Vivo Marker of Chemotherapy-Induced Gastrintestinal Toxicity in Sprague-Dawley Rats</span>. <i>Cancer Chemoth. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.1007/s00280-016-3150-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1007%2Fs00280-016-3150-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=27590707" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2016&pages=863-874&author=R.+A.+Forsg%C3%A5rdauthor=R.+Korpelaauthor=R.+Holmaauthor=J.+Lindenauthor=R.+Friasauthor=T.+Spillmannauthor=P.+Osterlund&title=Intestinal+Permeability+to+Iohexol+as+An+in+Vivo+Marker+of+Chemotherapy-Induced+Gastrintestinal+Toxicity+in+Sprague-Dawley+Rats&doi=10.1007%2Fs00280-016-3150-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-3150-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-3150-3%26sid%3Dliteratum%253Aachs%26aulast%3DForsg%25C3%25A5rd%26aufirst%3DR.%2BA.%26aulast%3DKorpela%26aufirst%3DR.%26aulast%3DHolma%26aufirst%3DR.%26aulast%3DLinden%26aufirst%3DJ.%26aulast%3DFrias%26aufirst%3DR.%26aulast%3DSpillmann%26aufirst%3DT.%26aulast%3DOsterlund%26aufirst%3DP.%26atitle%3DIntestinal%2520Permeability%2520to%2520Iohexol%2520as%2520An%2520in%2520Vivo%2520Marker%2520of%2520Chemotherapy-Induced%2520Gastrintestinal%2520Toxicity%2520in%2520Sprague-Dawley%2520Rats%26jtitle%3DCancer%2520Chemoth.%2520Pharm.%26date%3D2016%26volume%3D78%26spage%3D863%26epage%3D874%26doi%3D10.1007%2Fs00280-016-3150-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzaroni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porro, G. B.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal Side-Effects of Traditional Non-Steroidal Anti-Inflammatory Drugs and New Formulations</span>. <i>Aliment. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2036.2004.02037.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1111%2Fj.1365-2036.2004.02037.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=15335413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVylurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2004&pages=48-58&author=M.+Lazzaroniauthor=G.+B.+Porro&title=Gastrointestinal+Side-Effects+of+Traditional+Non-Steroidal+Anti-Inflammatory+Drugs+and+New+Formulations&doi=10.1111%2Fj.1365-2036.2004.02037.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36bR"><div class="casContent"><span class="casTitleNuber">36b</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations</span></div><div class="casAuthors">Lazzaroni, M.; Porro, G. Bianchi</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">Suppl. 2</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Although adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs) occur in only a small proportion of users, the widespread use of these drugs has resulted in a substantial overall no. of affected persons who experience serious gastrointestinal complications.  Dyspeptic symptoms are estd. to occur in 10-60% of NSAID users and lead to discontinuation of treatment in 5-15% of rheumatoid arthritis patients taking NSAIDs.  It is now well established that the point prevalence of peptic ulcer disease in patients receiving conventional NSAID therapy ranges between 10 and 30%, representing a 10-30-fold increase over that found in the general population.  One of 175 users of conventional NSAIDs in the USA will be hospitalized each year for NSAID-induced gastrointestinal damage.  The mortality of hospitalized patients remains about 5-10%, with an expected annual death rate of 0.08%.  The selective COX-II inhibitors (rofecoxib, celecoxib, parecoxib, etoricoxib, valdecoxib, lumiracoxib) show consistently comparable efficacy to that of conventional non-steroidal anti-inflammatory drugs (NSAIDs) in patients with rheumatoid arthritis and osteoarthritis, but have a significantly reduced propensity to cause gastrointestinal toxicity.  In many cases, the gastric effects of therapeutically active doses of COX-II inhibitors are indistinguishable from placebo.  The safety benefits of COX-2 inhibitors given alone appear similar to combined therapy with conventional NSAIDs and gastroprotective agents.  These findings warrant the consideration of COX-II inhibitors as first-line therapy in patients requiring long-term pain control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUdq4FK9ELkLVg90H21EOLACvtfcHk0lhtnqceZ1nBSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVylurk%253D&md5=719472f425b2fba21e3f224a82fe5d7b</span></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2036.2004.02037.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2036.2004.02037.x%26sid%3Dliteratum%253Aachs%26aulast%3DLazzaroni%26aufirst%3DM.%26aulast%3DPorro%26aufirst%3DG.%2BB.%26atitle%3DGastrointestinal%2520Side-Effects%2520of%2520Traditional%2520Non-Steroidal%2520Anti-Inflammatory%2520Drugs%2520and%2520New%2520Formulations%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2004%26volume%3D20%26spage%3D48%26epage%3D58%26doi%3D10.1111%2Fj.1365-2036.2004.02037.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Claustrat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chazot, G.</span></span> <span> </span><span class="NLM_article-title">The Basic Physiology and Pathophysiology of Melatonin</span>. <i>Sleep Med. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.smrv.2004.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.smrv.2004.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=15649735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252FisVaisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=11-24&author=B.+Claustratauthor=J.+Brunauthor=G.+Chazot&title=The+Basic+Physiology+and+Pathophysiology+of+Melatonin&doi=10.1016%2Fj.smrv.2004.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The basic physiology and pathophysiology of melatonin</span></div><div class="casAuthors">Claustrat Bruno; Brun Jocelyne; Chazot Guy</div><div class="citationInfo"><span class="NLM_cas:title">Sleep medicine reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-24</span>
        ISSN:<span class="NLM_cas:issn">1087-0792</span>.
    </div><div class="casAbstract">Melatonin is a methoxyindole synthesized and secreted principally by the pineal gland at night under normal environmental conditions.  The endogenous rhythm of secretion is generated by the suprachiasmatic nuclei and entrained to the light/dark cycle.  Light is able to either suppress or synchronize melatonin production according to the light schedule.  The nycthohemeral rhythm of this hormone can be determined by repeated measurement of plasma or saliva melatonin or urine sulfatoxymelatonin, the main hepatic metabolite.  The primary physiological function of melatonin, whose secretion adjusts to night length, is to convey information concerning the daily cycle of light and darkness to body physiology.  This information is used for the organisation of functions, which respond to changes in the photoperiod such as the seasonal rhythms.  Seasonal rhythmicity of physiological functions in humans related to possible alteration of the melatonin message remains, however, of limited evidence in temperate areas in field conditions.  Also, the daily melatonin secretion, which is a very robust biochemical signal of night, can be used for the organisation of circadian rhythms.  Although functions of this hormone in humans are mainly based on correlative observations, there is some evidence that melatonin stabilises and strengthens coupling of circadian rhythms, especially of core temperature and sleep-wake rhythms.  The circadian organisation of other physiological functions could depend on the melatonin signal, for instance immune, antioxidative defences, hemostasis and glucose regulation.  Since the regulating system of melatonin secretion is complex, following central and autonomic pathways, there are many pathophysiological situations where the melatonin secretion can be disturbed.  The resulting alteration could increase predisposition to disease, add to the severity of symptoms or modify the course and outcome of the disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSXjyWMXya5qjAyhZbj3lKdfW6udTcc2eaeTG11ZkgB2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252FisVaisA%253D%253D&md5=98b03fa9a2b0a6778c59bc29d7628ef2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.smrv.2004.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.smrv.2004.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DClaustrat%26aufirst%3DB.%26aulast%3DBrun%26aufirst%3DJ.%26aulast%3DChazot%26aufirst%3DG.%26atitle%3DThe%2520Basic%2520Physiology%2520and%2520Pathophysiology%2520of%2520Melatonin%26jtitle%3DSleep%2520Med.%2520Rev.%26date%3D2005%26volume%3D9%26spage%3D11%26epage%3D24%26doi%3D10.1016%2Fj.smrv.2004.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">New NSAID-Pt(IV) Prodrugs to Suppress Metastasis and Invasion of Tumor Cells and Enhance Anti-Tumor Effect in vitro and in vivo</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.02.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.ejmech.2019.02.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=30784875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsFSjtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2019&pages=377-387&author=X.+Q.+Songauthor=Z.+Y.+Maauthor=Y.+G.+Wuauthor=M.+L.+Daiauthor=D.+B.+Wangauthor=J.+Y.+Xuauthor=Y.+Liu&title=New+NSAID-Pt%28IV%29+Prodrugs+to+Suppress+Metastasis+and+Invasion+of+Tumor+Cells+and+Enhance+Anti-Tumor+Effect+in+vitro+and+in+vivo&doi=10.1016%2Fj.ejmech.2019.02.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">New NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo</span></div><div class="casAuthors">Song, Xue-Qing; Ma, Zhong-Ying; Wu, Yi-Gang; Dai, Miao-Liang; Wang, Dong-Bo; Xu, Jing-Yuan; Liu, Yangzhong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">377-387</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The great interest in epithelial-to-mesenchymal transition (EMT) program lies in its assocn. with process of metastasis and invasion, which is a crucial cause of cancer-related death.  Herein, we designed and reported three new NSAID-Pt(IV) prodrugs, taking Non-Steroid Anti-Inflammatory Drugs (NSAIDs) to disrupt EMT program and assist genotoxic platinum-based drugs as a cytotoxicity booster, to offer a class of potential anticarcinogens with a multi-functional action mechanism.  The NSAID-Pt(IV) prodrugs, esp. Eto-Pt(IV), highly enhanced cellular uptake with amt. up to 42-fold at 3 h compared with CDDP, and greatly increased DNA damage and cell apoptosis, showing much higher cytotoxicity than cisplatin in the tested cancer cells even in A549/cis cells.  Among of them, Eto-Pt(IV) and Car-Pt(IV) exhibited more excellent activity than Sul-Pt(IV), arising from their redn.-labile and favorable lipophilicity.  Most strikingly, Eto-Pt(IV) markedly inhibited metastasis and invasion of MCF-7 cells, owing to its COX-2 suppression that down-regulated active MMP-2, vimentin protein and up-regulated E-cadherin.  In vivo, Eto-Pt(IV) displayed potent antitumor activity and no observable toxicity in BALB/c nude mice bearing MCF-7 tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmGvDMxXf6z7Vg90H21EOLACvtfcHk0lhtnqceZ1nBSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsFSjtLY%253D&md5=644a759ac528d39f039e4020e845ab5e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.02.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.02.041%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DX.%2BQ.%26aulast%3DMa%26aufirst%3DZ.%2BY.%26aulast%3DWu%26aufirst%3DY.%2BG.%26aulast%3DDai%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DD.%2BB.%26aulast%3DXu%26aufirst%3DJ.%2BY.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DNew%2520NSAID-Pt%2528IV%2529%2520Prodrugs%2520to%2520Suppress%2520Metastasis%2520and%2520Invasion%2520of%2520Tumor%2520Cells%2520and%2520Enhance%2520Anti-Tumor%2520Effect%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D167%26spage%3D377%26epage%3D387%26doi%3D10.1016%2Fj.ejmech.2019.02.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">del Río, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia Pedrero, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Campa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuazua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, S.</span></span> <span> </span><span class="NLM_article-title">Melatonin, an Endogenous-Specific Inhibitor of Estrogen Receptor alpha via Calmodulin</span>. <i>Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">38294</span>– <span class="NLM_lpage">38302</span>, <span class="refDoi"> DOI: 10.1074/jbc.M403140200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1074%2Fjbc.M403140200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnt1Oqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=38294-38302&author=B.+del+R%C3%ADoauthor=J.+M.+Garcia+Pedreroauthor=C.+Martinez-Campaauthor=P.+Zuazuaauthor=P.+S.+Lazoauthor=S.+Ramos&title=Melatonin%2C+an+Endogenous-Specific+Inhibitor+of+Estrogen+Receptor+alpha+via+Calmodulin&doi=10.1074%2Fjbc.M403140200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin, an Endogenous-specific Inhibitor of Estrogen Receptor α via Calmodulin</span></div><div class="casAuthors">del Rio, Beatriz; Pedrero, Juana M. Garcia; Martinez-Campa, Carlos; Zuazua, Pedro; Lazo, Pedro S.; Ramos, Sofia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">38294-38302</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Melatonin is an indole hormone produced mainly by the pineal gland.  We have previously demonstrated that melatonin interferes with estrogen (E2) signaling in MCF7 cells by impairing estrogen receptor (ER) pathways.  Here we present the characterization of its mechanism of action showing that melatonin is a specific inhibitor of E2-induced ERα-mediated transcription in both estrogen response element- and AP1-contg. promoters, whereas ERβ-mediated transactivation is not inhibited or even activated at certain promoters.  We show that the sensitivity of MCF-7 cells to melatonin depends on the ERα/ERβ ratio, and ectopic expression of ERβ results in MCF-7 cells becoming insensitive to this hormone.  Melatonin acts as a calmodulin antagonist inducing conformational changes in the ERα-calmodulin (CaM) complex, thus impairing the binding of E2·ERα·CaM complex to DNA and, therefore, preventing ERα-dependent transcription.  Moreover the mutant ERα (K302G,K303G), unable to bind calmodulin, becomes insensitive to melatonin.  The effect of melatonin is specific since other related indoles neither interact with CaM nor inhibit ERα-mediated transactivation.  Interestingly, melatonin does not affect the binding of coactivators to ERα, indicating that melatonin action is different from that of current therapeutic anti-estrogens used in breast cancer therapy.  Thus, they target ERα at different levels, representing two independent ways to control ERα activity.  It is, therefore, conceivably a synergistic pharmacol. effect of melatonin and current anti-estrogen drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeOG9aFJS5OrVg90H21EOLACvtfcHk0ljsnA6v9LZQGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnt1Oqtro%253D&md5=9a2c31e3ed2ae6c6deac38b8461c56a2</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M403140200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M403140200%26sid%3Dliteratum%253Aachs%26aulast%3Ddel%2BR%25C3%25ADo%26aufirst%3DB.%26aulast%3DGarcia%2BPedrero%26aufirst%3DJ.%2BM.%26aulast%3DMartinez-Campa%26aufirst%3DC.%26aulast%3DZuazua%26aufirst%3DP.%26aulast%3DLazo%26aufirst%3DP.%2BS.%26aulast%3DRamos%26aufirst%3DS.%26atitle%3DMelatonin%252C%2520an%2520Endogenous-Specific%2520Inhibitor%2520of%2520Estrogen%2520Receptor%2520alpha%2520via%2520Calmodulin%26jtitle%3DBiol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D38294%26epage%3D38302%26doi%3D10.1074%2Fjbc.M403140200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit39b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choung, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, K. W.</span></span> <span> </span><span class="NLM_article-title">Germacrone Inhibits Estrogen Receptor alpha-Mediated Transcription in MCF-7 Breast Cancer Cells</span>. <i>Phytother. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2036</span>– <span class="NLM_lpage">2043</span>, <span class="refDoi"> DOI: 10.1002/ptr.5711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fptr.5711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=27573551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGnsbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=2036-2043&author=M.+S.+Limauthor=S.+Y.+Choungauthor=K.+W.+Jeong&title=Germacrone+Inhibits+Estrogen+Receptor+alpha-Mediated+Transcription+in+MCF-7+Breast+Cancer+Cells&doi=10.1002%2Fptr.5711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39bR"><div class="casContent"><span class="casTitleNuber">39b</span><div class="casTitle"><span class="NLM_cas:atitle">Germacrone Inhibits Estrogen Receptor α-Mediated Transcription in MCF-7 Breast Cancer Cells</span></div><div class="casAuthors">Lim, Mi-Sun; Choung, Se-Young; Jeong, Kwang Won</div><div class="citationInfo"><span class="NLM_cas:title">Phytotherapy Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2036-2043</span>CODEN:
                <span class="NLM_cas:coden">PHYREH</span>;
        ISSN:<span class="NLM_cas:issn">0951-418X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Estrogen receptor (ER)α-pos. breast cancer cells regulate the expression of estrogen-responsive genes, which are involved in cell proliferation, differentiation, and cell cycle progression.  Clin., the inhibition of ERα-mediated gene expression in breast cancer cells has long been considered an effective way to prevent the development and progression of cancer.  Germacrone, a terpenoid compd. isolated from Rhizoma curcuma, has been known to have antitumor activity in various human cancer cell lines.  However, the mechanism by which germacrone inhibits the proliferation of breast cancer cells is still unclear.  Here, we demonstrated that germacrone inhibits ERα-mediated gene expression at the transcriptional level in MCF-7 cells.  Germacrone inhibits the recruitment of ERα to the estrogen response element on chromatin and consequently compromises the binding of switch/sucrose non-fermentable chromatin remodeling complex and RNA polymerase II to target gene promoter, thereby inhibiting the estrogen-induced chromatin accessibility.  In addn., germacrone efficiently potentiates the antitumor activity of methotrexate and 5-fluorouracil.  Our results not only provide substantial mol. mechanism of germacrone on ERα-mediated signaling in breast cancer cells but also demonstrate the benefits of germacrone as a combination therapy with other drugs for the treatment of breast cancer.  Copyright 2016 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHB7tNEB1qp7Vg90H21EOLACvtfcHk0ljsnA6v9LZQGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGnsbzF&md5=48c168a425867d7224f531e88b019e2f</span></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.1002%2Fptr.5711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fptr.5711%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DM.%2BS.%26aulast%3DChoung%26aufirst%3DS.%2BY.%26aulast%3DJeong%26aufirst%3DK.%2BW.%26atitle%3DGermacrone%2520Inhibits%2520Estrogen%2520Receptor%2520alpha-Mediated%2520Transcription%2520in%2520MCF-7%2520Breast%2520Cancer%2520Cells%26jtitle%3DPhytother.%2520Res.%26date%3D2016%26volume%3D30%26spage%3D2036%26epage%3D2043%26doi%3D10.1002%2Fptr.5711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Barceló, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolores, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlos, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alicia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carolina, A. G.</span></span> <span> </span><span class="NLM_article-title">Melatonin-Estrogen Interactions in Breast Cancer</span>. <i>J. Pineal Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1111/j.1600-079X.2004.00207.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1111%2Fj.1600-079X.2004.00207.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=217-222&author=E.+J.+S%C3%A1nchez-Barcel%C3%B3author=C.+Samuelauthor=M.+Doloresauthor=M.+C.+Carlosauthor=G.+Aliciaauthor=A.+G.+Carolina&title=Melatonin-Estrogen+Interactions+in+Breast+Cancer&doi=10.1111%2Fj.1600-079X.2004.00207.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-079X.2004.00207.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-079X.2004.00207.x%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Barcel%25C3%25B3%26aufirst%3DE.%2BJ.%26aulast%3DSamuel%26aufirst%3DC.%26aulast%3DDolores%26aufirst%3DM.%26aulast%3DCarlos%26aufirst%3DM.%2BC.%26aulast%3DAlicia%26aufirst%3DG.%26aulast%3DCarolina%26aufirst%3DA.%2BG.%26atitle%3DMelatonin-Estrogen%2520Interactions%2520in%2520Breast%2520Cancer%26jtitle%3DJ.%2520Pineal%2520Res.%26date%3D2010%26volume%3D38%26spage%3D217%26epage%3D222%26doi%3D10.1111%2Fj.1600-079X.2004.00207.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ram, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. M.</span></span> <span> </span><span class="NLM_article-title">Melatonin Inhibits Estrogen Receptor Transactivation and cAMP Levels in Breast Cancer Cells</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1023/A:1013301408464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1023%2FA%3A1013301408464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=11859872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVGjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=37-45&author=T.+Kieferauthor=P.+T.+Ramauthor=L.+Yuanauthor=S.+M.+Hill&title=Melatonin+Inhibits+Estrogen+Receptor+Transactivation+and+cAMP+Levels+in+Breast+Cancer+Cells&doi=10.1023%2FA%3A1013301408464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41aR"><div class="casContent"><span class="casTitleNuber">41a</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells</span></div><div class="casAuthors">Kiefer, T.; Ram, P. T.; Yuan, L.; Hill, S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-45</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">The authors have previously demonstrated that the pineal hormone, melatonin, can inhibit the growth of estrogen receptor-alpha (ERα)-pos. breast cancer cells and suppress ERα gene transcription.  To investigate the relationship between the estrogen response pathway and melatonin's growth inhibition, ERα-pos. MCF-7 human breast cancer cells were transiently transfected with an estrogen response element (ERE) luciferase reporter construct and then treated with melatonin (10-9-10-6 M) for 30 min followed by 10-9 M 17β-estradiol (E2) or treated with each compd. alone.  Melatonin pre-treatment significantly reduced E2-induced ERα transactivation and ERα-ERE binding activity.  The authors also conducted expts. to det. if melatonin modulates cAMP levels in MCF-7 cells.  Melatonin inhibited the forskolin-induced and E2-induced elevation of cAMP levels by 57 and 45%, resp.  These data indicate that melatonin can act as a biol. modifier to affect ERα transcriptional activity by regulating signal transduction pathways which impinge on the ERα and by altering E2-mediated ERα transactivation and ERα DNA binding activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RRlXM0u90LVg90H21EOLACvtfcHk0lizVQSN4d9qsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVGjs74%253D&md5=5678066e6c561ae5c6d4f54fec2dabca</span></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=10.1023%2FA%3A1013301408464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1013301408464%26sid%3Dliteratum%253Aachs%26aulast%3DKiefer%26aufirst%3DT.%26aulast%3DRam%26aufirst%3DP.%2BT.%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DS.%2BM.%26atitle%3DMelatonin%2520Inhibits%2520Estrogen%2520Receptor%2520Transactivation%2520and%2520cAMP%2520Levels%2520in%2520Breast%2520Cancer%2520Cells%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2002%26volume%3D71%26spage%3D37%26epage%3D45%26doi%3D10.1023%2FA%3A1013301408464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit41b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubocovich, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. M.</span></span> <span> </span><span class="NLM_article-title">MT1 Melatonin Receptor Overexpression Enhances the Growth Suppressive Effect of Melatonin in Human Breast Cancer Cells</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/S0303-7207(02)00029-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2FS0303-7207%2802%2900029-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=12088876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD38XkslGrtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2002&pages=147-156&author=L.+Yuanauthor=A.+R.+Collinsauthor=J.+Daiauthor=M.+L.+Dubocovichauthor=S.+M.+Hill&title=MT1+Melatonin+Receptor+Overexpression+Enhances+the+Growth+Suppressive+Effect+of+Melatonin+in+Human+Breast+Cancer+Cells&doi=10.1016%2FS0303-7207%2802%2900029-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41bR"><div class="casContent"><span class="casTitleNuber">41b</span><div class="casTitle"><span class="NLM_cas:atitle">MT1 melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells</span></div><div class="casAuthors">Yuan, Lin; Collins, April R.; Dai, Jun; Dubocovich, Margarita L.; Hill, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Melatonin inhibits the proliferation of estrogen receptor alpha (ERα)-pos. (MCF-7), but not ERα-neg. (MDA-MB-231) breast cancer cells.  Here, we assessed the effect of MT1 melatonin receptor stable overexpression in MCF-7 and MDA-MB-231 breast cancer cells on the growth-suppressive effects of melatonin.  Parental and vector-transfected MCF-7 cells demonstrated a modest, but significant, growth-suppressive response to melatonin; however, melatonin treatment of MT1-transfected MCF-7 cells resulted in significantly enhanced growth-suppression.  This response was blocked by an MT1/MT2 melatonin receptor antagonist.  Interestingly, MT1-overexpression did not induce a melatonin-sensitive phenotype in melatonin-insensitive MDA-MB-231 cells.  Finally, Northern blot anal. demonstrated an enhanced inhibition of ERα mRNA expression and an enhanced induction of pancreatic spasmolytic polypeptide (pS2) by melatonin in MT1-transfected MCF-7 cells relative to vector-transfected MCF-7 cells.  These data suggest the involvement of the MT1 melatonin receptor in mediation of melatonin effects on growth-suppression and gene-modulation in breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxSmCw74JFN7Vg90H21EOLACvtfcHk0lizVQSN4d9qsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkslGrtb8%253D&md5=bb22a0a3023a6d64ab27e2834a847ca7</span></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=10.1016%2FS0303-7207%2802%2900029-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0303-7207%252802%252900029-1%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DCollins%26aufirst%3DA.%2BR.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DDubocovich%26aufirst%3DM.%2BL.%26aulast%3DHill%26aufirst%3DS.%2BM.%26atitle%3DMT1%2520Melatonin%2520Receptor%2520Overexpression%2520Enhances%2520the%2520Growth%2520Suppressive%2520Effect%2520of%2520Melatonin%2520in%2520Human%2520Breast%2520Cancer%2520Cells%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2002%26volume%3D192%26spage%3D147%26epage%3D156%26doi%3D10.1016%2FS0303-7207%2802%2900029-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halip, L. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borota, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bora, A.</span></span> <span> </span><span class="NLM_article-title">Insight the Binding Site of Human Melatonin MTR1A Receptor</span>. <i>Rev. Roum. Chim.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">218</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2015&pages=213-218&author=L.+R.+C.+Halipauthor=A.+Borotaauthor=A.+Bora&title=Insight+the+Binding+Site+of+Human+Melatonin+MTR1A+Receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHalip%26aufirst%3DL.%2BR.%2BC.%26aulast%3DBorota%26aufirst%3DA.%26aulast%3DBora%26aufirst%3DA.%26atitle%3DInsight%2520the%2520Binding%2520Site%2520of%2520Human%2520Melatonin%2520MTR1A%2520Receptor%26jtitle%3DRev.%2520Roum.%2520Chim.%26date%3D2015%26volume%3D60%26spage%3D213%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alkozi, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez Montero, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doadrio, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pintor, J.</span></span> <span> </span><span class="NLM_article-title">Docking Studies for Melatonin Receptors</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1080/17460441.2018.1419184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1080%2F17460441.2018.1419184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=29271261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=241-248&author=H.+A.+Alkoziauthor=J.+M.+Sanchez+Monteroauthor=A.+L.+Doadrioauthor=J.+Pintor&title=Docking+Studies+for+Melatonin+Receptors&doi=10.1080%2F17460441.2018.1419184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Docking studies for melatonin receptors</span></div><div class="casAuthors">Alkozi, Hanan Awad; Sanchez Montero, Jose Maria; Doadrio, Antonio Luis; Pintor, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">241-248</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Melatonin is a neurohormone that controls many relevant physiol. processes beyond the control of circadian rhythms.  Melatonin's actions are carried out by two main types of melatonin receptors; MT1 and MT2.  These receptors are important, and not just because of the biol. actions of its natural agonist; but also, because melatonin analogs can improve or antagonize their biol. effect.: The following article describes the importance of melatonin as a biol. relevant mol.  It also defines the receptors for this substance, as well as the second messengers coupled to these receptors.  Lastly, the article describes the amino acid residues involved in the docking process in both MT1 and MT2 melatonin receptors.: The biol. actions of melatonin and their interpretations are becoming more relevant and therefore require the development of new pharmacol. tools.  Understanding the second messenger mechanisms involved in melatonin actions, as well as the characteristics of the docking of this mol. to MT1 and MT2 melatonin receptors, will permit the development of more selective agonists and antagonists which will help us to better understand this mol. as well to develop new therapeutic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq71VWIeZOKqLVg90H21EOLACvtfcHk0lizVQSN4d9qsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yguw%253D%253D&md5=4fe96caeeecb37c2763dfa64a38a23df</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1080%2F17460441.2018.1419184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2018.1419184%26sid%3Dliteratum%253Aachs%26aulast%3DAlkozi%26aufirst%3DH.%2BA.%26aulast%3DSanchez%2BMontero%26aufirst%3DJ.%2BM.%26aulast%3DDoadrio%26aufirst%3DA.%2BL.%26aulast%3DPintor%26aufirst%3DJ.%26atitle%3DDocking%2520Studies%2520for%2520Melatonin%2520Receptors%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2018%26volume%3D13%26spage%3D241%26epage%3D248%26doi%3D10.1080%2F17460441.2018.1419184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ghezzi, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aceto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osella, D.</span></span> <span> </span><span class="NLM_article-title">Uptake of Antitumor Platinum(II)-Complexes by Cancer Cells, Assayed by Inductively Coupled Plasma Mass Spectrometry (ICP-MS)</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2003.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.jinorgbio.2003.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=14659635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsVSqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2004&pages=73-78&author=A.+R.+Ghezziauthor=M.+Acetoauthor=C.+Cassinoauthor=E.+Gabanoauthor=D.+Osella&title=Uptake+of+Antitumor+Platinum%28II%29-Complexes+by+Cancer+Cells%2C+Assayed+by+Inductively+Coupled+Plasma+Mass+Spectrometry+%28ICP-MS%29&doi=10.1016%2Fj.jinorgbio.2003.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44aR"><div class="casContent"><span class="casTitleNuber">44a</span><div class="casTitle"><span class="NLM_cas:atitle">Uptake of antitumor platinum(II) complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS)</span></div><div class="casAuthors">Ghezzi, AnnaRita; Aceto, Maurizio; Cassino, Claudio; Gabano, Elisabetta; Osella, Domenico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-78</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A systematic study on intracellular Pt uptake and Pt accumulation ratio in breast cancer MCF-7 cell line has been performed on a no. of Pt(II)-complexes, namely cisplatin, carboplatin and oxaliplatin, clin. employed as antitumor drugs, trans- and cis-[Pt(Cl)2(pyridine)2] and cis-[Pt(Cl)2(pyridine)(5-SO3H-isoquinoline)] complexes, previously investigated also as potential telomerase inhibitors.  In particular, long incubation times have been chosen in order to understand the fate of the complexes in the cells.  For this purpose, sub-acute drug concns. must be employed and, therefore, a very sensitive method of anal. like as inductively coupled plasma mass spectrometry (ICP-MS) superior to the widely employed at. absorption spectroscopy (AAS) has been adopted.  Any relationships among uptake/accumulation and several parameters such as drug structure, lipophilicity, drug concn. and incubation time have been sought and analyzed: the bulk of data point for a passive diffusion mechanism through the cell membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiE303tU5N9LVg90H21EOLACvtfcHk0lgTOXuLjh3YsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsVSqtro%253D&md5=c12bb312708fcd0df827ba7f1d8c7cb4</span></div><a href="/servlet/linkout?suffix=cit44a&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2003.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2003.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DGhezzi%26aufirst%3DA.%2BR.%26aulast%3DAceto%26aufirst%3DM.%26aulast%3DCassino%26aufirst%3DC.%26aulast%3DGabano%26aufirst%3DE.%26aulast%3DOsella%26aufirst%3DD.%26atitle%3DUptake%2520of%2520Antitumor%2520Platinum%2528II%2529-Complexes%2520by%2520Cancer%2520Cells%252C%2520Assayed%2520by%2520Inductively%2520Coupled%2520Plasma%2520Mass%2520Spectrometry%2520%2528ICP-MS%2529%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2004%26volume%3D98%26spage%3D73%26epage%3D78%26doi%3D10.1016%2Fj.jinorgbio.2003.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit44b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Petruzzella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braude, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich-Wright, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span> <span> </span><span class="NLM_article-title">A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity against KRAS Mutated Cancer Cell Lines</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">11539</span>– <span class="NLM_lpage">11544</span>, <span class="refDoi"> DOI: 10.1002/anie.201706739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fanie.201706739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSlsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=11539-11544&author=E.+Petruzzellaauthor=J.+P.+Braudeauthor=J.+R.+Aldrich-Wrightauthor=V.+Gandinauthor=D.+Gibson&title=A+Quadruple-Action+Platinum%28IV%29+Prodrug+with+Anticancer+Activity+against+KRAS+Mutated+Cancer+Cell+Lines&doi=10.1002%2Fanie.201706739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44bR"><div class="casContent"><span class="casTitleNuber">44b</span><div class="casTitle"><span class="NLM_cas:atitle">A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines</span></div><div class="casAuthors">Petruzzella, Emanuele; Braude, Jeremy Phillip; Aldrich-Wright, Janice R.; Gandin, Valentina; Gibson, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">11539-11544</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We developed a novel PtIV prodrug that simultaneously releases four different bioactive moieties inside the cancer cell.  Its cytotoxicity against monolayer cultures (2D) and spheroid (3D) cancer cells is significantly better than cisplatin.  It is 200-450-fold more potent than cisplatin against KRAS mutated pancreatic and colon cancers and is 40-fold more selective towards KRAS mutated cells compared to non-cancerous.  This is important since RAS proteins play a role in regulating cell differentiation, proliferation, and survival and KRAS is mutated in 90 % of pancreatic adenocarcinomas, 45 % of colorectal cancers, and 35 % of lung adenocarcinomas.  The selectivity index, detd. by dividing the IC50 value in non-cancerous cells by that of a cancerous cell line, is two-fold better than cisplatin, attesting to preferential cytotoxicity towards neoplastic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTQHgQHWGMgbVg90H21EOLACvtfcHk0lgTOXuLjh3YsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSlsbbJ&md5=4a9c4fcc8d6006775b09c9e4c246d175</span></div><a href="/servlet/linkout?suffix=cit44b&amp;dbid=16384&amp;doi=10.1002%2Fanie.201706739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201706739%26sid%3Dliteratum%253Aachs%26aulast%3DPetruzzella%26aufirst%3DE.%26aulast%3DBraude%26aufirst%3DJ.%2BP.%26aulast%3DAldrich-Wright%26aufirst%3DJ.%2BR.%26aulast%3DGandin%26aufirst%3DV.%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DA%2520Quadruple-Action%2520Platinum%2528IV%2529%2520Prodrug%2520with%2520Anticancer%2520Activity%2520against%2520KRAS%2520Mutated%2520Cancer%2520Cell%2520Lines%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D11539%26epage%3D11544%26doi%3D10.1002%2Fanie.201706739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt(IV) Anticancer Prodrug</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9098</span>– <span class="NLM_lpage">9102</span>, <span class="refDoi"> DOI: 10.1002/anie.201804314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fanie.201804314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFemur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=9098-9102&author=L.+Maauthor=W.+Naauthor=R.+Maauthor=C.+Liauthor=M.+K.+Tseauthor=G.+Zhu&title=Monochalcoplatin%3A+An+Actively+Transported%2C+Quickly+Reducible%2C+and+Highly+Potent+Pt%28IV%29+Anticancer+Prodrug&doi=10.1002%2Fanie.201804314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer Prodrug</span></div><div class="casAuthors">Ma, Lili; Wang, Na; Ma, Rong; Li, Cai; Xu, Zoufeng; Tse, Man-Kit; Zhu, Guangyu</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">9098-9102</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Recently, PtIV prodrugs have attracted much attention as the next generation of platinum-based antineoplastic drug candidates.  Here we report the discovery and evaluation of monochalcoplatin, a monocarboxylated PtIV prodrug that is among the most cytotoxic PtIV prodrugs to date.  Compared with its dicarboxylated counterpart chalcoplatin, monochalcoplatin accumulates astonishingly effectively and rapidly in cancer cells, which is not ascribed to its lipophilicity.  The prodrug is quickly reduced, causes DNA damage, and induces apoptosis, resulting in superior cytotoxicity with IC50 values in the nanomolar range in both cisplatin-sensitive and -resistant cells; these IC50 values are up to 422-fold higher than that of cisplatin.  A detailed mechanistic study reveals that monochalcoplatin actively enters cells through a transporter-mediated process.  Moreover, monochalcoplatin shows significant antitumor activity in an in vivo colorectal tumor model.  Our study implies a practical strategy for the design of more effective PtIV prodrugs to conquer drug resistance by tuning both cellular uptake pathways and activation processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwWzOjWinSirVg90H21EOLACvtfcHk0lgTOXuLjh3YsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFemur%252FJ&md5=ef0e0d30da62acf13f0ceeb6729961c7</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fanie.201804314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201804314%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DNa%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTse%26aufirst%3DM.%2BK.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DMonochalcoplatin%253A%2520An%2520Actively%2520Transported%252C%2520Quickly%2520Reducible%252C%2520and%2520Highly%2520Potent%2520Pt%2528IV%2529%2520Anticancer%2520Prodrug%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D9098%26epage%3D9102%26doi%3D10.1002%2Fanie.201804314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlinchey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osella, D.</span></span> <span> </span><span class="NLM_article-title">A View on Multi-Action Pt(IV) Antitumor Prodrugs</span>. <i>Inorg. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>492</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.ica.2019.04.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.ica.2019.04.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlOjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2019&pages=32-47&author=M.+Raveraauthor=E.+Gabanoauthor=M.+J.+McGlincheyauthor=D.+Osella&title=A+View+on+Multi-Action+Pt%28IV%29+Antitumor+Prodrugs&doi=10.1016%2Fj.ica.2019.04.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A view on multi-action Pt(IV) antitumor prodrugs</span></div><div class="casAuthors">Ravera, Mauro; Gabano, Elisabetta; McGlinchey, Michael J.; Osella, Domenico</div><div class="citationInfo"><span class="NLM_cas:title">Inorganica Chimica Acta</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-47</span>CODEN:
                <span class="NLM_cas:coden">ICHAA3</span>;
        ISSN:<span class="NLM_cas:issn">0020-1693</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Platinum(IV) complexes are particularly appealing as prodrugs since their relative inertness, and consequent low toxicity outside the cell is matched by their high activity inside the tumor cells upon redn. to their corresponding Pt(II) counterparts.  Synthetic routes to such systems, with particular emphasis on the bioactivity of the removable axial ligands, are described herein.  The kinetics and mechanisms of these reductive elimination processes are still not completely unraveled, and many questions remain unresolved.  We here present some of the more relevant examples of multi-action Pt(IV) complexes often grouped around their prototypal prodrugs (i.e., mitaplatin and mitochondria-targeted complexes, ethacraplatin and glutathione-S-transferase-targeted complexes, asplatin or platin-A and inhibitors of cyclooxygenases).  In addn., Pt(IV) conjugates with histone deacetylase inhibitors (HDACi) and "true" multiple-action complexes are exhaustively discussed.  These Pt(IV) conjugates contain adjuvant agents able to inhibit some specific (typically enzymic) mechanism characteristic of, or more active in, tumor cells.  These agents are able to act synergistically or at least additively with cisplatin and its congeners and overcome intrinsic or acquired chemoresistance.  Finally, we emphasize the need for a multidisciplinary approach in the battle against cancer using metallo-drugs by involving not only inorg. chemists, but also biochemists, mol. biologists and, of course, clinicians.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrolYCef0pyD7Vg90H21EOLACvtfcHk0lgTOXuLjh3YsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlOjt7Y%253D&md5=1236c2294fc5e0e4e5019ab2f21b4067</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ica.2019.04.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ica.2019.04.025%26sid%3Dliteratum%253Aachs%26aulast%3DRavera%26aufirst%3DM.%26aulast%3DGabano%26aufirst%3DE.%26aulast%3DMcGlinchey%26aufirst%3DM.%2BJ.%26aulast%3DOsella%26aufirst%3DD.%26atitle%3DA%2520View%2520on%2520Multi-Action%2520Pt%2528IV%2529%2520Antitumor%2520Prodrugs%26jtitle%3DInorg.%2520Chim.%2520Acta%26date%3D2019%26volume%3D492%26spage%3D32%26epage%3D47%26doi%3D10.1016%2Fj.ica.2019.04.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ong, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C. S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, W. H.</span></span> <span> </span><span class="NLM_article-title">A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1002/anie.201810361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fanie.201810361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVWks77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=164-167&author=J.+X.+Ongauthor=C.+S.+Q.+Limauthor=H.+V.+Leauthor=W.+H.+Ang&title=A+Ratiometric+Fluorescent+Probe+for+Cisplatin%3A+Investigating+the+Intracellular+Reduction+of+Platinum%28IV%29+Prodrug+Complexes&doi=10.1002%2Fanie.201810361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes</span></div><div class="casAuthors">Ong, Jun Xiang; Lim, Carine Shu Qing; Le, Hai Van; Ang, Wee Han</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">164-167</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The PtIV prodrug strategy has emerged as an excellent alternative to tackle the problems assocd. with conventional PtII drug therapy.  However, there is a lack of tools to study how this new class of PtIV drugs are processed at the cellular level.  Herein, we report the first ratiometric probe for cisplatin detection and use it to investigate PtIV anticancer complexes in biol. systems.  The probe was able to distinguish between cisplatin and its PtIV derivs., allowing us to probe the intracellular redn. of PtIV prodrug complexes.  The correlation between the amt. of active PtII species available after intracellular redn. of PtIV complexes and their cytotoxicity and the role glutathione plays in the redn. of PtIV complexes were investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4LDI8alc0JLVg90H21EOLACvtfcHk0ljWMLA1bFma6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVWks77I&md5=50cfc467400e54ed3a3dd5432acdf27b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fanie.201810361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201810361%26sid%3Dliteratum%253Aachs%26aulast%3DOng%26aufirst%3DJ.%2BX.%26aulast%3DLim%26aufirst%3DC.%2BS.%2BQ.%26aulast%3DLe%26aufirst%3DH.%2BV.%26aulast%3DAng%26aufirst%3DW.%2BH.%26atitle%3DA%2520Ratiometric%2520Fluorescent%2520Probe%2520for%2520Cisplatin%253A%2520Investigating%2520the%2520Intracellular%2520Reduction%2520of%2520Platinum%2528IV%2529%2520Prodrug%2520Complexes%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D164%26epage%3D167%26doi%3D10.1002%2Fanie.201810361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolbatov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Re, N.</span></span> <span> </span><span class="NLM_article-title">Insight into the Electrochemical Reduction Mechanism of Pt(IV) Anticancer Complexes</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3411</span>– <span class="NLM_lpage">3419</span>, <span class="refDoi"> DOI: 10.1021/acs.inorgchem.8b00177</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.inorgchem.8b00177" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslyju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=3411-3419&author=I.+Tolbatovauthor=C.+Colettiauthor=A.+Marroneauthor=N.+Re&title=Insight+into+the+Electrochemical+Reduction+Mechanism+of+Pt%28IV%29+Anticancer+Complexes&doi=10.1021%2Facs.inorgchem.8b00177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into the Electrochemical Reduction Mechanism of Pt(IV) Anticancer Complexes</span></div><div class="casAuthors">Tolbatov, Iogann; Coletti, Cecilia; Marrone, Alessandro; Re, Nazzareno</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3411-3419</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors carried out a theor. study on the mechanism of electrochem. redn. of the prototypical Pt(IV) anticancer complex [Pt(NH3)2(CH3COO)2Cl2] to the corresponding Pt(II) [Pt(NH3)2Cl2] deriv.  Energies and geometric structures of the original Pt(IV) complex and all possible Pt(III) and Pt(II) intermediates and transition states involved in the redn. process were calcd. using d. functional theory and Moller-Plesset perturbation theory.  This study allowed the authors to formulate a detailed mechanism for the two-electron redn. of the [PtIV(NH3)2(CH3COO)2Cl2] complex.  In agreement with the exptl. evidence from cyclic voltammetry, the initial 1-electron redn. of the [PtIV(NH3)2(CH3COO)2Cl2] complex occurs through a stepwise mechanism via a metastable hexacoordinated Pt(III) [PtIII(NH3)2(CH3COO)2Cl2]- intermediate and a subsequent acetate ligand detachment with an activation free energy of 5.1 kcal mol-1.  However, the 2nd electron redn. of the resulting pentacoordinated [PtIII(NH3)2(CH3COO)Cl2] species occurs through a barrierless concerted process to the final [PtII(NH3)2Cl2] deriv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCcsdizyeReLVg90H21EOLACvtfcHk0ljWMLA1bFma6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslyju7k%253D&md5=11d240d62c28080a82ee97e986c62ee1</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.inorgchem.8b00177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.inorgchem.8b00177%26sid%3Dliteratum%253Aachs%26aulast%3DTolbatov%26aufirst%3DI.%26aulast%3DColetti%26aufirst%3DC.%26aulast%3DMarrone%26aufirst%3DA.%26aulast%3DRe%26aufirst%3DN.%26atitle%3DInsight%2520into%2520the%2520Electrochemical%2520Reduction%2520Mechanism%2520of%2520Pt%2528IV%2529%2520Anticancer%2520Complexes%26jtitle%3DInorg.%2520Chem.%26date%3D2018%26volume%3D57%26spage%3D3411%26epage%3D3419%26doi%3D10.1021%2Facs.inorgchem.8b00177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filotto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisanzo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagasee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitworth, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jusko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willingham, J.</span></span> <span> </span><span class="NLM_article-title">Reduction and Anticancer Activity of Platinum(IV) Complexes</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2500</span>– <span class="NLM_lpage">2504</span>, <span class="refDoi"> DOI: 10.1021/ic971047x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic971047x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADyaK1cXis12ku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=2500-2504&author=S.+Choiauthor=C.+Filottoauthor=M.+Bisanzoauthor=S.+Delaneyauthor=D.+Lagaseeauthor=J.+L.+Whitworthauthor=A.+Juskoauthor=C.+Liauthor=N.+A.+Woodauthor=J.+Willingham&title=Reduction+and+Anticancer+Activity+of+Platinum%28IV%29+Complexes&doi=10.1021%2Fic971047x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction and Anticancer Activity of Platinum(IV) Complexes</span></div><div class="casAuthors">Choi, Sunhee; Filotto, Catherine; Bisanzo, Mark; Delaney, Sarah; Lagasee, Daniel; Whitworth, Jennifer L.; Jusko, Andrew; Li, Chengruo; Wood, Nicole A.; Willingham, Jennifer; Schwenker, Amy; Spaulding, Kathleen</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2500-2504</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of PtIV anticancer complexes with chloro leaving groups have been investigated for the effects of axial and carrier ligands on the redn. and cytotoxicity.  The redn. rates of the PtIV complexes such as Pt(d,l)(1,2-(NH2)2C6H10)Cl4 (tetraplatin, Pt(dach)Cl4; dach = diaminocyclohexane), cis,trans,cis-[Pt((CH3)2CHNH2)2(OH)2Cl2] (iproplatin, Pt(ipa)(OH)2Cl2; ipa = isopropylamine), cis,trans,cis-[Pt(NH3)(C6H11NH2)(OCOCH3)2Cl2] (JM-216, Pt(a,cha)(OCOCH3)2Cl2; a = ammine, cha = cyclohexylamine), cis,trans,cis-[Pt(NH3)(C6H11NH2)(OCOC3H7)2Cl2] (JM-221, Pt(a,cha)(OCOC3H7)2Cl2), cis,trans,cis-[Pt(en)(OH)2Cl2], Pt(en)Cl4 (en = ethylenediamine), cis,trans,cis-[Pt(en)(OCOCH3)2Cl2], and cis,trans,cis-[Pt(en)(OCOCF3)2Cl2] by ascorbate and cathodic redn. potentials strongly depend on the electron-withdrawing power and the steric hindrance of the axial and carrier ligands.  Beginning with PtIV complexes bearing en carrier ligands, redn. rates and redn. potentials increase in the following order of axial ligand substitutions: OH < OCOCH3 < Cl < OCOCF3, coinciding with increasing electron-withdrawing power of the axial ligand.  PtIV complexes with en carrier ligands tend to show slower redn. rates than the corresponding complexes with ipa or cha carrier ligands.  Ascorbic acid does not reduce Pt(en)(OH)2Cl2, but reduces Pt(ipa)(OH)2Cl2.  The redn. rate of Pt(a,cha)(OCOCH3)2Cl2 is about 12 times higher than that of Pt(en)(OCOCH3)2Cl2.  Overall, there is no strong correlation between redn. rate and cytotoxicity toward cisplatin-sensitive L1210/0 cells among the eight complexes studied.  However, when the four compds. with en carrier ligands were compared with one another, the one with the fastest redn. rate exhibited the highest cytotoxicity.  The cytotoxicity increases with axial ligand substitution in the order OH < OCOCH3 < Cl < OCOCF3, following the same trend as redn. rate.  Comparing complexes having different carrier ligands but the same axial ligands reveals that the compd. with the faster redn. rate exhibits the higher cytotoxicity.  Redn. rate and cytotoxicity increase in the order Pt(en)(OH)2Cl2 < Pt(ipa)(OH)2Cl2, Pt(en)(OCOCH3)2Cl2 < Pt(a,cha)(OCOCH3)2Cl2, Pt(en)Cl4 < Pt(dach)Cl4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSbVAQFm8w7bVg90H21EOLACvtfcHk0ljWMLA1bFma6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis12ku70%253D&md5=7818e9c8accf0ac302d1992a43ae7bee</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fic971047x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic971047x%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DFilotto%26aufirst%3DC.%26aulast%3DBisanzo%26aufirst%3DM.%26aulast%3DDelaney%26aufirst%3DS.%26aulast%3DLagasee%26aufirst%3DD.%26aulast%3DWhitworth%26aufirst%3DJ.%2BL.%26aulast%3DJusko%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DN.%2BA.%26aulast%3DWillingham%26aufirst%3DJ.%26atitle%3DReduction%2520and%2520Anticancer%2520Activity%2520of%2520Platinum%2528IV%2529%2520Complexes%26jtitle%3DInorg.%2520Chem.%26date%3D1998%26volume%3D37%26spage%3D2500%26epage%3D2504%26doi%3D10.1021%2Fic971047x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petermann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R. A.</span></span> <span> </span><span class="NLM_article-title">DNA Repair Pathways as Targets for Cancer Therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1038/nrc2342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1038%2Fnrc2342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=18256616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlOisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=193-204&author=T.+Helledayauthor=E.+Petermannauthor=C.+Lundinauthor=B.+Hodgsonauthor=R.+A.+Sharma&title=DNA+Repair+Pathways+as+Targets+for+Cancer+Therapy&doi=10.1038%2Fnrc2342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">DNA repair pathways as targets for cancer therapy</span></div><div class="casAuthors">Helleday, Thomas; Petermann, Eva; Lundin, Cecilia; Hodgson, Ben; Sharma, Ricky A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-204</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA repair pathways can enable tumor cells to survive DNA damage that is induced by chemotherapeutic treatments; therefore, inhibitors of specific DNA repair pathways might prove efficacious when used in combination with DNA-damaging chemotherapeutic drugs.  In addn., alterations in DNA repair pathways that arise during tumor development can make some cancer cells reliant on a reduced set of DNA repair pathways for survival.  There is evidence that drugs that inhibit one of these pathways in such tumors could prove useful as single-agent therapies, with the potential advantage that this approach could be selective for tumor cells and have fewer side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3W53LJmdCPrVg90H21EOLACvtfcHk0ljaLZQuaq-m6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlOisr8%253D&md5=8592af6d815e5ca9c80ee256791bafb7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnrc2342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2342%26sid%3Dliteratum%253Aachs%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DPetermann%26aufirst%3DE.%26aulast%3DLundin%26aufirst%3DC.%26aulast%3DHodgson%26aufirst%3DB.%26aulast%3DSharma%26aufirst%3DR.%2BA.%26atitle%3DDNA%2520Repair%2520Pathways%2520as%2520Targets%2520for%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D193%26epage%3D204%26doi%3D10.1038%2Fnrc2342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Roos, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernd, K.</span></span> <span> </span><span class="NLM_article-title">DNA Damage-Induced Cell Death: from Specific DNA Lesions to the DNA Damage Response and Apoptosis</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>332</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2012.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.canlet.2012.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=22261329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFKhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2013&pages=237-248&author=W.+P.+Roosauthor=K.+Bernd&title=DNA+Damage-Induced+Cell+Death%3A+from+Specific+DNA+Lesions+to+the+DNA+Damage+Response+and+Apoptosis&doi=10.1016%2Fj.canlet.2012.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51aR"><div class="casContent"><span class="casTitleNuber">51a</span><div class="casTitle"><span class="NLM_cas:atitle">DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis</span></div><div class="casAuthors">Roos, Wynand P.; Kaina, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">237-248</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  DNA damaging agents are potent inducers of cell death triggered by apoptosis.  Since these agents induce a plethora of different DNA lesions, it is firstly important to identify the specific lesions responsible for initiating apoptosis before the apoptotic executing pathways can be elucidated.  Here, we describe specific DNA lesions that were identified as apoptosis triggers, their repair and the signaling provoked by them.  We discuss methylating agents such as temozolomide, ionizing radiation and cisplatin, all of them are important in cancer therapy.  We show that the potentially lethal events for the cell are O6-methylguanine adducts that are converted by mismatch repair into DNA double-strand breaks (DSBs), non-repaired N-methylpurines and abasic sites as well as bulky adducts that block DNA replication leading to DSBs that are also directly induced following ionizing radiation.  Transcriptional inhibition may also contribute to apoptosis.  Cells are equipped with sensors that detect DNA damage and relay the signal via kinases to executors, who on their turn evoke a process that inhibits cell cycle progression and provokes DNA repair or, if this fails, activate the receptor and/or mitochondrial apoptotic cascade.  The main DNA damage recognition factors MRN and the PI3 kinases ATM, ATR and DNA-PK, which phosphorylate a multitude of proteins and thus induce the DNA damage response (DDR), will be discussed as well as the downstream players p53, NF-κB, Akt and survivin.  We review data and models describing the signaling from DNA damage to the apoptosis executing machinery and discuss the complex interplay between cell survival and death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9_P1z1Z5oBbVg90H21EOLACvtfcHk0ljaLZQuaq-m6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFKhsb8%253D&md5=aae5a110552faeb7644708047987f5e6</span></div><a href="/servlet/linkout?suffix=cit51a&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2012.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2012.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoos%26aufirst%3DW.%2BP.%26aulast%3DBernd%26aufirst%3DK.%26atitle%3DDNA%2520Damage-Induced%2520Cell%2520Death%253A%2520from%2520Specific%2520DNA%2520Lesions%2520to%2520the%2520DNA%2520Damage%2520Response%2520and%2520Apoptosis%26jtitle%3DCancer%2520Lett.%26date%3D2013%26volume%3D332%26spage%3D237%26epage%3D248%26doi%3D10.1016%2Fj.canlet.2012.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit51b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">8790</span>– <span class="NLM_lpage">8798</span>, <span class="refDoi"> DOI: 10.1021/ja5038269</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5038269" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=8790-8798&author=Y.+R.+Zhengauthor=K.+Suntharalingamauthor=T.+C.+Johnstoneauthor=H.+Yooauthor=W.+Linauthor=J.+G.+Brooksauthor=S.+J.+Lippard&title=Pt%28IV%29+Prodrugs+Designed+to+Bind+Non-Covalently+to+Human+Serum+Albumin+for+Drug+Delivery&doi=10.1021%2Fja5038269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51bR"><div class="casContent"><span class="casTitleNuber">51b</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery</span></div><div class="casAuthors">Zheng, Yao-Rong; Suntharalingam, Kogularamanan; Johnstone, Timothy C.; Yoo, Hyunsuk; Lin, Wei; Brooks, Jamar G.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8790-8798</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Albumin is the most abundant protein in human serum and drugs that are administered i.v. inevitably interact with it.  We present here a series of platinum(IV) prodrugs designed specifically to enhance interaction with human serum albumin (HSA) for drug delivery.  This goal is achieved by asym. functionalizing the axial ligands of the prodrug so as to mimic the overall features of a fatty acid.  Systematic variation of the length of the aliph. tail tunes the cellular uptake and, consequently, the cytotoxicity of cis,cis,trans-[Pt(NH3)2Cl2(O2CCH2CH2COOH)(OCONHR)], 4, where R is a linear alkyl group.  Investigation of an analog bearing a fluorophore conjugated to the succinate ligand confirmed that these compds. are reduced by biol. reductants with loss of the axial ligands.  Intracellular release of cisplatin from 4 was further confirmed by observing the characteristic effects of cisplatin on the cell cycle and morphol. following treatment with the prodrug.  The most potent member of series 4, for which R is a hexadecyl chain, interacts with HSA in a 1:1 stoichiometry to form the platinum-protein complex 7.  The interaction is non-covalent and extn. with octanol completely removes the prodrug from an aq. soln. of HSA.  Construct 7 is robust and can be isolated following fast protein liq. chromatog.  The nature of the tight interaction was investigated computationally, and these studies suggest that the prodrug is buried below the surface of the protein.  Consequently, complexation to HSA is able to reduce the rate of redn. of the prodrug by ascorbate.  The lead compd. from series 4 also exhibited significant stability in whole human blood, attributed to its interaction with HSA.  This favorable redox profile, in conjunction with the established nonimmunogenicity, biocompatibility, and enhanced tumor accumulation of HSA, produces a system that holds significant therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOojHJiVKj17Vg90H21EOLACvtfcHk0ljaLZQuaq-m6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D&md5=541fe9e155e3f4e2f8d6f61f3d81ee5a</span></div><a href="/servlet/linkout?suffix=cit51b&amp;dbid=16384&amp;doi=10.1021%2Fja5038269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5038269%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%2BR.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DYoo%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DBrooks%26aufirst%3DJ.%2BG.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DPt%2528IV%2529%2520Prodrugs%2520Designed%2520to%2520Bind%2520Non-Covalently%2520to%2520Human%2520Serum%2520Albumin%2520for%2520Drug%2520Delivery%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D8790%26epage%3D8798%26doi%3D10.1021%2Fja5038269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quercetin
Suppresses, D. N. A.</span></span> <span> </span><span class="NLM_article-title">Double-Strand Break Repair and Enhances the Radiosensitivity of Human Ovarian Cancer Cells via p53-Dependent Endoplasmic Reticulum Stress Pathway</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.2147/OTT.S147316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.2147%2FOTT.S147316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=29317830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BC1MzptFertQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=17-27&author=C.+Gongauthor=Z.+Yangauthor=L.+Zhangauthor=Y.+Wangauthor=W.+Gongauthor=Y.+Liuauthor=D.+N.+A.+Quercetin%0ASuppresses&title=Double-Strand+Break+Repair+and+Enhances+the+Radiosensitivity+of+Human+Ovarian+Cancer+Cells+via+p53-Dependent+Endoplasmic+Reticulum+Stress+Pathway&doi=10.2147%2FOTT.S147316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Quercetin suppresses DNA double-strand break repair and enhances the radiosensitivity of human ovarian cancer cells via p53-dependent endoplasmic reticulum stress pathway</span></div><div class="casAuthors">Gong Cheng; Yang Zongyuan; Zhang Lingyun; Wang Yuehua; Gong Wei; Liu Yi</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-27</span>
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    </div><div class="casAbstract">Quercetin is proven to have anticancer effects for many cancers.  However, the role of tumor suppressor p53 on quercetin's radiosensitization and regulation of endoplasmic reticulum (ER) stress response in this process remains obscure.  Here, quercetin exposure resulted in ER stress, prolonged DNA repair, and the expression of p53 protein; phosphorylation on serine 15 and 20 increased in combination with X-irradiation.  Quercetin pretreatment could potentiate radiation-induced cell death.  The combination of irradiation and quercetin treatment aggravated DNA damages and caused typical apoptotic cell death; as well the expression of Bax and p21 elevated and the expression of Bcl-2 decreased.  Knocking down of p53 could reverse all the above effects under quercetin in combination with radiation.  In addition, quercetin-induced radiosensitization was through stimulation of ATM phosphorylation.  In human ovarian cancer xenograft model, combined treatment of quercetin and radiation significantly restrained the growth of tumors, accompanied with the activation of p53, CCAAT/enhancer-binding protein homologous protein, and γ-H2AX.  Overall, these results indicated that quercetin acted as a promising radiosensitizer through p53-dependent ER stress signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0zwOqwxFgVv6AExegM5LLfW6udTcc2eYxZKtw7kNLF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzptFertQ%253D%253D&md5=b53eb17c833691edb656a1fa44e5f711</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2147%2FOTT.S147316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S147316%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DQuercetin%2BSuppresses%26aufirst%3DD.%2BN.%2BA.%26atitle%3DDouble-Strand%2520Break%2520Repair%2520and%2520Enhances%2520the%2520Radiosensitivity%2520of%2520Human%2520Ovarian%2520Cancer%2520Cells%2520via%2520p53-Dependent%2520Endoplasmic%2520Reticulum%2520Stress%2520Pathway%26jtitle%3DOncoTargets%2520Ther.%26date%3D2018%26volume%3D11%26spage%3D17%26epage%3D27%26doi%3D10.2147%2FOTT.S147316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biskup, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span> <span> </span><span class="NLM_article-title">Human RAD6 Promotes G1-S Transition and Cell Proliferation through Upregulation of Cyclin D1 Expression</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e113727</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0113727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1371%2Fjournal.pone.0113727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=25409181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVWqt77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=F.+F.+Caiauthor=P.+Chenauthor=L.+Chenauthor=E.+Biskupauthor=Y.+Liuauthor=P.+C.+Chenauthor=J.+F.+Changauthor=W.+J.+Jiangauthor=Y.+Y.+Jingauthor=Y.+W.+Chenauthor=H.+Jinauthor=S.+Chen&title=Human+RAD6+Promotes+G1-S+Transition+and+Cell+Proliferation+through+Upregulation+of+Cyclin+D1+Expression&doi=10.1371%2Fjournal.pone.0113727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53aR"><div class="casContent"><span class="casTitleNuber">53a</span><div class="casTitle"><span class="NLM_cas:atitle">Human RAD6 promotes G1-S transition and cell proliferation through upregulation of cyclin D1 expression</span></div><div class="casAuthors">Cai, Fengfeng; Chen, Ping; Chen, Li; Biskup, Ewelina; Liu, Yan; Chen, Pei-Chao; Chang, Jian-Feng; Jiang, Wenjie; Jing, Yuanya; Chen, Youwei; Jin, Hui; Chen, Su</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e113727/1-e113727/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Protein ubiquitinylation regulates protein stability and activity.  RAD6, an E2 ubiquitin-conjugating enzyme, which that has been substantially biochem. characterized, functions in a no. of biol. relevant pathways, including cell cycle progression.  In this study, we show that RAD6 promotes the G1-S transition and cell proliferation by regulating the expression of cyclin D1 (CCND1) in human cells.  Furthermore, our data indicate that RAD6 influences the transcription of CCND1 by increasing monoubiquitinylation of histone H2B and trimethylation of H3K4 in the CCND1 promoter region.  Our study presents, for the first time, an evidence for the function of RAD6 in cell cycle progression and cell proliferation in human cells, raising the possibility that RAD6 could be a new target for mol. diagnosis and prognosis in cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaR7-5tjsbfbVg90H21EOLACvtfcHk0li54hPvR-DWjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVWqt77L&md5=63b3be38093bf0114a26992a1a8b6b87</span></div><a href="/servlet/linkout?suffix=cit53a&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0113727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0113727%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DF.%2BF.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DBiskup%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DP.%2BC.%26aulast%3DChang%26aufirst%3DJ.%2BF.%26aulast%3DJiang%26aufirst%3DW.%2BJ.%26aulast%3DJing%26aufirst%3DY.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BW.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DS.%26atitle%3DHuman%2520RAD6%2520Promotes%2520G1-S%2520Transition%2520and%2520Cell%2520Proliferation%2520through%2520Upregulation%2520of%2520Cyclin%2520D1%2520Expression%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0113727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit53b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Council, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chignell, C. F.</span></span> <span> </span><span class="NLM_article-title">UVA-Induced Cell Cycle Progression Is Mediated by a Disintegrin and Metalloprotease/Epidermal Growth Factor Receptor/AKT/Cyclin D1 Pathways in Keratinocytes</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">3752</span>– <span class="NLM_lpage">3758</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-6138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1158%2F0008-5472.CAN-07-6138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=18483258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVOitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3752-3758&author=Y.+Y.+Heauthor=S.+E.+Councilauthor=L.+Fengauthor=C.+F.+Chignell&title=UVA-Induced+Cell+Cycle+Progression+Is+Mediated+by+a+Disintegrin+and+Metalloprotease%2FEpidermal+Growth+Factor+Receptor%2FAKT%2FCyclin+D1+Pathways+in+Keratinocytes&doi=10.1158%2F0008-5472.CAN-07-6138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53bR"><div class="casContent"><span class="casTitleNuber">53b</span><div class="casTitle"><span class="NLM_cas:atitle">UVA-Induced Cell Cycle Progression Is Mediated by a Disintegrin and Metalloprotease/Epidermal Growth Factor Receptor/AKT/Cyclin D1 Pathways in Keratinocytes</span></div><div class="casAuthors">He, Yu-Ying; Council, Sarah E.; Feng, Li; Chignell, Colin F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3752-3758</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">UVA (315-400 nm), which constitutes ∼95% of the UV irradn. in natural sunlight, represents a major environmental challenge to the skin and is clearly assocd. with human skin cancer.  Here, we show that a low, nonlethal dose of UVA induces dose-dependent cell cycle progression in human HaCaT keratinocytes.  We found that UVA induced cyclin D1 accumulation, whereas siRNA knockdown of cyclin D1 blocked the UVA-induced cell cycle progression, indicating that this process is mediated by cyclin D1.  UVA irradn. also induced AKT activation; when cells were incubated with phosphatidylinositol-3-OH kinase/AKT inhibitor or infected with dominant-neg. AKT, cyclin D1 up-regulation, cell cycle progression, and proliferation were inhibited, suggesting that AKT activation is required for UVA-induced cell cycle progression.  In contrast, extracellular signal-regulated kinase (ERK) was not activated by UVA exposure; incubation with ERK/mitogen-activated protein kinase inhibitor had no effect on UVA-induced cyclin D1 up-regulation and cell cycle progression.  Activation of epidermal growth factor receptor (EGFR) was obsd. after UVA exposure.  EGFR kinase inhibitor AG attenuated the UVA-induced AKT/cyclin D1 pathway and cell cycle progression, indicating that EGFR is upstream of AKT/cyclin D1 pathway activation.  Furthermore, metalloprotease inhibitor GM6001 blocked UVA-induced cell cycle progression, and siRNA knockdown of a disintegrin and metalloprotease (ADAM)17 had a similar inhibitory effect, demonstrating that ADAM17 mediates the EGFR/AKT/cyclin D1 pathway and cell cycle progression to the S phase induced by UVA radiation.  Identification of these signaling pathways in UVA-induced cell proliferation will facilitate the development of efficient and safe chemopreventive and therapeutic strategies for skin cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaxcMK8DipB7Vg90H21EOLACvtfcHk0li54hPvR-DWjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVOitbo%253D&md5=d7c212878a05e8c772b94528a747f52c</span></div><a href="/servlet/linkout?suffix=cit53b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6138%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%2BY.%26aulast%3DCouncil%26aufirst%3DS.%2BE.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DChignell%26aufirst%3DC.%2BF.%26atitle%3DUVA-Induced%2520Cell%2520Cycle%2520Progression%2520Is%2520Mediated%2520by%2520a%2520Disintegrin%2520and%2520Metalloprotease%252FEpidermal%2520Growth%2520Factor%2520Receptor%252FAKT%252FCyclin%2520D1%2520Pathways%2520in%2520Keratinocytes%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3752%26epage%3D3758%26doi%3D10.1158%2F0008-5472.CAN-07-6138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rodea-Palomares, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petre, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boltes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leganés, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdigón-Melón, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Piñas, F.</span></span> <span> </span><span class="NLM_article-title">Application of the Combination Index (CI)-Isobologram Equation to Study the Toxicological Interactions of Lipid Regulators in Two Aquatic Bioluminescent Organisms</span>. <i>Water Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1016/j.watres.2009.07.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.watres.2009.07.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=19683324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFegsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2010&pages=427-438&author=I.+Rodea-Palomaresauthor=A.+L.+Petreauthor=K.+Boltesauthor=F.+Legan%C3%A9sauthor=J.+A.+Perdig%C3%B3n-Mel%C3%B3nauthor=R.+Rosalauthor=F.+Fern%C3%A1ndez-Pi%C3%B1as&title=Application+of+the+Combination+Index+%28CI%29-Isobologram+Equation+to+Study+the+Toxicological+Interactions+of+Lipid+Regulators+in+Two+Aquatic+Bioluminescent+Organisms&doi=10.1016%2Fj.watres.2009.07.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54aR"><div class="casContent"><span class="casTitleNuber">54a</span><div class="casTitle"><span class="NLM_cas:atitle">Application of the combination index (CI)-isobologram equation to study the toxicological interactions of lipid regulators in two aquatic bioluminescent organisms</span></div><div class="casAuthors">Rodea-Palomares, Ismael; Petre, Alice L.; Boltes, Karina; Leganes, Francisco; Perdigon-Melon, Jose Antonio; Rosal, Roberto; Fernandez-Pinas, Francisca</div><div class="citationInfo"><span class="NLM_cas:title">Water Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">427-438</span>CODEN:
                <span class="NLM_cas:coden">WATRAG</span>;
        ISSN:<span class="NLM_cas:issn">0043-1354</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pharmaceuticals in the aquatic environment do not appear singly and usually occur as complex mixts., whose combined effect may exhibit toxicity to the aquatic biota.  We report an environmental application of the combination index (CI)-isobologram equation, a method widely used in pharmacol. to study drug interactions, to det. the nature of toxicol. interactions of three fibrates toward two aquatic bioluminescent organisms, Vibrio fischeri and the self-luminescent cyanobacterial recombinant strain Anabaena CPB4337.  The combination index-isobologram equation method allows computerized quantitation of synergism, additive effect and antagonism.  In the Vibrio test, the fibrate combinations showed antagonism at low effect levels that turned into an additive effect or synergism at higher effect levels; by contrast, in the Anabaena test, the fibrate combinations showed a strong synergism at the lowest effect levels and a very strong antagonism at high effect levels.  We also evaluated the nature of the interactions of the three fibrates with a real wastewater sample in the cyanobacterial test.  We propose that the combination index-isobologram equation method can serve as a useful tool in ecotoxicol. assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpufI8oCYYG47Vg90H21EOLACvtfcHk0ljgxP4zGSqJbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFegsrs%253D&md5=0eda8bb7b52e37e0f3657325d9e6df60</span></div><a href="/servlet/linkout?suffix=cit54a&amp;dbid=16384&amp;doi=10.1016%2Fj.watres.2009.07.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.watres.2009.07.026%26sid%3Dliteratum%253Aachs%26aulast%3DRodea-Palomares%26aufirst%3DI.%26aulast%3DPetre%26aufirst%3DA.%2BL.%26aulast%3DBoltes%26aufirst%3DK.%26aulast%3DLegan%25C3%25A9s%26aufirst%3DF.%26aulast%3DPerdig%25C3%25B3n-Mel%25C3%25B3n%26aufirst%3DJ.%2BA.%26aulast%3DRosal%26aufirst%3DR.%26aulast%3DFern%25C3%25A1ndez-Pi%25C3%25B1as%26aufirst%3DF.%26atitle%3DApplication%2520of%2520the%2520Combination%2520Index%2520%2528CI%2529-Isobologram%2520Equation%2520to%2520Study%2520the%2520Toxicological%2520Interactions%2520of%2520Lipid%2520Regulators%2520in%2520Two%2520Aquatic%2520Bioluminescent%2520Organisms%26jtitle%3DWater%2520Res.%26date%3D2010%26volume%3D44%26spage%3D427%26epage%3D438%26doi%3D10.1016%2Fj.watres.2009.07.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit54b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Najafi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salehi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farhood, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nashtaei, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goradel, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanlarkhani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namjoo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortezaee, K.</span></span> <span> </span><span class="NLM_article-title">Adjuvant Chemotherapy with Melatonin for Targeting Human Cancers: A Review</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">2356</span>– <span class="NLM_lpage">2372</span>, <span class="refDoi"> DOI: 10.1002/jcp.27259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fjcp.27259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=30192001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Kjs73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2019&pages=2356-2372&author=M.+Najafiauthor=E.+Salehiauthor=B.+Farhoodauthor=M.+S.+Nashtaeiauthor=N.+H.+Goradelauthor=N.+Khanlarkhaniauthor=Z.+Namjooauthor=K.+Mortezaee&title=Adjuvant+Chemotherapy+with+Melatonin+for+Targeting+Human+Cancers%3A+A+Review&doi=10.1002%2Fjcp.27259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54bR"><div class="casContent"><span class="casTitleNuber">54b</span><div class="casTitle"><span class="NLM_cas:atitle">Adjuvant chemotherapy with melatonin for targeting human cancers: A review</span></div><div class="casAuthors">Najafi, Masoud; Salehi, Eniseh; Farhood, Bagher; Nashtaei, Maryam Shabani; Hashemi Goradel, Nasser; Khanlarkhani, Neda; Namjoo, Zeinab; Mortezaee, Keywan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2356-2372</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Melatonin is a multifunctional hormone that has long been known for its antitumoral effects.  An advantage of the application of melatonin in cancer therapy is its ability to differentially influence tumors from normal cells.  In this review, the roles of melatonin adjuvant therapy in human cancer are discussed.  Combination of melatonin with chemotherapy could provide synergistic antitumoral outcomes and resolve drug resistance in affected patients.  This combination reduces the dosage for chemotherapeutic agents with the subsequent attenuation of side effects related to these drugs on normal cells around tumor and on healthy organs.  The combination therapy increases the rate of survival and improves the quality of life in affected patients.  Cancer cell viability is reduced after application of the combinational melatonin therapy.  Melatonin does all these functions by adjusting the signals involved in cancer progression, re-establishing the dark/light circadian rhythm, and disrupting the redox system for cancer cells.  To achieve effective therapeutic outcomes, melatonin concn. along with the time of incubation for this indoleamine needs to be adjusted.  Importantly, a special focus is required to be made on choosing an appropriate chemotherapy agent for using in combination with melatonin.  Because of different sensitivities of cancer cells for melatonin combination therapy, cancer-specific targeted therapy is also needed to be considered.  For this review, the PubMed database was searched for relevant articles based on the quality of journals, the novelty of articles published by the journals, and the no. of citations per yr focusing only on human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrph6CNvi1XH7Vg90H21EOLACvtfcHk0ljgxP4zGSqJbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Kjs73L&md5=c2638b33b03aedb30bb4321265f3d23a</span></div><a href="/servlet/linkout?suffix=cit54b&amp;dbid=16384&amp;doi=10.1002%2Fjcp.27259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.27259%26sid%3Dliteratum%253Aachs%26aulast%3DNajafi%26aufirst%3DM.%26aulast%3DSalehi%26aufirst%3DE.%26aulast%3DFarhood%26aufirst%3DB.%26aulast%3DNashtaei%26aufirst%3DM.%2BS.%26aulast%3DGoradel%26aufirst%3DN.%2BH.%26aulast%3DKhanlarkhani%26aufirst%3DN.%26aulast%3DNamjoo%26aufirst%3DZ.%26aulast%3DMortezaee%26aufirst%3DK.%26atitle%3DAdjuvant%2520Chemotherapy%2520with%2520Melatonin%2520for%2520Targeting%2520Human%2520Cancers%253A%2520A%2520Review%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D234%26spage%3D2356%26epage%3D2372%26doi%3D10.1002%2Fjcp.27259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Er, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartron, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallette, F. M.</span></span> <span> </span><span class="NLM_article-title">Mitochondria as the Target of the Pro-Apoptotic Protein Bax</span>. <i>Biochim. Biophys. Acta, Bioenerg.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1757</i></span>,  <span class="NLM_fpage">1301</span>– <span class="NLM_lpage">1311</span>, <span class="refDoi"> DOI: 10.1016/j.bbabio.2006.05.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.bbabio.2006.05.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=16836974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVanu77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1757&publication_year=2006&pages=1301-1311&author=E.+Erauthor=L.+Oliverauthor=P.+F.+Cartronauthor=P.+Juinauthor=S.+Manonauthor=F.+M.+Vallette&title=Mitochondria+as+the+Target+of+the+Pro-Apoptotic+Protein+Bax&doi=10.1016%2Fj.bbabio.2006.05.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondria as the target of the pro-apoptotic protein Bax</span></div><div class="casAuthors">Er, Emine; Oliver, Lisa; Cartron, Pierre-Francois; Juin, Philippe; Manon, Stephen; Vallette, Francois M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Bioenergetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1757</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">1301-1311</span>CODEN:
                <span class="NLM_cas:coden">BBBEB4</span>;
        ISSN:<span class="NLM_cas:issn">0005-2728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  During apoptosis, engagement of the mitochondrial pathway involves the permeabilization of the outer mitochondrial membrane (OMM), which leads to the release of cytochrome c and other apoptogenic proteins such as Smac/DIABLO, AIF, EndoG, Omi/HtraA2, and DDP/TIMM8a.  OMM permeabilization depends on activation, translocation, and oligomerization of multidomain Bcl-2 family proteins such as Bax or Bak.  Factors involved in Bax conformational change and the function(s) of the distinct domains controlling the addressing and the insertion of Bax into mitochondria are described in this review.  The authors also discuss their current knowledge on Bax oligomerization and on the mol. mechanisms underlying the different models accounting for OMM permeabilization during apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJBetDQjNh07Vg90H21EOLACvtfcHk0ljgxP4zGSqJbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVanu77J&md5=24719473dfa4b8b7ac13c81b26448680</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bbabio.2006.05.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbabio.2006.05.032%26sid%3Dliteratum%253Aachs%26aulast%3DEr%26aufirst%3DE.%26aulast%3DOliver%26aufirst%3DL.%26aulast%3DCartron%26aufirst%3DP.%2BF.%26aulast%3DJuin%26aufirst%3DP.%26aulast%3DManon%26aufirst%3DS.%26aulast%3DVallette%26aufirst%3DF.%2BM.%26atitle%3DMitochondria%2520as%2520the%2520Target%2520of%2520the%2520Pro-Apoptotic%2520Protein%2520Bax%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Bioenerg.%26date%3D2006%26volume%3D1757%26spage%3D1301%26epage%3D1311%26doi%3D10.1016%2Fj.bbabio.2006.05.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, D.</span></span> <span> </span><span class="NLM_article-title">Oxygen and Pt(II) Self-Generating Conjugate for Synergistic Photo-Chemo Therapy of Hypoxic Tumor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">2053</span> <span class="refDoi"> DOI: 10.1038/s41467-018-04318-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1038%2Fs41467-018-04318-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=29795534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BC1Mfms1Cqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=S.+Xuauthor=X.+Zhuauthor=C.+Zhangauthor=W.+Huangauthor=Y.+Zhouauthor=D.+Yan&title=Oxygen+and+Pt%28II%29+Self-Generating+Conjugate+for+Synergistic+Photo-Chemo+Therapy+of+Hypoxic+Tumor&doi=10.1038%2Fs41467-018-04318-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Oxygen and Pt(II) self-generating conjugate for synergistic photo-chemo therapy of hypoxic tumor</span></div><div class="casAuthors">Xu Shuting; Zhu Xinyuan; Zhang Chuan; Huang Wei; Zhou Yongfeng; Yan Deyue</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2053</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer cells in hypoxic tumors are remarkably resistant to photodynamic therapy.  Here, we hypothesize that an oxygen and Pt(II) self-generating multifunctional nanocomposite could reverse the hypoxia-triggered PDT resistance.  The nanocomposite contains Pt(IV) and chlorin e6, in which upconversion nanoparticles are loaded to convert 980 nm near-infrared light into 365 nm and 660 nm emissions.  Upon accumulation at the tumor site, a 980 nm laser is used to trigger the nanocomposite to generate O2 for consumption in the PDT process and to produce cytotoxic reactive oxygen species.  The composite also releases active Pt(II) for synergistic photo-chemo therapy to enhance antitumor efficiency.  The oxygen and Pt(II) self-generating prodrug is shown to have high potential to inhibit tumors out of the range of UV light, to overcome the hypoxia-triggered PDT resistance and significantly improve anticancer efficacy by the synergistic PDT-chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQw6CszwdCVeRLDWw4HIq2sfW6udTcc2eYTWcS4y5o-p7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mfms1Cqtw%253D%253D&md5=7ad2182118884023dfd2ac46e76cc4a3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04318-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04318-1%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DD.%26atitle%3DOxygen%2520and%2520Pt%2528II%2529%2520Self-Generating%2520Conjugate%2520for%2520Synergistic%2520Photo-Chemo%2520Therapy%2520of%2520Hypoxic%2520Tumor%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26doi%3D10.1038%2Fs41467-018-04318-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhouib, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jallouli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annabi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzouki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharbi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elfazaa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasram, M. M.</span></span> <span> </span><span class="NLM_article-title">From Immunotoxicity to Carcinogenicity: the Effects of Carbamate Pesticides on the Immune System</span>. <i>Environ. Sci. Pollut. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">9488</span>– <span class="NLM_lpage">9458</span>, <span class="refDoi"> DOI: 10.1007/s11356-016-6418-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1007%2Fs11356-016-6418-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=9488-9458&author=I.+Dhouibauthor=M.+Jallouliauthor=A.+Annabiauthor=S.+Marzoukiauthor=N.+Gharbiauthor=S.+Elfazaaauthor=M.+M.+Lasram&title=From+Immunotoxicity+to+Carcinogenicity%3A+the+Effects+of+Carbamate+Pesticides+on+the+Immune+System&doi=10.1007%2Fs11356-016-6418-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs11356-016-6418-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11356-016-6418-6%26sid%3Dliteratum%253Aachs%26aulast%3DDhouib%26aufirst%3DI.%26aulast%3DJallouli%26aufirst%3DM.%26aulast%3DAnnabi%26aufirst%3DA.%26aulast%3DMarzouki%26aufirst%3DS.%26aulast%3DGharbi%26aufirst%3DN.%26aulast%3DElfazaa%26aufirst%3DS.%26aulast%3DLasram%26aufirst%3DM.%2BM.%26atitle%3DFrom%2520Immunotoxicity%2520to%2520Carcinogenicity%253A%2520the%2520Effects%2520of%2520Carbamate%2520Pesticides%2520on%2520the%2520Immune%2520System%26jtitle%3DEnviron.%2520Sci.%2520Pollut.%2520Res.%26date%3D2016%26volume%3D23%26spage%3D9488%26epage%3D9458%26doi%3D10.1007%2Fs11356-016-6418-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kugel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konichezky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baniel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livne, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koren, R.</span></span> <span> </span><span class="NLM_article-title">Unusual Splenic Metastasis from Renal Cell Carcinoma. A Case Report and Review of the Literature</span>. <i>Pathol. Res. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">743</span>, <span class="refDoi"> DOI: 10.1078/0344-0338-00490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1078%2F0344-0338-00490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=14708640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FhtFWruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2003&pages=739-743&author=V.+Kugelauthor=Y.+Dekelauthor=M.+Konichezkyauthor=J.+Banielauthor=P.+M.+Livneauthor=R.+Koren&title=Unusual+Splenic+Metastasis+from+Renal+Cell+Carcinoma.+A+Case+Report+and+Review+of+the+Literature&doi=10.1078%2F0344-0338-00490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Unusual splenic metastasis from renal cell carcinoma. A case report and review of the literature</span></div><div class="casAuthors">Kugel Valentina; Dekel Yoram; Konichezky Miriam; Baniel Jacob; Livne Pinchas M; Koren Rumelia</div><div class="citationInfo"><span class="NLM_cas:title">Pathology, research and practice</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">739-43</span>
        ISSN:<span class="NLM_cas:issn">0344-0338</span>.
    </div><div class="casAbstract">This is a short report on a splenic metastasis from renal cell carcinoma.  Previously, the patient had renal carcinoma removed by nephrectomy.  The diagnosis of metastasis was based on morphology and immunohistochemistry.  It is certainly true that splenic metastases from renal cell carcinoma are rare.  Nevertheless, they have been well described in the literature.  A giant cell reaction to tumor is noted in a number of cancers and mainly represents an unusual phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnRUkPy0gMLcKL0FlyGHDofW6udTcc2eYTWcS4y5o-p7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FhtFWruw%253D%253D&md5=1b6e83b350da2ff521db569100d64019</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1078%2F0344-0338-00490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1078%252F0344-0338-00490%26sid%3Dliteratum%253Aachs%26aulast%3DKugel%26aufirst%3DV.%26aulast%3DDekel%26aufirst%3DY.%26aulast%3DKonichezky%26aufirst%3DM.%26aulast%3DBaniel%26aufirst%3DJ.%26aulast%3DLivne%26aufirst%3DP.%2BM.%26aulast%3DKoren%26aufirst%3DR.%26atitle%3DUnusual%2520Splenic%2520Metastasis%2520from%2520Renal%2520Cell%2520Carcinoma.%2520A%2520Case%2520Report%2520and%2520Review%2520of%2520the%2520Literature%26jtitle%3DPathol.%2520Res.%2520Pract.%26date%3D2003%26volume%3D199%26spage%3D739%26epage%3D743%26doi%3D10.1078%2F0344-0338-00490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sil, P. C.</span></span> <span> </span><span class="NLM_article-title">Unfolding the Mechanism of Cisplatin Induced Pathophysiology in Spleen and Its Amelioration by Carnosine</span>. <i>Chem. Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2017.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.cbi.2017.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=29191451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2018&pages=159-170&author=S.+Banerjeeauthor=K.+Sinhaauthor=S.+Chowdhuryauthor=P.+C.+Sil&title=Unfolding+the+Mechanism+of+Cisplatin+Induced+Pathophysiology+in+Spleen+and+Its+Amelioration+by+Carnosine&doi=10.1016%2Fj.cbi.2017.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Unfolding the mechanism of cisplatin induced pathophysiology in spleen and its amelioration by carnosine</span></div><div class="casAuthors">Banerjee, Sharmistha; Sinha, Krishnendu; Chowdhury, Sayantani; Sil, Parames C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-170</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Cis-Diamminedichloroplatinum (cisplatin) is an effective chemotherapeutic and is widely used for the treatment of various types of solid tumors.  Bio-distribution of cisplatin to other organs due to poor targeting towards only cancer cells constitutes the backbone of cisplatin-induced toxicity.  The adverse effect of this drug on spleen is not well characterized so far.  Therefore, we have set our goal to explore the mechanism of the cisplatin-induced pathophysiol. of the spleen and would also like to evaluate whether carnosine, an endogenous neurotransmitter and antioxidant, can ameliorate this pathophysiol. response.  We found a dose and time-dependent increase of the pro-inflammatory cytokine, TNF-α, in the spleen tissue of the exptl. mice exposed to 10 and 20 mg/kg body wt. of cisplatin.  The increase in inflammatory cytokine can be attributed to the activation of the transcription factor, NF-kB.  This also aids in the transcription of other pro-inflammatory cytokines and cellular adhesion mols.  Exposure of animals to cisplatin at both the doses resulted in ROS and NO prodn. leading to oxidative stress.  The MAP Kinase pathway, esp. JNK activation, was also triggered by cisplatin.  Eventually, the persistence of inflammatory response and oxidative stress lead to apoptosis through extrinsic pathway.  Carnosine has been found to restore the expression of inflammatory mols. and catalase to normal levels through inhibition of pro-inflammatory cytokines, oxidative stress, NF-kB and JNK.  Carnosine also protected the splenic cells from apoptosis.  Our study elucidated the detailed mechanism of cisplatin-induced spleen toxicity and use of carnosine as a protective agent against this cytotoxic response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBGfUCCTYyKrVg90H21EOLACvtfcHk0liBfRY2P9hK0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhurzL&md5=cae9a04b28761886b94dda413eda0386</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2017.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2017.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DSinha%26aufirst%3DK.%26aulast%3DChowdhury%26aufirst%3DS.%26aulast%3DSil%26aufirst%3DP.%2BC.%26atitle%3DUnfolding%2520the%2520Mechanism%2520of%2520Cisplatin%2520Induced%2520Pathophysiology%2520in%2520Spleen%2520and%2520Its%2520Amelioration%2520by%2520Carnosine%26jtitle%3DChem.%2520Biol.%2520Interact.%26date%3D2018%26volume%3D279%26spage%3D159%26epage%3D170%26doi%3D10.1016%2Fj.cbi.2017.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. F.</span></span> <span> </span><span class="NLM_article-title">Relationship between NF-Kappa B, MMP-9, and MICA Expression in Pituitary Adenomas Reveals A New Mechanism of Pituitary Adenomas Immune Escape</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>597</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2015.04.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.neulet.2015.04.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=25921632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntlGgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=597&publication_year=2015&pages=77-83&author=Z.+Chenauthor=Z.+Z.+Liauthor=Y.+W.+Changauthor=L.+X.+Maauthor=W.+H.+Xuauthor=M.+Liauthor=J.+M.+Liauthor=W.+S.+Zhangauthor=Q.+K.+Sunauthor=X.+J.+Anauthor=Z.+F.+Li&title=Relationship+between+NF-Kappa+B%2C+MMP-9%2C+and+MICA+Expression+in+Pituitary+Adenomas+Reveals+A+New+Mechanism+of+Pituitary+Adenomas+Immune+Escape&doi=10.1016%2Fj.neulet.2015.04.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between NF-κB, MMP-9, and MICA expression in pituitary adenomas reveals a new mechanism of pituitary adenomas immune escape</span></div><div class="casAuthors">Chen, Zheng; Li, Zhenzhu; Chang, Yingwei; Ma, Lixin; Xu, Wenhu; Li, Meng; Li, Jianmin; Zhang, Wensheng; Sun, Qikai; An, Xiaojing; Li, Zefu</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">597</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">77-83</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The aim of this study was to examine the expression levels of NF-κB, MMP-9, and MICA and their relationship between each other in pituitary adenomas as a histol. basis for the study of the expression and shedding mechanism of MICA and mechanism of immune escape of pituitary adenomas.  Our study indicated that MICA, MMP-9 and NF-κB mRNA and protein levels were more highly expressed in pituitary adenomas than healthy tissues.  The expression levels of NF-κB, MMP-9, and MICA were pos. related in patients with pituitary adenomas.  In conclusion, the activation of NF-κB can up-regulate the expression of MICA and induce the expression of MMP-9, which hydrolyzes MICA into sMICA to promote tumor immune escape.  The interactions of NF-κB, MMP-9, and MICA play an important role in the development of pituitary adenomas, and MMP-9 could be used as a new target for inhibiting tumor cell immune escape.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRCIRvI6HQ3rVg90H21EOLACvtfcHk0liBfRY2P9hK0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntlGgtrc%253D&md5=eb71c3db48d3f952fe611a80c0fc2eef</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2015.04.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2015.04.025%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%2BZ.%26aulast%3DChang%26aufirst%3DY.%2BW.%26aulast%3DMa%26aufirst%3DL.%2BX.%26aulast%3DXu%26aufirst%3DW.%2BH.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DW.%2BS.%26aulast%3DSun%26aufirst%3DQ.%2BK.%26aulast%3DAn%26aufirst%3DX.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%2BF.%26atitle%3DRelationship%2520between%2520NF-Kappa%2520B%252C%2520MMP-9%252C%2520and%2520MICA%2520Expression%2520in%2520Pituitary%2520Adenomas%2520Reveals%2520A%2520New%2520Mechanism%2520of%2520Pituitary%2520Adenomas%2520Immune%2520Escape%26jtitle%3DNeurosci.%2520Lett.%26date%3D2015%26volume%3D597%26spage%3D77%26epage%3D83%26doi%3D10.1016%2Fj.neulet.2015.04.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span> <span> </span><span class="NLM_article-title">NF-κB and the Immune Response</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6758</span>– <span class="NLM_lpage">6780</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1209943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1038%2Fsj.onc.1209943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=17072327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFektL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=6758-6780&author=M.+S.+Haydenauthor=A.+P.+Westauthor=S.+Ghosh&title=NF-%CE%BAB+and+the+Immune+Response&doi=10.1038%2Fsj.onc.1209943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB and the immune response</span></div><div class="casAuthors">Hayden, M. S.; West, A. P.; Ghosh, S.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">6758-6780</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One of the primary physiol. roles of nuclear factor-kappa B (NF-κB) is in the immune system.  In particular, NF-κB family members control the transcription of cytokines and antimicrobial effectors as well as genes that regulate cellular differentiation, survival, and proliferation, thereby regulating various aspects of innate and adaptive immune responses.  In addn., NF-κB also contributes to the development and survival of the cells and tissues that carry out immune responses in mammals.  This review, therefore, describes the role of the NF-κB pathway in the development and functioning of the immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL2vJmQD9HGrVg90H21EOLACvtfcHk0liBfRY2P9hK0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFektL7P&md5=33b28d0dd305ecec26c27e5bf4864022</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209943%26sid%3Dliteratum%253Aachs%26aulast%3DHayden%26aufirst%3DM.%2BS.%26aulast%3DWest%26aufirst%3DA.%2BP.%26aulast%3DGhosh%26aufirst%3DS.%26atitle%3DNF-%25CE%25BAB%2520and%2520the%2520Immune%2520Response%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D6758%26epage%3D6780%26doi%3D10.1038%2Fsj.onc.1209943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span> <span> </span><span class="NLM_article-title">IKK/NF-Kappa B Signaling: Balancing Life and Death-a New Approach to Cancer Therapy</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">2625</span>– <span class="NLM_lpage">2632</span>, <span class="refDoi"> DOI: 10.1172/JCI26322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1172%2FJCI26322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=16200195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVygt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=2625-2632&author=J.+L.+Luoauthor=H.+Kamataauthor=M.+Karin&title=IKK%2FNF-Kappa+B+Signaling%3A+Balancing+Life+and+Death-a+New+Approach+to+Cancer+Therapy&doi=10.1172%2FJCI26322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">IKK/NF-κB signaling: Balancing life and death - a new approach to cancer therapy</span></div><div class="casAuthors">Luo, Jun-Li; Kamata, Hideaki; Karin, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2625-2632</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  IκB kinase/NF-κB (IKK/NF-κB) signaling pathways play crit. roles in a variety of physiol. and pathol. processes.  One function of NF-κB is promotion of cell survival through induction of target genes, whose products inhibit components of the apoptotic machinery in normal and cancerous cells.  NF-κB can also prevent programmed necrosis by inducing genes encoding antioxidant proteins.  Regardless of mechanism, many cancer cells, of either epithelial or hematopoietic origin, use NF-κB to achieve resistance to anticancer drugs, radiation, and death cytokines.  Hence, inhibition of IKK-driven NF-κB activation offers a strategy for treatment of different malignancies and can convert inflammation-induced tumor growth to inflammation-induced tumor regression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHJSST-3qAzrVg90H21EOLACvtfcHk0liBfRY2P9hK0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVygt7vE&md5=f59858c52e2b20d0323a340dab754845</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1172%2FJCI26322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI26322%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%2BL.%26aulast%3DKamata%26aufirst%3DH.%26aulast%3DKarin%26aufirst%3DM.%26atitle%3DIKK%252FNF-Kappa%2520B%2520Signaling%253A%2520Balancing%2520Life%2520and%2520Death-a%2520New%2520Approach%2520to%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D2625%26epage%3D2632%26doi%3D10.1172%2FJCI26322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">George, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleksunes, L. M.</span></span> <span> </span><span class="NLM_article-title">Urinary Protein Biomarkers of Kidney Injury in Patients Receiving Cisplatin Chemotherapy</span>. <i>Exp. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>243</i></span>,  <span class="NLM_fpage">272</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.1177/1535370217745302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1177%2F1535370217745302" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=2017&pages=272-282&author=B.+Georgeauthor=M.+S.+Joyauthor=L.+M.+Aleksunes&title=Urinary+Protein+Biomarkers+of+Kidney+Injury+in+Patients+Receiving+Cisplatin+Chemotherapy&doi=10.1177%2F1535370217745302"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1177%2F1535370217745302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1535370217745302%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DB.%26aulast%3DJoy%26aufirst%3DM.%2BS.%26aulast%3DAleksunes%26aufirst%3DL.%2BM.%26atitle%3DUrinary%2520Protein%2520Biomarkers%2520of%2520Kidney%2520Injury%2520in%2520Patients%2520Receiving%2520Cisplatin%2520Chemotherapy%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2017%26volume%3D243%26spage%3D272%26epage%3D282%26doi%3D10.1177%2F1535370217745302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b','cit13c','cit13d','cit13e','cit13f'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18a','cit18b'],'ref19':['cit19'],'ref20':['cit20a','cit20b'],'ref21':['cit21a','cit21b'],'ref22':['cit22a','cit22b'],'ref23':['cit23'],'ref24':['cit24a','cit24b','cit24c'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32a','cit32b','cit32c','cit32d'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36a','cit36b'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39a','cit39b'],'ref40':['cit40'],'ref41':['cit41a','cit41b'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44a','cit44b'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51a','cit51b'],'ref52':['cit52'],'ref53':['cit53a','cit53b'],'ref54':['cit54a','cit54b'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 6 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Luo</span>, <span class="hlFld-ContribAuthor ">Xinqiang  Song</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive overview of β-carbolines and its derivatives as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113688. <a href="https://doi.org/10.1016/j.ejmech.2021.113688" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113688</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113688%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bcomprehensive%252Boverview%252Bof%252B%2525CE%2525B2-carbolines%252Band%252Bits%252Bderivatives%252Bas%252Banticancer%252Bagents%26aulast%3DLuo%26aufirst%3DBo%26date%3D2021%26volume%3D224%26spage%3D113688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinguang  Cao</span>, <span class="hlFld-ContribAuthor ">Rui  Li</span>, <span class="hlFld-ContribAuthor ">Huihua  Xiong</span>, <span class="hlFld-ContribAuthor ">Jinfang  Su</span>, <span class="hlFld-ContribAuthor ">Changqing  Guo</span>, <span class="hlFld-ContribAuthor ">Tianqi  An</span>, <span class="hlFld-ContribAuthor ">Hong  Zong</span>, <span class="hlFld-ContribAuthor ">Ruihua  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Pt(IV) complexes to overcome multidrug resistance in gastric cancer by targeting P-glycoprotein. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113520. <a href="https://doi.org/10.1016/j.ejmech.2021.113520" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113520%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BPt%252528IV%252529%252Bcomplexes%252Bto%252Bovercome%252Bmultidrug%252Bresistance%252Bin%252Bgastric%252Bcancer%252Bby%252Btargeting%252BP-glycoprotein%26aulast%3DCao%26aufirst%3DXinguang%26date%3D2021%26volume%3D221%26spage%3D113520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenbo  Huang</span>, <span class="hlFld-ContribAuthor ">Zilin  Gao</span>, <span class="hlFld-ContribAuthor ">Zhigang  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Fang</span>, <span class="hlFld-ContribAuthor ">Zuoqian  Wang</span>, <span class="hlFld-ContribAuthor ">Zhongyi  Wan</span>, <span class="hlFld-ContribAuthor ">Liqiao  Shi</span>, <span class="hlFld-ContribAuthor ">Kaimei  Wang</span>, <span class="hlFld-ContribAuthor ">Shaoyong  Ke</span>. </span><span class="cited-content_cbyCitation_article-title">Selective and effective anticancer agents: Synthesis, biological evaluation and structure–activity relationships of novel carbazole derivatives. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>113 </em>, 104991. <a href="https://doi.org/10.1016/j.bioorg.2021.104991" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104991</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104991%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSelective%252Band%252Beffective%252Banticancer%252Bagents%25253A%252BSynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bstructure%2525E2%252580%252593activity%252Brelationships%252Bof%252Bnovel%252Bcarbazole%252Bderivatives%26aulast%3DHuang%26aufirst%3DWenbo%26date%3D2021%26volume%3D113%26spage%3D104991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin  Qiao</span>, <span class="hlFld-ContribAuthor ">Yu-Yang  Gao</span>, <span class="hlFld-ContribAuthor ">Li-Xia  Zheng</span>, <span class="hlFld-ContribAuthor ">Xiao-Jing  Ding</span>, <span class="hlFld-ContribAuthor ">Ling-Wen  Xu</span>, <span class="hlFld-ContribAuthor ">Juan-Juan  Hu</span>, <span class="hlFld-ContribAuthor ">Wei-Zhen  Gao</span>, <span class="hlFld-ContribAuthor ">Jing-Yuan  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>25 </em>, 113730. <a href="https://doi.org/10.1016/j.ejmech.2021.113730" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113730</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113730%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BROS-AMPK%252Bpathway%252Bby%252Bmultiaction%252BPlatinum%252528IV%252529%252Bprodrugs%252Bcontaining%252Bhypolipidemic%252Bdrug%252Bbezafibrate%26aulast%3DQiao%26aufirst%3DXin%26date%3D2021%26volume%3D25%26spage%3D113730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrei R.  Timerbaev</span>. </span><span class="cited-content_cbyCitation_article-title">Application of ICP-MS to the development of metal-based drugs and diagnostic agents: where do we stand?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Analytical Atomic Spectrometry</span><span> <strong>2021,</strong> <em>36 </em>
                                    (2)
                                     , 254-266. <a href="https://doi.org/10.1039/D0JA00404A" title="DOI URL">https://doi.org/10.1039/D0JA00404A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0JA00404A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0JA00404A%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Analytical%2520Atomic%2520Spectrometry%26atitle%3DApplication%252Bof%252BICP-MS%252Bto%252Bthe%252Bdevelopment%252Bof%252Bmetal-based%252Bdrugs%252Band%252Bdiagnostic%252Bagents%25253A%252Bwhere%252Bdo%252Bwe%252Bstand%25253F%26aulast%3DTimerbaev%26aufirst%3DAndrei%2BR.%26date%3D2021%26date%3D2021%26volume%3D36%26issue%3D2%26spage%3D254%26epage%3D266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong-Po  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhong-Ying  Ma</span>, <span class="hlFld-ContribAuthor ">Pei-Pei  Qiao</span>, <span class="hlFld-ContribAuthor ">Chun-Yan  Gao</span>, <span class="hlFld-ContribAuthor ">Jin-Lei  Tian</span>, <span class="hlFld-ContribAuthor ">Jin-Zhong  Zhao</span>, <span class="hlFld-ContribAuthor ">Wei-Jun  Du</span>, <span class="hlFld-ContribAuthor ">Jing-Yuan  Xu</span>, <span class="hlFld-ContribAuthor ">Shi-Ping  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Design and biological evaluations of mono- and di-nuclear copper(II) complexes: Nuclease activity, cytotoxicity and apoptosis. </span><span class="cited-content_cbyCitation_journal-name">Polyhedron</span><span> <strong>2021,</strong> <em>193 </em>, 114880. <a href="https://doi.org/10.1016/j.poly.2020.114880" title="DOI URL">https://doi.org/10.1016/j.poly.2020.114880</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.poly.2020.114880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.poly.2020.114880%26sid%3Dliteratum%253Aachs%26jtitle%3DPolyhedron%26atitle%3DDesign%252Band%252Bbiological%252Bevaluations%252Bof%252Bmono-%252Band%252Bdi-nuclear%252Bcopper%252528II%252529%252Bcomplexes%25253A%252BNuclease%252Bactivity%25252C%252Bcytotoxicity%252Band%252Bapoptosis%26aulast%3DZhang%26aufirst%3DYong-Po%26date%3D2021%26volume%3D193%26spage%3D114880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/medium/jm0c00343_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00343&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/medium/jm0c00343_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of cisplatin, oxoplatin, staraplatin, MT, and compounds <b>1</b>–<b>6</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00343&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/medium/jm0c00343_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Route of Compounds <b>1</b>–<b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00343&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Condition and reagents: (a) succinic anhydride or glutaric anhydride, acetonitrile, triethylamine (TEA), 4-dimethylaminopyridine (DMAP), 50 °C, overnight; (b) H<sub>2</sub>O<sub>2</sub> (30%), 70 °C, 5 h; (c) 2-(1<i>H</i>-benzotriazole-1-yl)-1,1,3,3-tetramethyl-uronium tetrafluoroborate (TBTU), TEA, dimethyl sulfoxide (DMSO), room temperature, overnight; (d) TBTU, TEA, dimethylformamide (DMF), room temperature, 48 h.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/medium/jm0c00343_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. ERα expression was measured by western blot assay. (a) ERα expressions of MCF-7, MDA-MB-231, A549, HeLa, and HUVEC cells. (b) Inhibition of ERα in compounds treatment groups (10 μM). (c) Statistics analysis of protein gray values relative to GAPDH. <sup>***</sup><i>P</i> < 0.001 compared to MDA-MB-231 cells. (d) Statistics analysis of protein gray values relative to β-tubulin. <sup>***</sup><i>P</i> < 0.001 compared to the control group. (e) Crystal structure of beta1-adrenergic receptor (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VT4">2VT4</a>) was downloaded as template from RCSB Protein Data Bank. The lowest-energy structure of compounds MT (blue), <b>3</b> (green), and <b>4</b> (yellow) to dock with MT1 receptor. (f) Accumulation of Pt in MCF-7 that was exposed to CDDP, mixture, and compounds <b>3</b>–<b>6</b> at 10 μM for 5 h, respectively. <sup>***</sup><i>P</i> < 0.001, <sup>**</sup><i>P</i> < 0.01, compared with the CDDP group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00343&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/medium/jm0c00343_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Molecular docking data of MT, <b>3</b>, and <b>4</b> with MT receptor MT1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00343&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/medium/jm0c00343_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Imaging of compound <b>3</b> (10 μM), MT (10 μM), CDDP (10 μM), and an equimolar mixture of CDDP and MT treatment in fixed MCF-7 cells using Alexa Fluor 594-conjugated Goat Anti-Rabbit IgG (H + L). Single image planes of Alexa Fluor 594 (red), 4′,6-diamidino-2-phenylindole (DAPI) (blue), merged red and blue channels are displayed. (a) The γH2AX expression (9 h treatment) and (b) the p53 expression (12 h treatment). (c) Cell cycle distribution after treatment with 0.1 μM compounds for 24 h in MCF-7 cells. (d) The expression of Cyclin D1 in compound <b>3</b> treatment group (5 μM) tested by western blot assay. (e) MCF-7 cell apoptosis induced by compounds at 10 μM for 24 h tested by Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) double staining. (f) The expression of proapoptotic protein Bax in compound <b>3</b> treatment group (5 μM) tested by western blot assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00343&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/medium/jm0c00343_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antitumor effect in BALB/c nude mice model bearing MCF-7 tumors with different treatments (compound <b>3</b> at 2 mg-Pt/kg, MT equal to the mole number of Pt per mouse, CDDP at 2 mg-Pt/kg, and an equimolar mixture of CDDP and MT) in a period of 22 days. (a) Tumor volume in each group. <sup>***</sup><i>P</i> < 0.001, *<i>P</i> < 0.05, compared to the PBS group. (b) Tumor weight after final treatments. <sup>***</sup><i>P</i> < 0.001, compared to the PBS group. (c) Changes of mice bodyweight during treatments. <sup>###</sup><i>P</i> < 0.001, compared to the CDDP group. (d) Survival rate of mice. (The number of death includes dead mice and those lost weight over 20%). (e) Pt content in spleens and tumors. *<i>P</i> < 0.05. (f) Spleen index of mice. *<i>P</i> < 0.05, compared to the CDDP group. (g) Imaging of NF-κB expression in MCF-7 cells after exposed to compound <b>3</b> (1 μM), MT (1 μM), CDDP (1 μM), and an equimolar mixture of CDDP and MT for 12 h. Single image planes of Alexa Fluor 594-conjugated Goat Anti-Rabbit IgG (H + L) (red), DAPI (blue), and merged red and blue channels are displayed. (h) Hematoxylin and eosin (H&E) staining pictures of mice organs (spleen, kidney, and tumor).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00343/20200604/images/large/jm0c00343_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00343&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i28">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 63 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wassermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelber, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddy, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamimi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borges, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Come, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partridge, A. H.</span></span> <span> </span><span class="NLM_article-title">Nonadherent Behaviors among Young Women on Adjuvant Endocrine Therapy for Breast Cancer</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">3266</span>– <span class="NLM_lpage">3274</span>, <span class="refDoi"> DOI: 10.1002/cncr.32192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fcncr.32192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=31120571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12hur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2019&pages=3266-3274&author=J.+Wassermannauthor=S.+I.+Gelberauthor=S.+M.+Rosenbergauthor=K.+J.+Ruddyauthor=R.+M.+Tamimiauthor=L.+Schapiraauthor=V.+F.+Borgesauthor=S.+E.+Comeauthor=M.+E.+Meyerauthor=A.+H.+Partridge&title=Nonadherent+Behaviors+among+Young+Women+on+Adjuvant+Endocrine+Therapy+for+Breast+Cancer&doi=10.1002%2Fcncr.32192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer</span></div><div class="casAuthors">Wassermann, Johanna; Gelber, Shari I.; Rosenberg, Shoshana M.; Ruddy, Kathryn J.; Tamimi, Rulla M.; Schapira, Lidia; Borges, Virginia F.; Come, Steven E.; Meyer, Meghan E.; Partridge, Ann H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3266-3274</span>CODEN:
                <span class="NLM_cas:coden">CANCAR</span>;
        ISSN:<span class="NLM_cas:issn">0008-543X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Young age is a known factor assocd. with suboptimal adherence to endocrine therapy (ET) for adjuvant breast cancer (BC) treatment.  This study was aimed at assessing nonadherent behaviors and assocd. factors among young women with early-stage hormone receptor-pos. BC.  As part of a multicenter, prospective cohort of women with a diagnosis of BC at or under the age of 40 years, participants were surveyed 30 mo after their diagnosis about adherent behaviors.  Among those who reported taking ET, adherence was measured with a 3-item Likert-type scale: Do you ever forget to take your ET If you feel worse when you take your ET, do you stop taking it Did you take your ET exactly as directed by your doctor over the last 3 mo Women reporting at least 1 nonadherent behavior were classified as nonadherers.  Variables with a P value <.20 were included in a multivariable logistic model.  Among 384 women, 194 (51%) were classified as nonadherers.  Univariate factors that retained significance in the multivariable model included educational level (odds ratio [OR], 0.50 for high vs low; P = .04), level of social support according to the Medical Outcome Study Social Support Survey (OR, 0.98 per 1 point; P = .01), and confidence with the decision regarding ET measured on a 0 to 10 numerical scale (OR, 0.63 for high vs low; P = .04).  Findings from this study could help to identify young patients at higher risk for nonadherence.  Interventions adapted to the level of education and aimed at reinforcing support and patients' confidence in their decision to take ET could improve adherence and assocd. outcomes in this population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLP3Fz60_42LVg90H21EOLACvtfcHk0lifV6uk4bEXDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12hur3I&md5=c7e2f829fb89107a079931f9db4f4391</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1002%2Fcncr.32192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.32192%26sid%3Dliteratum%253Aachs%26aulast%3DWassermann%26aufirst%3DJ.%26aulast%3DGelber%26aufirst%3DS.%2BI.%26aulast%3DRosenberg%26aufirst%3DS.%2BM.%26aulast%3DRuddy%26aufirst%3DK.%2BJ.%26aulast%3DTamimi%26aufirst%3DR.%2BM.%26aulast%3DSchapira%26aufirst%3DL.%26aulast%3DBorges%26aufirst%3DV.%2BF.%26aulast%3DCome%26aufirst%3DS.%2BE.%26aulast%3DMeyer%26aufirst%3DM.%2BE.%26aulast%3DPartridge%26aufirst%3DA.%2BH.%26atitle%3DNonadherent%2520Behaviors%2520among%2520Young%2520Women%2520on%2520Adjuvant%2520Endocrine%2520Therapy%2520for%2520Breast%2520Cancer%26jtitle%3DCancer%26date%3D2019%26volume%3D125%26spage%3D3266%26epage%3D3274%26doi%3D10.1002%2Fcncr.32192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bahmanpour, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheervalilou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choupani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khaniani, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montazeri, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derakhshan, S. M.</span></span> <span> </span><span class="NLM_article-title">A New Insight on Serum MicroRNA Expression as Novel Biomarkers in Breast Cancer Patients</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">19199</span>– <span class="NLM_lpage">19211</span>, <span class="refDoi"> DOI: 10.1002/jcp.28656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fjcp.28656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=31026062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1MXot1Cis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2019&pages=19199-19211&author=Z.+Bahmanpourauthor=R.+Sheervalilouauthor=J.+Choupaniauthor=M.+S.+Khanianiauthor=V.+Montazeriauthor=S.+M.+Derakhshan&title=A+New+Insight+on+Serum+MicroRNA+Expression+as+Novel+Biomarkers+in+Breast+Cancer+Patients&doi=10.1002%2Fjcp.28656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">A new insight on serum microRNA expression as novel biomarkers in breast cancer patients</span></div><div class="casAuthors">Bahmanpour, Zahra; Sheervalilou, Roghayeh; Choupani, Jalal; Shekari Khaniani, Mahmoud; Montazeri, Vahid; Mansoori Derakhshan, Sima</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">19199-19211</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Breast cancer (BC) is one of the widespread lethal diseases affecting a large no. of women worldwide.  As such, employing and identifying significant markers for detecting BC in different stages can assist in better diagnosis and management of the disease.  Several diverse markers have been introduced for diagnosis, but their limitations, including low specificity and sensitivity, reduce their application. microRNAs (miRNAs), as short noncoding RNAs, have been shown to significantly influence gene expression in different disease pathologies, esp. BC.  Clearly, among different samples used for detecting miRNA expressions, circulating miRNAs present as promising and useful biomarkers.  Among different body fluid samples, serum serves as one of the most reliable samples, thanks to its high stability under various severe conditions and some unique features.  Extensive research has suggested that BC-related miRNAs can remain stable in the serum.  The objective of this review is to describe different samples used for detecting miRNAs in BC subjects with emphasis on serum miRNAs.  So, this study highlights serum miRNAs with the potential of acting as biomarkers for different stages of BC.  We reviewed the possible correlation between potential miRNAs and the risk of early breast cancer, metastatic breast cancer, response to chemotherapy, and relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobGWCxO5A0yLVg90H21EOLACvtfcHk0lifV6uk4bEXDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXot1Cis70%253D&md5=723c540bd4b9b6ec2183b7d33e1ce03a</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1002%2Fjcp.28656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.28656%26sid%3Dliteratum%253Aachs%26aulast%3DBahmanpour%26aufirst%3DZ.%26aulast%3DSheervalilou%26aufirst%3DR.%26aulast%3DChoupani%26aufirst%3DJ.%26aulast%3DKhaniani%26aufirst%3DM.%2BS.%26aulast%3DMontazeri%26aufirst%3DV.%26aulast%3DDerakhshan%26aufirst%3DS.%2BM.%26atitle%3DA%2520New%2520Insight%2520on%2520Serum%2520MicroRNA%2520Expression%2520as%2520Novel%2520Biomarkers%2520in%2520Breast%2520Cancer%2520Patients%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D234%26spage%3D19199%26epage%3D19211%26doi%3D10.1002%2Fjcp.28656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penault-Llorca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houssami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poortmans, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, F.</span></span> <span> </span><span class="NLM_article-title">Breast Cancer</span>. <i>Nat. Rev. Dis. Primers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">66</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1038/s41572-019-0111-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1038%2Fs41572-019-0111-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=31548545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhsFSguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=66-96&author=N.+Harbeckauthor=F.+Penault-Llorcaauthor=J.+Cortesauthor=M.+Gnantauthor=N.+Houssamiauthor=P.+Poortmansauthor=K.+Ruddyauthor=J.+Tsangauthor=F.+Cardoso&title=Breast+Cancer&doi=10.1038%2Fs41572-019-0111-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer</span></div><div class="casAuthors">Harbeck Nadia; Penault-Llorca Frederique; Cortes Javier; Cortes Javier; Gnant Michael; Houssami Nehmat; Poortmans Philip; Poortmans Philip; Ruddy Kathryn; Tsang Janice; Cardoso Fatima</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">66</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Breast cancer is the most frequent malignancy in women worldwide and is curable in ~70-80% of patients with early-stage, non-metastatic disease.  Advanced breast cancer with distant organ metastases is considered incurable with currently available therapies.  On the molecular level, breast cancer is a heterogeneous disease; molecular features include activation of human epidermal growth factor receptor 2 (HER2, encoded by ERBB2), activation of hormone receptors (oestrogen receptor and progesterone receptor) and/or BRCA mutations.  Treatment strategies differ according to molecular subtype.  Management of breast cancer is multidisciplinary; it includes locoregional (surgery and radiation therapy) and systemic therapy approaches.  Systemic therapies include endocrine therapy for hormone receptor-positive disease, chemotherapy, anti-HER2 therapy for HER2-positive disease, bone stabilizing agents, poly(ADP-ribose) polymerase inhibitors for BRCA mutation carriers and, quite recently, immunotherapy.  Future therapeutic concepts in breast cancer aim at individualization of therapy as well as at treatment de-escalation and escalation based on tumour biology and early therapy response.  Next to further treatment innovations, equal worldwide access to therapeutic advances remains the global challenge in breast cancer care for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEOiYgsNcoF0loaUqgkFHkfW6udTcc2eaQAungvKek07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhsFSguw%253D%253D&md5=e1d6ae6f77bff6a8fe96a0aa3364dd7c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fs41572-019-0111-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41572-019-0111-2%26sid%3Dliteratum%253Aachs%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DPenault-Llorca%26aufirst%3DF.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DHoussami%26aufirst%3DN.%26aulast%3DPoortmans%26aufirst%3DP.%26aulast%3DRuddy%26aufirst%3DK.%26aulast%3DTsang%26aufirst%3DJ.%26aulast%3DCardoso%26aufirst%3DF.%26atitle%3DBreast%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Dis.%2520Primers%26date%3D2019%26volume%3D5%26spage%3D66%26epage%3D96%26doi%3D10.1038%2Fs41572-019-0111-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Narod, S. A.</span></span> <span> </span><span class="NLM_article-title">Modifiers of Risk of Hereditary Breast Cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5832</span>– <span class="NLM_lpage">5836</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1209870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1038%2Fsj.onc.1209870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=16998497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVSgurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=5832-5836&author=S.+A.+Narod&title=Modifiers+of+Risk+of+Hereditary+Breast+Cancer&doi=10.1038%2Fsj.onc.1209870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Modifiers of risk of hereditary breast cancer</span></div><div class="casAuthors">Narod, S. A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">5832-5836</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mutations in the BRCA1 and BRCA2 genes confer a high lifetime risk of breast and ovarian cancer.  The risk varies from individual to individual, and it appears that the risk has increased in recent generations.  These observations imply that non-genetic factors may modify the inherited risk.  To date, the factors that appear most strongly to modify the risk include reproductive histories and exogenous hormones.  Oral contraceptives are assocd. with a profound redn. in the risk of ovarian cancer, and with little or no increase in the risk of breast cancer.  Other modifying factors include age of menarche, parity, breastfeeding and oophorectomy.  The effect of parity is different in BRCA1 and BRCA2 carriers.  Multiparity appears to be protective in BRCA1 carriers, but is assocd. with an increase in risk in BRCA2 carriers.  Oophorectomy has been assocd. with redns. in both the risk of breast and ovarian cancer.  Knowledge of these risk factors will be useful for managing risk and for developing prevention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-lcpbhzNenrVg90H21EOLACvtfcHk0liKEjUOqShXfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVSgurvK&md5=b85f97831ecd3530658f1b6213e6eb52</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209870%26sid%3Dliteratum%253Aachs%26aulast%3DNarod%26aufirst%3DS.%2BA.%26atitle%3DModifiers%2520of%2520Risk%2520of%2520Hereditary%2520Breast%2520Cancer%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D5832%26epage%3D5836%26doi%3D10.1038%2Fsj.onc.1209870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carascossa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenni, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briand, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picard, D.</span></span> <span> </span><span class="NLM_article-title">CARM1 Mediates the Ligand-Independent and Tamoxifen-Resistant Activation of the Estrogen Receptor alpha by cAMP</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">719</span>, <span class="refDoi"> DOI: 10.1101/gad.568410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1101%2Fgad.568410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=20360387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltFWls78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=708-719&author=S.+Carascossaauthor=P.+Dudekauthor=B.+Cenniauthor=P.+A.+Briandauthor=D.+Picard&title=CARM1+Mediates+the+Ligand-Independent+and+Tamoxifen-Resistant+Activation+of+the+Estrogen+Receptor+alpha+by+cAMP&doi=10.1101%2Fgad.568410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor α by cAMP</span></div><div class="casAuthors">Carascossa, Sophie; Dudek, Peter; Cenni, Bruno; Briand, Pierre-Andre; Picard, Didier</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">708-719</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">The estrogen receptor α (ERα) is activated as a transcription factor by both estrogen and a large variety of other extracellular signals.  The mechanisms of this ligand-independent activation, notably by cAMP signaling, are still largely unknown.  We now close the gap in the signaling pathway between cAMP and ERα.  Whereas the direct phosphorylation of ERα by the cAMP-activated protein kinase A (PKA) is dispensable, the phosphorylation of the coactivator-assocd. arginine methyltransferase 1 (CARM1) by PKA at a single serine is necessary and sufficient for direct binding to the unliganded hormone-binding domain (HBD) of ERα, and the interaction is necessary for cAMP activation of ERα.  Sustained PKA activity promoting a constitutive interaction may contribute to tamoxifen resistance of breast tumors.  Binding and activation involve a novel regulatory groove of the ERα HBD.  As a result, depending on the activating signal, ERα recruits different coactivator complexes to regulate alternate sets of target genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0maunIKcwK7Vg90H21EOLACvtfcHk0liKEjUOqShXfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltFWls78%253D&md5=17eb8d03810f76ba763d622729952c25</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1101%2Fgad.568410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.568410%26sid%3Dliteratum%253Aachs%26aulast%3DCarascossa%26aufirst%3DS.%26aulast%3DDudek%26aufirst%3DP.%26aulast%3DCenni%26aufirst%3DB.%26aulast%3DBriand%26aufirst%3DP.%2BA.%26aulast%3DPicard%26aufirst%3DD.%26atitle%3DCARM1%2520Mediates%2520the%2520Ligand-Independent%2520and%2520Tamoxifen-Resistant%2520Activation%2520of%2520the%2520Estrogen%2520Receptor%2520alpha%2520by%2520cAMP%26jtitle%3DGenes%2520Dev.%26date%3D2010%26volume%3D24%26spage%3D708%26epage%3D719%26doi%3D10.1101%2Fgad.568410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gornowicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymanowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szymanowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czarnomysy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaluza, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielawski, K.</span></span> <span> </span><span class="NLM_article-title">Monoclonal Anti-MUC1 Antibody with Novel Octahydropyrazino[2,1-a:5,4-a′]diisoquinoline Derivative as a Potential Multi-Targeted Strategy in MCF-7 Breast Cancer Cells</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1391</span>– <span class="NLM_lpage">1403</span>, <span class="refDoi"> DOI: 10.3892/or.2019.7256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3892%2For.2019.7256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVOrur7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=1391-1403&author=A.+Gornowiczauthor=W.+Szymanowskiauthor=A.+Bielawskaauthor=A.+Szymanowskaauthor=R.+Czarnomysyauthor=Z.+Kaluzaauthor=K.+Bielawski&title=Monoclonal+Anti-MUC1+Antibody+with+Novel+Octahydropyrazino%5B2%2C1-a%3A5%2C4-a%E2%80%B2%5Ddiisoquinoline+Derivative+as+a+Potential+Multi-Targeted+Strategy+in+MCF-7+Breast+Cancer+Cells&doi=10.3892%2For.2019.7256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Monoclonal anti-MUC1 antibody with novel octahydropyrazino[2,1-a:5,4-a']diisoquinoline derivative as a potential multi-targeted strategy in MCF-7 breast cancer cells</span></div><div class="casAuthors">Gornowicz, Agnieszka; Szymanowski, Wojciech; Bielawska, Anna; Szymanowska, Anna; Czarnomysy, Robert; Kaluza, Zbigniew; Bielawski, Krzysztof</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1391-1403</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">The aim of the present study was to examine the multi-targeted potential of a monoclonal antibody against mucin-1 (MUC1) and novel octahydropyrazin[2,1-a:5,4-a'] diisoquinoline deriv. (OM-86II) in estrogen receptor-pos. MCF-7 human breast cancer cells.  The cell viability was measured by an MTT assay.  The analyses of cell cycle and disruption of mitochondrial membrane potential were performed by flow cytometry.  Fluorescent microscopy and flow cytometry were used to demonstrate the effect of the compds. on apoptosis.  ELISA was conducted to check the concns. of proteins involved in multiple intracellular signaling pathways, responsible for the promotion of tumor growth and breast cancer progression, namely matrix metalloproteinase (MMP)-2, matrix MMP-9, tumor necrosis factor-α (TNF-α), cyclooxygenase-2 (COX-2), sol. intercellular adhesion mol. 1 (sICAM1) and mTOR.  The combination therapy based on anti-MUC1 antibody and novel OM-86II inhibited the proliferation of MCF-7 breast cancer cells.  Its inhibitory effects were assocd. with the induction of cell cycle arrest and apoptosis.  It was demonstrated that anti-MUC1 antibody with OM-86II decreased the concns. of MMP-2, MMP-9, sICAM1 and mTOR.  In addn., the combined therapy exhibited anti inflammatory activity, which was demonstrated by a decrease in TNF-α and COX-2 concns.  The present data provided evidence that the combination of anti-MUC1 antibody with novel OM-86II represents a multi-targeted strategy in MCF-7 breast cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnmyS4F66MoLVg90H21EOLACvtfcHk0liKEjUOqShXfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVOrur7N&md5=4ad21b4bd41e99fccb502a5a78e5f9e0</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3892%2For.2019.7256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2019.7256%26sid%3Dliteratum%253Aachs%26aulast%3DGornowicz%26aufirst%3DA.%26aulast%3DSzymanowski%26aufirst%3DW.%26aulast%3DBielawska%26aufirst%3DA.%26aulast%3DSzymanowska%26aufirst%3DA.%26aulast%3DCzarnomysy%26aufirst%3DR.%26aulast%3DKaluza%26aufirst%3DZ.%26aulast%3DBielawski%26aufirst%3DK.%26atitle%3DMonoclonal%2520Anti-MUC1%2520Antibody%2520with%2520Novel%2520Octahydropyrazino%255B2%252C1-a%253A5%252C4-a%25E2%2580%25B2%255Ddiisoquinoline%2520Derivative%2520as%2520a%2520Potential%2520Multi-Targeted%2520Strategy%2520in%2520MCF-7%2520Breast%2520Cancer%2520Cells%26jtitle%3DOncol.%2520Rep.%26date%3D2019%26volume%3D42%26spage%3D1391%26epage%3D1403%26doi%3D10.3892%2For.2019.7256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghasemi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeidi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohtashami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashemy, S. I.</span></span> <span> </span><span class="NLM_article-title">Estrogen-Independent Role of ERα in Ovarian Cancer Progression Induced by Leptin/Ob-Rb Axis</span>. <i>Mol. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>458</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">217</span>, <span class="refDoi"> DOI: 10.1007/s11010-019-03544-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1007%2Fs11010-019-03544-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=31077012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSqsrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=458&publication_year=2019&pages=207-217&author=A.+Ghasemiauthor=J.+Saeidiauthor=M.+Mohtashamiauthor=S.+I.+Hashemy&title=Estrogen-Independent+Role+of+ER%CE%B1+in+Ovarian+Cancer+Progression+Induced+by+Leptin%2FOb-Rb+Axis&doi=10.1007%2Fs11010-019-03544-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen-independent role of ERα in ovarian cancer progression induced by leptin/Ob-Rb axis</span></div><div class="casAuthors">Ghasemi, Ahmad; Saeidi, Jafar; Mohtashami, Mahnaz; Hashemy, Seyed Isaac</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">458</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">207-217</span>CODEN:
                <span class="NLM_cas:coden">MCBIB8</span>;
        ISSN:<span class="NLM_cas:issn">0300-8177</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The present study was designed to evaluate the E2-independent effect of ERα/β on leptin-mediated cell invasion and cell proliferation in ovarian cancer.  We utilized SKOV3 cancer (expressing OB-Rb and ERα/β, insensitive to estrogen) and OVCAR3 (expressing OB-Rb) cell lines to show the involvement of ER in leptin-mediated effects in an E2-independent manner.  MTT, BrdU, and BD matrigel invasion assays were applied to analyze cell growth, proliferation, and invasion.  The siRNA approach was used to confirm the role of ERα/β in leptin effects.  Moreover, western blotting and Real-time PCR were employed to detect the OB-Rb, ER, MMP9/7, and upA proteins and mRNAs.  Leptin, in the absence of E2, increased ERα expression in SKOV3 cells, which was attenuated using knockdown of OB-Rb gene by siRNA.  The effect of leptin on the cell growth was promoted in the presence of PPT, but not in the presence of DNP and E2, which was lost when OB-Rb siRNA was transfected.  Furthermore, ERα gene silencing and/or pre-incubation with ER antagonist (ICI 182,780, 10 nM) significantly reduced cell invasion and MMP9 expression stimulated by leptin.  In conclusion, our findings demonstrated that ERα, but not ERβ, is involved in leptin-induced ovarian cancer in an E2-independent manner, providing new evidence for cancer progression in obesity-assocd. ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodd53zranoz7Vg90H21EOLACvtfcHk0lgv_Pcn1-6x4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSqsrvN&md5=567fe5723be71002d3ff25335addab22</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs11010-019-03544-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11010-019-03544-5%26sid%3Dliteratum%253Aachs%26aulast%3DGhasemi%26aufirst%3DA.%26aulast%3DSaeidi%26aufirst%3DJ.%26aulast%3DMohtashami%26aufirst%3DM.%26aulast%3DHashemy%26aufirst%3DS.%2BI.%26atitle%3DEstrogen-Independent%2520Role%2520of%2520ER%25CE%25B1%2520in%2520Ovarian%2520Cancer%2520Progression%2520Induced%2520by%2520Leptin%252FOb-Rb%2520Axis%26jtitle%3DMol.%2520Cell.%2520Biochem.%26date%3D2019%26volume%3D458%26spage%3D207%26epage%3D217%26doi%3D10.1007%2Fs11010-019-03544-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilder, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shajahan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khattar, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilder, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rushing, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaven, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaetzel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueland, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Nagell, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryscio, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lele, S. M.</span></span> <span> </span><span class="NLM_article-title">Tamoxifen-Associated Malignant Endometrial Tumors: Pathologic Features and Expression of Hormone Receptors Estrogen-α, Estrogen-β and Progesterone; A Case Controlled Study</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1016/j.ygyno.2003.10.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.ygyno.2003.10.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=14766247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXptV2rug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2004&pages=553-558&author=J.+L.+Wilderauthor=S.+Shajahanauthor=N.+H.+Khattarauthor=D.+M.+Wilderauthor=J.+Yinauthor=R.+S.+Rushingauthor=R.+Beavenauthor=C.+Kaetzelauthor=F.+R.+Uelandauthor=J.+R.+van+Nagellauthor=R.+J.+Kryscioauthor=S.+M.+Lele&title=Tamoxifen-Associated+Malignant+Endometrial+Tumors%3A+Pathologic+Features+and+Expression+of+Hormone+Receptors+Estrogen-%CE%B1%2C+Estrogen-%CE%B2+and+Progesterone%3B+A+Case+Controlled+Study&doi=10.1016%2Fj.ygyno.2003.10.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-α, estrogen-β and progesterone; a case controlled study</span></div><div class="casAuthors">Wilder, James L.; Shajahan, Shahin; Khattar, Nada H.; Wilder, Dawn M.; Yin, Jianming; Rushing, Rodney S.; Beaven, Rick; Kaetzel, Charlotte; Ueland, Frederick R.; van Nagell, John R.; Kryscio, Richard J.; Lele, Subodh M.</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">553-558</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">Objective: Expression anal. of estrogen receptor-beta (ER-β) and estrogen receptor-alpha (ER-α) in tamoxifen-assocd. malignant endometrial tumors (TAMET) has not previously been published.  Antiestrogens complexed with ER-β have been reported to result in activation of the activator protein-1 (AP-1) pathway that may result in cell proliferation and tumor growth.  In this study, the pathol. features and expression of ER-α, ER-β and progesterone receptor (PR) in TAMET were detd. and compared to matched cases of non-tamoxifen-assocd. endometrial cancers.  Methods: TAMET (n = 33) were evaluated for pathol. features (tumor type, grade, depth of myometrial invasion, lymph-vascular space invasion and lymph node status), expression of ER-α, ER-β and PR, and survival data (mean follow-up: 28.7 mo).  Each case was matched to two control patients with spontaneous endometrial cancers according to tumor type, grade and stage as well as patient age and wt. (mean follow-up: 51.5 mo).  Formalin-fixed paraffin-embedded tissue sections were immunostained with anti-ER-α (1D5, Dako, Carpinteria, CA) and anti-PR (PgR636, Dako).  Expression scores were detd. as a sum of the product of staining intensity and proportion of cells staining (H-score).  Deparaffinized sections of tumor were microdissected followed by RNA isolation.  Quantification of ER-β mRNA was performed by real-time quant. RT-PCR with results expressed as a percentage of β-actin mRNA.  Results: Of the 33 cases 20 were endometrioid (8 grade 1, 10 grade 2, 2 grade 3), 9 papillary serous and 4 malignant mullerian mixed tumors.  Using a multivariate conditional regression model, TAMET had lower ER-α expression (P = 0.018), higher PR expression (P = 0.029), and more frequent expression of ER-β (P = 0.032) as compared to control cases.  Cases with TAMET had more deaths from cancer and significantly worse survival from disease than controls (P = 0.01 by a log rank test).  Conclusion: TAMET are characterized by a lower expression of ER-α, higher expression of PR and more frequent expression of ER-β as compared to spontaneous tumors.  Differential expression of ER-α and ER-β may alter the expression of key target genes (such as those induced by AP-1-dependent gene transcription), and contribute to the pathogenesis and clin. behavior of these tumors.  Survival from disease was significantly worse for cases with TAMET as compared to controls.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfx490_iAxSLVg90H21EOLACvtfcHk0lgv_Pcn1-6x4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXptV2rug%253D%253D&md5=41223c87f69fad44a572052b4a119fc9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2003.10.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2003.10.040%26sid%3Dliteratum%253Aachs%26aulast%3DWilder%26aufirst%3DJ.%2BL.%26aulast%3DShajahan%26aufirst%3DS.%26aulast%3DKhattar%26aufirst%3DN.%2BH.%26aulast%3DWilder%26aufirst%3DD.%2BM.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DRushing%26aufirst%3DR.%2BS.%26aulast%3DBeaven%26aufirst%3DR.%26aulast%3DKaetzel%26aufirst%3DC.%26aulast%3DUeland%26aufirst%3DF.%2BR.%26aulast%3Dvan%2BNagell%26aufirst%3DJ.%2BR.%26aulast%3DKryscio%26aufirst%3DR.%2BJ.%26aulast%3DLele%26aufirst%3DS.%2BM.%26atitle%3DTamoxifen-Associated%2520Malignant%2520Endometrial%2520Tumors%253A%2520Pathologic%2520Features%2520and%2520Expression%2520of%2520Hormone%2520Receptors%2520Estrogen-%25CE%25B1%252C%2520Estrogen-%25CE%25B2%2520and%2520Progesterone%253B%2520A%2520Case%2520Controlled%2520Study%26jtitle%3DGynecol.%2520Oncol.%26date%3D2004%26volume%3D92%26spage%3D553%26epage%3D558%26doi%3D10.1016%2Fj.ygyno.2003.10.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, O. P.</span></span> <span> </span><span class="NLM_article-title">Estrogen Receptor 1 Mutations in 260 Cervical Cancer Samples from Chinese Patients</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2771</span>– <span class="NLM_lpage">2776</span>, <span class="refDoi"> DOI: 10.3892/ol.2019.10612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3892%2Fol.2019.10612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=31452755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjvFaiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=2771-2776&author=X.+M.+Yangauthor=Z.+M.+Wuauthor=H.+Huangauthor=X.+Y.+Chuauthor=J.+Louauthor=L.+X.+Xuauthor=Y.+T.+Chenauthor=L.+Q.+Wangauthor=O.+P.+Huang&title=Estrogen+Receptor+1+Mutations+in+260+Cervical+Cancer+Samples+from+Chinese+Patients&doi=10.3892%2Fol.2019.10612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor 1 mutations in 260 cervical cancer samples from Chinese patients</span></div><div class="casAuthors">Yang, Xin-Min; Wu, Zhi-Min; Huang, Huang; Chu, Xiao-Yan; Lou, Jun; Xu, Li-Xian; Chen, Yuan-Ting; Wang, Li-Qun; Huang, Ou-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2771-2776</span>CODEN:
                <span class="NLM_cas:coden">OLNEB5</span>;
        ISSN:<span class="NLM_cas:issn">1792-1082</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Cervical cancer is one of the leading causes of cancer-assocd. mortality among females; however, the underlying mol. mechanisms of its carcinogenesis remain largely unclear.  Previous comprehensive genomic studies have revealed prevalent estrogen receptor 1 (ESR1) mutations in breast cancer, which are rare in certain other types of cancer.  To the best of our knowledge, it is unknown whether ESR1 mutations also exist in cervical cancer.  Considering the evidence that cervical cancer shares certain genetic aberrations with breast cancer, and that the progression of both breast and cervical cancers can be affected by estrogen, it is possible that cervical cancer may also harbor ESR1 mutations.  In the present study, a total of 260 Chinese cervical cancer samples with distinct subtypes were tested for the presence of ESR1 mutations.  A total of three heterozygous missense ESR1 mutations, p.K303R (c.908A>G), p.T311M (c.932C>T) and p.Y537C (c.1610A>G), were identified in 3/207 (1.4%) cervical squamous cell carcinoma samples, which were absent in 27 adenosquamous carcinomas and 26 adenocarcinomas samples.  Of the three individuals with an ESR1mutation, 1 patient was also diagnosed with ovarian endometriosis and the other 2 patients were diagnosed with a uterine fibroid.  A bioinformatics anal. suggested that these ESR1 mutations may be pathogenic by promoting the development of cervical cancer.  Furthermore, a previous comprehensive study confirmed that individuals with cervical squamous cell carcinoma possessed ESR1 mutations.  These combined studies indicate that ESR1 mutations may participate in the carcinogenesis of cervical squamous cell carcinoma, albeit at a low frequency.  In conclusion, the present study identified three potentially pathogenic ESR1 mutations in Chinese cervical squamous cell carcinoma samples, but not in other subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr80XndRdfJ-bVg90H21EOLACvtfcHk0lgW49fme_JFhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjvFaiurg%253D&md5=bce4a98bc70904e4150b149bb087139b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3892%2Fol.2019.10612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2019.10612%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%2BM.%26aulast%3DWu%26aufirst%3DZ.%2BM.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DChu%26aufirst%3DX.%2BY.%26aulast%3DLou%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DL.%2BX.%26aulast%3DChen%26aufirst%3DY.%2BT.%26aulast%3DWang%26aufirst%3DL.%2BQ.%26aulast%3DHuang%26aufirst%3DO.%2BP.%26atitle%3DEstrogen%2520Receptor%25201%2520Mutations%2520in%2520260%2520Cervical%2520Cancer%2520Samples%2520from%2520Chinese%2520Patients%26jtitle%3DOncol.%2520Lett.%26date%3D2019%26volume%3D18%26spage%3D2771%26epage%3D2776%26doi%3D10.3892%2Fol.2019.10612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaturantabut, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shwartz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evason, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labella, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepers, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acuna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houvras, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancio-Silva, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorelick, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zon, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">North, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goessling, W.</span></span> <span> </span><span class="NLM_article-title">Estrogen Activation of G-Protein-Coupled Estrogen Receptor 1 Regulates Phosphoinositide 3-Kinase and mTOR Signaling to Promote Liver Growth in Zebrafish and Proliferation of Human Hepatocytes</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2019.01.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1053%2Fj.gastro.2019.01.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2019&pages=1-17&author=S.+Chaturantabutauthor=A.+Shwartzauthor=K.+J.+Evasonauthor=A.+G.+Coxauthor=K.+Labellaauthor=A.+G.+Schepersauthor=S.+Yangauthor=M.+Acunaauthor=Y.+Houvrasauthor=L.+Mancio-Silvaauthor=S.+Romanoauthor=D.+A.+Gorelickauthor=D.+E.+Cohenauthor=L.+I.+Zonauthor=S.+N.+Bhatiaauthor=T.+E.+Northauthor=W.+Goessling&title=Estrogen+Activation+of+G-Protein-Coupled+Estrogen+Receptor+1+Regulates+Phosphoinositide+3-Kinase+and+mTOR+Signaling+to+Promote+Liver+Growth+in+Zebrafish+and+Proliferation+of+Human+Hepatocytes&doi=10.1053%2Fj.gastro.2019.01.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2019.01.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2019.01.010%26sid%3Dliteratum%253Aachs%26aulast%3DChaturantabut%26aufirst%3DS.%26aulast%3DShwartz%26aufirst%3DA.%26aulast%3DEvason%26aufirst%3DK.%2BJ.%26aulast%3DCox%26aufirst%3DA.%2BG.%26aulast%3DLabella%26aufirst%3DK.%26aulast%3DSchepers%26aufirst%3DA.%2BG.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DAcuna%26aufirst%3DM.%26aulast%3DHouvras%26aufirst%3DY.%26aulast%3DMancio-Silva%26aufirst%3DL.%26aulast%3DRomano%26aufirst%3DS.%26aulast%3DGorelick%26aufirst%3DD.%2BA.%26aulast%3DCohen%26aufirst%3DD.%2BE.%26aulast%3DZon%26aufirst%3DL.%2BI.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26aulast%3DNorth%26aufirst%3DT.%2BE.%26aulast%3DGoessling%26aufirst%3DW.%26atitle%3DEstrogen%2520Activation%2520of%2520G-Protein-Coupled%2520Estrogen%2520Receptor%25201%2520Regulates%2520Phosphoinositide%25203-Kinase%2520and%2520mTOR%2520Signaling%2520to%2520Promote%2520Liver%2520Growth%2520in%2520Zebrafish%2520and%2520Proliferation%2520of%2520Human%2520Hepatocytes%26jtitle%3DGastroenterology%26date%3D2019%26volume%3D156%26spage%3D1%26epage%3D17%26doi%3D10.1053%2Fj.gastro.2019.01.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. B.</span></span> <span> </span><span class="NLM_article-title">Prognostic Role of Estrogen Receptor α and Estrogen Receptor beta in Gastric Cancer</span>. <i>Ann. Surg. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2503</span>– <span class="NLM_lpage">2509</span>, <span class="refDoi"> DOI: 10.1245/s10434-010-1031-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1245%2Fs10434-010-1031-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=20339947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BC3cjmtVCksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=2503-2509&author=C.+Y.+Xuauthor=J.+L.+Guoauthor=Z.+N.+Jiangauthor=S.+D.+Xieauthor=J.+G.+Shenauthor=J.+Y.+Shenauthor=L.+B.+Wang&title=Prognostic+Role+of+Estrogen+Receptor+%CE%B1+and+Estrogen+Receptor+beta+in+Gastric+Cancer&doi=10.1245%2Fs10434-010-1031-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic role of estrogen receptor alpha and estrogen receptor beta in gastric cancer</span></div><div class="casAuthors">Xu C Y; Guo J L; Jiang Z N; Xie S D; Shen J G; Shen J Y; Wang L B</div><div class="citationInfo"><span class="NLM_cas:title">Annals of surgical oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2503-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The presence of estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta) have been reported in cell and tissue level in gastric cancer, but its impact on patients' survival remains unclear.  This study was designed to investigate the expression level of ERalpha and ERbeta and to assess clinical significance of ERalpha and ERbeta expression in gastric cancer.  METHODS:  The expression level of ERalpha and ERbeta were assessed by reverse-transcriptase polymerase chain reaction (RT-PCR) in 35 surgically resected gastric cancer and corresponding normal tissues and by immunohistochemical staining in 211 surgically resected gastric cancer and match normal tissues.  RESULTS:  The expression level between ERalpha mRNA expression in gastric cancer tissues and match normal tissues had no statistically significant difference.  The ERbeta mRNA level in normal tissues was significantly higher than that observed in gastric cancer tissues (P = 0.001).  Neither ERalpha nor ERbeta mRNA expression levels had significant correlation with clinicopathologic parameters.  Forty-eight of 211 (22.7%) gastric cancer tissues showed positive expression of ERalpha and ERbeta detected in gastric cancer.  ERalpha-positive expression correlated with poorer overall survival (P = 0.014), as did the absence of ERbeta expression in patients with gastric cancer (P = 0.001).  In multivariate analysis, the positive expression of ERalpha and the absence of ERbeta were significant independent prognostic factors for overall survival (hazard ratio 2.159, P = 0.013, and hazard ratio 2.016, P = 0.025 respectively).  CONCLUSIONS:  Our results indicated that ERalpha and ERbeta were expressed in both gastric cancer and corresponding normal tissues.  ERalpha expression and the absence of ERbeta expression are associated with poor survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQIclrO6TQgB5PlX7E30qdzfW6udTcc2ebbzuOfoGZ2LLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjmtVCksw%253D%253D&md5=92664c4e682b25d838bdfa9a6cf9fbd3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1245%2Fs10434-010-1031-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1245%252Fs10434-010-1031-2%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DC.%2BY.%26aulast%3DGuo%26aufirst%3DJ.%2BL.%26aulast%3DJiang%26aufirst%3DZ.%2BN.%26aulast%3DXie%26aufirst%3DS.%2BD.%26aulast%3DShen%26aufirst%3DJ.%2BG.%26aulast%3DShen%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DL.%2BB.%26atitle%3DPrognostic%2520Role%2520of%2520Estrogen%2520Receptor%2520%25CE%25B1%2520and%2520Estrogen%2520Receptor%2520beta%2520in%2520Gastric%2520Cancer%26jtitle%3DAnn.%2520Surg.%2520Oncol.%26date%3D2010%26volume%3D17%26spage%3D2503%26epage%3D2509%26doi%3D10.1245%2Fs10434-010-1031-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, S. H.</span></span> <span> </span><span class="NLM_article-title">Estrogen, Estrogen Receptor and Lung Cancer</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>, <span class="NLM_elocation-id">1713</span> <span class="refDoi"> DOI: 10.3390/ijms18081713</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3390%2Fijms18081713" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWgu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&author=L.+H.+Hsuauthor=N.+M.+Chuauthor=S.+H.+Kao&title=Estrogen%2C+Estrogen+Receptor+and+Lung+Cancer&doi=10.3390%2Fijms18081713"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen, estrogen receptor and lung cancer</span></div><div class="casAuthors">Hsu, Li-Han; Chu, Nei-Min; Kao, Shu-Huei</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1713/1-1713/17</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Estrogen has been postulated as a contributor for lung cancer development and progression.  We reviewed the current knowledge about the expression and prognostic implications of the estrogen receptors (ER) in lung cancer, the effect and signaling pathway of estrogen on lung cancer, the hormone replacement therapy and lung cancer risk and survival, the mechanistic relationship between the ER and the epidermal growth factor receptor (EGFR), and the relevant clin. trials combining the ER antagonist and the EGFR antagonist, to investigate the role of estrogen in lung cancer.  Estrogen and its receptor have the potential to become a prognosticator and a therapeutic target in lung cancer.  On the other hand, tobacco smoking aggravates the effect of estrogen and endocrine disruptive chems. from the environment targeting ER may well contribute to the lung carcinogenesis.  They have gradually become important issues in the course of preventive medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhkIb2iEDMi7Vg90H21EOLACvtfcHk0lgW49fme_JFhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWgu7fN&md5=6a4b45e178f28aebe507db8a8af401fa</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3390%2Fijms18081713&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18081713%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DL.%2BH.%26aulast%3DChu%26aufirst%3DN.%2BM.%26aulast%3DKao%26aufirst%3DS.%2BH.%26atitle%3DEstrogen%252C%2520Estrogen%2520Receptor%2520and%2520Lung%2520Cancer%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26doi%3D10.3390%2Fijms18081713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foley, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jazaeri, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shupnik, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jazaeri, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, L. W.</span></span> <span> </span><span class="NLM_article-title">Selective Loss of Estrogen Receptor β in Malignant Human Colon</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">245</span>– <span class="NLM_lpage">248</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10667568" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtVahsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=245-248&author=E.+F.+Foleyauthor=A.+A.+Jazaeriauthor=M.+A.+Shupnikauthor=O.+Jazaeriauthor=L.+W.+Rice&title=Selective+Loss+of+Estrogen+Receptor+%CE%B2+in+Malignant+Human+Colon"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Selective loss of estrogen receptor β in malignant human colon</span></div><div class="casAuthors">Foley, Eugene F.; Jazaeri, Amir A.; Shupnik, Margaret A.; Jazaeri, Omid; Rice, Laurel W.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-248</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Epidemiol. data suggest a protective effect for estrogen replacement therapy on colon cancer.  The ER-β isoform is functionally similar to ER-α but has a distinct pattern of expression and transcriptional response to selective estrogen response modulators.  The authors' goal was to investigate the presence of ER-α and ER-β in normal and malignant colon tissue.  Human colon cancer tissue and adjacent normal colon tissue were harvested from five male and six female patients undergoing segmental colon resection for colon cancer.  Western blot anal. revealed very low levels of ER-α protein in tumor and normal colon tissue.  In both male and female patients, malignant colon tissue showed a selective loss of ER-β protein expression when compared to normal colon tissue in the same patient.  Semiquant. reverse transcription-PCR revealed no difference in ER-β mRNA levels between normal and malignant colon tissue.  Malignant transformation of the colon is assocd. with a marked diminution of ER-β protein expression, possibly through a posttranscriptional mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYQq9J7Jcn-LVg90H21EOLACvtfcHk0lhtwoxOcPfK_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtVahsro%253D&md5=0cc9bc561c56ffa131999db98dfb1513</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFoley%26aufirst%3DE.%2BF.%26aulast%3DJazaeri%26aufirst%3DA.%2BA.%26aulast%3DShupnik%26aufirst%3DM.%2BA.%26aulast%3DJazaeri%26aufirst%3DO.%26aulast%3DRice%26aufirst%3DL.%2BW.%26atitle%3DSelective%2520Loss%2520of%2520Estrogen%2520Receptor%2520%25CE%25B2%2520in%2520Malignant%2520Human%2520Colon%26jtitle%3DCancer%2520Res.%26date%3D2000%26volume%3D60%26spage%3D245%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pasqualini, J. R.</span></span> <span> </span><span class="NLM_article-title">The Selective Estrogen Enzyme Modulators in Breast Cancer: A Review</span>. <i>Biochim. Biophys. Acta, Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1654</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1016/j.bbcan.2004.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.bbcan.2004.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=15172700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVCitr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1654&publication_year=2004&pages=123-143&author=J.+R.+Pasqualini&title=The+Selective+Estrogen+Enzyme+Modulators+in+Breast+Cancer%3A+A+Review&doi=10.1016%2Fj.bbcan.2004.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">The selective estrogen enzyme modulators in breast cancer: a review</span></div><div class="casAuthors">Pasqualini, Jorge R.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1654</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-143</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  It is well established that increased exposure to estradiol (E2) is an important risk factor for the genesis and evolution of breast tumors, most of which (approx. 95-97%) in their early stage are estrogen-sensitive.  However, two thirds of breast cancers occur during the postmenopausal period when the ovaries have ceased to be functional.  Despite the low levels of circulating estrogens, the tissular concns. of these hormones are significantly higher than those found in the plasma or in the area of the breast considered as normal tissue, suggesting a specific tumoral biosynthesis and accumulation of these hormones.  Several factors could be implicated in this process, including higher uptake of steroids from plasma and local formation of the potent E2 by the breast cancer tissue itself.  This information extends the concept of intracrinol. where a hormone can have its biol. response in the same organ where it is produced.  There is substantial information that mammary cancer tissue contains all the enzymes responsible for the local biosynthesis of E2 from circulating precursors.  Two principal pathways are implicated in the last steps of E2 formation in breast cancer tissues: the aromatase pathway which transforms androgens into estrogens, and the sulfatase pathway which converts estrone sulfate (E1S) into E1 by the estrone-sulfatase.  The final step of steroidogenesis is the conversion of the weak E1 to the potent biol. active E2 by the action of a reductive 17β-hydroxysteroid dehydrogenase type 1 activity (17β-HSD-1).  Quant. evaluation indicates that in human breast tumor E1S via sulfatase is a much more likely precursor for E2 than is androgens via aromatase.  Human breast cancer tissue contains all the enzymes (estrone sulfatase, 17β-hydroxysteroid dehydrogenase, aromatase) involved in the last steps of E2 biosynthesis.  This tissue also contains sulfotransferase for the formation of the biol. inactive estrogen sulfates.  In recent years, it was demonstrated that various progestins (promegestone, nomegestrol acetate, medrogestone, dydrogesterone, norelgestromin), tibolone and its metabolites, as well as other steroidal (e.g., sulfamates) and non-steroidal compds., are potent sulfatase inhibitors.  Various progestins can also block 17β-hydroxysteroid dehydrogenase activities.  In other studies, it was shown that medrogestone, nomegestrol acetate, promegestone or tibolone can stimulate the sulfotransferase activity for the local prodn. of estrogen sulfates.  All these data, in addn. to numerous agents which can block the aromatase action, lead to the new concept of 'Selective Estrogen Enzyme Modulators' (SEEM) which can largely apply to breast cancer tissue.  The exploration of various progestins and other active agents in trials with breast cancer patients, showing an inhibitory effect on sulfatase and 17β-hydroxysteroid dehydrogenase, or a stimulatory effect on sulfotransferase and consequently on the levels of tissular levels of E2, will provide a new possibility in the treatment of this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcF-MirOzz5LVg90H21EOLACvtfcHk0lhtwoxOcPfK_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVCitr8%253D&md5=667fc99e8162752fc15702951c26e15b</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2004.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2004.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DPasqualini%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520Selective%2520Estrogen%2520Enzyme%2520Modulators%2520in%2520Breast%2520Cancer%253A%2520A%2520Review%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2004%26volume%3D1654%26spage%3D123%26epage%3D143%26doi%3D10.1016%2Fj.bbcan.2004.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Roger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daures, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maudelonde, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pignodel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleizes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapelle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marty-Double, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mares, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laffargue, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochefort, H.</span></span> <span> </span><span class="NLM_article-title">Dissociated Overexpression of Cathepsin D and Estrogen Receptor alpha in Preinvasive Mammary Tumors</span>. <i>Hum. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1053/hp.2000.6687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1053%2Fhp.2000.6687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10836299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjvFShtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2000&pages=593-600&author=P.+Rogerauthor=J.+P.+Dauresauthor=T.+Maudelondeauthor=C.+Pignodelauthor=M.+Gleizesauthor=J.+Chapelleauthor=C.+Marty-Doubleauthor=P.+Baldetauthor=P.+Maresauthor=F.+Laffargueauthor=H.+Rochefort&title=Dissociated+Overexpression+of+Cathepsin+D+and+Estrogen+Receptor+alpha+in+Preinvasive+Mammary+Tumors&doi=10.1053%2Fhp.2000.6687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors</span></div><div class="casAuthors">Roger, Pascal; Daures, Jean-Pierre; Maudelonde, Thierry; Pignodel, Christine; Gleizes, Michel; Chapelle, Jean; Marty-Double, Christiane; Baldet, Pierre; Mares, Pierre; Laffargue, Francois; Rochefort, Henri</div><div class="citationInfo"><span class="NLM_cas:title">Human Pathology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">593-600</span>CODEN:
                <span class="NLM_cas:coden">HPCQA4</span>;
        ISSN:<span class="NLM_cas:issn">0046-8177</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">The role of estrogen as a promoter agent of sporadic breast cancer has been considered by assaying, in benign breast disease (BBD) and in situ carcinomas (CIS), 2 markers, the estrogen receptor α (ERα) and cathepsin D (cath-D) involved in estrogen action on mammary tissue.  ERα and cath-D were assayed by quant. immunohistochem. using an image analyzer in 170 lesions of varying histol. risk (94 BBD and 76 CIS), and in "normal" glands close to these lesions.  The ERα level increased significantly in proliferative BBD with atypia (P < .001), in non-high-grade CIS (P < .001), and in adjacent "normal" glands.  ERα level was decreased in high-grade ductal CIS (DCIS) and also in adjacent "normal" glands.  Cath-D level increased in ductal proliferative BBD (P ≤ .01) and in high-grade DCIS (P ≤ .003), but not in the other lesions.  After menopause, ERα level was increased (P = .012) but not cath-D level.  According to Mac Neman test, the high-grade DCIS were predominantly ERα neg. and cath-D pos. (P = .0017), and the other CIS were predominantly ERα pos. and cath-D neg. (P = .0002).  The 2 markers are overexpressed early in premalignant lesions, but independently.  This dissocn. suggests a branched model of mammary carcinogenesis involving 1 estrogen-independent pathway with high cath-D and low ERα levels (including high-grade DCIS) and 1 estrogen-dependent pathway, with high ERα level (including proliferative BBD with atypia and low-grade DCIS).  We propose that ERα-neg. breast cancers may develop directly from high-grade DCIS and that ERα assay in preinvasive lesions should be considered in prevention trials with antiestrogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKc7B_4chCabVg90H21EOLACvtfcHk0lhtwoxOcPfK_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjvFShtLg%253D&md5=3b09b5c0343d1c0c3e1b86df4bd3b79a</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1053%2Fhp.2000.6687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fhp.2000.6687%26sid%3Dliteratum%253Aachs%26aulast%3DRoger%26aufirst%3DP.%26aulast%3DDaures%26aufirst%3DJ.%2BP.%26aulast%3DMaudelonde%26aufirst%3DT.%26aulast%3DPignodel%26aufirst%3DC.%26aulast%3DGleizes%26aufirst%3DM.%26aulast%3DChapelle%26aufirst%3DJ.%26aulast%3DMarty-Double%26aufirst%3DC.%26aulast%3DBaldet%26aufirst%3DP.%26aulast%3DMares%26aufirst%3DP.%26aulast%3DLaffargue%26aufirst%3DF.%26aulast%3DRochefort%26aufirst%3DH.%26atitle%3DDissociated%2520Overexpression%2520of%2520Cathepsin%2520D%2520and%2520Estrogen%2520Receptor%2520alpha%2520in%2520Preinvasive%2520Mammary%2520Tumors%26jtitle%3DHum.%2520Pathol.%26date%3D2000%26volume%3D31%26spage%3D593%26epage%3D600%26doi%3D10.1053%2Fhp.2000.6687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, J.</span></span> <span> </span><span class="NLM_article-title">ER-alpha 36, A Novel Variant of Estrogen Receptor alpha, is Involved in EGFR-Related Carcinogenesis in Endometrial Cancer</span>. <i>Am. J. Obstet. Gynecol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1016/j.ajog.2011.04.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.ajog.2011.04.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=22088891" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2011&pages=1-6&author=B.+B.+Tuauthor=S.+L.+Linauthor=L.+Y.+Yanauthor=Z.+Y.+Wangauthor=Q.+Y.+Sunauthor=J.+Qiao&title=ER-alpha+36%2C+A+Novel+Variant+of+Estrogen+Receptor+alpha%2C+is+Involved+in+EGFR-Related+Carcinogenesis+in+Endometrial+Cancer&doi=10.1016%2Fj.ajog.2011.04.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13c&amp;dbid=16384&amp;doi=10.1016%2Fj.ajog.2011.04.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajog.2011.04.015%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DB.%2BB.%26aulast%3DLin%26aufirst%3DS.%2BL.%26aulast%3DYan%26aufirst%3DL.%2BY.%26aulast%3DWang%26aufirst%3DZ.%2BY.%26aulast%3DSun%26aufirst%3DQ.%2BY.%26aulast%3DQiao%26aufirst%3DJ.%26atitle%3DER-alpha%252036%252C%2520A%2520Novel%2520Variant%2520of%2520Estrogen%2520Receptor%2520alpha%252C%2520is%2520Involved%2520in%2520EGFR-Related%2520Carcinogenesis%2520in%2520Endometrial%2520Cancer%26jtitle%3DAm.%2520J.%2520Obstet.%2520Gynecol.%26date%3D2011%26volume%3D205%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.ajog.2011.04.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latimer, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt-Enderby, P. A.</span></span> <span> </span><span class="NLM_article-title">Melatonin and Breast Cancer: Cellular Mechanisms, Clinical Studies and Future Perspectives</span>. <i>Expert Rev. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e5</span> <span class="refDoi"> DOI: 10.1017/S1462399409000982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1017%2FS1462399409000982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=19193248" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&author=S.+G.+Grantauthor=M.+A.+Melanauthor=J.+J.+Latimerauthor=P.+A.+Witt-Enderby&title=Melatonin+and+Breast+Cancer%3A+Cellular+Mechanisms%2C+Clinical+Studies+and+Future+Perspectives&doi=10.1017%2FS1462399409000982"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13d&amp;dbid=16384&amp;doi=10.1017%2FS1462399409000982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1462399409000982%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DS.%2BG.%26aulast%3DMelan%26aufirst%3DM.%2BA.%26aulast%3DLatimer%26aufirst%3DJ.%2BJ.%26aulast%3DWitt-Enderby%26aufirst%3DP.%2BA.%26atitle%3DMelatonin%2520and%2520Breast%2520Cancer%253A%2520Cellular%2520Mechanisms%252C%2520Clinical%2520Studies%2520and%2520Future%2520Perspectives%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Med.%26date%3D2009%26volume%3D11%26doi%3D10.1017%2FS1462399409000982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajapaksa, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolos, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, J. A.</span></span> <span> </span><span class="NLM_article-title">Estrogen Receptor beta Inhibits Migration and Invasion of Breast Cancer Cells by Regulating E-cadherin Levels</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">2</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=2&author=C.+Thomasauthor=G.+Rajapaksaauthor=F.+Nikolosauthor=J.+A.+Gustafsson&title=Estrogen+Receptor+beta+Inhibits+Migration+and+Invasion+of+Breast+Cancer+Cells+by+Regulating+E-cadherin+Levels"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DC.%26aulast%3DRajapaksa%26aufirst%3DG.%26aulast%3DNikolos%26aufirst%3DF.%26aulast%3DGustafsson%26aufirst%3DJ.%2BA.%26atitle%3DEstrogen%2520Receptor%2520beta%2520Inhibits%2520Migration%2520and%2520Invasion%2520of%2520Breast%2520Cancer%2520Cells%2520by%2520Regulating%2520E-cadherin%2520Levels%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Busch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landberg, G.</span></span> <span> </span><span class="NLM_article-title">Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1457</span>– <span class="NLM_lpage">1469</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-1583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1158%2F0008-5472.CAN-14-1583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=25833830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsleisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1457-1469&author=S.+Buschauthor=A.+H.+Simsauthor=O.+Stalauthor=M.+Fernoauthor=G.+Landberg&title=Loss+of+TGF%CE%B2+Receptor+Type+2+Expression+Impairs+Estrogen+Response+and+Confers+Tamoxifen+Resistance&doi=10.1158%2F0008-5472.CAN-14-1583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13fR"><div class="casContent"><span class="casTitleNuber">13f</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance</span></div><div class="casAuthors">Busch, Susann; Sims, Andrew H.; Stal, Olle; Fernoe, Marten; Landberg, Goeran</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1457-1469</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This important study not only advances understanding of tamoxifen resistance in breast cancer, but it also raises concerns about the use of TGFβ-targeting therapies to attack ER+ tumors, given evidence of how disruption of TGFβ signaling appears to generate endocrine resistance.  One third of the patients with estrogen receptor α (ERα)-pos. breast cancer who are treated with the antiestrogen tamoxifen will either not respond to initial therapy or will develop drug resistance.  Endocrine response involves crosstalk between ERα and TGFβ signaling, such that tamoxifen nonresponsiveness or resistance in breast cancer might involve aberrant TGFβ signaling.  In this study, we analyzed TGFβ receptor type 2 (TGFBR2) expression and correlated it with ERα status and phosphorylation in a cohort of 564 patients who had been randomized to tamoxifen or no-adjuvant treatment for invasive breast carcinoma.  We also evaluated an addnl. four independent genetic datasets in invasive breast cancer.  In all the cohorts we analyzed, we documented an assocn. of low TGFBR2 protein and mRNA expression with tamoxifen resistance.  Functional investigations confirmed that cell cycle or apoptosis responses to estrogen or tamoxifen in ERα-pos. breast cancer cells were impaired by TGFBR2 silencing, as was ERα phosphorylation, tamoxifen-induced transcriptional activation of TGFβ, and upregulation of the multidrug resistance protein ABCG2.  Acquisition of low TGFBR2 expression as a contributing factor to endocrine resistance was validated prospectively in a tamoxifen-resistant cell line generated by long-term drug treatment.  Collectively, our results established a central contribution of TGFβ signaling in endocrine resistance in breast cancer and offered evidence that TGFBR2 can serve as an independent biomarker to predict treatment outcomes in ERα-pos. forms of this disease.  Cancer Res; 75(7); 1457-69. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm2HO3eedBYbVg90H21EOLACvtfcHk0ljZ5JGmJ43iZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsleisLc%253D&md5=dd086c6cd8aaaf83618b046e533f00f3</span></div><a href="/servlet/linkout?suffix=cit13f&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-1583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-1583%26sid%3Dliteratum%253Aachs%26aulast%3DBusch%26aufirst%3DS.%26aulast%3DSims%26aufirst%3DA.%2BH.%26aulast%3DStal%26aufirst%3DO.%26aulast%3DFerno%26aufirst%3DM.%26aulast%3DLandberg%26aufirst%3DG.%26atitle%3DLoss%2520of%2520TGF%25CE%25B2%2520Receptor%2520Type%25202%2520Expression%2520Impairs%2520Estrogen%2520Response%2520and%2520Confers%2520Tamoxifen%2520Resistance%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D1457%26epage%3D1469%26doi%3D10.1158%2F0008-5472.CAN-14-1583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, S. R.</span></span> <span> </span><span class="NLM_article-title">Drugs for the Gynecologist to Prescribe in the Prevention of Breast Cancer: Current Status and Future Trends</span>. <i>Am. J. Obstet. Gynecol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1126</span>, <span class="refDoi"> DOI: 10.1067/mob.2000.105941</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1067%2Fmob.2000.105941" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10819845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BD3c3nvFOhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2000&pages=1121-1126&author=S.+R.+Goldstein&title=Drugs+for+the+Gynecologist+to+Prescribe+in+the+Prevention+of+Breast+Cancer%3A+Current+Status+and+Future+Trends&doi=10.1067%2Fmob.2000.105941"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs for the gynecologist to prescribe in the prevention of breast cancer: current status and future trends</span></div><div class="casAuthors">Goldstein S R</div><div class="citationInfo"><span class="NLM_cas:title">American journal of obstetrics and gynecology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1121-6</span>
        ISSN:<span class="NLM_cas:issn">0002-9378</span>.
    </div><div class="casAbstract">Tamoxifen was approved for breast cancer prevention in October 1998.  Thus, for the first time, we as gynecologists are being asked to prescribe this drug to healthy women.  In the past each one of us has cared for women with breast cancer who have been treated with tamoxifen by oncologists or breast surgeons for the malignancy.  Effects of tamoxifen on the uterus resulting in carcinomas, hyperplasia, and polyps are well known.  Furthermore, tamoxifen has estrogenic properties in the venous system, increasing the incidence of deep vein thrombosis and pulmonary emboli.  A new SERM (selective estrogen receptor modulator), raloxifene, has been approved for prevention and treatment of osteoporosis in postmenopausal women.  It does not have stimulatory effects on the endometrium; however, it is estrogenic in the venous system.  Preclinical data, as well as the breast cancer incidence reported in studies of the skeleton, seem to indicate that its effects in the breast are similar to those of tamoxifen.  This article reviews tamoxifen and the new SERM, raloxifene, in an attempt to help gynecologists better understand each compound and what data are currently known, what we hope to learn from future studies, and what currently makes sense for clinical practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTln8cwbv12mf9pSBfyDvp7fW6udTcc2ebsWmCdcsw1Ebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3nvFOhtA%253D%253D&md5=4fd9b209e80195111d7d6389ee931d18</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1067%2Fmob.2000.105941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1067%252Fmob.2000.105941%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DS.%2BR.%26atitle%3DDrugs%2520for%2520the%2520Gynecologist%2520to%2520Prescribe%2520in%2520the%2520Prevention%2520of%2520Breast%2520Cancer%253A%2520Current%2520Status%2520and%2520Future%2520Trends%26jtitle%3DAm.%2520J.%2520Obstet.%2520Gynecol.%26date%3D2000%26volume%3D182%26spage%3D1121%26epage%3D1126%26doi%3D10.1067%2Fmob.2000.105941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lorizio, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerlikowske, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv, E.</span></span> <span> </span><span class="NLM_article-title">Clinical and Biomarker Predictors of Side Effects from Tamoxifen</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1118</span>, <span class="refDoi"> DOI: 10.1007/s10549-011-1893-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1007%2Fs10549-011-1893-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=22207277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFWgsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2012&pages=1107-1118&author=W.+Lorizioauthor=A.+H.+Wuauthor=M.+S.+Beattieauthor=H.+Rugoauthor=S.+Tchuauthor=K.+Kerlikowskeauthor=E.+Ziv&title=Clinical+and+Biomarker+Predictors+of+Side+Effects+from+Tamoxifen&doi=10.1007%2Fs10549-011-1893-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and biomarker predictors of side effects from tamoxifen</span></div><div class="casAuthors">Lorizio, Wendy; Wu, Alan H. B.; Beattie, Mary S.; Rugo, Hope; Tchu, Simone; Kerlikowske, Karla; Ziv, Elad</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1107-1118</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Tamoxifen decreases breast cancer recurrence, mortality, and breast cancer risk in high-risk women.  Despite these proven benefits, tamoxifen use is often limited due to side effects.  We identified predictors of tamoxifen-induced side effects based on clin. variables and serum tamoxifen metabolite biomarkers in a cross-sectional study of patients taking tamoxifen.  We enrolled 241 women and collected data on demographics, tamoxifen use and side effects, as well as potential clin. and serum predictors.  We used logistic regression models and adjusted for age, body mass index, ethnicity, education, prior post-menopausal hormone therapy (HT), tamoxifen duration, and endoxifen levels to identify factors assocd. with side effects.  Common tamoxifen attributed side effects were hot flashes (64%), vaginal dryness (35%), sleep problems (36%), wt. gain (6%), and depression, irritability or mood swings (6%).  In multi-variate models, tamoxifen duration, age, prior post-menopausal HT, and endoxifen levels all predicted side effects.  Women who had been on tamoxifen for >12 mo were less likely to report side effects (OR 0.15, 95% CI 0.04-0.58) or severe side effects (OR 0.05, 95% CI 0.005-0.58) compared to women on tamoxifen for <12 mo.  Compared to women younger than 50, women who were age 60-70 and older than 70 were less likely to report side effects (OR 0.22, 95% CI 0.03-1.35; OR 0.13, 95% CI 0.01-0.99; resp.).  Women who previously took post-menopausal HT were more likely to report severe side effects.  Women with higher endoxifen levels were more likely to report side effects (OR 1.67, 95% CI 1.01-2.77 per std. deviation increase in endoxifen).  Clinicians should consider closely monitoring adherence in women taking tamoxifen, esp. in younger women, and women who previously took HT.  The assocn. between endoxifen levels and side effects is consistent with the data that suggest that endoxifen is the most highly active metabolite of tamoxifen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ8fSi9MklsLVg90H21EOLACvtfcHk0lhFqHFO9fwdwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFWgsro%253D&md5=e5792fcc5ec6e4f6cc1de3703295473e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1893-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1893-4%26sid%3Dliteratum%253Aachs%26aulast%3DLorizio%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DA.%2BH.%26aulast%3DBeattie%26aufirst%3DM.%2BS.%26aulast%3DRugo%26aufirst%3DH.%26aulast%3DTchu%26aufirst%3DS.%26aulast%3DKerlikowske%26aufirst%3DK.%26aulast%3DZiv%26aufirst%3DE.%26atitle%3DClinical%2520and%2520Biomarker%2520Predictors%2520of%2520Side%2520Effects%2520from%2520Tamoxifen%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D132%26spage%3D1107%26epage%3D1118%26doi%3D10.1007%2Fs10549-011-1893-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. D.</span></span> <span> </span><span class="NLM_article-title">MiR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">136</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1159/000493964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1159%2F000493964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=30278449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2is7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=136-149&author=J.+Liauthor=M.+J.+Luauthor=J.+Jinauthor=X.+Y.+Luauthor=T.+P.+Xuauthor=S.+D.+Jin&title=MiR-449a+Suppresses+Tamoxifen+Resistance+in+Human+Breast+Cancer+Cells+by+Targeting+ADAM22&doi=10.1159%2F000493964"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22</span></div><div class="casAuthors">Li, Jun; Lu, Mingjie; Jin, Jiao; Lu, Xiyi; Xu, Tongpeng; Jin, Shidai</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">136-149</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background/Aims: Most of estrogen receptor pos. breast cancer patients respond well initially to endocrine therapies, but often develop resistance during treatment with selective estrogen receptor modulators (SERMs) such as tamoxifen.  Altered expression and functions of microRNAs (miRNAs) have been reportedly assocd. with tamoxifen resistance.  Thus, it is necessary to further elucidate the function and mechanism of miRNAs in tamoxifen resistance.  Methods: Tamoxifen sensitivity was validated by using Cell Counting Kit-8 in tamoxifen-sensitive breast cancer cells (MCF-7, T47D) and tamoxifen-resistant cells (MCF-7/TAM, T47D/ TAM).  Quant. real-time polymerase chain reaction (qRT-PCR) was performed to detect the expression level of miR-449a in tamoxifen-sensitive/-resistant cells and patient serums.  Dual-luciferase assay was used to identify the binding of miR-449a and predicted gene ADAM22.  The expression level of ADAM22 was detd. by qRT-PCR and western blotting in miR-449a /- breast cancer cells.  Subsequently, rescue expts. were carried out to identify the function of ADAM22 in miR-449a-reduced tamoxifen resistance.  Finally, Gene ontol. (GO) and Protein-protein interaction analyses were performed to evaluate the potential mechanisms of ADAM22 in regulating tamoxifen resistance.  Results: MiR-449a levels were downregulated significantly in tamoxifen-resistant breast cancer cells when compared with their parental cells, as well as in clin. breast cancer serum samples.  Overexpression of miR-449a re-sensitized the tamoxifen-resistant breast cancer cells, while inhibition of miR-449a conferred tamoxifen resistance in parental cells.  Luciferase assay identified ADAM22 as a direct target gene of miR-449a.  Addnl., silencing of ADAM22 could reverse tamoxifen resistance induced by miR-449a inhibition in ER-pos. breast cancer cells.  GO anal. results showed ADAM22 was mainly enriched in the biol. processes of cell adhesion, cell differentiation, gliogenesis and so on.  Protein-protein interaction analyses appeared that ADAM22 might regulate tamoxifen resistance through PPARG, LGI1, KRAS and LYN.  Conclusion: Decreased miR-449a causes the upregulation of ADAM22, which induces tamoxifen resistance of breast cancer cells.  These results suggest that miR-449a, functioning by targeting ADAM22, contributes to the mechanisms underlying breast cancer endocrine resistance, which may provide a potential therapeutic strategy in ER-pos. breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvLKyxaG9dULVg90H21EOLACvtfcHk0lhFqHFO9fwdwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2is7%252FP&md5=111b8ef79a762491c2e1949f6af920e6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1159%2F000493964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000493964%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DM.%2BJ.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%2BY.%26aulast%3DXu%26aufirst%3DT.%2BP.%26aulast%3DJin%26aufirst%3DS.%2BD.%26atitle%3DMiR-449a%2520Suppresses%2520Tamoxifen%2520Resistance%2520in%2520Human%2520Breast%2520Cancer%2520Cells%2520by%2520Targeting%2520ADAM22%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2018%26volume%3D50%26spage%3D136%26epage%3D149%26doi%3D10.1159%2F000493964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubocovich, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delagrange, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardinali, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olcese, J.</span></span> <span> </span><span class="NLM_article-title">International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1124/pr.110.002832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1124%2Fpr.110.002832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=20605968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=343-380&author=M.+L.+Dubocovichauthor=P.+Delagrangeauthor=D.+N.+Krauseauthor=D.+Sugdenauthor=D.+P.+Cardinaliauthor=J.+Olcese&title=International+Union+of+Basic+and+Clinical+Pharmacology.+LXXV.+Nomenclature%2C+Classification%2C+and+Pharmacology+of+G+Protein-Coupled+Melatonin+Receptors&doi=10.1124%2Fpr.110.002832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors</span></div><div class="casAuthors">Dubocovich, Margarita L.; Delagrange, Philippe; Krause, Diana N.; Sugden, David; Cardinali, Daniel P.; Olcese, James</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">343-380</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The hormone melatonin (5-methoxy-N-acetyltryptamine) is synthesized primarily in the pineal gland and retina, and in several peripheral tissues and organs.  In the circulation, the concn. of melatonin follows a circadian rhythm, with high levels at night providing timing cues to target tissues endowed with melatonin receptors.  Melatonin receptors receive and translate melatonin's message to influence daily and seasonal rhythms of physiol. and behavior.  The melatonin message is translated through activation of two G protein-coupled receptors, MT1 and MT2, that are potential therapeutic targets in disorders ranging from insomnia and circadian sleep disorders to depression, cardiovascular diseases, and cancer.  This review summarizes the steps taken since melatonin's discovery by Aaron Lerner in 1958 to functionally characterize, clone, and localize receptors in mammalian tissues.  The pharmacol. and mol. properties of the receptors are described as well as current efforts to discover and develop ligands for treatment of a no. of illnesses, including sleep disorders, depression, and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwVZWJdmiBObVg90H21EOLACvtfcHk0lhFqHFO9fwdwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVSltbbP&md5=85e94b5269c550f2509992830f6012c1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.002832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.002832%26sid%3Dliteratum%253Aachs%26aulast%3DDubocovich%26aufirst%3DM.%2BL.%26aulast%3DDelagrange%26aufirst%3DP.%26aulast%3DKrause%26aufirst%3DD.%2BN.%26aulast%3DSugden%26aufirst%3DD.%26aulast%3DCardinali%26aufirst%3DD.%2BP.%26aulast%3DOlcese%26aufirst%3DJ.%26atitle%3DInternational%2520Union%2520of%2520Basic%2520and%2520Clinical%2520Pharmacology.%2520LXXV.%2520Nomenclature%252C%2520Classification%252C%2520and%2520Pharmacology%2520of%2520G%2520Protein-Coupled%2520Melatonin%2520Receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2010%26volume%3D62%26spage%3D343%26epage%3D380%26doi%3D10.1124%2Fpr.110.002832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales-Corral, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acuna-Castroviejo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span> <span> </span><span class="NLM_article-title">Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">843</span>, <span class="refDoi"> DOI: 10.3390/ijms18040843</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3390%2Fijms18040843" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGjs7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=843&author=R.+J.+Reiterauthor=S.+A.+Rosales-Corralauthor=D.+X.+Tanauthor=D.+Acuna-Castroviejoauthor=L.+Qinauthor=S.+F.+Yangauthor=K.+Xu&title=Melatonin%2C+a+Full+Service+Anti-Cancer+Agent%3A+Inhibition+of+Initiation%2C+Progression+and+Metastasis&doi=10.3390%2Fijms18040843"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin, a full service anti-cancer agent: inhibition of initiation, progression and metastasis</span></div><div class="casAuthors">Reiter, Russel J.; Rosales-Corral, Sergio A.; Tan, Dun-Xian; Acuna-Castroviejo, Dario; Qin, Lilan; Yang, Shun-Fa; Xu, Kexin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">843/1-843/47</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">There is highly credible evidence that melatonin mitigates cancer at the initiation, progression and metastasis phases.  In many cases, the mol. mechanisms underpinning these inhibitory actions have been proposed.  What is rather perplexing, however, is the large no. of processes by which melatonin reportedly restrains cancer development and growth.  These diverse actions suggest that what is being obsd. are merely epiphenomena of an underlying more fundamental action of melatonin that remains to be disclosed.  Some of the arresting actions of melatonin on cancer are clearly membrane receptor-mediated while others are membrane receptor-independent and involve direct intracellular actions of this ubiquitously-distributed mol.  While the emphasis of melatonin/cancer research has been on the role of the indoleamine in restraining breast cancer, this is changing quickly with many cancer types having been shown to be susceptible to inhibition by melatonin.  There are several facets of this research which could have immediate applications at the clin. level.  Many studies have shown that melatonin's co-administration improves the sensitivity of cancers to inhibition by conventional drugs.  Even more important are the findings that melatonin renders cancers previously totally resistant to treatment sensitive to these same therapies.  Melatonin also inhibits mol. processes assocd. with metastasis by limiting the entrance of cancer cells into the vascular system and preventing them from establishing secondary growths at distant sites.  This is of particular importance since cancer metastasis often significantly contributes to death of the patient.  Another area that deserves addnl. consideration is related to the capacity of melatonin in reducing the toxic consequences of anti-cancer drugs while increasing their efficacy.  Although this information has been available for more than a decade, it has not been adequately exploited at the clin. level.  Even if the only beneficial actions of melatonin in cancer patients are its ability to attenuate acute and long-term drug toxicity, melatonin should be used to improve the phys. wellbeing of the patients.  The exptl. findings, however, suggest that the advantages of using melatonin as a co-treatment with conventional cancer therapies would far exceed improvements in the wellbeing of the patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozdzwNs8nI5bVg90H21EOLACvtfcHk0liwLW_jZ3TLYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGjs7bP&md5=1bb28bdff4aa4e971c76c069cc72f341</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.3390%2Fijms18040843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18040843%26sid%3Dliteratum%253Aachs%26aulast%3DReiter%26aufirst%3DR.%2BJ.%26aulast%3DRosales-Corral%26aufirst%3DS.%2BA.%26aulast%3DTan%26aufirst%3DD.%2BX.%26aulast%3DAcuna-Castroviejo%26aufirst%3DD.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%2BF.%26aulast%3DXu%26aufirst%3DK.%26atitle%3DMelatonin%252C%2520a%2520Full%2520Service%2520Anti-Cancer%2520Agent%253A%2520Inhibition%2520of%2520Initiation%252C%2520Progression%2520and%2520Metastasis%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D843%26doi%3D10.3390%2Fijms18040843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Santos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Blanco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casado-Zapico, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Sanchez, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suarez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puente-Moncada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anitua, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antolin, I.</span></span> <span> </span><span class="NLM_article-title">Mechanisms Involved in the Pro-Apoptotic Effect of Melatonin in Cancer Cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">6597</span>– <span class="NLM_lpage">6613</span>, <span class="refDoi"> DOI: 10.3390/ijms14046597</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3390%2Fijms14046597" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=23528889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlslCntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=6597-6613&author=C.+Rodriguezauthor=V.+Martinauthor=F.+Herreraauthor=G.+Garcia-Santosauthor=J.+Rodriguez-Blancoauthor=S.+Casado-Zapicoauthor=A.+M.+Sanchez-Sanchezauthor=S.+Suarezauthor=N.+Puente-Moncadaauthor=M.+J.+Anituaauthor=I.+Antolin&title=Mechanisms+Involved+in+the+Pro-Apoptotic+Effect+of+Melatonin+in+Cancer+Cells&doi=10.3390%2Fijms14046597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms involved in the pro-apoptotic effect of melatonin in cancer cells</span></div><div class="casAuthors">Rodriguez, Carmen; Martin, Vanesa; Herrera, Federico; Garcia-Santos, Guillermo; Rodriguez-Blanco, Jezabel; Casado-Zapico, Sara; Sanchez-Sanchez, Ana Maria; Suarez, Santos; Puente-Moncada, Noelia; Anitua, Maria Jose; Antolin, Isaac</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6597-6613</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  It is well established that melatonin exerts antitumoral effects in many cancer types, mostly decreasing cell proliferation at low concns.  On the other hand, induction of apoptosis by melatonin has been described in the last few years in some particular cancer types.  The cytotoxic effect occurs after its administration at high concns., and the mol. pathways involved have been only partially detd.  Moreover, a synergistic effect has been found in several cancer types when it is administered in combination with chemotherapeutic agents.  In the present review, we will summarize published work on the pro-apoptotic effect of melatonin in cancer cells and the reported mechanisms involved in such action.  We will also construct a hypothesis on how different cell signaling pathways may relate each other on account for such effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAoiJPXexfObVg90H21EOLACvtfcHk0liwLW_jZ3TLYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlslCntbk%253D&md5=475b8d1d97165d1b0e41b037d9eaffa3</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.3390%2Fijms14046597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms14046597%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DV.%26aulast%3DHerrera%26aufirst%3DF.%26aulast%3DGarcia-Santos%26aufirst%3DG.%26aulast%3DRodriguez-Blanco%26aufirst%3DJ.%26aulast%3DCasado-Zapico%26aufirst%3DS.%26aulast%3DSanchez-Sanchez%26aufirst%3DA.%2BM.%26aulast%3DSuarez%26aufirst%3DS.%26aulast%3DPuente-Moncada%26aufirst%3DN.%26aulast%3DAnitua%26aufirst%3DM.%2BJ.%26aulast%3DAntolin%26aufirst%3DI.%26atitle%3DMechanisms%2520Involved%2520in%2520the%2520Pro-Apoptotic%2520Effect%2520of%2520Melatonin%2520in%2520Cancer%2520Cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2013%26volume%3D14%26spage%3D6597%26epage%3D6613%26doi%3D10.3390%2Fijms14046597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabner, B.</span></span> <span> </span><span class="NLM_article-title">Role of Pineal Gland in Aetiology and Treatment of Breast Cancer</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">814</span>– <span class="NLM_lpage">816</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(78)92591-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2FS0140-6736%2878%2992591-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=81365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADyaE1MXhvVCmsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1978&pages=814-816&author=M.+Cohenauthor=M.+Lippmanauthor=B.+Chabner&title=Role+of+Pineal+Gland+in+Aetiology+and+Treatment+of+Breast+Cancer&doi=10.1016%2FS0140-6736%2878%2992591-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Role of pineal gland in etiology and treatment of breast cancer</span></div><div class="casAuthors">Cohen, Michael; Lippman, Marc; Chabner, Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8094</span>),
    <span class="NLM_cas:pages">814-16</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0023-7507</span>.
    </div><div class="casAbstract">The hypothesis discussed is that diminished pineal gland function may promote the development of breast cancer in humans, as suggested by the relation between breast cancer and prolonged estrogen excess, and by the inhibition by melatonin of ovarian estrogen prodn., pituitary gonadotropin prodn., and sexual development and maturation.  The hypothesis is supported by the relations between pineal calcification, breast cancer incidence, and chlorpromazine's effect on serum melatonin, and by pineal gland and melatonin influences on tumor induction and growth in exptl. animals, the presence of a melatonin receptor in the human ovary, and the pineal's role in the stimulation of puberty.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfJzghfAG6z7Vg90H21EOLACvtfcHk0liwLW_jZ3TLYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXhvVCmsro%253D&md5=08c22e5f4df934d47bcc7dbca57c81e8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2878%2992591-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252878%252992591-6%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%26aulast%3DLippman%26aufirst%3DM.%26aulast%3DChabner%26aufirst%3DB.%26atitle%3DRole%2520of%2520Pineal%2520Gland%2520in%2520Aetiology%2520and%2520Treatment%2520of%2520Breast%2520Cancer%26jtitle%3DLancet%26date%3D1978%26volume%3D2%26spage%3D814%26epage%3D816%26doi%3D10.1016%2FS0140-6736%2878%2992591-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rondanelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milena Anna, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neldo, A.</span></span> <span> </span><span class="NLM_article-title">Update on the Role of Melatonin in the Prevention of Cancer Tumorigenesis and in the Management of Cancer Correlates, Such as Sleep-Wake and Mood Disturbances: Review and Remarks</span>. <i>Aging: Clin. Exp. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">510</span>, <span class="refDoi"> DOI: 10.1007/s40520-013-0118-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1007%2Fs40520-013-0118-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=24046037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BC3sbpsVOmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2013&pages=499-510&author=M.+Rondanelliauthor=F.+Milena+Annaauthor=P.+Simoneauthor=A.+Neldo&title=Update+on+the+Role+of+Melatonin+in+the+Prevention+of+Cancer+Tumorigenesis+and+in+the+Management+of+Cancer+Correlates%2C+Such+as+Sleep-Wake+and+Mood+Disturbances%3A+Review+and+Remarks&doi=10.1007%2Fs40520-013-0118-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks</span></div><div class="casAuthors">Rondanelli Mariangela; Faliva Milena Anna; Perna Simone; Antoniello Neldo</div><div class="citationInfo"><span class="NLM_cas:title">Aging clinical and experimental research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">499-510</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The aim of this article was to perform a systematic review on the role of melatonin in the prevention of cancer tumorigenesis--in vivo and in vitro--as well as in the management of cancer correlates, such as sleep-wake and mood disturbances.  The International Agency for Research on Cancer recently classified "shift-work that involves circadian disruption" as "probably carcinogenic to humans" (Group 2A) based on "limited evidence in humans for the carcinogenicity of shift-work that involves night-work", and "sufficient evidence in experimental animals for the carcinogenicity of light during the daily dark period (biological night)".  The clinical implications and the potential uses of melatonin in terms of biologic clock influence (e.g. sleep and mood), immune function, cancer initiation and growth, as well as the correlation between melatonin levels and cancer risk, are hereinafter recorded and summarized.  Additionally, this paper includes a description of the newly discovered effects that melatonin has on the management of sleep-wake and mood disturbances as well as with regard to cancer patients' life quality.  In cancer patients depression and insomnia are frequent and serious comorbid conditions which definitely require a special attention.  The data presented in this review encourage the performance of new clinical trials to investigate the possible use of melatonin in cancer patients suffering from sleep-wake and mood disturbances, also considering that melatonin registered a low toxicity in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9jVqKKGuAQ3l8icjszYl0fW6udTcc2earZaUJ_dOos7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbpsVOmtg%253D%253D&md5=cc6df920d1d49851ea650b902c47847c</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1007%2Fs40520-013-0118-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40520-013-0118-6%26sid%3Dliteratum%253Aachs%26aulast%3DRondanelli%26aufirst%3DM.%26aulast%3DMilena%2BAnna%26aufirst%3DF.%26aulast%3DSimone%26aufirst%3DP.%26aulast%3DNeldo%26aufirst%3DA.%26atitle%3DUpdate%2520on%2520the%2520Role%2520of%2520Melatonin%2520in%2520the%2520Prevention%2520of%2520Cancer%2520Tumorigenesis%2520and%2520in%2520the%2520Management%2520of%2520Cancer%2520Correlates%252C%2520Such%2520as%2520Sleep-Wake%2520and%2520Mood%2520Disturbances%253A%2520Review%2520and%2520Remarks%26jtitle%3DAging%253A%2520Clin.%2520Exp.%2520Res.%26date%3D2013%26volume%3D25%26spage%3D499%26epage%3D510%26doi%3D10.1007%2Fs40520-013-0118-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, J.</span></span> <span> </span><span class="NLM_article-title">Increased Breast Cancer Risk among Women Who Work Predominantly at Night</span>. <i>Epidemiology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1097/00001648-200101000-00013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1097%2F00001648-200101000-00013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=11138824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BD3M7hsFKjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=74-77&author=J.+Hansen&title=Increased+Breast+Cancer+Risk+among+Women+Who+Work+Predominantly+at+Night&doi=10.1097%2F00001648-200101000-00013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Increased breast cancer risk among women who work predominantly at night</span></div><div class="casAuthors">Hansen J</div><div class="citationInfo"><span class="NLM_cas:title">Epidemiology (Cambridge, Mass.)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-7</span>
        ISSN:<span class="NLM_cas:issn">1044-3983</span>.
    </div><div class="casAbstract">Irregular working hours, including working at night, have serious psychological and physiological effects.  In a nationwide population-based case-control study, we investigated the breast cancer risk among 30- to 54-year-old Danish women who worked predominantly at night.  Individual employment histories were reconstructed back to 1964 for each of 7035 women with breast cancer and their individually matched controls from the records of a nationwide pension scheme with compulsory membership.  Odds ratios, including 5 years of induction time and adjusted for socio-economic status, age at the birth of first and last child and number of children, were estimated by conditional logistic regression analysis.  The odds ratio for breast cancer among women who worked at night at least half of a year was 1.5 (95% confidence interval, 1.2 to 1.7), and there was a tendency to increasing odds ratio by increasing duration of nighttime employment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkuxKQQB4KCjAyhZbj3lKdfW6udTcc2earZaUJ_dOos7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3M7hsFKjtg%253D%253D&md5=7e0563f19a8c5f5c80e47790c37939bb</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1097%2F00001648-200101000-00013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001648-200101000-00013%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DJ.%26atitle%3DIncreased%2520Breast%2520Cancer%2520Risk%2520among%2520Women%2520Who%2520Work%2520Predominantly%2520at%2520Night%26jtitle%3DEpidemiology%26date%3D2001%26volume%3D12%26spage%3D74%26epage%3D77%26doi%3D10.1097%2F00001648-200101000-00013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nooshinfar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safaroghli-Azar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashash, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbari, M. E.</span></span> <span> </span><span class="NLM_article-title">Melatonin, an Inhibitory Agent in Breast Cancer</span>. <i>Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1007/s12282-016-0690-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1007%2Fs12282-016-0690-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=27017208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BC28fktFeiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=42-51&author=E.+Nooshinfarauthor=A.+Safaroghli-Azarauthor=D.+Bashashauthor=M.+E.+Akbari&title=Melatonin%2C+an+Inhibitory+Agent+in+Breast+Cancer&doi=10.1007%2Fs12282-016-0690-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin, an inhibitory agent in breast cancer</span></div><div class="casAuthors">Nooshinfar Elaheh; Akbari Mohammad Esmaeil; Nooshinfar Elaheh; Safaroghli-Azar Ava; Bashash Davood</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The heterogeneous nature of breast cancer makes it one of the most challenging cancers to treat.  Due to the stimulatory effect of estrogen in mammary cancer progression, anti-estrogenic agents like melatonin have found their way into breast cancer treatment.  Further studies confirmed a reverse correlation between nocturnal melatonin levels and the development of mammary cancer.  In this study we reviewed the molecular inhibitory effects of melatonin in breast cancer therapy.  METHODS:  To open access the articles, Google scholar and science direct were used as a motor search.  We used from valid external and internal databases.  To reach the search formula, we determined mean key words like breast cancer, melatonin, cell proliferation and death.  To retrieval the related articles, we continuously search the articles from 1984 to 2015.  The relevance and the quality of the 480 articles were screened; at least we selected 80 eligible articles about melatonin molecular mechanism in breast cancer.  RESULT:  The results showed that melatonin not only inhibits breast cancer cell growth, but also is capable of inhibiting angiogenesis, cancer cell invasion, and telomerase activity.  Interestingly this hormone is able to induce apoptosis through the suppression or induction of a wide range of signaling pathways.  Moreover, it seems that the concomitant administration of melatonin with other conventional chemotherapy agents had beneficial effects for patients with breast cancer, by alleviating unfavorable effects of those agents and enhancing their efficacy.  CONCLUSION:  The broad inhibitory effects of melatonin in breast cancer make it a promising agent and may add it to the list of potential drugs in treatment of this cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2IPvZKjsw6r9KldV63DuefW6udTcc2earZaUJ_dOos7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fktFeiug%253D%253D&md5=7291353056e47afe950610f4ee4c9eff</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1007%2Fs12282-016-0690-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12282-016-0690-7%26sid%3Dliteratum%253Aachs%26aulast%3DNooshinfar%26aufirst%3DE.%26aulast%3DSafaroghli-Azar%26aufirst%3DA.%26aulast%3DBashash%26aufirst%3DD.%26aulast%3DAkbari%26aufirst%3DM.%2BE.%26atitle%3DMelatonin%252C%2520an%2520Inhibitory%2520Agent%2520in%2520Breast%2520Cancer%26jtitle%3DBreast%2520Cancer%26date%3D2017%26volume%3D24%26spage%3D42%26epage%3D51%26doi%3D10.1007%2Fs12282-016-0690-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">González-González, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mediavilla, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Barcelo, E. J.</span></span> <span> </span><span class="NLM_article-title">Melatonin: A Molecule for Reducing Breast Cancer Risk</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.3390/molecules23020336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3390%2Fmolecules23020336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Gqsr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=336-356&author=A.+Gonz%C3%A1lez-Gonz%C3%A1lezauthor=M.+D.+Mediavillaauthor=E.+J.+Sanchez-Barcelo&title=Melatonin%3A+A+Molecule+for+Reducing+Breast+Cancer+Risk&doi=10.3390%2Fmolecules23020336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin: a molecule for reducing breast cancer risk</span></div><div class="casAuthors">Gonzalez-Gonzalez, Alicia; Mediavilla, Maria Dolores; Sanchez-Barcelo, Emilio J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">336/1-336/21</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The objective of this article is to review the basis supporting the usefulness of melatonin as an adjuvant therapy for breast cancer (BC) prevention in several groups of individuals at high risk for this disease.  Melatonin, as a result of its antiestrogenic and antioxidant properties, as well as its ability to improve the efficacy and reduce the side effects of conventional antiestrogens, could safely be assocd. with the antiestrogenic drugs presently in use.  In individuals at risk of BC due to night shift work, the light-induced inhibition of melatonin secretion, with the consequent loss of its antiestrogenic effects, would be countered by administering this neurohormone.  BC risk from exposure to metalloestrogens, such as cadmium, could be treated with melatonin supplements to individuals at risk of BC due to exposure to this xenoestrogen.  The BC risk related to obesity may be reduced by melatonin which decrease body fat mass, inhibits the enhanced aromatase expression in obese women, increases adiponectin secretion, counteracts the oncogenic effects of elevated concns. of leptin; and decreases blood glucose levels and insulin resistance.  Despite compelling exptl. evidence of melatonin's oncostatic actions being susceptible to lowering BC risk, there is still a paucity of clin. trials focused on this subject.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8UGQHhSdACrVg90H21EOLACvtfcHk0lgVyEB80YHJpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Gqsr3P&md5=305a6032e9bf987174057ff63203fd75</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.3390%2Fmolecules23020336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules23020336%26sid%3Dliteratum%253Aachs%26aulast%3DGonz%25C3%25A1lez-Gonz%25C3%25A1lez%26aufirst%3DA.%26aulast%3DMediavilla%26aufirst%3DM.%2BD.%26aulast%3DSanchez-Barcelo%26aufirst%3DE.%2BJ.%26atitle%3DMelatonin%253A%2520A%2520Molecule%2520for%2520Reducing%2520Breast%2520Cancer%2520Risk%26jtitle%3DMolecules%26date%3D2018%26volume%3D23%26spage%3D336%26epage%3D356%26doi%3D10.3390%2Fmolecules23020336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Maestroni, G. J.</span></span> <span> </span><span class="NLM_article-title">The Immunoneuroendocrine Role of Melatonin</span>. <i>J. Pineal Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1111/j.1600-079X.1993.tb00478.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1111%2Fj.1600-079X.1993.tb00478.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=8483103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADyaK3sXksVWjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1993&pages=1-10&author=G.+J.+Maestroni&title=The+Immunoneuroendocrine+Role+of+Melatonin&doi=10.1111%2Fj.1600-079X.1993.tb00478.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">The immunoneuroendocrine role of melatonin</span></div><div class="casAuthors">Maestroni, Georges J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pineal Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">JPRSE9</span>;
        ISSN:<span class="NLM_cas:issn">0742-3098</span>.
    </div><div class="casAbstract">A review, with 55 refs., of the physiol. link between the pineal gland and the immune system.  This link might reflect the evolutionary connection between self-recognition and reprodn.  Pinealectomy or other exptl. methods which inhibit melatonin synthesis and secretion induce a state of immunodepression which is counteracted by melatonin.  In general, melatonin seems to have an immunoenhancing effect that is particularly apparent in immunodepressive states.  The neg. effect of acute stress or immunosuppressive pharmacol. treatments on various immune parameters are counteracted by melatonin.  It seems important to note that one of the main targets of melatonin is the thymus, i.e., the central organ of the immune system.  The immunoenhancing action of melatonin seems to be mediated by T-helper cell-derived opioid peptides, as well as by lymphokines and, perhaps, by pituitary hormones.  Melatonin-induced-immuno-opioids (MIIO) and lymphokines imply the presence of specific binding sites or melatonin receptors on cells of the immune system.  On the other hand, lymphokines such as γ-interferon and interleukin-2, as well as thymic hormones, can modulate the synthesis of melatonin in the pineal gland.  The pineal gland might thus be viewed as the crux of a sophisticated immunoneuroendocrine network which functions as an unconscious, diffuse sensory organ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs8O6nPK4EI7Vg90H21EOLACvtfcHk0lgVyEB80YHJpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXksVWjtLw%253D&md5=ce5cc71ae8a75eff491d9316269c52f8</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-079X.1993.tb00478.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-079X.1993.tb00478.x%26sid%3Dliteratum%253Aachs%26aulast%3DMaestroni%26aufirst%3DG.%2BJ.%26atitle%3DThe%2520Immunoneuroendocrine%2520Role%2520of%2520Melatonin%26jtitle%3DJ.%2520Pineal%2520Res.%26date%3D1993%26volume%3D14%26spage%3D1%26epage%3D10%26doi%3D10.1111%2Fj.1600-079X.1993.tb00478.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paola, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caputi, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuzzocrea, S.</span></span> <span> </span><span class="NLM_article-title">Melatonin Limits Lung Injury in Bleomycin Treated Mice</span>. <i>J. Pineal Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1111/j.1600-079X.2005.00229.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1111%2Fj.1600-079X.2005.00229.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=16098086" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD2MXovFSjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2005&pages=105-112&author=T.+Genoveseauthor=R.+Di+Paolaauthor=E.+Mazzonauthor=C.+Muiaauthor=A.+P.+Caputiauthor=S.+Cuzzocrea&title=Melatonin+Limits+Lung+Injury+in+Bleomycin+Treated+Mice&doi=10.1111%2Fj.1600-079X.2005.00229.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin limits lung injury in bleomycin treated mice</span></div><div class="casAuthors">Genovese, Tiziana; Di Paola, Rosanna; Mazzon, Emanuela; Muia, Carmelo; Caputi, Achille P.; Cuzzocrea, Salvatore</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pineal Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">105-112</span>CODEN:
                <span class="NLM_cas:coden">JPRSE9</span>;
        ISSN:<span class="NLM_cas:issn">0742-3098</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Melatonin is the principal secretory product of the pineal gland and its role as an immuno-modulator is well established.  Recent evidence shows that melatonin is a scavenger of oxyradicals and peroxynitrite and exerts protective effects in septic shock, hemorrhagic shock and inflammation.  The aim of this study was to investigate the effect of melatonin on the lung injury caused by bleomycin (BLM) administration.  Mice subjected to intratracheal administration of BLM developed significant lung injury characterized by a marked neutrophil infiltration [assessed by myeloperoxidase (MPO) activity] and by tissue edema.  In addn., an increase of immunoreactivity to nitrotyrosine, poly-ADP-ribose (PAR) was also obsd. in the lung of BLM-treated mice.  Also, lung injury induced by BLM administration was correlated with a significant loss of body wt. and with a significant mortality.  Administration of melatonin (10 mg/kg i.p.) daily significantly reduced the (i) loss of body wt., (ii) mortality rate, (iii) infiltration of the lung with polymorphonuclear neutrophils (MPO activity), (iv) edema formation and (v) histol. evidence of lung injury.  Administration of melatonin also markedly reduced the nitrotyrosine and PAR formation.  Taken together, the authors' results demonstrate that treatment with melatonin significantly reduces lung injury induced by BLM in the mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq30-KSeLz7hLVg90H21EOLACvtfcHk0lgVyEB80YHJpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXovFSjsbw%253D&md5=d25274492616031bba2f8768b8b3fb7e</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-079X.2005.00229.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-079X.2005.00229.x%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DT.%26aulast%3DDi%2BPaola%26aufirst%3DR.%26aulast%3DMazzon%26aufirst%3DE.%26aulast%3DMuia%26aufirst%3DC.%26aulast%3DCaputi%26aufirst%3DA.%2BP.%26aulast%3DCuzzocrea%26aufirst%3DS.%26atitle%3DMelatonin%2520Limits%2520Lung%2520Injury%2520in%2520Bleomycin%2520Treated%2520Mice%26jtitle%3DJ.%2520Pineal%2520Res.%26date%3D2005%26volume%3D39%26spage%3D105%26epage%3D112%26doi%3D10.1111%2Fj.1600-079X.2005.00229.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drazen, D. L.</span></span> <span> </span><span class="NLM_article-title">Melatonin Mediates Seasonal Adjustments in Immune Function</span>. <i>Reprod., Nutr., Dev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1051/rnd:19990310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1051%2Frnd%3A19990310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10420440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADyaK1MXksVaqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1999&pages=383-398&author=R.+J.+Nelsonauthor=D.+L.+Drazen&title=Melatonin+Mediates+Seasonal+Adjustments+in+Immune+Function&doi=10.1051%2Frnd%3A19990310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin mediates seasonal adjustments in immune function</span></div><div class="casAuthors">Nelson, Randy J.; Drazen, Deborah L.</div><div class="citationInfo"><span class="NLM_cas:title">Reproduction, Nutrition, Development</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-398</span>CODEN:
                <span class="NLM_cas:coden">RNDEE5</span>;
        ISSN:<span class="NLM_cas:issn">0926-5287</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review, with 148 refs.  The authors discuss photoperiod control of reprodn. and immune function; energetics of immune function; and melatonin effects on immune function and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6soG1vAT8-bVg90H21EOLACvtfcHk0lgK0VGDI-J0dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXksVaqtLc%253D&md5=99ac0a68bce9f7270bcc3276b56304c2</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1051%2Frnd%3A19990310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1051%252Frnd%253A19990310%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DR.%2BJ.%26aulast%3DDrazen%26aufirst%3DD.%2BL.%26atitle%3DMelatonin%2520Mediates%2520Seasonal%2520Adjustments%2520in%2520Immune%2520Function%26jtitle%3DReprod.%252C%2520Nutr.%252C%2520Dev.%26date%3D1999%26volume%3D39%26spage%3D383%26epage%3D398%26doi%3D10.1051%2Frnd%3A19990310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Moradkhani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moloudizargari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asghari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoei, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asghari, M. H.</span></span> <span> </span><span class="NLM_article-title">Immunoregulatory Role of Melatonin in Cancer</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>235</i></span>,  <span class="NLM_fpage">745</span>– <span class="NLM_lpage">757</span>, <span class="refDoi"> DOI: 10.1002/jcp.29036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fjcp.29036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=31270813" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2019&pages=745-757&author=F.+Moradkhaniauthor=M.+Moloudizargariauthor=M.+Fallahauthor=N.+Asghariauthor=H.+H.+Khoeiauthor=M.+H.+Asghari&title=Immunoregulatory+Role+of+Melatonin+in+Cancer&doi=10.1002%2Fjcp.29036"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=10.1002%2Fjcp.29036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.29036%26sid%3Dliteratum%253Aachs%26aulast%3DMoradkhani%26aufirst%3DF.%26aulast%3DMoloudizargari%26aufirst%3DM.%26aulast%3DFallah%26aufirst%3DM.%26aulast%3DAsghari%26aufirst%3DN.%26aulast%3DKhoei%26aufirst%3DH.%2BH.%26aulast%3DAsghari%26aufirst%3DM.%2BH.%26atitle%3DImmunoregulatory%2520Role%2520of%2520Melatonin%2520in%2520Cancer%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D235%26spage%3D745%26epage%3D757%26doi%3D10.1002%2Fjcp.29036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, V. W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yau, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiu, S. Y. W.</span></span> <span> </span><span class="NLM_article-title">Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.3390/ijms18010001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3390%2Fijms18010001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ahtrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1-13&author=V.+W.+S.+Liuauthor=W.+L.+Yauauthor=C.+W.+Tamauthor=K.+M.+Yaoauthor=S.+Y.+W.+Shiu&title=Melatonin+Inhibits+Androgen+Receptor+Splice+Variant-7+%28AR-V7%29-Induced+Nuclear+Factor-Kappa+B+%28NF-%CE%BAB%29+Activation+and+NF-%CE%BAB+Activator-Induced+AR-V7+Expression+in+Prostate+Cancer+Cells%3A+Potential+Implications+for+the+Use+of+Melatonin+in+Castration-Resistant+Prostate+Cancer+%28CRPC%29+Therapy&doi=10.3390%2Fijms18010001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24bR"><div class="casContent"><span class="casTitleNuber">24b</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of biosynthesis, accumulation and antioxidant activityof vitamin E in sweet corn (Zea mays L.) during kernel development</span></div><div class="casAuthors">Xie, Lihua; Yu, Yongtao; Mao, Jihua; Liu, Haiying; Hu, Jian Guang; Li, Tong; Guo, Xinbo; Liu, Rui Hai</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Sweet corn kernels were used in this research to study the dynamics of vitamin E, by evaluatingthe expression levels of genes involved in vitamin E synthesis, the accumulation of vitamin E, and the antioxidant activity during the different stage of kernel development.  Results showed that expression levels of ZmHPT and ZmTC genes increased, whereas Zm TMT gene dramatically decreased during kernel development.  The contents of all the types of vitamin E in sweet corn had a significant upward increase during kernel development, and reached the highest level at 30 days after pollination (DAP).  Amongst the eight isomers of vitamin E, the content of γ-tocotrienol was the highest, and increased by 14.9 folds, followed by α-tocopherolwith an increase of 22 folds, and thecontents of isomers γ-tocopherol, α-tocotrienol, and -tocopherol were also followed during kernel development.  The antioxidant activity of sweet corn during kernel development was increased, and was up to 101.8 ± 22.3 mol of -tocopherol equivlent/100 g in fresh wt. (FW) at 30 DAP.  There was a pos. correlation between vitamin E contents and antioxidant activity in sweet corn during the kernel development, and a neg. correlation between the expressions of ZmTMT gene and vitamin E contents.  These results revealed the relations amongst the content of vitamin E isomers and the gene expression, vitamin E accumulation, and antioxidant activity.  The study can provide a harvesting strategy for vitamin E bio-fortification in sweet corn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZFo7iD4oyhrVg90H21EOLACvtfcHk0lgK0VGDI-J0dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ahtrvM&md5=cbefcf9854cfa99501420817639dff62</span></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=10.3390%2Fijms18010001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18010001%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DV.%2BW.%2BS.%26aulast%3DYau%26aufirst%3DW.%2BL.%26aulast%3DTam%26aufirst%3DC.%2BW.%26aulast%3DYao%26aufirst%3DK.%2BM.%26aulast%3DShiu%26aufirst%3DS.%2BY.%2BW.%26atitle%3DMelatonin%2520Inhibits%2520Androgen%2520Receptor%2520Splice%2520Variant-7%2520%2528AR-V7%2529-Induced%2520Nuclear%2520Factor-Kappa%2520B%2520%2528NF-%25CE%25BAB%2529%2520Activation%2520and%2520NF-%25CE%25BAB%2520Activator-Induced%2520AR-V7%2520Expression%2520in%2520Prostate%2520Cancer%2520Cells%253A%2520Potential%2520Implications%2520for%2520the%2520Use%2520of%2520Melatonin%2520in%2520Castration-Resistant%2520Prostate%2520Cancer%2520%2528CRPC%2529%2520Therapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1%26epage%3D13%26doi%3D10.3390%2Fijms18010001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit24c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mirza-Aghazadeh-Attari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mostavafi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihanfar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghazizadeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadighparvar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gholamzadeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majidinia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yousefi, B.</span></span> <span> </span><span class="NLM_article-title">Melatonin: An Important Anticancer Agent in Colorectal Cancer</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>235</i></span>,  <span class="NLM_fpage">804</span>– <span class="NLM_lpage">817</span>, <span class="refDoi"> DOI: 10.1002/jcp.29049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fjcp.29049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=31276205" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2019&pages=804-817&author=M.+Mirza-Aghazadeh-Attariauthor=A.+Mohammadzadehauthor=S.+Mostavafiauthor=A.+Mihanfarauthor=S.+Ghazizadehauthor=S.+Sadighparvarauthor=S.+Gholamzadehauthor=M.+Majidiniaauthor=B.+Yousefi&title=Melatonin%3A+An+Important+Anticancer+Agent+in+Colorectal+Cancer&doi=10.1002%2Fjcp.29049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=10.1002%2Fjcp.29049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.29049%26sid%3Dliteratum%253Aachs%26aulast%3DMirza-Aghazadeh-Attari%26aufirst%3DM.%26aulast%3DMohammadzadeh%26aufirst%3DA.%26aulast%3DMostavafi%26aufirst%3DS.%26aulast%3DMihanfar%26aufirst%3DA.%26aulast%3DGhazizadeh%26aufirst%3DS.%26aulast%3DSadighparvar%26aufirst%3DS.%26aulast%3DGholamzadeh%26aufirst%3DS.%26aulast%3DMajidinia%26aufirst%3DM.%26aulast%3DYousefi%26aufirst%3DB.%26atitle%3DMelatonin%253A%2520An%2520Important%2520Anticancer%2520Agent%2520in%2520Colorectal%2520Cancer%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D235%26spage%3D804%26epage%3D817%26doi%3D10.1002%2Fjcp.29049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menéndez-Menéndez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Campa, C.</span></span> <span> </span><span class="NLM_article-title">Melatonin: An Anti-Tumor Agent in Hormone-Dependent Cancers</span>. <i>Int. J. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2018</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1155/2018/3271948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1155%2F2018%2F3271948" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2018&publication_year=2018&pages=1-20&author=J.+Men%C3%A9ndez-Men%C3%A9ndezauthor=C.+Martinez-Campa&title=Melatonin%3A+An+Anti-Tumor+Agent+in+Hormone-Dependent+Cancers&doi=10.1155%2F2018%2F3271948"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1155%2F2018%2F3271948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2018%252F3271948%26sid%3Dliteratum%253Aachs%26aulast%3DMen%25C3%25A9ndez-Men%25C3%25A9ndez%26aufirst%3DJ.%26aulast%3DMartinez-Campa%26aufirst%3DC.%26atitle%3DMelatonin%253A%2520An%2520Anti-Tumor%2520Agent%2520in%2520Hormone-Dependent%2520Cancers%26jtitle%3DInt.%2520J.%2520Endocrinol.%26date%3D2018%26volume%3D2018%26spage%3D1%26epage%3D20%26doi%3D10.1155%2F2018%2F3271948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangoda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. R.</span></span> <span> </span><span class="NLM_article-title">Coordination-Driven Self-Assembly of a Pt(IV) Prodrug-Conjugated Supramolecular Hexagon</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">734</span>, <span class="refDoi"> DOI: 10.1039/C7CC07622C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1039%2FC7CC07622C" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=731-734&author=Z.+Z.+Yueauthor=H.+Wangauthor=Y.+M.+Liauthor=Y.+Qinauthor=L.+Xuauthor=D.+J.+Bowersauthor=M.+Gangodaauthor=X.+P.+Liauthor=H.+B.+Yangauthor=Y.+R.+Zheng&title=Coordination-Driven+Self-Assembly+of+a+Pt%28IV%29+Prodrug-Conjugated+Supramolecular+Hexagon&doi=10.1039%2FC7CC07622C"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2FC7CC07622C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7CC07622C%26sid%3Dliteratum%253Aachs%26aulast%3DYue%26aufirst%3DZ.%2BZ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%2BM.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DBowers%26aufirst%3DD.%2BJ.%26aulast%3DGangoda%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%2BP.%26aulast%3DYang%26aufirst%3DH.%2BB.%26aulast%3DZheng%26aufirst%3DY.%2BR.%26atitle%3DCoordination-Driven%2520Self-Assembly%2520of%2520a%2520Pt%2528IV%2529%2520Prodrug-Conjugated%2520Supramolecular%2520Hexagon%26jtitle%3DChem.%2520Commun.%26date%3D2018%26volume%3D57%26spage%3D731%26epage%3D734%26doi%3D10.1039%2FC7CC07622C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Cellular Processing of Platinum Anti-cancer Drugs</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1038/nrd1691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1038%2Fnrd1691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=15789122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVart7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2005&pages=307-320&author=D.+Wangauthor=S.+J.+Lippard&title=Cellular+Processing+of+Platinum+Anti-cancer+Drugs&doi=10.1038%2Fnrd1691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular processing of platinum anticancer drugs</span></div><div class="casAuthors">Wang, Dong; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-320</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cisplatin, carboplatin and oxaliplatin are platinum-based drugs that are widely used in cancer chemotherapy.  Platinum-DNA adducts, which are formed following uptake of the drug into the nucleus of cells, activate several cellular processes that mediate the cytotoxicity of these platinum drugs.  This review focuses on recently discovered cellular pathways that are activated in response to cisplatin, including those involved in regulating drug uptake, the signaling of DNA damage, cell-cycle checkpoints and arrest, DNA repair and cell death.  Such knowledge of the cellular processing of cisplatin adducts with DNA provides valuable clues for the rational design of more efficient platinum-based drugs as well as the development of new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHJfZNaqwy67Vg90H21EOLACvtfcHk0lhnQVDTupZZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVart7c%253D&md5=e44a8e87683ba5cfe3e165f9f4229fee</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrd1691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1691%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DCellular%2520Processing%2520of%2520Platinum%2520Anti-cancer%2520Drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2005%26volume%3D4%26spage%3D307%26epage%3D320%26doi%3D10.1038%2Fnrd1691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Florea, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busselberg, D.</span></span> <span> </span><span class="NLM_article-title">Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1351</span>– <span class="NLM_lpage">1371</span>, <span class="refDoi"> DOI: 10.3390/cancers3011351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.3390%2Fcancers3011351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=24212665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVWiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1351-1371&author=A.+M.+Floreaauthor=D.+Busselberg&title=Cisplatin+as+an+Anti-Tumor+Drug%3A+Cellular+Mechanisms+of+Activity%2C+Drug+Resistance+and+Induced+Side+Effects&doi=10.3390%2Fcancers3011351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects</span></div><div class="casAuthors">Florea, Ana-Maria; Buesselberg, Dietrich</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1351-1371</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Platinum complexes are clin. used as adjuvant therapy of cancers aiming to induce tumor cell death.  Depending on cell type and concn., cisplatin induces cytotoxicity, e.g., by interference with transcription and/or DNA replication mechanisms.  Addnl., cisplatin damages tumors via induction of apoptosis, mediated by the activation of various signal transduction pathways, including calcium signaling, death receptor signaling, and the activation of mitochondrial pathways.  Unfortunately, neither cytotoxicity nor apoptosis are exclusively induced in cancer cells, thus, cisplatin might also lead to diverse side-effects such as neuro- and/or renal-toxicity or bone marrow-suppression.  Moreover, the binding of cisplatin to proteins and enzymes may modulate its biochem. mechanism of action.  While a combination-chemotherapy with cisplatin is a cornerstone for the treatment of multiple cancers, the challenge is that cancer cells could become cisplatin-resistant.  Numerous mechanisms of cisplatin resistance were described including changes in cellular uptake, drug efflux, increased detoxification, inhibition of apoptosis and increased DNA repair.  To minimize cisplatin resistance, combinatorial therapies were developed and have proven more effective to defeat cancers.  Thus, understanding of the biochem. mechanisms triggered by cisplatin in tumor cells may lead to the design of more efficient platinum derivates (or other drugs) and might provide new therapeutic strategies and reduce side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-7eCBHQ5T5rVg90H21EOLACvtfcHk0lhnQVDTupZZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVWiuro%253D&md5=368b8ef25e06a41747ec0940872966b3</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.3390%2Fcancers3011351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers3011351%26sid%3Dliteratum%253Aachs%26aulast%3DFlorea%26aufirst%3DA.%2BM.%26aulast%3DBusselberg%26aufirst%3DD.%26atitle%3DCisplatin%2520as%2520an%2520Anti-Tumor%2520Drug%253A%2520Cellular%2520Mechanisms%2520of%2520Activity%252C%2520Drug%2520Resistance%2520and%2520Induced%2520Side%2520Effects%26jtitle%3DCancers%26date%3D2011%26volume%3D3%26spage%3D1351%26epage%3D1371%26doi%3D10.3390%2Fcancers3011351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">A Novel Ion-Imprinted Membrane Induced by Amphiphilic Block Copolymer for Selective Separation of Pt(IV) from Aqueous Solutions</span>. <i>J. Membr. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>572</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">441</span>, <span class="refDoi"> DOI: 10.1016/j.memsci.2018.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.memsci.2018.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlSqsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=572&publication_year=2019&pages=428-441&author=J.+X.+Zengauthor=C.+Q.+Lvauthor=G.+Q.+Liuauthor=Z.+Zhangauthor=Z.+H.+Dongauthor=J.+Y.+Liuauthor=Y.+Wang&title=A+Novel+Ion-Imprinted+Membrane+Induced+by+Amphiphilic+Block+Copolymer+for+Selective+Separation+of+Pt%28IV%29+from+Aqueous+Solutions&doi=10.1016%2Fj.memsci.2018.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A novel ion-i61printed membrane induced by amphiphilic block copolymer for selective separation of Pt(IV) from aqueous solutions</span></div><div class="casAuthors">Zeng, Jianxian; Lv, Chaoqiang; Liu, Guoqing; Zhang, Zhe; Dong, Zhihui; Liu, JinYan; Wang, Ying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Membrane Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">572</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">428-441</span>CODEN:
                <span class="NLM_cas:coden">JMESDO</span>;
        ISSN:<span class="NLM_cas:issn">0376-7388</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel ion-imprinted blend membrane was fabricated to sep. selectively platinum(IV) from aq. media.  An amphiphilic copolymer poly(Me methacrylate)-b-poly(4-vinylpyridine) (PMMA-b-P4VP) was firstly synthesized via the reversible addn. fragmentation chain transfer polymn., and characterized by 1H NMR, FT-IR and GPC.  Subsequently, poly(vinylidene fluoride) (PVDF) blend membranes were prepd. using PMMA-b-P4VP as a blending additive.  Effects of the following factors on performance of blend membranes were systematically examd.: P4VP content of PMMA-b-P4VP, solvent type, and PMMA-b-P4VP/PVDF ratio.  Further, platinum(IV) ion-imprinted membrane (Pt(IV)-IIM) was fabricated by blending polymer-Pt(IV) complexes with PVDF.  SEM, FTIR-ATR, contact angle, water flux and adsorption capacity were employed to characterize all membranes.  Results indicated that the membrane, which was prepd. using the copolymer with high P4VP content (polymn. time 10 h) as a functional polymer, N,N-dimethylacetamide as a solvent and PMMA-b-P4VP/PVDF ratio of 30 wt%, exhibited an intriguing morphol. and much higher performance.  Pt(IV)-IIM showed higher adsorption and selectivity for Pt(IV) (selectivity coeffs. of 27.66 ± 1.38 and 77.16 ± 3.86 for Pt(IV)/Cu(II) and Pt(IV)/Ni(II), resp.) compared with a non-imprinted membrane.  During membrane filtration, Pt(IV)-IIM was effective and selective for sepn. of Pt(IV) in the presence of Cu(II) and Ni(II) ions.  Also, Pt(IV)-IIM was chem. stable, and had a good regeneration performance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosJwNL--aBL7Vg90H21EOLACvtfcHk0lhnQVDTupZZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlSqsb7E&md5=689eff676e437578afaa537a46284ae6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.memsci.2018.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.memsci.2018.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DJ.%2BX.%26aulast%3DLv%26aufirst%3DC.%2BQ.%26aulast%3DLiu%26aufirst%3DG.%2BQ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DZ.%2BH.%26aulast%3DLiu%26aufirst%3DJ.%2BY.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DA%2520Novel%2520Ion-Imprinted%2520Membrane%2520Induced%2520by%2520Amphiphilic%2520Block%2520Copolymer%2520for%2520Selective%2520Separation%2520of%2520Pt%2528IV%2529%2520from%2520Aqueous%2520Solutions%26jtitle%3DJ.%2520Membr.%2520Sci.%26date%3D2019%26volume%3D572%26spage%3D428%26epage%3D441%26doi%3D10.1016%2Fj.memsci.2018.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">3436</span>– <span class="NLM_lpage">3486</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrev.5b00597</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrev.5b00597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=3436-3486&author=T.+C.+Johnstoneauthor=K.+Suntharalingamauthor=S.+J.+Lippard&title=The+Next+Generation+of+Platinum+Drugs%3A+Targeted+Pt%28II%29+Agents%2C+Nanoparticle+Delivery%2C+and+Pt%28IV%29+Prodrugs&doi=10.1021%2Facs.chemrev.5b00597"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</span></div><div class="casAuthors">Johnstone, Timothy C.; Suntharalingam, Kogularamanan; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3436-3486</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic.  Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs.  The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs.  In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs.  The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished.  We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compds., platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes.  Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles.  Addnl. nanoformulations, including supramol. self-assembled structures, proteins, peptides, metal-org. frameworks, and coordination polymers, will then be described.  Finally, the significant clin. progress made by nanoparticle formulations of platinum(II) agents will be reviewed.  We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzKCOwDrVtJrVg90H21EOLACvtfcHk0ljBADBgY315gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xit1aksr8%253D&md5=d7adf3279441d8e56bddf501f06cda6e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrev.5b00597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrev.5b00597%26sid%3Dliteratum%253Aachs%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520Next%2520Generation%2520of%2520Platinum%2520Drugs%253A%2520Targeted%2520Pt%2528II%2529%2520Agents%252C%2520Nanoparticle%2520Delivery%252C%2520and%2520Pt%2528IV%2529%2520Prodrugs%26jtitle%3DChem.%2520Rev.%26date%3D2016%26volume%3D116%26spage%3D3436%26epage%3D3486%26doi%3D10.1021%2Facs.chemrev.5b00597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choy, H.</span></span> <span> </span><span class="NLM_article-title">An Orally Available Platinum Analog for the Treatment of Cancer</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">982</span>, <span class="refDoi"> DOI: 10.1586/14737140.6.7.973</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1586%2F14737140.6.7.973" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=16831070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvVeqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=973-982&author=H.+Choy&title=An+Orally+Available+Platinum+Analog+for+the+Treatment+of+Cancer&doi=10.1586%2F14737140.6.7.973"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Satraplatin: an orally available platinum analog for the treatment of cancer</span></div><div class="casAuthors">Choy, Hak</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">973-982</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Future Drugs Ltd.</span>)
        </div><div class="casAbstract">A review.  Satraplatin is a novel, orally bioavailable, platinum anticancer drug.  Platinum analogs form the mainstay of treatment for a no. of cancers, including lung, ovarian, colorectal and head and neck cancer.  A disadvantage of the currently marketed platinum analogs is that they must all be administered via i.v. infusion.  In addn., their utility is often limited by toxicity, particularly neurotoxicity, ototoxicity and renal toxicity.  Satraplatin has preclin. antitumor activity comparable with that of cisplatin and, clin., has a more manageable side-effect profile.  Satraplatin is active in lung, ovarian and prostate cancer, and appears to have good efficacy in combination with radiation for lung and head and neck cancer.  Preclin. data suggest it may also be effective for the treatment of certain cisplatin-refractory tumors.  A large, randomized Phase III trial is currently evaluating Satraplatin in combination with prednisone for the treatment of patients with hormone-refractory prostate cancer whose disease has progressed following prior systemic therapy.  Pos. results from this trial would support regulatory approval for satraplatin for this indication.  The availability of an active oral platinum agent, such as satraplatin, with few of the serious toxicities assocd. with traditional i.v. platinum compds. makes satraplatin an alternative to other platinum agents and a new treatment option in the oncologist's armamentarium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozCHqYYpVjzLVg90H21EOLACvtfcHk0ljBADBgY315gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvVeqtL0%253D&md5=00660d58a909b1f2a7b1f73ddafa68cf</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1586%2F14737140.6.7.973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.6.7.973%26sid%3Dliteratum%253Aachs%26aulast%3DChoy%26aufirst%3DH.%26atitle%3DAn%2520Orally%2520Available%2520Platinum%2520Analog%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2006%26volume%3D6%26spage%3D973%26epage%3D982%26doi%3D10.1586%2F14737140.6.7.973" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S. W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, B. Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. H.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">13091</span>– <span class="NLM_lpage">13095</span>, <span class="refDoi"> DOI: 10.1002/anie.201807305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fanie.201807305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlCls7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=13091-13095&author=G.+Y.+Yangauthor=W.+Wangauthor=S.+W.+F.+Mokauthor=C.+Wuauthor=B.+Y.+K.+Lawauthor=X.+M.+Miaoauthor=K.+J.+Wuauthor=H.+J.+Zhongauthor=C.+Y.+Wongauthor=V.+K.+W.+Wongauthor=D.+L.+Maauthor=C.+H.+Leung&title=Selective+Inhibition+of+Lysine-Specific+Demethylase+5A+%28KDM5A%29+Using+a+Rhodium%28III%29+Complex+for+Triple-Negative+Breast+Cancer+Therapy&doi=10.1002%2Fanie.201807305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy</span></div><div class="casAuthors">Yang, Guan-Jun; Wang, Wanhe; Mok, Simon Wing Fai; Wu, Chun; Law, Betty Yuen Kwan; Miao, Xiang-Min; Wu, Ke-Jia; Zhong, Hai-Jing; Wong, Chun-Yuen; Wong, Vincent Kam Wai; Ma, Dik-Lung; Leung, Chung-Hang</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">13091-13095</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Lysine-specific demethylase 5A (KDM5A) has recently become a promising target for epigenetic therapy.  In this study, the authors designed and synthesized metal complexes bearing ligands with reported demethylase and p27 modulating activities.  The Rh(III) complex 1 (I) was identified as a direct, selective and potent inhibitor of KDM5A that directly abrogate KDM5A demethylase activity via antagonizing the KDM5A-tri-/di-methylated histone 3 protein-protein interaction (PPI) in vitro and in cellulo.  Complex 1 induced accumulation of H3K4me3 and H3K4me2 levels in cells, causing growth arrest at G1 phase in the triple-neg. breast cancer (TNBC) cell lines, MDA-MB-231 and 4T1.  Finally, 1 exhibited potent anti-tumor activity against TNBC xenografts in an in vivo mouse model, presumably via targeting of KDM5A and hence upregulating p27.  Moreover, complex 1 was less toxic compared with two clin. drugs, cisplatin and doxorubicin.  To the authors' knowledge, complex 1 is the first metal-based KDM5A inhibitor reported in the literature.  The authors anticipate that complex 1 may be used as a novel scaffold for the further development of more potent epigenetic agents against cancers, including TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriUnhpINRuOrVg90H21EOLACvtfcHk0ljBADBgY315gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlCls7vM&md5=9a8f6097e7401592667690c255f1c9e6</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1002%2Fanie.201807305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201807305%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DG.%2BY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMok%26aufirst%3DS.%2BW.%2BF.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DLaw%26aufirst%3DB.%2BY.%2BK.%26aulast%3DMiao%26aufirst%3DX.%2BM.%26aulast%3DWu%26aufirst%3DK.%2BJ.%26aulast%3DZhong%26aufirst%3DH.%2BJ.%26aulast%3DWong%26aufirst%3DC.%2BY.%26aulast%3DWong%26aufirst%3DV.%2BK.%2BW.%26aulast%3DMa%26aufirst%3DD.%2BL.%26aulast%3DLeung%26aufirst%3DC.%2BH.%26atitle%3DSelective%2520Inhibition%2520of%2520Lysine-Specific%2520Demethylase%25205A%2520%2528KDM5A%2529%2520Using%2520a%2520Rhodium%2528III%2529%2520Complex%2520for%2520Triple-Negative%2520Breast%2520Cancer%2520Therapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D13091%26epage%3D13095%26doi%3D10.1002%2Fanie.201807305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. L.</span></span> <span> </span><span class="NLM_article-title">Identification of an Iridium(III)-Based Inhibitor of Tumor Necrosis Factor-α</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4026</span>– <span class="NLM_lpage">4031</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00112</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00112" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOjur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4026-4031&author=T.+S.+Kangauthor=Z.+Maoauthor=C.+T.+Ngauthor=M.+Wangauthor=W.+Wangauthor=C.+Wangauthor=S.+M.+Y.+Leeauthor=Y.+Wangauthor=C.+H.+Leungauthor=D.+L.+Ma&title=Identification+of+an+Iridium%28III%29-Based+Inhibitor+of+Tumor+Necrosis+Factor-%CE%B1&doi=10.1021%2Facs.jmedchem.6b00112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an Iridium(III)-Based Inhibitor of Tumor Necrosis Factor-α</span></div><div class="casAuthors">Kang, Tian-Shu; Mao, Zhifeng; Ng, Chan-Tat; Wang, Modi; Wang, Wanhe; Wang, Chunming; Lee, Simon Ming-Yuen; Wang, Yitao; Leung, Chung-Hang; Ma, Dik-Lung</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4026-4031</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The novel iridium(III) complex 1 was verified as a potent inhibitor of the TNF-α-TNFR protein-protein interaction in vitro and in cellulo.  The iridium(III) center plays a crit. role in organizing the structure of the bioactive metal complex, as the isolated ligands were found to be completely inactive.  Both iridium enantiomers inhibited TNF-α-induced NF-κB activity and TNF-α-TNFR binding. 1 represents a promising scaffold for the further development of more potent organometallic TNF-α inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGSZhWsnl-lLVg90H21EOLACvtfcHk0lj9-Kb3yfvbTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOjur8%253D&md5=646d93f9b37bed3dd865bd59499ad54f</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00112%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DT.%2BS.%26aulast%3DMao%26aufirst%3DZ.%26aulast%3DNg%26aufirst%3DC.%2BT.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DS.%2BM.%2BY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLeung%26aufirst%3DC.%2BH.%26aulast%3DMa%26aufirst%3DD.%2BL.%26atitle%3DIdentification%2520of%2520an%2520Iridium%2528III%2529-Based%2520Inhibitor%2520of%2520Tumor%2520Necrosis%2520Factor-%25CE%25B1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4026%26epage%3D4031%26doi%3D10.1021%2Facs.jmedchem.6b00112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, D.</span></span> <span> </span><span class="NLM_article-title">Platinum Drugs: from Pt(II) Compounds, Pt(IV) Prodrugs, to Pt Nanocrystals/Nanoclusters</span>. <i>Sci. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">596</span>, <span class="refDoi"> DOI: 10.1016/j.scib.2017.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.scib.2017.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGjsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2017&pages=589-596&author=X.+Huauthor=F.+Liauthor=N.+Noorauthor=D.+Ling&title=Platinum+Drugs%3A+from+Pt%28II%29+Compounds%2C+Pt%28IV%29+Prodrugs%2C+to+Pt+Nanocrystals%2FNanoclusters&doi=10.1016%2Fj.scib.2017.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32cR"><div class="casContent"><span class="casTitleNuber">32c</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum drugs: from Pt(II) compounds, Pt(IV) prodrugs, to Pt nanocrystals/nanoclusters</span></div><div class="casAuthors">Hu, Xi; Li, Fangyuan; Noor, Nabila; Ling, Daishun</div><div class="citationInfo"><span class="NLM_cas:title">Science Bulletin</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">589-596</span>CODEN:
                <span class="NLM_cas:coden">SBCUA5</span>;
        ISSN:<span class="NLM_cas:issn">2095-9281</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Platinum (Pt) based drugs, such as cisplatin, are widely used as anti-cancer agents, but their severe adverse reactions and resistance of cancer patients have limited their board clin. use.  For the last few decades, Pt(II) compds., Pt(IV) prodrugs as well as smart drug delivery systems have been developed to overcome these problems.  However, most conventional strategies rely on the similar anti-cancer mechanism with cisplatin and consequently only achieve limited success.  Recently, Pt nanocrystals/nanoclusters (Pt NCs), with a brand new anti-cancer mechanism, have shown a promising potential in targeted cancer therapy, esp. in Pt resistance circumvention.  This review is helpful to understand the research strategies of Pt drugs, particularly, the recent developments and medical applications of Pt NCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-Chotf7yUtrVg90H21EOLACvtfcHk0lj9-Kb3yfvbTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGjsLrM&md5=deca656db6fa01b915776a4c5c17ca52</span></div><a href="/servlet/linkout?suffix=cit32c&amp;dbid=16384&amp;doi=10.1016%2Fj.scib.2017.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.scib.2017.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DNoor%26aufirst%3DN.%26aulast%3DLing%26aufirst%3DD.%26atitle%3DPlatinum%2520Drugs%253A%2520from%2520Pt%2528II%2529%2520Compounds%252C%2520Pt%2528IV%2529%2520Prodrugs%252C%2520to%2520Pt%2520Nanocrystals%252FNanoclusters%26jtitle%3DSci.%2520Bull.%26date%3D2017%26volume%3D62%26spage%3D589%26epage%3D596%26doi%3D10.1016%2Fj.scib.2017.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span> <span> </span><span class="NLM_article-title">Platinum(IV) Prodrugs with Long Lipid Chains for Drug Delivery and Overcoming Cisplatin Resistance</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5369</span>– <span class="NLM_lpage">5372</span>, <span class="refDoi"> DOI: 10.1039/C8CC02791A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1039%2FC8CC02791A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=29744485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVOntrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2018&pages=5369-5372&author=Q.+Chenauthor=Y.+Yangauthor=X.+Linauthor=W.+Maauthor=G.+Chenauthor=W.+Liauthor=X.+Wangauthor=Z.+Yu&title=Platinum%28IV%29+Prodrugs+with+Long+Lipid+Chains+for+Drug+Delivery+and+Overcoming+Cisplatin+Resistance&doi=10.1039%2FC8CC02791A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32dR"><div class="casContent"><span class="casTitleNuber">32d</span><div class="casTitle"><span class="NLM_cas:atitle">Platinum(IV) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance</span></div><div class="casAuthors">Chen, Qiling; Yang, Yuanyuan; Lin, Xun; Ma, Wen; Chen, Gui; Li, Wenliang; Wang, Xuefeng; Yu, Zhiqiang</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">5369-5372</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Platinum(IV) prodrugs of clin. used cisplatin and oxaliplatin with two axial long lipid chains were developed for nanoparticle delivery to combat cisplatin resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_iuw0-GjjL7Vg90H21EOLACvtfcHk0lj9-Kb3yfvbTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVOntrk%253D&md5=64089c68c1063bb1f5e4c43b83aee428</span></div><a href="/servlet/linkout?suffix=cit32d&amp;dbid=16384&amp;doi=10.1039%2FC8CC02791A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8CC02791A%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DZ.%26atitle%3DPlatinum%2528IV%2529%2520Prodrugs%2520with%2520Long%2520Lipid%2520Chains%2520for%2520Drug%2520Delivery%2520and%2520Overcoming%2520Cisplatin%2520Resistance%26jtitle%3DChem.%2520Commun.%26date%3D2018%26volume%3D54%26spage%3D5369%26epage%3D5372%26doi%3D10.1039%2FC8CC02791A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrache, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berding, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, S.</span></span> <span> </span><span class="NLM_article-title">The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1963</span>– <span class="NLM_lpage">1967</span>, <span class="refDoi"> DOI: 10.1002/anie.201308899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fanie.201308899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVyktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=1963-1967&author=R.+K.+Pathakauthor=S.+Marracheauthor=J.+H.+Choiauthor=T.+B.+Berdingauthor=S.+Dhar&title=The+Prodrug+Platin-A%3A+Simultaneous+Release+of+Cisplatin+and+Aspirin&doi=10.1002%2Fanie.201308899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The Prodrug Platin-A: Simultaneous Release of Cisplatin and Aspirin</span></div><div class="casAuthors">Pathak, Rakesh K.; Marrache, Sean; Choi, Joshua H.; Berding, Trenton B.; Dhar, Shanta</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1963-1967</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cancer-assocd. inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers.  The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin.  Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin.  These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHIPcwRalkB7Vg90H21EOLACvtfcHk0lipCzaoYhspig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVyktrw%253D&md5=d40b197ee5448e5a64a60c656eb0fde9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fanie.201308899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201308899%26sid%3Dliteratum%253Aachs%26aulast%3DPathak%26aufirst%3DR.%2BK.%26aulast%3DMarrache%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DJ.%2BH.%26aulast%3DBerding%26aufirst%3DT.%2BB.%26aulast%3DDhar%26aufirst%3DS.%26atitle%3DThe%2520Prodrug%2520Platin-A%253A%2520Simultaneous%2520Release%2520of%2520Cisplatin%2520and%2520Aspirin%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D1963%26epage%3D1967%26doi%3D10.1002%2Fanie.201308899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. Y.</span></span> <span> </span><span class="NLM_article-title">Fuplatin: An Efficient and Low-Toxic Dual-Prodrug</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4543</span>– <span class="NLM_lpage">4554</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00128</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00128" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFCgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4543-4554&author=R.+Zhangauthor=X.+Q.+Songauthor=R.+P.+Liuauthor=Z.+Y.+Maauthor=J.+Y.+Xu&title=Fuplatin%3A+An+Efficient+and+Low-Toxic+Dual-Prodrug&doi=10.1021%2Facs.jmedchem.9b00128"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Fuplatin: An Efficient and Low-Toxic Dual-Prodrug</span></div><div class="casAuthors">Zhang, Ran; Song, Xue-Qing; Liu, Rui-Ping; Ma, Zhong-Ying; Xu, Jing-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4543-4554</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">As FDA-approved chemotherapeutic agents, cisplatin, oxaliplatin, and 5-fluorouracil are widely used in clinic but limited by severe side-effects.  To ameliorate their resp. defects, a series of "dual-prodrug" by linking oxoplatin and 5-FU were designed and synthesized.  The assembled compds. 10-17, named Fuplatin, exhibited much higher cytotoxicity against the tested cancer cells while lower cytotoxicity toward the human normal lung cells than free drugs or their combinations.  Among them, 14 enhanced cellular accumulation with 62- and 825-fold amt. of oxaliplatin and 8 at 9 h, resp., significantly induced DNA damage and cell apoptosis, and inhibited migration and invasion in HCT-116 cells.  Compd. 14 arrested the cell cycle at S and G2 phases and up-regulated thymidylate synthase and p53, consistent with the results of the combination, suggesting 14 adopted a collaborative mode of 5-FU and oxaliplatin to kill cancer cells.  In vivo, compd. 14 showed high antitumor effect and no observable toxicity in NOD/SCID mice bearing HCT-116 tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhZrU6zmfHWbVg90H21EOLACvtfcHk0lipCzaoYhspig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFCgs7Y%253D&md5=4dc3d04c95e2f9fb1266e25511e6e491</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00128%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DSong%26aufirst%3DX.%2BQ.%26aulast%3DLiu%26aufirst%3DR.%2BP.%26aulast%3DMa%26aufirst%3DZ.%2BY.%26aulast%3DXu%26aufirst%3DJ.%2BY.%26atitle%3DFuplatin%253A%2520An%2520Efficient%2520and%2520Low-Toxic%2520Dual-Prodrug%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4543%26epage%3D4554%26doi%3D10.1021%2Facs.jmedchem.9b00128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolishetti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, S.</span></span> <span> </span><span class="NLM_article-title">A Prodrug of Two Approved Drugs, Cisplatin and Chlorambucil, for Chemo War against Cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1158%2F1535-7163.MCT-16-0445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=28148716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltlOqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=625-636&author=R.+K.+Pathakauthor=R.+Wenauthor=N.+Kolishettiauthor=S.+Dhar&title=A+Prodrug+of+Two+Approved+Drugs%2C+Cisplatin+and+Chlorambucil%2C+for+Chemo+War+against+Cancer&doi=10.1158%2F1535-7163.MCT-16-0445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A Prodrug of Two Approved Drugs, Cisplatin and Chlorambucil, for Chemo War Against Cancer</span></div><div class="casAuthors">Pathak, Rakesh K.; Wen, Ru; Kolishetti, Nagesh; Dhar, Shanta</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">625-636</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cancer cells maintain normal mitochondrial glutathione as one of the defense mechanisms to inhibit mitochondrial membrane polarization and hence apoptosis.  A combinational therapeutic modality Platin-Cbl, a prodrug of FDA-approved chemotherapeutic agents, cisplatin and chlorambucil (Cbl), was synthesized and characterized to explore the potential of this compd. to initiate chemo war on cancer cells using the active drugs, cisplatin and Cbl, when delivered to the cellular power house mitochondrion using a targeted nanoparticle designed to get assocd. with this organelle.  Platin-Cbl demonstrated significantly high cytotoxic activity across a no. of tumor cell lines as well as in a cisplatin-resistant cancer cell line compared with cisplatin or its mixt. with Cbl suggesting its unique potency in cisplatin-resistant tumors.  A mitochondria-targeted nanoparticle formulation of Platin-Cbl allowed for its efficacious mitochondrial delivery.  In vitro studies documented high potency of Platin-Cbl nanoparticle formulations.  Cisplatin-resistant cells upon treatment with Platin-Cbl were still able to manage energy prodn. to a certain extent via fatty acid pathway; the advantage of using T-Platin-Cbl-NP is that this nanoparticle treatment causes impairment of all metabolic pathways in cisplatin-resistant cells forcing the cells to undergo efficient apoptosis.  This study highlights a combination of several beneficial effects for a cascade of events to overcome resistance assocd. with single drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfFjdSpGRDPrVg90H21EOLACvtfcHk0lipCzaoYhspig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltlOqurg%253D&md5=09c2ece4b1c1dde0da12ac78ee282b26</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0445%26sid%3Dliteratum%253Aachs%26aulast%3DPathak%26aufirst%3DR.%2BK.%26aulast%3DWen%26aufirst%3DR.%26aulast%3DKolishetti%26aufirst%3DN.%26aulast%3DDhar%26aufirst%3DS.%26atitle%3DA%2520Prodrug%2520of%2520Two%2520Approved%2520Drugs%252C%2520Cisplatin%2520and%2520Chlorambucil%252C%2520for%2520Chemo%2520War%2520against%2520Cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D625%26epage%3D636%26doi%3D10.1158%2F1535-7163.MCT-16-0445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Forsgård, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korpela, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frias, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spillmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterlund, P.</span></span> <span> </span><span class="NLM_article-title">Intestinal Permeability to Iohexol as An in Vivo Marker of Chemotherapy-Induced Gastrintestinal Toxicity in Sprague-Dawley Rats</span>. <i>Cancer Chemoth. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.1007/s00280-016-3150-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1007%2Fs00280-016-3150-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=27590707" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2016&pages=863-874&author=R.+A.+Forsg%C3%A5rdauthor=R.+Korpelaauthor=R.+Holmaauthor=J.+Lindenauthor=R.+Friasauthor=T.+Spillmannauthor=P.+Osterlund&title=Intestinal+Permeability+to+Iohexol+as+An+in+Vivo+Marker+of+Chemotherapy-Induced+Gastrintestinal+Toxicity+in+Sprague-Dawley+Rats&doi=10.1007%2Fs00280-016-3150-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-3150-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-3150-3%26sid%3Dliteratum%253Aachs%26aulast%3DForsg%25C3%25A5rd%26aufirst%3DR.%2BA.%26aulast%3DKorpela%26aufirst%3DR.%26aulast%3DHolma%26aufirst%3DR.%26aulast%3DLinden%26aufirst%3DJ.%26aulast%3DFrias%26aufirst%3DR.%26aulast%3DSpillmann%26aufirst%3DT.%26aulast%3DOsterlund%26aufirst%3DP.%26atitle%3DIntestinal%2520Permeability%2520to%2520Iohexol%2520as%2520An%2520in%2520Vivo%2520Marker%2520of%2520Chemotherapy-Induced%2520Gastrintestinal%2520Toxicity%2520in%2520Sprague-Dawley%2520Rats%26jtitle%3DCancer%2520Chemoth.%2520Pharm.%26date%3D2016%26volume%3D78%26spage%3D863%26epage%3D874%26doi%3D10.1007%2Fs00280-016-3150-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzaroni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porro, G. B.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal Side-Effects of Traditional Non-Steroidal Anti-Inflammatory Drugs and New Formulations</span>. <i>Aliment. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2036.2004.02037.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1111%2Fj.1365-2036.2004.02037.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=15335413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovVylurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2004&pages=48-58&author=M.+Lazzaroniauthor=G.+B.+Porro&title=Gastrointestinal+Side-Effects+of+Traditional+Non-Steroidal+Anti-Inflammatory+Drugs+and+New+Formulations&doi=10.1111%2Fj.1365-2036.2004.02037.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36bR"><div class="casContent"><span class="casTitleNuber">36b</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations</span></div><div class="casAuthors">Lazzaroni, M.; Porro, G. Bianchi</div><div class="citationInfo"><span class="NLM_cas:title">Alimentary Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">Suppl. 2</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">APTHEN</span>;
        ISSN:<span class="NLM_cas:issn">0269-2813</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Although adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs) occur in only a small proportion of users, the widespread use of these drugs has resulted in a substantial overall no. of affected persons who experience serious gastrointestinal complications.  Dyspeptic symptoms are estd. to occur in 10-60% of NSAID users and lead to discontinuation of treatment in 5-15% of rheumatoid arthritis patients taking NSAIDs.  It is now well established that the point prevalence of peptic ulcer disease in patients receiving conventional NSAID therapy ranges between 10 and 30%, representing a 10-30-fold increase over that found in the general population.  One of 175 users of conventional NSAIDs in the USA will be hospitalized each year for NSAID-induced gastrointestinal damage.  The mortality of hospitalized patients remains about 5-10%, with an expected annual death rate of 0.08%.  The selective COX-II inhibitors (rofecoxib, celecoxib, parecoxib, etoricoxib, valdecoxib, lumiracoxib) show consistently comparable efficacy to that of conventional non-steroidal anti-inflammatory drugs (NSAIDs) in patients with rheumatoid arthritis and osteoarthritis, but have a significantly reduced propensity to cause gastrointestinal toxicity.  In many cases, the gastric effects of therapeutically active doses of COX-II inhibitors are indistinguishable from placebo.  The safety benefits of COX-2 inhibitors given alone appear similar to combined therapy with conventional NSAIDs and gastroprotective agents.  These findings warrant the consideration of COX-II inhibitors as first-line therapy in patients requiring long-term pain control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUdq4FK9ELkLVg90H21EOLACvtfcHk0lh1gZ8owobDFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovVylurk%253D&md5=719472f425b2fba21e3f224a82fe5d7b</span></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2036.2004.02037.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2036.2004.02037.x%26sid%3Dliteratum%253Aachs%26aulast%3DLazzaroni%26aufirst%3DM.%26aulast%3DPorro%26aufirst%3DG.%2BB.%26atitle%3DGastrointestinal%2520Side-Effects%2520of%2520Traditional%2520Non-Steroidal%2520Anti-Inflammatory%2520Drugs%2520and%2520New%2520Formulations%26jtitle%3DAliment.%2520Pharmacol.%2520Ther.%26date%3D2004%26volume%3D20%26spage%3D48%26epage%3D58%26doi%3D10.1111%2Fj.1365-2036.2004.02037.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Claustrat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chazot, G.</span></span> <span> </span><span class="NLM_article-title">The Basic Physiology and Pathophysiology of Melatonin</span>. <i>Sleep Med. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">11</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/j.smrv.2004.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.smrv.2004.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=15649735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BD2M%252FisVaisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2005&pages=11-24&author=B.+Claustratauthor=J.+Brunauthor=G.+Chazot&title=The+Basic+Physiology+and+Pathophysiology+of+Melatonin&doi=10.1016%2Fj.smrv.2004.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The basic physiology and pathophysiology of melatonin</span></div><div class="casAuthors">Claustrat Bruno; Brun Jocelyne; Chazot Guy</div><div class="citationInfo"><span class="NLM_cas:title">Sleep medicine reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-24</span>
        ISSN:<span class="NLM_cas:issn">1087-0792</span>.
    </div><div class="casAbstract">Melatonin is a methoxyindole synthesized and secreted principally by the pineal gland at night under normal environmental conditions.  The endogenous rhythm of secretion is generated by the suprachiasmatic nuclei and entrained to the light/dark cycle.  Light is able to either suppress or synchronize melatonin production according to the light schedule.  The nycthohemeral rhythm of this hormone can be determined by repeated measurement of plasma or saliva melatonin or urine sulfatoxymelatonin, the main hepatic metabolite.  The primary physiological function of melatonin, whose secretion adjusts to night length, is to convey information concerning the daily cycle of light and darkness to body physiology.  This information is used for the organisation of functions, which respond to changes in the photoperiod such as the seasonal rhythms.  Seasonal rhythmicity of physiological functions in humans related to possible alteration of the melatonin message remains, however, of limited evidence in temperate areas in field conditions.  Also, the daily melatonin secretion, which is a very robust biochemical signal of night, can be used for the organisation of circadian rhythms.  Although functions of this hormone in humans are mainly based on correlative observations, there is some evidence that melatonin stabilises and strengthens coupling of circadian rhythms, especially of core temperature and sleep-wake rhythms.  The circadian organisation of other physiological functions could depend on the melatonin signal, for instance immune, antioxidative defences, hemostasis and glucose regulation.  Since the regulating system of melatonin secretion is complex, following central and autonomic pathways, there are many pathophysiological situations where the melatonin secretion can be disturbed.  The resulting alteration could increase predisposition to disease, add to the severity of symptoms or modify the course and outcome of the disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSXjyWMXya5qjAyhZbj3lKdfW6udTcc2eYfm45eTdtyWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M%252FisVaisA%253D%253D&md5=98b03fa9a2b0a6778c59bc29d7628ef2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.smrv.2004.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.smrv.2004.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DClaustrat%26aufirst%3DB.%26aulast%3DBrun%26aufirst%3DJ.%26aulast%3DChazot%26aufirst%3DG.%26atitle%3DThe%2520Basic%2520Physiology%2520and%2520Pathophysiology%2520of%2520Melatonin%26jtitle%3DSleep%2520Med.%2520Rev.%26date%3D2005%26volume%3D9%26spage%3D11%26epage%3D24%26doi%3D10.1016%2Fj.smrv.2004.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">New NSAID-Pt(IV) Prodrugs to Suppress Metastasis and Invasion of Tumor Cells and Enhance Anti-Tumor Effect in vitro and in vivo</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.02.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.ejmech.2019.02.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=30784875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsFSjtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2019&pages=377-387&author=X.+Q.+Songauthor=Z.+Y.+Maauthor=Y.+G.+Wuauthor=M.+L.+Daiauthor=D.+B.+Wangauthor=J.+Y.+Xuauthor=Y.+Liu&title=New+NSAID-Pt%28IV%29+Prodrugs+to+Suppress+Metastasis+and+Invasion+of+Tumor+Cells+and+Enhance+Anti-Tumor+Effect+in+vitro+and+in+vivo&doi=10.1016%2Fj.ejmech.2019.02.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">New NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo</span></div><div class="casAuthors">Song, Xue-Qing; Ma, Zhong-Ying; Wu, Yi-Gang; Dai, Miao-Liang; Wang, Dong-Bo; Xu, Jing-Yuan; Liu, Yangzhong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">377-387</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The great interest in epithelial-to-mesenchymal transition (EMT) program lies in its assocn. with process of metastasis and invasion, which is a crucial cause of cancer-related death.  Herein, we designed and reported three new NSAID-Pt(IV) prodrugs, taking Non-Steroid Anti-Inflammatory Drugs (NSAIDs) to disrupt EMT program and assist genotoxic platinum-based drugs as a cytotoxicity booster, to offer a class of potential anticarcinogens with a multi-functional action mechanism.  The NSAID-Pt(IV) prodrugs, esp. Eto-Pt(IV), highly enhanced cellular uptake with amt. up to 42-fold at 3 h compared with CDDP, and greatly increased DNA damage and cell apoptosis, showing much higher cytotoxicity than cisplatin in the tested cancer cells even in A549/cis cells.  Among of them, Eto-Pt(IV) and Car-Pt(IV) exhibited more excellent activity than Sul-Pt(IV), arising from their redn.-labile and favorable lipophilicity.  Most strikingly, Eto-Pt(IV) markedly inhibited metastasis and invasion of MCF-7 cells, owing to its COX-2 suppression that down-regulated active MMP-2, vimentin protein and up-regulated E-cadherin.  In vivo, Eto-Pt(IV) displayed potent antitumor activity and no observable toxicity in BALB/c nude mice bearing MCF-7 tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmGvDMxXf6z7Vg90H21EOLACvtfcHk0lh1gZ8owobDFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsFSjtLY%253D&md5=644a759ac528d39f039e4020e845ab5e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.02.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.02.041%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DX.%2BQ.%26aulast%3DMa%26aufirst%3DZ.%2BY.%26aulast%3DWu%26aufirst%3DY.%2BG.%26aulast%3DDai%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DD.%2BB.%26aulast%3DXu%26aufirst%3DJ.%2BY.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DNew%2520NSAID-Pt%2528IV%2529%2520Prodrugs%2520to%2520Suppress%2520Metastasis%2520and%2520Invasion%2520of%2520Tumor%2520Cells%2520and%2520Enhance%2520Anti-Tumor%2520Effect%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D167%26spage%3D377%26epage%3D387%26doi%3D10.1016%2Fj.ejmech.2019.02.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">del Río, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia Pedrero, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Campa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuazua, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, S.</span></span> <span> </span><span class="NLM_article-title">Melatonin, an Endogenous-Specific Inhibitor of Estrogen Receptor alpha via Calmodulin</span>. <i>Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">38294</span>– <span class="NLM_lpage">38302</span>, <span class="refDoi"> DOI: 10.1074/jbc.M403140200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1074%2Fjbc.M403140200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnt1Oqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=38294-38302&author=B.+del+R%C3%ADoauthor=J.+M.+Garcia+Pedreroauthor=C.+Martinez-Campaauthor=P.+Zuazuaauthor=P.+S.+Lazoauthor=S.+Ramos&title=Melatonin%2C+an+Endogenous-Specific+Inhibitor+of+Estrogen+Receptor+alpha+via+Calmodulin&doi=10.1074%2Fjbc.M403140200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39aR"><div class="casContent"><span class="casTitleNuber">39a</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin, an Endogenous-specific Inhibitor of Estrogen Receptor α via Calmodulin</span></div><div class="casAuthors">del Rio, Beatriz; Pedrero, Juana M. Garcia; Martinez-Campa, Carlos; Zuazua, Pedro; Lazo, Pedro S.; Ramos, Sofia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">38294-38302</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Melatonin is an indole hormone produced mainly by the pineal gland.  We have previously demonstrated that melatonin interferes with estrogen (E2) signaling in MCF7 cells by impairing estrogen receptor (ER) pathways.  Here we present the characterization of its mechanism of action showing that melatonin is a specific inhibitor of E2-induced ERα-mediated transcription in both estrogen response element- and AP1-contg. promoters, whereas ERβ-mediated transactivation is not inhibited or even activated at certain promoters.  We show that the sensitivity of MCF-7 cells to melatonin depends on the ERα/ERβ ratio, and ectopic expression of ERβ results in MCF-7 cells becoming insensitive to this hormone.  Melatonin acts as a calmodulin antagonist inducing conformational changes in the ERα-calmodulin (CaM) complex, thus impairing the binding of E2·ERα·CaM complex to DNA and, therefore, preventing ERα-dependent transcription.  Moreover the mutant ERα (K302G,K303G), unable to bind calmodulin, becomes insensitive to melatonin.  The effect of melatonin is specific since other related indoles neither interact with CaM nor inhibit ERα-mediated transactivation.  Interestingly, melatonin does not affect the binding of coactivators to ERα, indicating that melatonin action is different from that of current therapeutic anti-estrogens used in breast cancer therapy.  Thus, they target ERα at different levels, representing two independent ways to control ERα activity.  It is, therefore, conceivably a synergistic pharmacol. effect of melatonin and current anti-estrogen drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeOG9aFJS5OrVg90H21EOLACvtfcHk0liT_5Y0Em7SiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnt1Oqtro%253D&md5=9a2c31e3ed2ae6c6deac38b8461c56a2</span></div><a href="/servlet/linkout?suffix=cit39a&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M403140200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M403140200%26sid%3Dliteratum%253Aachs%26aulast%3Ddel%2BR%25C3%25ADo%26aufirst%3DB.%26aulast%3DGarcia%2BPedrero%26aufirst%3DJ.%2BM.%26aulast%3DMartinez-Campa%26aufirst%3DC.%26aulast%3DZuazua%26aufirst%3DP.%26aulast%3DLazo%26aufirst%3DP.%2BS.%26aulast%3DRamos%26aufirst%3DS.%26atitle%3DMelatonin%252C%2520an%2520Endogenous-Specific%2520Inhibitor%2520of%2520Estrogen%2520Receptor%2520alpha%2520via%2520Calmodulin%26jtitle%3DBiol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D38294%26epage%3D38302%26doi%3D10.1074%2Fjbc.M403140200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit39b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choung, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, K. W.</span></span> <span> </span><span class="NLM_article-title">Germacrone Inhibits Estrogen Receptor alpha-Mediated Transcription in MCF-7 Breast Cancer Cells</span>. <i>Phytother. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2036</span>– <span class="NLM_lpage">2043</span>, <span class="refDoi"> DOI: 10.1002/ptr.5711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fptr.5711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=27573551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGnsbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=2036-2043&author=M.+S.+Limauthor=S.+Y.+Choungauthor=K.+W.+Jeong&title=Germacrone+Inhibits+Estrogen+Receptor+alpha-Mediated+Transcription+in+MCF-7+Breast+Cancer+Cells&doi=10.1002%2Fptr.5711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39bR"><div class="casContent"><span class="casTitleNuber">39b</span><div class="casTitle"><span class="NLM_cas:atitle">Germacrone Inhibits Estrogen Receptor α-Mediated Transcription in MCF-7 Breast Cancer Cells</span></div><div class="casAuthors">Lim, Mi-Sun; Choung, Se-Young; Jeong, Kwang Won</div><div class="citationInfo"><span class="NLM_cas:title">Phytotherapy Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2036-2043</span>CODEN:
                <span class="NLM_cas:coden">PHYREH</span>;
        ISSN:<span class="NLM_cas:issn">0951-418X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Estrogen receptor (ER)α-pos. breast cancer cells regulate the expression of estrogen-responsive genes, which are involved in cell proliferation, differentiation, and cell cycle progression.  Clin., the inhibition of ERα-mediated gene expression in breast cancer cells has long been considered an effective way to prevent the development and progression of cancer.  Germacrone, a terpenoid compd. isolated from Rhizoma curcuma, has been known to have antitumor activity in various human cancer cell lines.  However, the mechanism by which germacrone inhibits the proliferation of breast cancer cells is still unclear.  Here, we demonstrated that germacrone inhibits ERα-mediated gene expression at the transcriptional level in MCF-7 cells.  Germacrone inhibits the recruitment of ERα to the estrogen response element on chromatin and consequently compromises the binding of switch/sucrose non-fermentable chromatin remodeling complex and RNA polymerase II to target gene promoter, thereby inhibiting the estrogen-induced chromatin accessibility.  In addn., germacrone efficiently potentiates the antitumor activity of methotrexate and 5-fluorouracil.  Our results not only provide substantial mol. mechanism of germacrone on ERα-mediated signaling in breast cancer cells but also demonstrate the benefits of germacrone as a combination therapy with other drugs for the treatment of breast cancer.  Copyright 2016 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHB7tNEB1qp7Vg90H21EOLACvtfcHk0liT_5Y0Em7SiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGnsbzF&md5=48c168a425867d7224f531e88b019e2f</span></div><a href="/servlet/linkout?suffix=cit39b&amp;dbid=16384&amp;doi=10.1002%2Fptr.5711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fptr.5711%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DM.%2BS.%26aulast%3DChoung%26aufirst%3DS.%2BY.%26aulast%3DJeong%26aufirst%3DK.%2BW.%26atitle%3DGermacrone%2520Inhibits%2520Estrogen%2520Receptor%2520alpha-Mediated%2520Transcription%2520in%2520MCF-7%2520Breast%2520Cancer%2520Cells%26jtitle%3DPhytother.%2520Res.%26date%3D2016%26volume%3D30%26spage%3D2036%26epage%3D2043%26doi%3D10.1002%2Fptr.5711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Barceló, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolores, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlos, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alicia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carolina, A. G.</span></span> <span> </span><span class="NLM_article-title">Melatonin-Estrogen Interactions in Breast Cancer</span>. <i>J. Pineal Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1111/j.1600-079X.2004.00207.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1111%2Fj.1600-079X.2004.00207.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=217-222&author=E.+J.+S%C3%A1nchez-Barcel%C3%B3author=C.+Samuelauthor=M.+Doloresauthor=M.+C.+Carlosauthor=G.+Aliciaauthor=A.+G.+Carolina&title=Melatonin-Estrogen+Interactions+in+Breast+Cancer&doi=10.1111%2Fj.1600-079X.2004.00207.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-079X.2004.00207.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-079X.2004.00207.x%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Barcel%25C3%25B3%26aufirst%3DE.%2BJ.%26aulast%3DSamuel%26aufirst%3DC.%26aulast%3DDolores%26aufirst%3DM.%26aulast%3DCarlos%26aufirst%3DM.%2BC.%26aulast%3DAlicia%26aufirst%3DG.%26aulast%3DCarolina%26aufirst%3DA.%2BG.%26atitle%3DMelatonin-Estrogen%2520Interactions%2520in%2520Breast%2520Cancer%26jtitle%3DJ.%2520Pineal%2520Res.%26date%3D2010%26volume%3D38%26spage%3D217%26epage%3D222%26doi%3D10.1111%2Fj.1600-079X.2004.00207.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ram, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. M.</span></span> <span> </span><span class="NLM_article-title">Melatonin Inhibits Estrogen Receptor Transactivation and cAMP Levels in Breast Cancer Cells</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1023/A:1013301408464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1023%2FA%3A1013301408464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=11859872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVGjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=37-45&author=T.+Kieferauthor=P.+T.+Ramauthor=L.+Yuanauthor=S.+M.+Hill&title=Melatonin+Inhibits+Estrogen+Receptor+Transactivation+and+cAMP+Levels+in+Breast+Cancer+Cells&doi=10.1023%2FA%3A1013301408464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41aR"><div class="casContent"><span class="casTitleNuber">41a</span><div class="casTitle"><span class="NLM_cas:atitle">Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells</span></div><div class="casAuthors">Kiefer, T.; Ram, P. T.; Yuan, L.; Hill, S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-45</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">The authors have previously demonstrated that the pineal hormone, melatonin, can inhibit the growth of estrogen receptor-alpha (ERα)-pos. breast cancer cells and suppress ERα gene transcription.  To investigate the relationship between the estrogen response pathway and melatonin's growth inhibition, ERα-pos. MCF-7 human breast cancer cells were transiently transfected with an estrogen response element (ERE) luciferase reporter construct and then treated with melatonin (10-9-10-6 M) for 30 min followed by 10-9 M 17β-estradiol (E2) or treated with each compd. alone.  Melatonin pre-treatment significantly reduced E2-induced ERα transactivation and ERα-ERE binding activity.  The authors also conducted expts. to det. if melatonin modulates cAMP levels in MCF-7 cells.  Melatonin inhibited the forskolin-induced and E2-induced elevation of cAMP levels by 57 and 45%, resp.  These data indicate that melatonin can act as a biol. modifier to affect ERα transcriptional activity by regulating signal transduction pathways which impinge on the ERα and by altering E2-mediated ERα transactivation and ERα DNA binding activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RRlXM0u90LVg90H21EOLACvtfcHk0liT_5Y0Em7SiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVGjs74%253D&md5=5678066e6c561ae5c6d4f54fec2dabca</span></div><a href="/servlet/linkout?suffix=cit41a&amp;dbid=16384&amp;doi=10.1023%2FA%3A1013301408464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1013301408464%26sid%3Dliteratum%253Aachs%26aulast%3DKiefer%26aufirst%3DT.%26aulast%3DRam%26aufirst%3DP.%2BT.%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DS.%2BM.%26atitle%3DMelatonin%2520Inhibits%2520Estrogen%2520Receptor%2520Transactivation%2520and%2520cAMP%2520Levels%2520in%2520Breast%2520Cancer%2520Cells%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2002%26volume%3D71%26spage%3D37%26epage%3D45%26doi%3D10.1023%2FA%3A1013301408464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit41b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubocovich, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, S. M.</span></span> <span> </span><span class="NLM_article-title">MT1 Melatonin Receptor Overexpression Enhances the Growth Suppressive Effect of Melatonin in Human Breast Cancer Cells</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/S0303-7207(02)00029-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2FS0303-7207%2802%2900029-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=12088876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD38XkslGrtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2002&pages=147-156&author=L.+Yuanauthor=A.+R.+Collinsauthor=J.+Daiauthor=M.+L.+Dubocovichauthor=S.+M.+Hill&title=MT1+Melatonin+Receptor+Overexpression+Enhances+the+Growth+Suppressive+Effect+of+Melatonin+in+Human+Breast+Cancer+Cells&doi=10.1016%2FS0303-7207%2802%2900029-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41bR"><div class="casContent"><span class="casTitleNuber">41b</span><div class="casTitle"><span class="NLM_cas:atitle">MT1 melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells</span></div><div class="casAuthors">Yuan, Lin; Collins, April R.; Dai, Jun; Dubocovich, Margarita L.; Hill, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">Melatonin inhibits the proliferation of estrogen receptor alpha (ERα)-pos. (MCF-7), but not ERα-neg. (MDA-MB-231) breast cancer cells.  Here, we assessed the effect of MT1 melatonin receptor stable overexpression in MCF-7 and MDA-MB-231 breast cancer cells on the growth-suppressive effects of melatonin.  Parental and vector-transfected MCF-7 cells demonstrated a modest, but significant, growth-suppressive response to melatonin; however, melatonin treatment of MT1-transfected MCF-7 cells resulted in significantly enhanced growth-suppression.  This response was blocked by an MT1/MT2 melatonin receptor antagonist.  Interestingly, MT1-overexpression did not induce a melatonin-sensitive phenotype in melatonin-insensitive MDA-MB-231 cells.  Finally, Northern blot anal. demonstrated an enhanced inhibition of ERα mRNA expression and an enhanced induction of pancreatic spasmolytic polypeptide (pS2) by melatonin in MT1-transfected MCF-7 cells relative to vector-transfected MCF-7 cells.  These data suggest the involvement of the MT1 melatonin receptor in mediation of melatonin effects on growth-suppression and gene-modulation in breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxSmCw74JFN7Vg90H21EOLACvtfcHk0liS_yrdsjiTRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkslGrtb8%253D&md5=bb22a0a3023a6d64ab27e2834a847ca7</span></div><a href="/servlet/linkout?suffix=cit41b&amp;dbid=16384&amp;doi=10.1016%2FS0303-7207%2802%2900029-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0303-7207%252802%252900029-1%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DL.%26aulast%3DCollins%26aufirst%3DA.%2BR.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DDubocovich%26aufirst%3DM.%2BL.%26aulast%3DHill%26aufirst%3DS.%2BM.%26atitle%3DMT1%2520Melatonin%2520Receptor%2520Overexpression%2520Enhances%2520the%2520Growth%2520Suppressive%2520Effect%2520of%2520Melatonin%2520in%2520Human%2520Breast%2520Cancer%2520Cells%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2002%26volume%3D192%26spage%3D147%26epage%3D156%26doi%3D10.1016%2FS0303-7207%2802%2900029-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halip, L. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borota, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bora, A.</span></span> <span> </span><span class="NLM_article-title">Insight the Binding Site of Human Melatonin MTR1A Receptor</span>. <i>Rev. Roum. Chim.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">218</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2015&pages=213-218&author=L.+R.+C.+Halipauthor=A.+Borotaauthor=A.+Bora&title=Insight+the+Binding+Site+of+Human+Melatonin+MTR1A+Receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHalip%26aufirst%3DL.%2BR.%2BC.%26aulast%3DBorota%26aufirst%3DA.%26aulast%3DBora%26aufirst%3DA.%26atitle%3DInsight%2520the%2520Binding%2520Site%2520of%2520Human%2520Melatonin%2520MTR1A%2520Receptor%26jtitle%3DRev.%2520Roum.%2520Chim.%26date%3D2015%26volume%3D60%26spage%3D213%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alkozi, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez Montero, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doadrio, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pintor, J.</span></span> <span> </span><span class="NLM_article-title">Docking Studies for Melatonin Receptors</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1080/17460441.2018.1419184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1080%2F17460441.2018.1419184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=29271261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=241-248&author=H.+A.+Alkoziauthor=J.+M.+Sanchez+Monteroauthor=A.+L.+Doadrioauthor=J.+Pintor&title=Docking+Studies+for+Melatonin+Receptors&doi=10.1080%2F17460441.2018.1419184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Docking studies for melatonin receptors</span></div><div class="casAuthors">Alkozi, Hanan Awad; Sanchez Montero, Jose Maria; Doadrio, Antonio Luis; Pintor, Jesus</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">241-248</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Melatonin is a neurohormone that controls many relevant physiol. processes beyond the control of circadian rhythms.  Melatonin's actions are carried out by two main types of melatonin receptors; MT1 and MT2.  These receptors are important, and not just because of the biol. actions of its natural agonist; but also, because melatonin analogs can improve or antagonize their biol. effect.: The following article describes the importance of melatonin as a biol. relevant mol.  It also defines the receptors for this substance, as well as the second messengers coupled to these receptors.  Lastly, the article describes the amino acid residues involved in the docking process in both MT1 and MT2 melatonin receptors.: The biol. actions of melatonin and their interpretations are becoming more relevant and therefore require the development of new pharmacol. tools.  Understanding the second messenger mechanisms involved in melatonin actions, as well as the characteristics of the docking of this mol. to MT1 and MT2 melatonin receptors, will permit the development of more selective agonists and antagonists which will help us to better understand this mol. as well to develop new therapeutic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq71VWIeZOKqLVg90H21EOLACvtfcHk0liS_yrdsjiTRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yguw%253D%253D&md5=4fe96caeeecb37c2763dfa64a38a23df</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1080%2F17460441.2018.1419184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2018.1419184%26sid%3Dliteratum%253Aachs%26aulast%3DAlkozi%26aufirst%3DH.%2BA.%26aulast%3DSanchez%2BMontero%26aufirst%3DJ.%2BM.%26aulast%3DDoadrio%26aufirst%3DA.%2BL.%26aulast%3DPintor%26aufirst%3DJ.%26atitle%3DDocking%2520Studies%2520for%2520Melatonin%2520Receptors%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2018%26volume%3D13%26spage%3D241%26epage%3D248%26doi%3D10.1080%2F17460441.2018.1419184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ghezzi, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aceto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osella, D.</span></span> <span> </span><span class="NLM_article-title">Uptake of Antitumor Platinum(II)-Complexes by Cancer Cells, Assayed by Inductively Coupled Plasma Mass Spectrometry (ICP-MS)</span>. <i>J. Inorg. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.jinorgbio.2003.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.jinorgbio.2003.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=14659635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsVSqtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2004&pages=73-78&author=A.+R.+Ghezziauthor=M.+Acetoauthor=C.+Cassinoauthor=E.+Gabanoauthor=D.+Osella&title=Uptake+of+Antitumor+Platinum%28II%29-Complexes+by+Cancer+Cells%2C+Assayed+by+Inductively+Coupled+Plasma+Mass+Spectrometry+%28ICP-MS%29&doi=10.1016%2Fj.jinorgbio.2003.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44aR"><div class="casContent"><span class="casTitleNuber">44a</span><div class="casTitle"><span class="NLM_cas:atitle">Uptake of antitumor platinum(II) complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS)</span></div><div class="casAuthors">Ghezzi, AnnaRita; Aceto, Maurizio; Cassino, Claudio; Gabano, Elisabetta; Osella, Domenico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inorganic Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-78</span>CODEN:
                <span class="NLM_cas:coden">JIBIDJ</span>;
        ISSN:<span class="NLM_cas:issn">0162-0134</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A systematic study on intracellular Pt uptake and Pt accumulation ratio in breast cancer MCF-7 cell line has been performed on a no. of Pt(II)-complexes, namely cisplatin, carboplatin and oxaliplatin, clin. employed as antitumor drugs, trans- and cis-[Pt(Cl)2(pyridine)2] and cis-[Pt(Cl)2(pyridine)(5-SO3H-isoquinoline)] complexes, previously investigated also as potential telomerase inhibitors.  In particular, long incubation times have been chosen in order to understand the fate of the complexes in the cells.  For this purpose, sub-acute drug concns. must be employed and, therefore, a very sensitive method of anal. like as inductively coupled plasma mass spectrometry (ICP-MS) superior to the widely employed at. absorption spectroscopy (AAS) has been adopted.  Any relationships among uptake/accumulation and several parameters such as drug structure, lipophilicity, drug concn. and incubation time have been sought and analyzed: the bulk of data point for a passive diffusion mechanism through the cell membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiE303tU5N9LVg90H21EOLACvtfcHk0liS_yrdsjiTRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsVSqtro%253D&md5=c12bb312708fcd0df827ba7f1d8c7cb4</span></div><a href="/servlet/linkout?suffix=cit44a&amp;dbid=16384&amp;doi=10.1016%2Fj.jinorgbio.2003.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinorgbio.2003.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DGhezzi%26aufirst%3DA.%2BR.%26aulast%3DAceto%26aufirst%3DM.%26aulast%3DCassino%26aufirst%3DC.%26aulast%3DGabano%26aufirst%3DE.%26aulast%3DOsella%26aufirst%3DD.%26atitle%3DUptake%2520of%2520Antitumor%2520Platinum%2528II%2529-Complexes%2520by%2520Cancer%2520Cells%252C%2520Assayed%2520by%2520Inductively%2520Coupled%2520Plasma%2520Mass%2520Spectrometry%2520%2528ICP-MS%2529%26jtitle%3DJ.%2520Inorg.%2520Biochem.%26date%3D2004%26volume%3D98%26spage%3D73%26epage%3D78%26doi%3D10.1016%2Fj.jinorgbio.2003.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit44b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Petruzzella, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braude, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich-Wright, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, D.</span></span> <span> </span><span class="NLM_article-title">A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity against KRAS Mutated Cancer Cell Lines</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">11539</span>– <span class="NLM_lpage">11544</span>, <span class="refDoi"> DOI: 10.1002/anie.201706739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fanie.201706739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSlsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=11539-11544&author=E.+Petruzzellaauthor=J.+P.+Braudeauthor=J.+R.+Aldrich-Wrightauthor=V.+Gandinauthor=D.+Gibson&title=A+Quadruple-Action+Platinum%28IV%29+Prodrug+with+Anticancer+Activity+against+KRAS+Mutated+Cancer+Cell+Lines&doi=10.1002%2Fanie.201706739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44bR"><div class="casContent"><span class="casTitleNuber">44b</span><div class="casTitle"><span class="NLM_cas:atitle">A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines</span></div><div class="casAuthors">Petruzzella, Emanuele; Braude, Jeremy Phillip; Aldrich-Wright, Janice R.; Gandin, Valentina; Gibson, Dan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">11539-11544</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">We developed a novel PtIV prodrug that simultaneously releases four different bioactive moieties inside the cancer cell.  Its cytotoxicity against monolayer cultures (2D) and spheroid (3D) cancer cells is significantly better than cisplatin.  It is 200-450-fold more potent than cisplatin against KRAS mutated pancreatic and colon cancers and is 40-fold more selective towards KRAS mutated cells compared to non-cancerous.  This is important since RAS proteins play a role in regulating cell differentiation, proliferation, and survival and KRAS is mutated in 90 % of pancreatic adenocarcinomas, 45 % of colorectal cancers, and 35 % of lung adenocarcinomas.  The selectivity index, detd. by dividing the IC50 value in non-cancerous cells by that of a cancerous cell line, is two-fold better than cisplatin, attesting to preferential cytotoxicity towards neoplastic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTQHgQHWGMgbVg90H21EOLACvtfcHk0lgR3fgN6C7S3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSlsbbJ&md5=4a9c4fcc8d6006775b09c9e4c246d175</span></div><a href="/servlet/linkout?suffix=cit44b&amp;dbid=16384&amp;doi=10.1002%2Fanie.201706739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201706739%26sid%3Dliteratum%253Aachs%26aulast%3DPetruzzella%26aufirst%3DE.%26aulast%3DBraude%26aufirst%3DJ.%2BP.%26aulast%3DAldrich-Wright%26aufirst%3DJ.%2BR.%26aulast%3DGandin%26aufirst%3DV.%26aulast%3DGibson%26aufirst%3DD.%26atitle%3DA%2520Quadruple-Action%2520Platinum%2528IV%2529%2520Prodrug%2520with%2520Anticancer%2520Activity%2520against%2520KRAS%2520Mutated%2520Cancer%2520Cell%2520Lines%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D11539%26epage%3D11544%26doi%3D10.1002%2Fanie.201706739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt(IV) Anticancer Prodrug</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9098</span>– <span class="NLM_lpage">9102</span>, <span class="refDoi"> DOI: 10.1002/anie.201804314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fanie.201804314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFemur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=9098-9102&author=L.+Maauthor=W.+Naauthor=R.+Maauthor=C.+Liauthor=M.+K.+Tseauthor=G.+Zhu&title=Monochalcoplatin%3A+An+Actively+Transported%2C+Quickly+Reducible%2C+and+Highly+Potent+Pt%28IV%29+Anticancer+Prodrug&doi=10.1002%2Fanie.201804314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer Prodrug</span></div><div class="casAuthors">Ma, Lili; Wang, Na; Ma, Rong; Li, Cai; Xu, Zoufeng; Tse, Man-Kit; Zhu, Guangyu</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">9098-9102</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Recently, PtIV prodrugs have attracted much attention as the next generation of platinum-based antineoplastic drug candidates.  Here we report the discovery and evaluation of monochalcoplatin, a monocarboxylated PtIV prodrug that is among the most cytotoxic PtIV prodrugs to date.  Compared with its dicarboxylated counterpart chalcoplatin, monochalcoplatin accumulates astonishingly effectively and rapidly in cancer cells, which is not ascribed to its lipophilicity.  The prodrug is quickly reduced, causes DNA damage, and induces apoptosis, resulting in superior cytotoxicity with IC50 values in the nanomolar range in both cisplatin-sensitive and -resistant cells; these IC50 values are up to 422-fold higher than that of cisplatin.  A detailed mechanistic study reveals that monochalcoplatin actively enters cells through a transporter-mediated process.  Moreover, monochalcoplatin shows significant antitumor activity in an in vivo colorectal tumor model.  Our study implies a practical strategy for the design of more effective PtIV prodrugs to conquer drug resistance by tuning both cellular uptake pathways and activation processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwWzOjWinSirVg90H21EOLACvtfcHk0lgR3fgN6C7S3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFemur%252FJ&md5=ef0e0d30da62acf13f0ceeb6729961c7</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fanie.201804314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201804314%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DL.%26aulast%3DNa%26aufirst%3DW.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTse%26aufirst%3DM.%2BK.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DMonochalcoplatin%253A%2520An%2520Actively%2520Transported%252C%2520Quickly%2520Reducible%252C%2520and%2520Highly%2520Potent%2520Pt%2528IV%2529%2520Anticancer%2520Prodrug%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D9098%26epage%3D9102%26doi%3D10.1002%2Fanie.201804314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlinchey, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osella, D.</span></span> <span> </span><span class="NLM_article-title">A View on Multi-Action Pt(IV) Antitumor Prodrugs</span>. <i>Inorg. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>492</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1016/j.ica.2019.04.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.ica.2019.04.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlOjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=492&publication_year=2019&pages=32-47&author=M.+Raveraauthor=E.+Gabanoauthor=M.+J.+McGlincheyauthor=D.+Osella&title=A+View+on+Multi-Action+Pt%28IV%29+Antitumor+Prodrugs&doi=10.1016%2Fj.ica.2019.04.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A view on multi-action Pt(IV) antitumor prodrugs</span></div><div class="casAuthors">Ravera, Mauro; Gabano, Elisabetta; McGlinchey, Michael J.; Osella, Domenico</div><div class="citationInfo"><span class="NLM_cas:title">Inorganica Chimica Acta</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">492</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-47</span>CODEN:
                <span class="NLM_cas:coden">ICHAA3</span>;
        ISSN:<span class="NLM_cas:issn">0020-1693</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Platinum(IV) complexes are particularly appealing as prodrugs since their relative inertness, and consequent low toxicity outside the cell is matched by their high activity inside the tumor cells upon redn. to their corresponding Pt(II) counterparts.  Synthetic routes to such systems, with particular emphasis on the bioactivity of the removable axial ligands, are described herein.  The kinetics and mechanisms of these reductive elimination processes are still not completely unraveled, and many questions remain unresolved.  We here present some of the more relevant examples of multi-action Pt(IV) complexes often grouped around their prototypal prodrugs (i.e., mitaplatin and mitochondria-targeted complexes, ethacraplatin and glutathione-S-transferase-targeted complexes, asplatin or platin-A and inhibitors of cyclooxygenases).  In addn., Pt(IV) conjugates with histone deacetylase inhibitors (HDACi) and "true" multiple-action complexes are exhaustively discussed.  These Pt(IV) conjugates contain adjuvant agents able to inhibit some specific (typically enzymic) mechanism characteristic of, or more active in, tumor cells.  These agents are able to act synergistically or at least additively with cisplatin and its congeners and overcome intrinsic or acquired chemoresistance.  Finally, we emphasize the need for a multidisciplinary approach in the battle against cancer using metallo-drugs by involving not only inorg. chemists, but also biochemists, mol. biologists and, of course, clinicians.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrolYCef0pyD7Vg90H21EOLACvtfcHk0lgR3fgN6C7S3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlOjt7Y%253D&md5=1236c2294fc5e0e4e5019ab2f21b4067</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ica.2019.04.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ica.2019.04.025%26sid%3Dliteratum%253Aachs%26aulast%3DRavera%26aufirst%3DM.%26aulast%3DGabano%26aufirst%3DE.%26aulast%3DMcGlinchey%26aufirst%3DM.%2BJ.%26aulast%3DOsella%26aufirst%3DD.%26atitle%3DA%2520View%2520on%2520Multi-Action%2520Pt%2528IV%2529%2520Antitumor%2520Prodrugs%26jtitle%3DInorg.%2520Chim.%2520Acta%26date%3D2019%26volume%3D492%26spage%3D32%26epage%3D47%26doi%3D10.1016%2Fj.ica.2019.04.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ong, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, C. S. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ang, W. H.</span></span> <span> </span><span class="NLM_article-title">A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1002/anie.201810361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fanie.201810361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVWks77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=164-167&author=J.+X.+Ongauthor=C.+S.+Q.+Limauthor=H.+V.+Leauthor=W.+H.+Ang&title=A+Ratiometric+Fluorescent+Probe+for+Cisplatin%3A+Investigating+the+Intracellular+Reduction+of+Platinum%28IV%29+Prodrug+Complexes&doi=10.1002%2Fanie.201810361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes</span></div><div class="casAuthors">Ong, Jun Xiang; Lim, Carine Shu Qing; Le, Hai Van; Ang, Wee Han</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">164-167</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The PtIV prodrug strategy has emerged as an excellent alternative to tackle the problems assocd. with conventional PtII drug therapy.  However, there is a lack of tools to study how this new class of PtIV drugs are processed at the cellular level.  Herein, we report the first ratiometric probe for cisplatin detection and use it to investigate PtIV anticancer complexes in biol. systems.  The probe was able to distinguish between cisplatin and its PtIV derivs., allowing us to probe the intracellular redn. of PtIV prodrug complexes.  The correlation between the amt. of active PtII species available after intracellular redn. of PtIV complexes and their cytotoxicity and the role glutathione plays in the redn. of PtIV complexes were investigated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4LDI8alc0JLVg90H21EOLACvtfcHk0lh6cfMrq08HjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVWks77I&md5=50cfc467400e54ed3a3dd5432acdf27b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fanie.201810361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201810361%26sid%3Dliteratum%253Aachs%26aulast%3DOng%26aufirst%3DJ.%2BX.%26aulast%3DLim%26aufirst%3DC.%2BS.%2BQ.%26aulast%3DLe%26aufirst%3DH.%2BV.%26aulast%3DAng%26aufirst%3DW.%2BH.%26atitle%3DA%2520Ratiometric%2520Fluorescent%2520Probe%2520for%2520Cisplatin%253A%2520Investigating%2520the%2520Intracellular%2520Reduction%2520of%2520Platinum%2528IV%2529%2520Prodrug%2520Complexes%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D164%26epage%3D167%26doi%3D10.1002%2Fanie.201810361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolbatov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coletti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Re, N.</span></span> <span> </span><span class="NLM_article-title">Insight into the Electrochemical Reduction Mechanism of Pt(IV) Anticancer Complexes</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3411</span>– <span class="NLM_lpage">3419</span>, <span class="refDoi"> DOI: 10.1021/acs.inorgchem.8b00177</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.inorgchem.8b00177" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslyju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=3411-3419&author=I.+Tolbatovauthor=C.+Colettiauthor=A.+Marroneauthor=N.+Re&title=Insight+into+the+Electrochemical+Reduction+Mechanism+of+Pt%28IV%29+Anticancer+Complexes&doi=10.1021%2Facs.inorgchem.8b00177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into the Electrochemical Reduction Mechanism of Pt(IV) Anticancer Complexes</span></div><div class="casAuthors">Tolbatov, Iogann; Coletti, Cecilia; Marrone, Alessandro; Re, Nazzareno</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3411-3419</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors carried out a theor. study on the mechanism of electrochem. redn. of the prototypical Pt(IV) anticancer complex [Pt(NH3)2(CH3COO)2Cl2] to the corresponding Pt(II) [Pt(NH3)2Cl2] deriv.  Energies and geometric structures of the original Pt(IV) complex and all possible Pt(III) and Pt(II) intermediates and transition states involved in the redn. process were calcd. using d. functional theory and Moller-Plesset perturbation theory.  This study allowed the authors to formulate a detailed mechanism for the two-electron redn. of the [PtIV(NH3)2(CH3COO)2Cl2] complex.  In agreement with the exptl. evidence from cyclic voltammetry, the initial 1-electron redn. of the [PtIV(NH3)2(CH3COO)2Cl2] complex occurs through a stepwise mechanism via a metastable hexacoordinated Pt(III) [PtIII(NH3)2(CH3COO)2Cl2]- intermediate and a subsequent acetate ligand detachment with an activation free energy of 5.1 kcal mol-1.  However, the 2nd electron redn. of the resulting pentacoordinated [PtIII(NH3)2(CH3COO)Cl2] species occurs through a barrierless concerted process to the final [PtII(NH3)2Cl2] deriv.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCcsdizyeReLVg90H21EOLACvtfcHk0lh6cfMrq08HjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslyju7k%253D&md5=11d240d62c28080a82ee97e986c62ee1</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.inorgchem.8b00177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.inorgchem.8b00177%26sid%3Dliteratum%253Aachs%26aulast%3DTolbatov%26aufirst%3DI.%26aulast%3DColetti%26aufirst%3DC.%26aulast%3DMarrone%26aufirst%3DA.%26aulast%3DRe%26aufirst%3DN.%26atitle%3DInsight%2520into%2520the%2520Electrochemical%2520Reduction%2520Mechanism%2520of%2520Pt%2528IV%2529%2520Anticancer%2520Complexes%26jtitle%3DInorg.%2520Chem.%26date%3D2018%26volume%3D57%26spage%3D3411%26epage%3D3419%26doi%3D10.1021%2Facs.inorgchem.8b00177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filotto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisanzo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagasee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitworth, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jusko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willingham, J.</span></span> <span> </span><span class="NLM_article-title">Reduction and Anticancer Activity of Platinum(IV) Complexes</span>. <i>Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">2500</span>– <span class="NLM_lpage">2504</span>, <span class="refDoi"> DOI: 10.1021/ic971047x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ic971047x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADyaK1cXis12ku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1998&pages=2500-2504&author=S.+Choiauthor=C.+Filottoauthor=M.+Bisanzoauthor=S.+Delaneyauthor=D.+Lagaseeauthor=J.+L.+Whitworthauthor=A.+Juskoauthor=C.+Liauthor=N.+A.+Woodauthor=J.+Willingham&title=Reduction+and+Anticancer+Activity+of+Platinum%28IV%29+Complexes&doi=10.1021%2Fic971047x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction and Anticancer Activity of Platinum(IV) Complexes</span></div><div class="casAuthors">Choi, Sunhee; Filotto, Catherine; Bisanzo, Mark; Delaney, Sarah; Lagasee, Daniel; Whitworth, Jennifer L.; Jusko, Andrew; Li, Chengruo; Wood, Nicole A.; Willingham, Jennifer; Schwenker, Amy; Spaulding, Kathleen</div><div class="citationInfo"><span class="NLM_cas:title">Inorganic Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2500-2504</span>CODEN:
                <span class="NLM_cas:coden">INOCAJ</span>;
        ISSN:<span class="NLM_cas:issn">0020-1669</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of PtIV anticancer complexes with chloro leaving groups have been investigated for the effects of axial and carrier ligands on the redn. and cytotoxicity.  The redn. rates of the PtIV complexes such as Pt(d,l)(1,2-(NH2)2C6H10)Cl4 (tetraplatin, Pt(dach)Cl4; dach = diaminocyclohexane), cis,trans,cis-[Pt((CH3)2CHNH2)2(OH)2Cl2] (iproplatin, Pt(ipa)(OH)2Cl2; ipa = isopropylamine), cis,trans,cis-[Pt(NH3)(C6H11NH2)(OCOCH3)2Cl2] (JM-216, Pt(a,cha)(OCOCH3)2Cl2; a = ammine, cha = cyclohexylamine), cis,trans,cis-[Pt(NH3)(C6H11NH2)(OCOC3H7)2Cl2] (JM-221, Pt(a,cha)(OCOC3H7)2Cl2), cis,trans,cis-[Pt(en)(OH)2Cl2], Pt(en)Cl4 (en = ethylenediamine), cis,trans,cis-[Pt(en)(OCOCH3)2Cl2], and cis,trans,cis-[Pt(en)(OCOCF3)2Cl2] by ascorbate and cathodic redn. potentials strongly depend on the electron-withdrawing power and the steric hindrance of the axial and carrier ligands.  Beginning with PtIV complexes bearing en carrier ligands, redn. rates and redn. potentials increase in the following order of axial ligand substitutions: OH < OCOCH3 < Cl < OCOCF3, coinciding with increasing electron-withdrawing power of the axial ligand.  PtIV complexes with en carrier ligands tend to show slower redn. rates than the corresponding complexes with ipa or cha carrier ligands.  Ascorbic acid does not reduce Pt(en)(OH)2Cl2, but reduces Pt(ipa)(OH)2Cl2.  The redn. rate of Pt(a,cha)(OCOCH3)2Cl2 is about 12 times higher than that of Pt(en)(OCOCH3)2Cl2.  Overall, there is no strong correlation between redn. rate and cytotoxicity toward cisplatin-sensitive L1210/0 cells among the eight complexes studied.  However, when the four compds. with en carrier ligands were compared with one another, the one with the fastest redn. rate exhibited the highest cytotoxicity.  The cytotoxicity increases with axial ligand substitution in the order OH < OCOCH3 < Cl < OCOCF3, following the same trend as redn. rate.  Comparing complexes having different carrier ligands but the same axial ligands reveals that the compd. with the faster redn. rate exhibits the higher cytotoxicity.  Redn. rate and cytotoxicity increase in the order Pt(en)(OH)2Cl2 < Pt(ipa)(OH)2Cl2, Pt(en)(OCOCH3)2Cl2 < Pt(a,cha)(OCOCH3)2Cl2, Pt(en)Cl4 < Pt(dach)Cl4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSbVAQFm8w7bVg90H21EOLACvtfcHk0lh6cfMrq08HjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis12ku70%253D&md5=7818e9c8accf0ac302d1992a43ae7bee</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fic971047x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fic971047x%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DS.%26aulast%3DFilotto%26aufirst%3DC.%26aulast%3DBisanzo%26aufirst%3DM.%26aulast%3DDelaney%26aufirst%3DS.%26aulast%3DLagasee%26aufirst%3DD.%26aulast%3DWhitworth%26aufirst%3DJ.%2BL.%26aulast%3DJusko%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DN.%2BA.%26aulast%3DWillingham%26aufirst%3DJ.%26atitle%3DReduction%2520and%2520Anticancer%2520Activity%2520of%2520Platinum%2528IV%2529%2520Complexes%26jtitle%3DInorg.%2520Chem.%26date%3D1998%26volume%3D37%26spage%3D2500%26epage%3D2504%26doi%3D10.1021%2Fic971047x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petermann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R. A.</span></span> <span> </span><span class="NLM_article-title">DNA Repair Pathways as Targets for Cancer Therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1038/nrc2342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1038%2Fnrc2342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=18256616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlOisr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=193-204&author=T.+Helledayauthor=E.+Petermannauthor=C.+Lundinauthor=B.+Hodgsonauthor=R.+A.+Sharma&title=DNA+Repair+Pathways+as+Targets+for+Cancer+Therapy&doi=10.1038%2Fnrc2342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">DNA repair pathways as targets for cancer therapy</span></div><div class="casAuthors">Helleday, Thomas; Petermann, Eva; Lundin, Cecilia; Hodgson, Ben; Sharma, Ricky A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-204</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  DNA repair pathways can enable tumor cells to survive DNA damage that is induced by chemotherapeutic treatments; therefore, inhibitors of specific DNA repair pathways might prove efficacious when used in combination with DNA-damaging chemotherapeutic drugs.  In addn., alterations in DNA repair pathways that arise during tumor development can make some cancer cells reliant on a reduced set of DNA repair pathways for survival.  There is evidence that drugs that inhibit one of these pathways in such tumors could prove useful as single-agent therapies, with the potential advantage that this approach could be selective for tumor cells and have fewer side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3W53LJmdCPrVg90H21EOLACvtfcHk0ljnSzJPnwZ3KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlOisr8%253D&md5=8592af6d815e5ca9c80ee256791bafb7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnrc2342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2342%26sid%3Dliteratum%253Aachs%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DPetermann%26aufirst%3DE.%26aulast%3DLundin%26aufirst%3DC.%26aulast%3DHodgson%26aufirst%3DB.%26aulast%3DSharma%26aufirst%3DR.%2BA.%26atitle%3DDNA%2520Repair%2520Pathways%2520as%2520Targets%2520for%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D193%26epage%3D204%26doi%3D10.1038%2Fnrc2342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Roos, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernd, K.</span></span> <span> </span><span class="NLM_article-title">DNA Damage-Induced Cell Death: from Specific DNA Lesions to the DNA Damage Response and Apoptosis</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>332</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2012.01.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.canlet.2012.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=22261329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC38XisFKhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2013&pages=237-248&author=W.+P.+Roosauthor=K.+Bernd&title=DNA+Damage-Induced+Cell+Death%3A+from+Specific+DNA+Lesions+to+the+DNA+Damage+Response+and+Apoptosis&doi=10.1016%2Fj.canlet.2012.01.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51aR"><div class="casContent"><span class="casTitleNuber">51a</span><div class="casTitle"><span class="NLM_cas:atitle">DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis</span></div><div class="casAuthors">Roos, Wynand P.; Kaina, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">237-248</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  DNA damaging agents are potent inducers of cell death triggered by apoptosis.  Since these agents induce a plethora of different DNA lesions, it is firstly important to identify the specific lesions responsible for initiating apoptosis before the apoptotic executing pathways can be elucidated.  Here, we describe specific DNA lesions that were identified as apoptosis triggers, their repair and the signaling provoked by them.  We discuss methylating agents such as temozolomide, ionizing radiation and cisplatin, all of them are important in cancer therapy.  We show that the potentially lethal events for the cell are O6-methylguanine adducts that are converted by mismatch repair into DNA double-strand breaks (DSBs), non-repaired N-methylpurines and abasic sites as well as bulky adducts that block DNA replication leading to DSBs that are also directly induced following ionizing radiation.  Transcriptional inhibition may also contribute to apoptosis.  Cells are equipped with sensors that detect DNA damage and relay the signal via kinases to executors, who on their turn evoke a process that inhibits cell cycle progression and provokes DNA repair or, if this fails, activate the receptor and/or mitochondrial apoptotic cascade.  The main DNA damage recognition factors MRN and the PI3 kinases ATM, ATR and DNA-PK, which phosphorylate a multitude of proteins and thus induce the DNA damage response (DDR), will be discussed as well as the downstream players p53, NF-κB, Akt and survivin.  We review data and models describing the signaling from DNA damage to the apoptosis executing machinery and discuss the complex interplay between cell survival and death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9_P1z1Z5oBbVg90H21EOLACvtfcHk0ljnSzJPnwZ3KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisFKhsb8%253D&md5=aae5a110552faeb7644708047987f5e6</span></div><a href="/servlet/linkout?suffix=cit51a&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2012.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2012.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DRoos%26aufirst%3DW.%2BP.%26aulast%3DBernd%26aufirst%3DK.%26atitle%3DDNA%2520Damage-Induced%2520Cell%2520Death%253A%2520from%2520Specific%2520DNA%2520Lesions%2520to%2520the%2520DNA%2520Damage%2520Response%2520and%2520Apoptosis%26jtitle%3DCancer%2520Lett.%26date%3D2013%26volume%3D332%26spage%3D237%26epage%3D248%26doi%3D10.1016%2Fj.canlet.2012.01.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit51b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suntharalingam, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">8790</span>– <span class="NLM_lpage">8798</span>, <span class="refDoi"> DOI: 10.1021/ja5038269</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja5038269" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2014&pages=8790-8798&author=Y.+R.+Zhengauthor=K.+Suntharalingamauthor=T.+C.+Johnstoneauthor=H.+Yooauthor=W.+Linauthor=J.+G.+Brooksauthor=S.+J.+Lippard&title=Pt%28IV%29+Prodrugs+Designed+to+Bind+Non-Covalently+to+Human+Serum+Albumin+for+Drug+Delivery&doi=10.1021%2Fja5038269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51bR"><div class="casContent"><span class="casTitleNuber">51b</span><div class="casTitle"><span class="NLM_cas:atitle">Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery</span></div><div class="casAuthors">Zheng, Yao-Rong; Suntharalingam, Kogularamanan; Johnstone, Timothy C.; Yoo, Hyunsuk; Lin, Wei; Brooks, Jamar G.; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8790-8798</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Albumin is the most abundant protein in human serum and drugs that are administered i.v. inevitably interact with it.  We present here a series of platinum(IV) prodrugs designed specifically to enhance interaction with human serum albumin (HSA) for drug delivery.  This goal is achieved by asym. functionalizing the axial ligands of the prodrug so as to mimic the overall features of a fatty acid.  Systematic variation of the length of the aliph. tail tunes the cellular uptake and, consequently, the cytotoxicity of cis,cis,trans-[Pt(NH3)2Cl2(O2CCH2CH2COOH)(OCONHR)], 4, where R is a linear alkyl group.  Investigation of an analog bearing a fluorophore conjugated to the succinate ligand confirmed that these compds. are reduced by biol. reductants with loss of the axial ligands.  Intracellular release of cisplatin from 4 was further confirmed by observing the characteristic effects of cisplatin on the cell cycle and morphol. following treatment with the prodrug.  The most potent member of series 4, for which R is a hexadecyl chain, interacts with HSA in a 1:1 stoichiometry to form the platinum-protein complex 7.  The interaction is non-covalent and extn. with octanol completely removes the prodrug from an aq. soln. of HSA.  Construct 7 is robust and can be isolated following fast protein liq. chromatog.  The nature of the tight interaction was investigated computationally, and these studies suggest that the prodrug is buried below the surface of the protein.  Consequently, complexation to HSA is able to reduce the rate of redn. of the prodrug by ascorbate.  The lead compd. from series 4 also exhibited significant stability in whole human blood, attributed to its interaction with HSA.  This favorable redox profile, in conjunction with the established nonimmunogenicity, biocompatibility, and enhanced tumor accumulation of HSA, produces a system that holds significant therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOojHJiVKj17Vg90H21EOLACvtfcHk0ljnSzJPnwZ3KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXptl2itrs%253D&md5=541fe9e155e3f4e2f8d6f61f3d81ee5a</span></div><a href="/servlet/linkout?suffix=cit51b&amp;dbid=16384&amp;doi=10.1021%2Fja5038269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja5038269%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%2BR.%26aulast%3DSuntharalingam%26aufirst%3DK.%26aulast%3DJohnstone%26aufirst%3DT.%2BC.%26aulast%3DYoo%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DBrooks%26aufirst%3DJ.%2BG.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DPt%2528IV%2529%2520Prodrugs%2520Designed%2520to%2520Bind%2520Non-Covalently%2520to%2520Human%2520Serum%2520Albumin%2520for%2520Drug%2520Delivery%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2014%26volume%3D136%26spage%3D8790%26epage%3D8798%26doi%3D10.1021%2Fja5038269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quercetin
Suppresses, D. N. A.</span></span> <span> </span><span class="NLM_article-title">Double-Strand Break Repair and Enhances the Radiosensitivity of Human Ovarian Cancer Cells via p53-Dependent Endoplasmic Reticulum Stress Pathway</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.2147/OTT.S147316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.2147%2FOTT.S147316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=29317830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BC1MzptFertQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=17-27&author=C.+Gongauthor=Z.+Yangauthor=L.+Zhangauthor=Y.+Wangauthor=W.+Gongauthor=Y.+Liuauthor=D.+N.+A.+Quercetin%0ASuppresses&title=Double-Strand+Break+Repair+and+Enhances+the+Radiosensitivity+of+Human+Ovarian+Cancer+Cells+via+p53-Dependent+Endoplasmic+Reticulum+Stress+Pathway&doi=10.2147%2FOTT.S147316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Quercetin suppresses DNA double-strand break repair and enhances the radiosensitivity of human ovarian cancer cells via p53-dependent endoplasmic reticulum stress pathway</span></div><div class="casAuthors">Gong Cheng; Yang Zongyuan; Zhang Lingyun; Wang Yuehua; Gong Wei; Liu Yi</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-27</span>
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    </div><div class="casAbstract">Quercetin is proven to have anticancer effects for many cancers.  However, the role of tumor suppressor p53 on quercetin's radiosensitization and regulation of endoplasmic reticulum (ER) stress response in this process remains obscure.  Here, quercetin exposure resulted in ER stress, prolonged DNA repair, and the expression of p53 protein; phosphorylation on serine 15 and 20 increased in combination with X-irradiation.  Quercetin pretreatment could potentiate radiation-induced cell death.  The combination of irradiation and quercetin treatment aggravated DNA damages and caused typical apoptotic cell death; as well the expression of Bax and p21 elevated and the expression of Bcl-2 decreased.  Knocking down of p53 could reverse all the above effects under quercetin in combination with radiation.  In addition, quercetin-induced radiosensitization was through stimulation of ATM phosphorylation.  In human ovarian cancer xenograft model, combined treatment of quercetin and radiation significantly restrained the growth of tumors, accompanied with the activation of p53, CCAAT/enhancer-binding protein homologous protein, and γ-H2AX.  Overall, these results indicated that quercetin acted as a promising radiosensitizer through p53-dependent ER stress signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0zwOqwxFgVv6AExegM5LLfW6udTcc2ebK81Ie09pIa7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzptFertQ%253D%253D&md5=b53eb17c833691edb656a1fa44e5f711</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2147%2FOTT.S147316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S147316%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DQuercetin%2BSuppresses%26aufirst%3DD.%2BN.%2BA.%26atitle%3DDouble-Strand%2520Break%2520Repair%2520and%2520Enhances%2520the%2520Radiosensitivity%2520of%2520Human%2520Ovarian%2520Cancer%2520Cells%2520via%2520p53-Dependent%2520Endoplasmic%2520Reticulum%2520Stress%2520Pathway%26jtitle%3DOncoTargets%2520Ther.%26date%3D2018%26volume%3D11%26spage%3D17%26epage%3D27%26doi%3D10.2147%2FOTT.S147316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biskup, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span> <span> </span><span class="NLM_article-title">Human RAD6 Promotes G1-S Transition and Cell Proliferation through Upregulation of Cyclin D1 Expression</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e113727</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0113727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1371%2Fjournal.pone.0113727" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=25409181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVWqt77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=F.+F.+Caiauthor=P.+Chenauthor=L.+Chenauthor=E.+Biskupauthor=Y.+Liuauthor=P.+C.+Chenauthor=J.+F.+Changauthor=W.+J.+Jiangauthor=Y.+Y.+Jingauthor=Y.+W.+Chenauthor=H.+Jinauthor=S.+Chen&title=Human+RAD6+Promotes+G1-S+Transition+and+Cell+Proliferation+through+Upregulation+of+Cyclin+D1+Expression&doi=10.1371%2Fjournal.pone.0113727"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53aR"><div class="casContent"><span class="casTitleNuber">53a</span><div class="casTitle"><span class="NLM_cas:atitle">Human RAD6 promotes G1-S transition and cell proliferation through upregulation of cyclin D1 expression</span></div><div class="casAuthors">Cai, Fengfeng; Chen, Ping; Chen, Li; Biskup, Ewelina; Liu, Yan; Chen, Pei-Chao; Chang, Jian-Feng; Jiang, Wenjie; Jing, Yuanya; Chen, Youwei; Jin, Hui; Chen, Su</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e113727/1-e113727/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Protein ubiquitinylation regulates protein stability and activity.  RAD6, an E2 ubiquitin-conjugating enzyme, which that has been substantially biochem. characterized, functions in a no. of biol. relevant pathways, including cell cycle progression.  In this study, we show that RAD6 promotes the G1-S transition and cell proliferation by regulating the expression of cyclin D1 (CCND1) in human cells.  Furthermore, our data indicate that RAD6 influences the transcription of CCND1 by increasing monoubiquitinylation of histone H2B and trimethylation of H3K4 in the CCND1 promoter region.  Our study presents, for the first time, an evidence for the function of RAD6 in cell cycle progression and cell proliferation in human cells, raising the possibility that RAD6 could be a new target for mol. diagnosis and prognosis in cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaR7-5tjsbfbVg90H21EOLACvtfcHk0lgjIsvE88AJag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVWqt77L&md5=63b3be38093bf0114a26992a1a8b6b87</span></div><a href="/servlet/linkout?suffix=cit53a&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0113727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0113727%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DF.%2BF.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DBiskup%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DP.%2BC.%26aulast%3DChang%26aufirst%3DJ.%2BF.%26aulast%3DJiang%26aufirst%3DW.%2BJ.%26aulast%3DJing%26aufirst%3DY.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BW.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DS.%26atitle%3DHuman%2520RAD6%2520Promotes%2520G1-S%2520Transition%2520and%2520Cell%2520Proliferation%2520through%2520Upregulation%2520of%2520Cyclin%2520D1%2520Expression%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0113727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit53b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Council, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chignell, C. F.</span></span> <span> </span><span class="NLM_article-title">UVA-Induced Cell Cycle Progression Is Mediated by a Disintegrin and Metalloprotease/Epidermal Growth Factor Receptor/AKT/Cyclin D1 Pathways in Keratinocytes</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">3752</span>– <span class="NLM_lpage">3758</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-6138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1158%2F0008-5472.CAN-07-6138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=18483258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVOitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3752-3758&author=Y.+Y.+Heauthor=S.+E.+Councilauthor=L.+Fengauthor=C.+F.+Chignell&title=UVA-Induced+Cell+Cycle+Progression+Is+Mediated+by+a+Disintegrin+and+Metalloprotease%2FEpidermal+Growth+Factor+Receptor%2FAKT%2FCyclin+D1+Pathways+in+Keratinocytes&doi=10.1158%2F0008-5472.CAN-07-6138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53bR"><div class="casContent"><span class="casTitleNuber">53b</span><div class="casTitle"><span class="NLM_cas:atitle">UVA-Induced Cell Cycle Progression Is Mediated by a Disintegrin and Metalloprotease/Epidermal Growth Factor Receptor/AKT/Cyclin D1 Pathways in Keratinocytes</span></div><div class="casAuthors">He, Yu-Ying; Council, Sarah E.; Feng, Li; Chignell, Colin F.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3752-3758</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">UVA (315-400 nm), which constitutes ∼95% of the UV irradn. in natural sunlight, represents a major environmental challenge to the skin and is clearly assocd. with human skin cancer.  Here, we show that a low, nonlethal dose of UVA induces dose-dependent cell cycle progression in human HaCaT keratinocytes.  We found that UVA induced cyclin D1 accumulation, whereas siRNA knockdown of cyclin D1 blocked the UVA-induced cell cycle progression, indicating that this process is mediated by cyclin D1.  UVA irradn. also induced AKT activation; when cells were incubated with phosphatidylinositol-3-OH kinase/AKT inhibitor or infected with dominant-neg. AKT, cyclin D1 up-regulation, cell cycle progression, and proliferation were inhibited, suggesting that AKT activation is required for UVA-induced cell cycle progression.  In contrast, extracellular signal-regulated kinase (ERK) was not activated by UVA exposure; incubation with ERK/mitogen-activated protein kinase inhibitor had no effect on UVA-induced cyclin D1 up-regulation and cell cycle progression.  Activation of epidermal growth factor receptor (EGFR) was obsd. after UVA exposure.  EGFR kinase inhibitor AG attenuated the UVA-induced AKT/cyclin D1 pathway and cell cycle progression, indicating that EGFR is upstream of AKT/cyclin D1 pathway activation.  Furthermore, metalloprotease inhibitor GM6001 blocked UVA-induced cell cycle progression, and siRNA knockdown of a disintegrin and metalloprotease (ADAM)17 had a similar inhibitory effect, demonstrating that ADAM17 mediates the EGFR/AKT/cyclin D1 pathway and cell cycle progression to the S phase induced by UVA radiation.  Identification of these signaling pathways in UVA-induced cell proliferation will facilitate the development of efficient and safe chemopreventive and therapeutic strategies for skin cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaxcMK8DipB7Vg90H21EOLACvtfcHk0lgjIsvE88AJag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVOitbo%253D&md5=d7c212878a05e8c772b94528a747f52c</span></div><a href="/servlet/linkout?suffix=cit53b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6138%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%2BY.%26aulast%3DCouncil%26aufirst%3DS.%2BE.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DChignell%26aufirst%3DC.%2BF.%26atitle%3DUVA-Induced%2520Cell%2520Cycle%2520Progression%2520Is%2520Mediated%2520by%2520a%2520Disintegrin%2520and%2520Metalloprotease%252FEpidermal%2520Growth%2520Factor%2520Receptor%252FAKT%252FCyclin%2520D1%2520Pathways%2520in%2520Keratinocytes%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3752%26epage%3D3758%26doi%3D10.1158%2F0008-5472.CAN-07-6138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rodea-Palomares, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petre, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boltes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leganés, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perdigón-Melón, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Piñas, F.</span></span> <span> </span><span class="NLM_article-title">Application of the Combination Index (CI)-Isobologram Equation to Study the Toxicological Interactions of Lipid Regulators in Two Aquatic Bioluminescent Organisms</span>. <i>Water Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1016/j.watres.2009.07.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.watres.2009.07.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=19683324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFegsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2010&pages=427-438&author=I.+Rodea-Palomaresauthor=A.+L.+Petreauthor=K.+Boltesauthor=F.+Legan%C3%A9sauthor=J.+A.+Perdig%C3%B3n-Mel%C3%B3nauthor=R.+Rosalauthor=F.+Fern%C3%A1ndez-Pi%C3%B1as&title=Application+of+the+Combination+Index+%28CI%29-Isobologram+Equation+to+Study+the+Toxicological+Interactions+of+Lipid+Regulators+in+Two+Aquatic+Bioluminescent+Organisms&doi=10.1016%2Fj.watres.2009.07.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54aR"><div class="casContent"><span class="casTitleNuber">54a</span><div class="casTitle"><span class="NLM_cas:atitle">Application of the combination index (CI)-isobologram equation to study the toxicological interactions of lipid regulators in two aquatic bioluminescent organisms</span></div><div class="casAuthors">Rodea-Palomares, Ismael; Petre, Alice L.; Boltes, Karina; Leganes, Francisco; Perdigon-Melon, Jose Antonio; Rosal, Roberto; Fernandez-Pinas, Francisca</div><div class="citationInfo"><span class="NLM_cas:title">Water Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">427-438</span>CODEN:
                <span class="NLM_cas:coden">WATRAG</span>;
        ISSN:<span class="NLM_cas:issn">0043-1354</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pharmaceuticals in the aquatic environment do not appear singly and usually occur as complex mixts., whose combined effect may exhibit toxicity to the aquatic biota.  We report an environmental application of the combination index (CI)-isobologram equation, a method widely used in pharmacol. to study drug interactions, to det. the nature of toxicol. interactions of three fibrates toward two aquatic bioluminescent organisms, Vibrio fischeri and the self-luminescent cyanobacterial recombinant strain Anabaena CPB4337.  The combination index-isobologram equation method allows computerized quantitation of synergism, additive effect and antagonism.  In the Vibrio test, the fibrate combinations showed antagonism at low effect levels that turned into an additive effect or synergism at higher effect levels; by contrast, in the Anabaena test, the fibrate combinations showed a strong synergism at the lowest effect levels and a very strong antagonism at high effect levels.  We also evaluated the nature of the interactions of the three fibrates with a real wastewater sample in the cyanobacterial test.  We propose that the combination index-isobologram equation method can serve as a useful tool in ecotoxicol. assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpufI8oCYYG47Vg90H21EOLACvtfcHk0lilDYNSTOPDtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFegsrs%253D&md5=0eda8bb7b52e37e0f3657325d9e6df60</span></div><a href="/servlet/linkout?suffix=cit54a&amp;dbid=16384&amp;doi=10.1016%2Fj.watres.2009.07.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.watres.2009.07.026%26sid%3Dliteratum%253Aachs%26aulast%3DRodea-Palomares%26aufirst%3DI.%26aulast%3DPetre%26aufirst%3DA.%2BL.%26aulast%3DBoltes%26aufirst%3DK.%26aulast%3DLegan%25C3%25A9s%26aufirst%3DF.%26aulast%3DPerdig%25C3%25B3n-Mel%25C3%25B3n%26aufirst%3DJ.%2BA.%26aulast%3DRosal%26aufirst%3DR.%26aulast%3DFern%25C3%25A1ndez-Pi%25C3%25B1as%26aufirst%3DF.%26atitle%3DApplication%2520of%2520the%2520Combination%2520Index%2520%2528CI%2529-Isobologram%2520Equation%2520to%2520Study%2520the%2520Toxicological%2520Interactions%2520of%2520Lipid%2520Regulators%2520in%2520Two%2520Aquatic%2520Bioluminescent%2520Organisms%26jtitle%3DWater%2520Res.%26date%3D2010%26volume%3D44%26spage%3D427%26epage%3D438%26doi%3D10.1016%2Fj.watres.2009.07.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit54b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Najafi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salehi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farhood, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nashtaei, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goradel, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanlarkhani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namjoo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortezaee, K.</span></span> <span> </span><span class="NLM_article-title">Adjuvant Chemotherapy with Melatonin for Targeting Human Cancers: A Review</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">2356</span>– <span class="NLM_lpage">2372</span>, <span class="refDoi"> DOI: 10.1002/jcp.27259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1002%2Fjcp.27259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=30192001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Kjs73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2019&pages=2356-2372&author=M.+Najafiauthor=E.+Salehiauthor=B.+Farhoodauthor=M.+S.+Nashtaeiauthor=N.+H.+Goradelauthor=N.+Khanlarkhaniauthor=Z.+Namjooauthor=K.+Mortezaee&title=Adjuvant+Chemotherapy+with+Melatonin+for+Targeting+Human+Cancers%3A+A+Review&doi=10.1002%2Fjcp.27259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54bR"><div class="casContent"><span class="casTitleNuber">54b</span><div class="casTitle"><span class="NLM_cas:atitle">Adjuvant chemotherapy with melatonin for targeting human cancers: A review</span></div><div class="casAuthors">Najafi, Masoud; Salehi, Eniseh; Farhood, Bagher; Nashtaei, Maryam Shabani; Hashemi Goradel, Nasser; Khanlarkhani, Neda; Namjoo, Zeinab; Mortezaee, Keywan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2356-2372</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Melatonin is a multifunctional hormone that has long been known for its antitumoral effects.  An advantage of the application of melatonin in cancer therapy is its ability to differentially influence tumors from normal cells.  In this review, the roles of melatonin adjuvant therapy in human cancer are discussed.  Combination of melatonin with chemotherapy could provide synergistic antitumoral outcomes and resolve drug resistance in affected patients.  This combination reduces the dosage for chemotherapeutic agents with the subsequent attenuation of side effects related to these drugs on normal cells around tumor and on healthy organs.  The combination therapy increases the rate of survival and improves the quality of life in affected patients.  Cancer cell viability is reduced after application of the combinational melatonin therapy.  Melatonin does all these functions by adjusting the signals involved in cancer progression, re-establishing the dark/light circadian rhythm, and disrupting the redox system for cancer cells.  To achieve effective therapeutic outcomes, melatonin concn. along with the time of incubation for this indoleamine needs to be adjusted.  Importantly, a special focus is required to be made on choosing an appropriate chemotherapy agent for using in combination with melatonin.  Because of different sensitivities of cancer cells for melatonin combination therapy, cancer-specific targeted therapy is also needed to be considered.  For this review, the PubMed database was searched for relevant articles based on the quality of journals, the novelty of articles published by the journals, and the no. of citations per yr focusing only on human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrph6CNvi1XH7Vg90H21EOLACvtfcHk0lilDYNSTOPDtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Kjs73L&md5=c2638b33b03aedb30bb4321265f3d23a</span></div><a href="/servlet/linkout?suffix=cit54b&amp;dbid=16384&amp;doi=10.1002%2Fjcp.27259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.27259%26sid%3Dliteratum%253Aachs%26aulast%3DNajafi%26aufirst%3DM.%26aulast%3DSalehi%26aufirst%3DE.%26aulast%3DFarhood%26aufirst%3DB.%26aulast%3DNashtaei%26aufirst%3DM.%2BS.%26aulast%3DGoradel%26aufirst%3DN.%2BH.%26aulast%3DKhanlarkhani%26aufirst%3DN.%26aulast%3DNamjoo%26aufirst%3DZ.%26aulast%3DMortezaee%26aufirst%3DK.%26atitle%3DAdjuvant%2520Chemotherapy%2520with%2520Melatonin%2520for%2520Targeting%2520Human%2520Cancers%253A%2520A%2520Review%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2019%26volume%3D234%26spage%3D2356%26epage%3D2372%26doi%3D10.1002%2Fjcp.27259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Er, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartron, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallette, F. M.</span></span> <span> </span><span class="NLM_article-title">Mitochondria as the Target of the Pro-Apoptotic Protein Bax</span>. <i>Biochim. Biophys. Acta, Bioenerg.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1757</i></span>,  <span class="NLM_fpage">1301</span>– <span class="NLM_lpage">1311</span>, <span class="refDoi"> DOI: 10.1016/j.bbabio.2006.05.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.bbabio.2006.05.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=16836974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVanu77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1757&publication_year=2006&pages=1301-1311&author=E.+Erauthor=L.+Oliverauthor=P.+F.+Cartronauthor=P.+Juinauthor=S.+Manonauthor=F.+M.+Vallette&title=Mitochondria+as+the+Target+of+the+Pro-Apoptotic+Protein+Bax&doi=10.1016%2Fj.bbabio.2006.05.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondria as the target of the pro-apoptotic protein Bax</span></div><div class="casAuthors">Er, Emine; Oliver, Lisa; Cartron, Pierre-Francois; Juin, Philippe; Manon, Stephen; Vallette, Francois M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Bioenergetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1757</span>
        (<span class="NLM_cas:issue">9-10</span>),
    <span class="NLM_cas:pages">1301-1311</span>CODEN:
                <span class="NLM_cas:coden">BBBEB4</span>;
        ISSN:<span class="NLM_cas:issn">0005-2728</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  During apoptosis, engagement of the mitochondrial pathway involves the permeabilization of the outer mitochondrial membrane (OMM), which leads to the release of cytochrome c and other apoptogenic proteins such as Smac/DIABLO, AIF, EndoG, Omi/HtraA2, and DDP/TIMM8a.  OMM permeabilization depends on activation, translocation, and oligomerization of multidomain Bcl-2 family proteins such as Bax or Bak.  Factors involved in Bax conformational change and the function(s) of the distinct domains controlling the addressing and the insertion of Bax into mitochondria are described in this review.  The authors also discuss their current knowledge on Bax oligomerization and on the mol. mechanisms underlying the different models accounting for OMM permeabilization during apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJBetDQjNh07Vg90H21EOLACvtfcHk0lilDYNSTOPDtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVanu77J&md5=24719473dfa4b8b7ac13c81b26448680</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bbabio.2006.05.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbabio.2006.05.032%26sid%3Dliteratum%253Aachs%26aulast%3DEr%26aufirst%3DE.%26aulast%3DOliver%26aufirst%3DL.%26aulast%3DCartron%26aufirst%3DP.%2BF.%26aulast%3DJuin%26aufirst%3DP.%26aulast%3DManon%26aufirst%3DS.%26aulast%3DVallette%26aufirst%3DF.%2BM.%26atitle%3DMitochondria%2520as%2520the%2520Target%2520of%2520the%2520Pro-Apoptotic%2520Protein%2520Bax%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Bioenerg.%26date%3D2006%26volume%3D1757%26spage%3D1301%26epage%3D1311%26doi%3D10.1016%2Fj.bbabio.2006.05.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, D.</span></span> <span> </span><span class="NLM_article-title">Oxygen and Pt(II) Self-Generating Conjugate for Synergistic Photo-Chemo Therapy of Hypoxic Tumor</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">2053</span> <span class="refDoi"> DOI: 10.1038/s41467-018-04318-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1038%2Fs41467-018-04318-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=29795534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BC1Mfms1Cqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=S.+Xuauthor=X.+Zhuauthor=C.+Zhangauthor=W.+Huangauthor=Y.+Zhouauthor=D.+Yan&title=Oxygen+and+Pt%28II%29+Self-Generating+Conjugate+for+Synergistic+Photo-Chemo+Therapy+of+Hypoxic+Tumor&doi=10.1038%2Fs41467-018-04318-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Oxygen and Pt(II) self-generating conjugate for synergistic photo-chemo therapy of hypoxic tumor</span></div><div class="casAuthors">Xu Shuting; Zhu Xinyuan; Zhang Chuan; Huang Wei; Zhou Yongfeng; Yan Deyue</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2053</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer cells in hypoxic tumors are remarkably resistant to photodynamic therapy.  Here, we hypothesize that an oxygen and Pt(II) self-generating multifunctional nanocomposite could reverse the hypoxia-triggered PDT resistance.  The nanocomposite contains Pt(IV) and chlorin e6, in which upconversion nanoparticles are loaded to convert 980 nm near-infrared light into 365 nm and 660 nm emissions.  Upon accumulation at the tumor site, a 980 nm laser is used to trigger the nanocomposite to generate O2 for consumption in the PDT process and to produce cytotoxic reactive oxygen species.  The composite also releases active Pt(II) for synergistic photo-chemo therapy to enhance antitumor efficiency.  The oxygen and Pt(II) self-generating prodrug is shown to have high potential to inhibit tumors out of the range of UV light, to overcome the hypoxia-triggered PDT resistance and significantly improve anticancer efficacy by the synergistic PDT-chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQw6CszwdCVeRLDWw4HIq2sfW6udTcc2eb-6EKGNMSqILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mfms1Cqtw%253D%253D&md5=7ad2182118884023dfd2ac46e76cc4a3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04318-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04318-1%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DD.%26atitle%3DOxygen%2520and%2520Pt%2528II%2529%2520Self-Generating%2520Conjugate%2520for%2520Synergistic%2520Photo-Chemo%2520Therapy%2520of%2520Hypoxic%2520Tumor%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26doi%3D10.1038%2Fs41467-018-04318-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhouib, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jallouli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annabi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzouki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharbi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elfazaa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasram, M. M.</span></span> <span> </span><span class="NLM_article-title">From Immunotoxicity to Carcinogenicity: the Effects of Carbamate Pesticides on the Immune System</span>. <i>Environ. Sci. Pollut. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">9488</span>– <span class="NLM_lpage">9458</span>, <span class="refDoi"> DOI: 10.1007/s11356-016-6418-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1007%2Fs11356-016-6418-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=9488-9458&author=I.+Dhouibauthor=M.+Jallouliauthor=A.+Annabiauthor=S.+Marzoukiauthor=N.+Gharbiauthor=S.+Elfazaaauthor=M.+M.+Lasram&title=From+Immunotoxicity+to+Carcinogenicity%3A+the+Effects+of+Carbamate+Pesticides+on+the+Immune+System&doi=10.1007%2Fs11356-016-6418-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs11356-016-6418-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11356-016-6418-6%26sid%3Dliteratum%253Aachs%26aulast%3DDhouib%26aufirst%3DI.%26aulast%3DJallouli%26aufirst%3DM.%26aulast%3DAnnabi%26aufirst%3DA.%26aulast%3DMarzouki%26aufirst%3DS.%26aulast%3DGharbi%26aufirst%3DN.%26aulast%3DElfazaa%26aufirst%3DS.%26aulast%3DLasram%26aufirst%3DM.%2BM.%26atitle%3DFrom%2520Immunotoxicity%2520to%2520Carcinogenicity%253A%2520the%2520Effects%2520of%2520Carbamate%2520Pesticides%2520on%2520the%2520Immune%2520System%26jtitle%3DEnviron.%2520Sci.%2520Pollut.%2520Res.%26date%3D2016%26volume%3D23%26spage%3D9488%26epage%3D9458%26doi%3D10.1007%2Fs11356-016-6418-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kugel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dekel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konichezky, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baniel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livne, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koren, R.</span></span> <span> </span><span class="NLM_article-title">Unusual Splenic Metastasis from Renal Cell Carcinoma. A Case Report and Review of the Literature</span>. <i>Pathol. Res. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">743</span>, <span class="refDoi"> DOI: 10.1078/0344-0338-00490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1078%2F0344-0338-00490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=14708640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A280%3ADC%252BD2c%252FhtFWruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2003&pages=739-743&author=V.+Kugelauthor=Y.+Dekelauthor=M.+Konichezkyauthor=J.+Banielauthor=P.+M.+Livneauthor=R.+Koren&title=Unusual+Splenic+Metastasis+from+Renal+Cell+Carcinoma.+A+Case+Report+and+Review+of+the+Literature&doi=10.1078%2F0344-0338-00490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Unusual splenic metastasis from renal cell carcinoma. A case report and review of the literature</span></div><div class="casAuthors">Kugel Valentina; Dekel Yoram; Konichezky Miriam; Baniel Jacob; Livne Pinchas M; Koren Rumelia</div><div class="citationInfo"><span class="NLM_cas:title">Pathology, research and practice</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">739-43</span>
        ISSN:<span class="NLM_cas:issn">0344-0338</span>.
    </div><div class="casAbstract">This is a short report on a splenic metastasis from renal cell carcinoma.  Previously, the patient had renal carcinoma removed by nephrectomy.  The diagnosis of metastasis was based on morphology and immunohistochemistry.  It is certainly true that splenic metastases from renal cell carcinoma are rare.  Nevertheless, they have been well described in the literature.  A giant cell reaction to tumor is noted in a number of cancers and mainly represents an unusual phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnRUkPy0gMLcKL0FlyGHDofW6udTcc2eb-6EKGNMSqILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c%252FhtFWruw%253D%253D&md5=1b6e83b350da2ff521db569100d64019</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1078%2F0344-0338-00490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1078%252F0344-0338-00490%26sid%3Dliteratum%253Aachs%26aulast%3DKugel%26aufirst%3DV.%26aulast%3DDekel%26aufirst%3DY.%26aulast%3DKonichezky%26aufirst%3DM.%26aulast%3DBaniel%26aufirst%3DJ.%26aulast%3DLivne%26aufirst%3DP.%2BM.%26aulast%3DKoren%26aufirst%3DR.%26atitle%3DUnusual%2520Splenic%2520Metastasis%2520from%2520Renal%2520Cell%2520Carcinoma.%2520A%2520Case%2520Report%2520and%2520Review%2520of%2520the%2520Literature%26jtitle%3DPathol.%2520Res.%2520Pract.%26date%3D2003%26volume%3D199%26spage%3D739%26epage%3D743%26doi%3D10.1078%2F0344-0338-00490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chowdhury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sil, P. C.</span></span> <span> </span><span class="NLM_article-title">Unfolding the Mechanism of Cisplatin Induced Pathophysiology in Spleen and Its Amelioration by Carnosine</span>. <i>Chem. Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2017.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.cbi.2017.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=29191451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2018&pages=159-170&author=S.+Banerjeeauthor=K.+Sinhaauthor=S.+Chowdhuryauthor=P.+C.+Sil&title=Unfolding+the+Mechanism+of+Cisplatin+Induced+Pathophysiology+in+Spleen+and+Its+Amelioration+by+Carnosine&doi=10.1016%2Fj.cbi.2017.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Unfolding the mechanism of cisplatin induced pathophysiology in spleen and its amelioration by carnosine</span></div><div class="casAuthors">Banerjee, Sharmistha; Sinha, Krishnendu; Chowdhury, Sayantani; Sil, Parames C.</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-170</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Cis-Diamminedichloroplatinum (cisplatin) is an effective chemotherapeutic and is widely used for the treatment of various types of solid tumors.  Bio-distribution of cisplatin to other organs due to poor targeting towards only cancer cells constitutes the backbone of cisplatin-induced toxicity.  The adverse effect of this drug on spleen is not well characterized so far.  Therefore, we have set our goal to explore the mechanism of the cisplatin-induced pathophysiol. of the spleen and would also like to evaluate whether carnosine, an endogenous neurotransmitter and antioxidant, can ameliorate this pathophysiol. response.  We found a dose and time-dependent increase of the pro-inflammatory cytokine, TNF-α, in the spleen tissue of the exptl. mice exposed to 10 and 20 mg/kg body wt. of cisplatin.  The increase in inflammatory cytokine can be attributed to the activation of the transcription factor, NF-kB.  This also aids in the transcription of other pro-inflammatory cytokines and cellular adhesion mols.  Exposure of animals to cisplatin at both the doses resulted in ROS and NO prodn. leading to oxidative stress.  The MAP Kinase pathway, esp. JNK activation, was also triggered by cisplatin.  Eventually, the persistence of inflammatory response and oxidative stress lead to apoptosis through extrinsic pathway.  Carnosine has been found to restore the expression of inflammatory mols. and catalase to normal levels through inhibition of pro-inflammatory cytokines, oxidative stress, NF-kB and JNK.  Carnosine also protected the splenic cells from apoptosis.  Our study elucidated the detailed mechanism of cisplatin-induced spleen toxicity and use of carnosine as a protective agent against this cytotoxic response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBGfUCCTYyKrVg90H21EOLACvtfcHk0liW7g1LVOn7Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhurzL&md5=cae9a04b28761886b94dda413eda0386</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2017.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2017.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DBanerjee%26aufirst%3DS.%26aulast%3DSinha%26aufirst%3DK.%26aulast%3DChowdhury%26aufirst%3DS.%26aulast%3DSil%26aufirst%3DP.%2BC.%26atitle%3DUnfolding%2520the%2520Mechanism%2520of%2520Cisplatin%2520Induced%2520Pathophysiology%2520in%2520Spleen%2520and%2520Its%2520Amelioration%2520by%2520Carnosine%26jtitle%3DChem.%2520Biol.%2520Interact.%26date%3D2018%26volume%3D279%26spage%3D159%26epage%3D170%26doi%3D10.1016%2Fj.cbi.2017.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. F.</span></span> <span> </span><span class="NLM_article-title">Relationship between NF-Kappa B, MMP-9, and MICA Expression in Pituitary Adenomas Reveals A New Mechanism of Pituitary Adenomas Immune Escape</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>597</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2015.04.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1016%2Fj.neulet.2015.04.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=25921632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntlGgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=597&publication_year=2015&pages=77-83&author=Z.+Chenauthor=Z.+Z.+Liauthor=Y.+W.+Changauthor=L.+X.+Maauthor=W.+H.+Xuauthor=M.+Liauthor=J.+M.+Liauthor=W.+S.+Zhangauthor=Q.+K.+Sunauthor=X.+J.+Anauthor=Z.+F.+Li&title=Relationship+between+NF-Kappa+B%2C+MMP-9%2C+and+MICA+Expression+in+Pituitary+Adenomas+Reveals+A+New+Mechanism+of+Pituitary+Adenomas+Immune+Escape&doi=10.1016%2Fj.neulet.2015.04.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between NF-κB, MMP-9, and MICA expression in pituitary adenomas reveals a new mechanism of pituitary adenomas immune escape</span></div><div class="casAuthors">Chen, Zheng; Li, Zhenzhu; Chang, Yingwei; Ma, Lixin; Xu, Wenhu; Li, Meng; Li, Jianmin; Zhang, Wensheng; Sun, Qikai; An, Xiaojing; Li, Zefu</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">597</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">77-83</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The aim of this study was to examine the expression levels of NF-κB, MMP-9, and MICA and their relationship between each other in pituitary adenomas as a histol. basis for the study of the expression and shedding mechanism of MICA and mechanism of immune escape of pituitary adenomas.  Our study indicated that MICA, MMP-9 and NF-κB mRNA and protein levels were more highly expressed in pituitary adenomas than healthy tissues.  The expression levels of NF-κB, MMP-9, and MICA were pos. related in patients with pituitary adenomas.  In conclusion, the activation of NF-κB can up-regulate the expression of MICA and induce the expression of MMP-9, which hydrolyzes MICA into sMICA to promote tumor immune escape.  The interactions of NF-κB, MMP-9, and MICA play an important role in the development of pituitary adenomas, and MMP-9 could be used as a new target for inhibiting tumor cell immune escape.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRCIRvI6HQ3rVg90H21EOLACvtfcHk0liW7g1LVOn7Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntlGgtrc%253D&md5=eb71c3db48d3f952fe611a80c0fc2eef</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2015.04.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2015.04.025%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%2BZ.%26aulast%3DChang%26aufirst%3DY.%2BW.%26aulast%3DMa%26aufirst%3DL.%2BX.%26aulast%3DXu%26aufirst%3DW.%2BH.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DW.%2BS.%26aulast%3DSun%26aufirst%3DQ.%2BK.%26aulast%3DAn%26aufirst%3DX.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%2BF.%26atitle%3DRelationship%2520between%2520NF-Kappa%2520B%252C%2520MMP-9%252C%2520and%2520MICA%2520Expression%2520in%2520Pituitary%2520Adenomas%2520Reveals%2520A%2520New%2520Mechanism%2520of%2520Pituitary%2520Adenomas%2520Immune%2520Escape%26jtitle%3DNeurosci.%2520Lett.%26date%3D2015%26volume%3D597%26spage%3D77%26epage%3D83%26doi%3D10.1016%2Fj.neulet.2015.04.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span> <span> </span><span class="NLM_article-title">NF-κB and the Immune Response</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6758</span>– <span class="NLM_lpage">6780</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1209943</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1038%2Fsj.onc.1209943" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=17072327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFektL7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=6758-6780&author=M.+S.+Haydenauthor=A.+P.+Westauthor=S.+Ghosh&title=NF-%CE%BAB+and+the+Immune+Response&doi=10.1038%2Fsj.onc.1209943"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">NF-κB and the immune response</span></div><div class="casAuthors">Hayden, M. S.; West, A. P.; Ghosh, S.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">6758-6780</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One of the primary physiol. roles of nuclear factor-kappa B (NF-κB) is in the immune system.  In particular, NF-κB family members control the transcription of cytokines and antimicrobial effectors as well as genes that regulate cellular differentiation, survival, and proliferation, thereby regulating various aspects of innate and adaptive immune responses.  In addn., NF-κB also contributes to the development and survival of the cells and tissues that carry out immune responses in mammals.  This review, therefore, describes the role of the NF-κB pathway in the development and functioning of the immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpL2vJmQD9HGrVg90H21EOLACvtfcHk0liW7g1LVOn7Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFektL7P&md5=33b28d0dd305ecec26c27e5bf4864022</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209943%26sid%3Dliteratum%253Aachs%26aulast%3DHayden%26aufirst%3DM.%2BS.%26aulast%3DWest%26aufirst%3DA.%2BP.%26aulast%3DGhosh%26aufirst%3DS.%26atitle%3DNF-%25CE%25BAB%2520and%2520the%2520Immune%2520Response%26jtitle%3DOncogene%26date%3D2006%26volume%3D25%26spage%3D6758%26epage%3D6780%26doi%3D10.1038%2Fsj.onc.1209943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karin, M.</span></span> <span> </span><span class="NLM_article-title">IKK/NF-Kappa B Signaling: Balancing Life and Death-a New Approach to Cancer Therapy</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">2625</span>– <span class="NLM_lpage">2632</span>, <span class="refDoi"> DOI: 10.1172/JCI26322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1172%2FJCI26322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=16200195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVygt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=2625-2632&author=J.+L.+Luoauthor=H.+Kamataauthor=M.+Karin&title=IKK%2FNF-Kappa+B+Signaling%3A+Balancing+Life+and+Death-a+New+Approach+to+Cancer+Therapy&doi=10.1172%2FJCI26322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">IKK/NF-κB signaling: Balancing life and death - a new approach to cancer therapy</span></div><div class="casAuthors">Luo, Jun-Li; Kamata, Hideaki; Karin, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2625-2632</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  IκB kinase/NF-κB (IKK/NF-κB) signaling pathways play crit. roles in a variety of physiol. and pathol. processes.  One function of NF-κB is promotion of cell survival through induction of target genes, whose products inhibit components of the apoptotic machinery in normal and cancerous cells.  NF-κB can also prevent programmed necrosis by inducing genes encoding antioxidant proteins.  Regardless of mechanism, many cancer cells, of either epithelial or hematopoietic origin, use NF-κB to achieve resistance to anticancer drugs, radiation, and death cytokines.  Hence, inhibition of IKK-driven NF-κB activation offers a strategy for treatment of different malignancies and can convert inflammation-induced tumor growth to inflammation-induced tumor regression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHJSST-3qAzrVg90H21EOLACvtfcHk0ljK2pwreysS6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVygt7vE&md5=f59858c52e2b20d0323a340dab754845</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1172%2FJCI26322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI26322%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%2BL.%26aulast%3DKamata%26aufirst%3DH.%26aulast%3DKarin%26aufirst%3DM.%26atitle%3DIKK%252FNF-Kappa%2520B%2520Signaling%253A%2520Balancing%2520Life%2520and%2520Death-a%2520New%2520Approach%2520to%2520Cancer%2520Therapy%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D2625%26epage%3D2632%26doi%3D10.1172%2FJCI26322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">George, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleksunes, L. M.</span></span> <span> </span><span class="NLM_article-title">Urinary Protein Biomarkers of Kidney Injury in Patients Receiving Cisplatin Chemotherapy</span>. <i>Exp. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>243</i></span>,  <span class="NLM_fpage">272</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.1177/1535370217745302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;key=10.1177%2F1535370217745302" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=243&publication_year=2017&pages=272-282&author=B.+Georgeauthor=M.+S.+Joyauthor=L.+M.+Aleksunes&title=Urinary+Protein+Biomarkers+of+Kidney+Injury+in+Patients+Receiving+Cisplatin+Chemotherapy&doi=10.1177%2F1535370217745302"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1177%2F1535370217745302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1535370217745302%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DB.%26aulast%3DJoy%26aufirst%3DM.%2BS.%26aulast%3DAleksunes%26aufirst%3DL.%2BM.%26atitle%3DUrinary%2520Protein%2520Biomarkers%2520of%2520Kidney%2520Injury%2520in%2520Patients%2520Receiving%2520Cisplatin%2520Chemotherapy%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2017%26volume%3D243%26spage%3D272%26epage%3D282%26doi%3D10.1177%2F1535370217745302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VT4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VT4','PDB','2VT4'); return false;">PDB: 2VT4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2vt4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2vt4','PDB','2vt4'); return false;">PDB: 2vt4</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i24"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00343">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_77741"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00343?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00343</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">HR-MS spectra of oxoplatin; <sup>1</sup>H/<sup>13</sup>C NMR, HR-MS spectra, and HPLC of all of the target compounds; HPLC for the stability and reduction of compounds <b>3</b>–<b>6</b>; cyclic voltammetry for compounds <b>3</b>–<b>6</b>; isobolograms and combination index for the combination of CDDP/MT; Pt biodistribution in mice, organ indexes, H&E staining, and tumor image; materials and instrumentations; and all of the bioassay details (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_002.csv">CSV</a>)</p></li><li><p class="inline">Docking of MT (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Docking of compound <b>3</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Docking of compound <b>4</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Docking of compound <b>5</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_006.pdb">PDB</a>)</p></li><li><p class="inline">Docking of compound <b>6</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_007.pdb">PDB</a>)</p></li><li><p class="inline">Modeled from <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2vt4">2vt4</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_008.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_001.pdf">jm0c00343_si_001.pdf (2.9 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_002.csv">jm0c00343_si_002.csv (1.44 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_003.pdb">jm0c00343_si_003.pdb (2.17 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_004.pdb">jm0c00343_si_004.pdb (3.08 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_005.pdb">jm0c00343_si_005.pdb (3.16 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_006.pdb">jm0c00343_si_006.pdb (6.59 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_007.pdb">jm0c00343_si_007.pdb (6.79 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00343/suppl_file/jm0c00343_si_008.pdb">jm0c00343_si_008.pdb (377.2 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00343&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00343%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-11" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00343" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b1485396424d3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
